Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,15049800,C(0),"The mean C(0) and C(2) levels were as follows: day 1: C(0) 77.0 +/- 39.6, C(2) 340.5 +/- 140.0 ng/mL; day 2: C(0) 135.5 +/- 53.2, C(2) 467.0 +/- 168.2 ng/mL; day 3: C(0) 146.5 +/- 70.8, C(2) 519.0 +/- 219.1 ng/mL; day 4: C(0) 168.5 +/- 55.1, C(2) 570.0 +/- 163.7 ng/mL; day 5: C(0) 156.5 +/- 38.0, C(2) 612.0 +/- 132.4 ng/mL; day 6: C(0) 177.0 +/- 41.1, C(2) 606.0 +/- 149.2 ng/mL; day 7: C(0) 174.0 +/- 27.2, C(2) 622.0 +/- 98.8 ng/mL (r = 0.82, p < 0.05).",C2 blood concentrations of orally administered cyclosporine in pediatric liver graft recipients with a body weight below 10 kg. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15049800/),,77.0,45,DB00860,Prednisolone
,15049800,C(2),"The mean C(0) and C(2) levels were as follows: day 1: C(0) 77.0 +/- 39.6, C(2) 340.5 +/- 140.0 ng/mL; day 2: C(0) 135.5 +/- 53.2, C(2) 467.0 +/- 168.2 ng/mL; day 3: C(0) 146.5 +/- 70.8, C(2) 519.0 +/- 219.1 ng/mL; day 4: C(0) 168.5 +/- 55.1, C(2) 570.0 +/- 163.7 ng/mL; day 5: C(0) 156.5 +/- 38.0, C(2) 612.0 +/- 132.4 ng/mL; day 6: C(0) 177.0 +/- 41.1, C(2) 606.0 +/- 149.2 ng/mL; day 7: C(0) 174.0 +/- 27.2, C(2) 622.0 +/- 98.8 ng/mL (r = 0.82, p < 0.05).",C2 blood concentrations of orally administered cyclosporine in pediatric liver graft recipients with a body weight below 10 kg. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15049800/),[ng] / [ml],340.5,46,DB00860,Prednisolone
,15049800,C(0),"The mean C(0) and C(2) levels were as follows: day 1: C(0) 77.0 +/- 39.6, C(2) 340.5 +/- 140.0 ng/mL; day 2: C(0) 135.5 +/- 53.2, C(2) 467.0 +/- 168.2 ng/mL; day 3: C(0) 146.5 +/- 70.8, C(2) 519.0 +/- 219.1 ng/mL; day 4: C(0) 168.5 +/- 55.1, C(2) 570.0 +/- 163.7 ng/mL; day 5: C(0) 156.5 +/- 38.0, C(2) 612.0 +/- 132.4 ng/mL; day 6: C(0) 177.0 +/- 41.1, C(2) 606.0 +/- 149.2 ng/mL; day 7: C(0) 174.0 +/- 27.2, C(2) 622.0 +/- 98.8 ng/mL (r = 0.82, p < 0.05).",C2 blood concentrations of orally administered cyclosporine in pediatric liver graft recipients with a body weight below 10 kg. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15049800/),,135.5,47,DB00860,Prednisolone
,15049800,C(2),"The mean C(0) and C(2) levels were as follows: day 1: C(0) 77.0 +/- 39.6, C(2) 340.5 +/- 140.0 ng/mL; day 2: C(0) 135.5 +/- 53.2, C(2) 467.0 +/- 168.2 ng/mL; day 3: C(0) 146.5 +/- 70.8, C(2) 519.0 +/- 219.1 ng/mL; day 4: C(0) 168.5 +/- 55.1, C(2) 570.0 +/- 163.7 ng/mL; day 5: C(0) 156.5 +/- 38.0, C(2) 612.0 +/- 132.4 ng/mL; day 6: C(0) 177.0 +/- 41.1, C(2) 606.0 +/- 149.2 ng/mL; day 7: C(0) 174.0 +/- 27.2, C(2) 622.0 +/- 98.8 ng/mL (r = 0.82, p < 0.05).",C2 blood concentrations of orally administered cyclosporine in pediatric liver graft recipients with a body weight below 10 kg. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15049800/),[ng] / [ml],467.0,48,DB00860,Prednisolone
,15049800,C(0),"The mean C(0) and C(2) levels were as follows: day 1: C(0) 77.0 +/- 39.6, C(2) 340.5 +/- 140.0 ng/mL; day 2: C(0) 135.5 +/- 53.2, C(2) 467.0 +/- 168.2 ng/mL; day 3: C(0) 146.5 +/- 70.8, C(2) 519.0 +/- 219.1 ng/mL; day 4: C(0) 168.5 +/- 55.1, C(2) 570.0 +/- 163.7 ng/mL; day 5: C(0) 156.5 +/- 38.0, C(2) 612.0 +/- 132.4 ng/mL; day 6: C(0) 177.0 +/- 41.1, C(2) 606.0 +/- 149.2 ng/mL; day 7: C(0) 174.0 +/- 27.2, C(2) 622.0 +/- 98.8 ng/mL (r = 0.82, p < 0.05).",C2 blood concentrations of orally administered cyclosporine in pediatric liver graft recipients with a body weight below 10 kg. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15049800/),,146.5,49,DB00860,Prednisolone
,15049800,C(2),"The mean C(0) and C(2) levels were as follows: day 1: C(0) 77.0 +/- 39.6, C(2) 340.5 +/- 140.0 ng/mL; day 2: C(0) 135.5 +/- 53.2, C(2) 467.0 +/- 168.2 ng/mL; day 3: C(0) 146.5 +/- 70.8, C(2) 519.0 +/- 219.1 ng/mL; day 4: C(0) 168.5 +/- 55.1, C(2) 570.0 +/- 163.7 ng/mL; day 5: C(0) 156.5 +/- 38.0, C(2) 612.0 +/- 132.4 ng/mL; day 6: C(0) 177.0 +/- 41.1, C(2) 606.0 +/- 149.2 ng/mL; day 7: C(0) 174.0 +/- 27.2, C(2) 622.0 +/- 98.8 ng/mL (r = 0.82, p < 0.05).",C2 blood concentrations of orally administered cyclosporine in pediatric liver graft recipients with a body weight below 10 kg. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15049800/),[ng] / [ml],519.0,50,DB00860,Prednisolone
,15049800,C(0),"The mean C(0) and C(2) levels were as follows: day 1: C(0) 77.0 +/- 39.6, C(2) 340.5 +/- 140.0 ng/mL; day 2: C(0) 135.5 +/- 53.2, C(2) 467.0 +/- 168.2 ng/mL; day 3: C(0) 146.5 +/- 70.8, C(2) 519.0 +/- 219.1 ng/mL; day 4: C(0) 168.5 +/- 55.1, C(2) 570.0 +/- 163.7 ng/mL; day 5: C(0) 156.5 +/- 38.0, C(2) 612.0 +/- 132.4 ng/mL; day 6: C(0) 177.0 +/- 41.1, C(2) 606.0 +/- 149.2 ng/mL; day 7: C(0) 174.0 +/- 27.2, C(2) 622.0 +/- 98.8 ng/mL (r = 0.82, p < 0.05).",C2 blood concentrations of orally administered cyclosporine in pediatric liver graft recipients with a body weight below 10 kg. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15049800/),,168.5,51,DB00860,Prednisolone
,15049800,C(2),"The mean C(0) and C(2) levels were as follows: day 1: C(0) 77.0 +/- 39.6, C(2) 340.5 +/- 140.0 ng/mL; day 2: C(0) 135.5 +/- 53.2, C(2) 467.0 +/- 168.2 ng/mL; day 3: C(0) 146.5 +/- 70.8, C(2) 519.0 +/- 219.1 ng/mL; day 4: C(0) 168.5 +/- 55.1, C(2) 570.0 +/- 163.7 ng/mL; day 5: C(0) 156.5 +/- 38.0, C(2) 612.0 +/- 132.4 ng/mL; day 6: C(0) 177.0 +/- 41.1, C(2) 606.0 +/- 149.2 ng/mL; day 7: C(0) 174.0 +/- 27.2, C(2) 622.0 +/- 98.8 ng/mL (r = 0.82, p < 0.05).",C2 blood concentrations of orally administered cyclosporine in pediatric liver graft recipients with a body weight below 10 kg. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15049800/),[ng] / [ml],570.0,52,DB00860,Prednisolone
,15049800,C(0),"The mean C(0) and C(2) levels were as follows: day 1: C(0) 77.0 +/- 39.6, C(2) 340.5 +/- 140.0 ng/mL; day 2: C(0) 135.5 +/- 53.2, C(2) 467.0 +/- 168.2 ng/mL; day 3: C(0) 146.5 +/- 70.8, C(2) 519.0 +/- 219.1 ng/mL; day 4: C(0) 168.5 +/- 55.1, C(2) 570.0 +/- 163.7 ng/mL; day 5: C(0) 156.5 +/- 38.0, C(2) 612.0 +/- 132.4 ng/mL; day 6: C(0) 177.0 +/- 41.1, C(2) 606.0 +/- 149.2 ng/mL; day 7: C(0) 174.0 +/- 27.2, C(2) 622.0 +/- 98.8 ng/mL (r = 0.82, p < 0.05).",C2 blood concentrations of orally administered cyclosporine in pediatric liver graft recipients with a body weight below 10 kg. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15049800/),,156.5,53,DB00860,Prednisolone
,15049800,C(2),"The mean C(0) and C(2) levels were as follows: day 1: C(0) 77.0 +/- 39.6, C(2) 340.5 +/- 140.0 ng/mL; day 2: C(0) 135.5 +/- 53.2, C(2) 467.0 +/- 168.2 ng/mL; day 3: C(0) 146.5 +/- 70.8, C(2) 519.0 +/- 219.1 ng/mL; day 4: C(0) 168.5 +/- 55.1, C(2) 570.0 +/- 163.7 ng/mL; day 5: C(0) 156.5 +/- 38.0, C(2) 612.0 +/- 132.4 ng/mL; day 6: C(0) 177.0 +/- 41.1, C(2) 606.0 +/- 149.2 ng/mL; day 7: C(0) 174.0 +/- 27.2, C(2) 622.0 +/- 98.8 ng/mL (r = 0.82, p < 0.05).",C2 blood concentrations of orally administered cyclosporine in pediatric liver graft recipients with a body weight below 10 kg. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15049800/),[ng] / [ml],612.0,54,DB00860,Prednisolone
,15049800,C(0),"The mean C(0) and C(2) levels were as follows: day 1: C(0) 77.0 +/- 39.6, C(2) 340.5 +/- 140.0 ng/mL; day 2: C(0) 135.5 +/- 53.2, C(2) 467.0 +/- 168.2 ng/mL; day 3: C(0) 146.5 +/- 70.8, C(2) 519.0 +/- 219.1 ng/mL; day 4: C(0) 168.5 +/- 55.1, C(2) 570.0 +/- 163.7 ng/mL; day 5: C(0) 156.5 +/- 38.0, C(2) 612.0 +/- 132.4 ng/mL; day 6: C(0) 177.0 +/- 41.1, C(2) 606.0 +/- 149.2 ng/mL; day 7: C(0) 174.0 +/- 27.2, C(2) 622.0 +/- 98.8 ng/mL (r = 0.82, p < 0.05).",C2 blood concentrations of orally administered cyclosporine in pediatric liver graft recipients with a body weight below 10 kg. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15049800/),,177.0,55,DB00860,Prednisolone
,15049800,C(2),"The mean C(0) and C(2) levels were as follows: day 1: C(0) 77.0 +/- 39.6, C(2) 340.5 +/- 140.0 ng/mL; day 2: C(0) 135.5 +/- 53.2, C(2) 467.0 +/- 168.2 ng/mL; day 3: C(0) 146.5 +/- 70.8, C(2) 519.0 +/- 219.1 ng/mL; day 4: C(0) 168.5 +/- 55.1, C(2) 570.0 +/- 163.7 ng/mL; day 5: C(0) 156.5 +/- 38.0, C(2) 612.0 +/- 132.4 ng/mL; day 6: C(0) 177.0 +/- 41.1, C(2) 606.0 +/- 149.2 ng/mL; day 7: C(0) 174.0 +/- 27.2, C(2) 622.0 +/- 98.8 ng/mL (r = 0.82, p < 0.05).",C2 blood concentrations of orally administered cyclosporine in pediatric liver graft recipients with a body weight below 10 kg. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15049800/),[ng] / [ml],606.0,56,DB00860,Prednisolone
,15049800,C(0),"The mean C(0) and C(2) levels were as follows: day 1: C(0) 77.0 +/- 39.6, C(2) 340.5 +/- 140.0 ng/mL; day 2: C(0) 135.5 +/- 53.2, C(2) 467.0 +/- 168.2 ng/mL; day 3: C(0) 146.5 +/- 70.8, C(2) 519.0 +/- 219.1 ng/mL; day 4: C(0) 168.5 +/- 55.1, C(2) 570.0 +/- 163.7 ng/mL; day 5: C(0) 156.5 +/- 38.0, C(2) 612.0 +/- 132.4 ng/mL; day 6: C(0) 177.0 +/- 41.1, C(2) 606.0 +/- 149.2 ng/mL; day 7: C(0) 174.0 +/- 27.2, C(2) 622.0 +/- 98.8 ng/mL (r = 0.82, p < 0.05).",C2 blood concentrations of orally administered cyclosporine in pediatric liver graft recipients with a body weight below 10 kg. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15049800/),,174.0,57,DB00860,Prednisolone
,15049800,C(2),"The mean C(0) and C(2) levels were as follows: day 1: C(0) 77.0 +/- 39.6, C(2) 340.5 +/- 140.0 ng/mL; day 2: C(0) 135.5 +/- 53.2, C(2) 467.0 +/- 168.2 ng/mL; day 3: C(0) 146.5 +/- 70.8, C(2) 519.0 +/- 219.1 ng/mL; day 4: C(0) 168.5 +/- 55.1, C(2) 570.0 +/- 163.7 ng/mL; day 5: C(0) 156.5 +/- 38.0, C(2) 612.0 +/- 132.4 ng/mL; day 6: C(0) 177.0 +/- 41.1, C(2) 606.0 +/- 149.2 ng/mL; day 7: C(0) 174.0 +/- 27.2, C(2) 622.0 +/- 98.8 ng/mL (r = 0.82, p < 0.05).",C2 blood concentrations of orally administered cyclosporine in pediatric liver graft recipients with a body weight below 10 kg. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15049800/),,622,58,DB00860,Prednisolone
,2892921,AUC unbound prednisolone,The method was used to compare the AUC unbound prednisolone in a nephrotic child (plasma albumin concentration 18 g L-1) with a control (plasma albumin concentration 43 g L-1); their respective AUC unbound prednisolone values were 4.02 mg h L-1 and 1.07 mg h L-1.,The separation of unbound prednisolone in plasma by centrifugal ultrafiltration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2892921/),[h·mg] / [l],4.02,1482,DB00860,Prednisolone
,2892921,AUC unbound prednisolone,The method was used to compare the AUC unbound prednisolone in a nephrotic child (plasma albumin concentration 18 g L-1) with a control (plasma albumin concentration 43 g L-1); their respective AUC unbound prednisolone values were 4.02 mg h L-1 and 1.07 mg h L-1.,The separation of unbound prednisolone in plasma by centrifugal ultrafiltration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2892921/),[h·mg] / [l],1.07,1483,DB00860,Prednisolone
,25707517,oral clearance,"Typical mean value of MPA oral clearance, estimated by base model (without covariates) was 0.741 L h(-1).",Variability of mycophenolic acid elimination in the renal transplant recipients – population pharmacokinetic approach. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25707517/),[l] / [h],0.741,1786,DB00860,Prednisolone
,11294518,flow rate,"The mobile phase consisted of 16% isopropanol in water containing 0.1% trifluoroacetic acid, set at a flow rate of 1.2 mL/min.","Simultaneous determination of plasma prednisolone, prednisone, and cortisol levels by high-performance liquid chromatography. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11294518/),[ml] / [min],1.2,3291,DB00860,Prednisolone
,11294518,imprecision,"Mean intra-assay and interassay imprecision levels were 6.0% and 7.2%, respectively, for prednisolone, 5.8% and 7.2% for prednisone, and 5.6% and 7.9% for cortisol.","Simultaneous determination of plasma prednisolone, prednisone, and cortisol levels by high-performance liquid chromatography. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11294518/),%,7.2,3292,DB00860,Prednisolone
,11294518,imprecision,"Mean intra-assay and interassay imprecision levels were 6.0% and 7.2%, respectively, for prednisolone, 5.8% and 7.2% for prednisone, and 5.6% and 7.9% for cortisol.","Simultaneous determination of plasma prednisolone, prednisone, and cortisol levels by high-performance liquid chromatography. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11294518/),%,5.8,3293,DB00860,Prednisolone
,11294518,imprecision,"Mean intra-assay and interassay imprecision levels were 6.0% and 7.2%, respectively, for prednisolone, 5.8% and 7.2% for prednisone, and 5.6% and 7.9% for cortisol.","Simultaneous determination of plasma prednisolone, prednisone, and cortisol levels by high-performance liquid chromatography. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11294518/),%,5.6,3294,DB00860,Prednisolone
,11294518,imprecision,"Mean intra-assay and interassay imprecision levels were 6.0% and 7.2%, respectively, for prednisolone, 5.8% and 7.2% for prednisone, and 5.6% and 7.9% for cortisol.","Simultaneous determination of plasma prednisolone, prednisone, and cortisol levels by high-performance liquid chromatography. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11294518/),%,7.9,3295,DB00860,Prednisolone
,11294518,recoveries,"Corticosteroid recoveries were 73%, 74%, and 90% for prednisolone, prednisone, and cortisol, respectively.","Simultaneous determination of plasma prednisolone, prednisone, and cortisol levels by high-performance liquid chromatography. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11294518/),%,73,3296,DB00860,Prednisolone
,11294518,recoveries,"Corticosteroid recoveries were 73%, 74%, and 90% for prednisolone, prednisone, and cortisol, respectively.","Simultaneous determination of plasma prednisolone, prednisone, and cortisol levels by high-performance liquid chromatography. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11294518/),%,74,3297,DB00860,Prednisolone
,11294518,recoveries,"Corticosteroid recoveries were 73%, 74%, and 90% for prednisolone, prednisone, and cortisol, respectively.","Simultaneous determination of plasma prednisolone, prednisone, and cortisol levels by high-performance liquid chromatography. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11294518/),%,90,3298,DB00860,Prednisolone
,15726877,ratio,"The prednisolone/prednisone ratio in urine was 11.1 in group L, 7.3 in group HA and 45.6 in group HC.",Pharmacokinetics of prednisolone in man during acute and chronic exposure to high altitude. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15726877/),,11.1,5588,DB00860,Prednisolone
,15726877,ratio,"The prednisolone/prednisone ratio in urine was 11.1 in group L, 7.3 in group HA and 45.6 in group HC.",Pharmacokinetics of prednisolone in man during acute and chronic exposure to high altitude. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15726877/),,7.3,5589,DB00860,Prednisolone
,15726877,ratio,"The prednisolone/prednisone ratio in urine was 11.1 in group L, 7.3 in group HA and 45.6 in group HC.",Pharmacokinetics of prednisolone in man during acute and chronic exposure to high altitude. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15726877/),,45.6,5590,DB00860,Prednisolone
,7202937,relative bioavailability,The relative bioavailability of prednisone after prednisone-antacid treatments compared to that after prednisone-water treatment was 74% +/- 13% (p less than 0.05) with Melox and 57% +/- 15% (p less than 0.01) with Aldrox in healthy volunteers.,Decreased bioavailability of prednisone due to antacids in patients with chronic active liver disease and in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7202937/),%,74,5855,DB00860,Prednisolone
,7202937,relative bioavailability,The relative bioavailability of prednisone after prednisone-antacid treatments compared to that after prednisone-water treatment was 74% +/- 13% (p less than 0.05) with Melox and 57% +/- 15% (p less than 0.01) with Aldrox in healthy volunteers.,Decreased bioavailability of prednisone due to antacids in patients with chronic active liver disease and in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7202937/),%,57,5856,DB00860,Prednisolone
,7202937,bioavailability,"In patients with chronic active liver disease responding to treatment, prednisone bioavailability was 65% +/- 120% (p less than 0.01) and 87% +/- 20%, respectively.",Decreased bioavailability of prednisone due to antacids in patients with chronic active liver disease and in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7202937/),%,65,5857,DB00860,Prednisolone
,7202937,bioavailability,"In patients with chronic active liver disease responding to treatment, prednisone bioavailability was 65% +/- 120% (p less than 0.01) and 87% +/- 20%, respectively.",Decreased bioavailability of prednisone due to antacids in patients with chronic active liver disease and in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7202937/),%,87,5858,DB00860,Prednisolone
,1445479,specific radioactivity,The ointments used for treatment on days 1 and 8 contained 14C-MPA with a specific radioactivity of 2.5 MBq/mg MPA.,Percutaneous absorption of methylprednisolone aceponate after single and multiple dermal application as ointment in male volunteers. ,Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1445479/),[Mbq] / [mg],2.5,6472,DB00860,Prednisolone
,30080939,plasma concentration,"The MP plasma concentration at 6 days for injection for the entire group (mean ± standard deviation [s.d.], pg/mL) was 96 ± 104.",Variability in plasma concentrations of methylprednisolone 6 days after intrasynovial injection of methylprednisolone acetate in racing horses: A field study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30080939/),,96,6730,DB00860,Prednisolone
,14621866,trough level,"In conclusion, the therapeutic dose of FK 506 should be adjusted by monitoring the trough level in whole blood, the range of which might be recommended to be 15-20 ng/ml during the early phase after transplantation.",Japanese study of kidney transplantation: 1. Results of early phase II study. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14621866/),[ng] / [ml],15-20,8112,DB00860,Prednisolone
,3814762,Elimination half-lives,"Elimination half-lives were shorter in the patients than in the 9 healthy subjects (1.98 +/- 0.48 versus 2.73 +/- 0.76 h, mean +/- SD, 0.02 less than p less than 0.05), and total clearances higher (4.20 +/- 0.53 versus 2.96 +/- 0.54 ml X min-1 X kg-1, p less than 0.02), while the volumes of distribution did not differ significantly.","Modified elimination of prednisolone in epileptic patients on carbamazepine monotherapy, and in women using low-dose oral contraceptives. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3814762/),h,1.98,8399,DB00860,Prednisolone
,3814762,Elimination half-lives,"Elimination half-lives were shorter in the patients than in the 9 healthy subjects (1.98 +/- 0.48 versus 2.73 +/- 0.76 h, mean +/- SD, 0.02 less than p less than 0.05), and total clearances higher (4.20 +/- 0.53 versus 2.96 +/- 0.54 ml X min-1 X kg-1, p less than 0.02), while the volumes of distribution did not differ significantly.","Modified elimination of prednisolone in epileptic patients on carbamazepine monotherapy, and in women using low-dose oral contraceptives. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3814762/),h,2.73,8400,DB00860,Prednisolone
,3814762,total clearances,"Elimination half-lives were shorter in the patients than in the 9 healthy subjects (1.98 +/- 0.48 versus 2.73 +/- 0.76 h, mean +/- SD, 0.02 less than p less than 0.05), and total clearances higher (4.20 +/- 0.53 versus 2.96 +/- 0.54 ml X min-1 X kg-1, p less than 0.02), while the volumes of distribution did not differ significantly.","Modified elimination of prednisolone in epileptic patients on carbamazepine monotherapy, and in women using low-dose oral contraceptives. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3814762/),[ml] / [kg·min],4.20,8401,DB00860,Prednisolone
,3814762,total clearances,"Elimination half-lives were shorter in the patients than in the 9 healthy subjects (1.98 +/- 0.48 versus 2.73 +/- 0.76 h, mean +/- SD, 0.02 less than p less than 0.05), and total clearances higher (4.20 +/- 0.53 versus 2.96 +/- 0.54 ml X min-1 X kg-1, p less than 0.02), while the volumes of distribution did not differ significantly.","Modified elimination of prednisolone in epileptic patients on carbamazepine monotherapy, and in women using low-dose oral contraceptives. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3814762/),[ml] / [kg·min],2.96,8402,DB00860,Prednisolone
,3814762,elimination half-life,"Among the healthy subjects, the oral contraceptive group exhibited a longer elimination half-life, and a lower total clearance, than each of the other two groups, who gave similar results (respectively 4.75 +/- 1.27, 3.05 +/- 0.75, and 2.33 +/- 0.66 h, p less than or equal to 0.05; 1.91 +/- 0.57, 2.95 +/- 0.60, and 2.97 +/- 0.57 ml X min-1 X kg-1, p less than or equal to 0.05); the volumes of distribution were not significantly different.","Modified elimination of prednisolone in epileptic patients on carbamazepine monotherapy, and in women using low-dose oral contraceptives. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3814762/),h,4.75,8403,DB00860,Prednisolone
,3814762,elimination half-life,"Among the healthy subjects, the oral contraceptive group exhibited a longer elimination half-life, and a lower total clearance, than each of the other two groups, who gave similar results (respectively 4.75 +/- 1.27, 3.05 +/- 0.75, and 2.33 +/- 0.66 h, p less than or equal to 0.05; 1.91 +/- 0.57, 2.95 +/- 0.60, and 2.97 +/- 0.57 ml X min-1 X kg-1, p less than or equal to 0.05); the volumes of distribution were not significantly different.","Modified elimination of prednisolone in epileptic patients on carbamazepine monotherapy, and in women using low-dose oral contraceptives. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3814762/),h,3.05,8404,DB00860,Prednisolone
,3814762,elimination half-life,"Among the healthy subjects, the oral contraceptive group exhibited a longer elimination half-life, and a lower total clearance, than each of the other two groups, who gave similar results (respectively 4.75 +/- 1.27, 3.05 +/- 0.75, and 2.33 +/- 0.66 h, p less than or equal to 0.05; 1.91 +/- 0.57, 2.95 +/- 0.60, and 2.97 +/- 0.57 ml X min-1 X kg-1, p less than or equal to 0.05); the volumes of distribution were not significantly different.","Modified elimination of prednisolone in epileptic patients on carbamazepine monotherapy, and in women using low-dose oral contraceptives. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3814762/),[ml] / [kg·min],1.91,8405,DB00860,Prednisolone
,3814762,total clearance,"Among the healthy subjects, the oral contraceptive group exhibited a longer elimination half-life, and a lower total clearance, than each of the other two groups, who gave similar results (respectively 4.75 +/- 1.27, 3.05 +/- 0.75, and 2.33 +/- 0.66 h, p less than or equal to 0.05; 1.91 +/- 0.57, 2.95 +/- 0.60, and 2.97 +/- 0.57 ml X min-1 X kg-1, p less than or equal to 0.05); the volumes of distribution were not significantly different.","Modified elimination of prednisolone in epileptic patients on carbamazepine monotherapy, and in women using low-dose oral contraceptives. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3814762/),h,3.05,8406,DB00860,Prednisolone
,3814762,total clearance,"Among the healthy subjects, the oral contraceptive group exhibited a longer elimination half-life, and a lower total clearance, than each of the other two groups, who gave similar results (respectively 4.75 +/- 1.27, 3.05 +/- 0.75, and 2.33 +/- 0.66 h, p less than or equal to 0.05; 1.91 +/- 0.57, 2.95 +/- 0.60, and 2.97 +/- 0.57 ml X min-1 X kg-1, p less than or equal to 0.05); the volumes of distribution were not significantly different.","Modified elimination of prednisolone in epileptic patients on carbamazepine monotherapy, and in women using low-dose oral contraceptives. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3814762/),h,2.33,8407,DB00860,Prednisolone
,3814762,total clearance,"Among the healthy subjects, the oral contraceptive group exhibited a longer elimination half-life, and a lower total clearance, than each of the other two groups, who gave similar results (respectively 4.75 +/- 1.27, 3.05 +/- 0.75, and 2.33 +/- 0.66 h, p less than or equal to 0.05; 1.91 +/- 0.57, 2.95 +/- 0.60, and 2.97 +/- 0.57 ml X min-1 X kg-1, p less than or equal to 0.05); the volumes of distribution were not significantly different.","Modified elimination of prednisolone in epileptic patients on carbamazepine monotherapy, and in women using low-dose oral contraceptives. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3814762/),[ml] / [kg·min],1.91,8408,DB00860,Prednisolone
,3814762,total clearance,"Among the healthy subjects, the oral contraceptive group exhibited a longer elimination half-life, and a lower total clearance, than each of the other two groups, who gave similar results (respectively 4.75 +/- 1.27, 3.05 +/- 0.75, and 2.33 +/- 0.66 h, p less than or equal to 0.05; 1.91 +/- 0.57, 2.95 +/- 0.60, and 2.97 +/- 0.57 ml X min-1 X kg-1, p less than or equal to 0.05); the volumes of distribution were not significantly different.","Modified elimination of prednisolone in epileptic patients on carbamazepine monotherapy, and in women using low-dose oral contraceptives. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3814762/),[ml] / [kg·min],2.95,8409,DB00860,Prednisolone
,3814762,total clearance,"Among the healthy subjects, the oral contraceptive group exhibited a longer elimination half-life, and a lower total clearance, than each of the other two groups, who gave similar results (respectively 4.75 +/- 1.27, 3.05 +/- 0.75, and 2.33 +/- 0.66 h, p less than or equal to 0.05; 1.91 +/- 0.57, 2.95 +/- 0.60, and 2.97 +/- 0.57 ml X min-1 X kg-1, p less than or equal to 0.05); the volumes of distribution were not significantly different.","Modified elimination of prednisolone in epileptic patients on carbamazepine monotherapy, and in women using low-dose oral contraceptives. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3814762/),[ml] / [kg·min],2.97,8410,DB00860,Prednisolone
,18223462,Cmax,"The mean dose-unadjusted and -adjusted Cmax of MPA with 30 mg lansoprazole were significantly lower than those without PPI (11.8 vs. 17.8 microg/mL, P = 0.0197, and 22.6 vs. 33.1 ng/mL/mg MMF, P = 0.0222, respectively).",Influence of lansoprazole and rabeprazole on mycophenolic acid pharmacokinetics one year after renal transplantation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18223462/),[μg] / [ml],11.8,9335,DB00860,Prednisolone
,18223462,Cmax,"The mean dose-unadjusted and -adjusted Cmax of MPA with 30 mg lansoprazole were significantly lower than those without PPI (11.8 vs. 17.8 microg/mL, P = 0.0197, and 22.6 vs. 33.1 ng/mL/mg MMF, P = 0.0222, respectively).",Influence of lansoprazole and rabeprazole on mycophenolic acid pharmacokinetics one year after renal transplantation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18223462/),[μg] / [ml],17.8,9336,DB00860,Prednisolone
,18223462,Cmax,"The mean dose-unadjusted and -adjusted Cmax of MPA with 30 mg lansoprazole were significantly lower than those without PPI (11.8 vs. 17.8 microg/mL, P = 0.0197, and 22.6 vs. 33.1 ng/mL/mg MMF, P = 0.0222, respectively).",Influence of lansoprazole and rabeprazole on mycophenolic acid pharmacokinetics one year after renal transplantation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18223462/),[ng] / [mg·ml],22.6,9337,DB00860,Prednisolone
,18223462,Cmax,"The mean dose-unadjusted and -adjusted Cmax of MPA with 30 mg lansoprazole were significantly lower than those without PPI (11.8 vs. 17.8 microg/mL, P = 0.0197, and 22.6 vs. 33.1 ng/mL/mg MMF, P = 0.0222, respectively).",Influence of lansoprazole and rabeprazole on mycophenolic acid pharmacokinetics one year after renal transplantation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18223462/),[ng] / [mg·ml],33.1,9338,DB00860,Prednisolone
,23714676,steady-state plasma levels,"At each infusion, a mean of 9.8 ± 4.6 mg dexamethasone 21-phosphate was administered at each infusion, which allowed steady-state plasma levels of 8 ng/mL for the following 28 days.","Erythrocytes-mediated delivery of dexamethasone 21-phosphate in steroid-dependent ulcerative colitis: a randomized, double-blind Sham-controlled study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23714676/),[ng] / [ml],8,9613,DB00860,Prednisolone
,26333097,Maximum measured plasma isoflupredone concentrations,"Maximum measured plasma isoflupredone concentrations were 1.76 ± 0.526 ng/mL at 4.0 ± 1.31 h and 1.63 ± 0.243 ng/mL at 4.75 ± 0.5 h, respectively, for horses that had synovial fluid collected and for those that did not.","Disposition of isoflupredone acetate in plasma, urine and synovial fluid following intra-articular administration to exercised Thoroughbred horses. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26333097/),[ng] / [ml],1.76,14259,DB00860,Prednisolone
,26333097,Maximum measured plasma isoflupredone concentrations,"Maximum measured plasma isoflupredone concentrations were 1.76 ± 0.526 ng/mL at 4.0 ± 1.31 h and 1.63 ± 0.243 ng/mL at 4.75 ± 0.5 h, respectively, for horses that had synovial fluid collected and for those that did not.","Disposition of isoflupredone acetate in plasma, urine and synovial fluid following intra-articular administration to exercised Thoroughbred horses. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26333097/),[ng] / [ml],1.63,14260,DB00860,Prednisolone
,26333097,plasma beta half-life,The plasma beta half-life was 24.2 h.,"Disposition of isoflupredone acetate in plasma, urine and synovial fluid following intra-articular administration to exercised Thoroughbred horses. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26333097/),h,24.2,14261,DB00860,Prednisolone
,8668664,clearance,Increasing the dose from 2 to 10 mg/kg led to increased clearance from 5.9 to 10.5 (MPL) and from 1.8 to 2.3 L/hr/kg (L-MPL).,Liposomal methylprednisolone in rats: dose-proportionality and chronic-dose pharmacokinetics/pharmacodynamics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8668664/),[l] / [h·kg],5.9 to 10.5,15307,DB00860,Prednisolone
,8668664,clearance,Increasing the dose from 2 to 10 mg/kg led to increased clearance from 5.9 to 10.5 (MPL) and from 1.8 to 2.3 L/hr/kg (L-MPL).,Liposomal methylprednisolone in rats: dose-proportionality and chronic-dose pharmacokinetics/pharmacodynamics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8668664/),[l] / [h·kg],1.8 to 2.3,15308,DB00860,Prednisolone
,8668664,half-life,Liposomes without drug simultaneously administered with MPL caused partial prolongation of plasma steroid half-life (8.4 hr).,Liposomal methylprednisolone in rats: dose-proportionality and chronic-dose pharmacokinetics/pharmacodynamics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8668664/),h,8.4,15309,DB00860,Prednisolone
,6626699,half-life,The disposition of methylprednisolone from plasma following intravenous (i.v.) infusion of its succinate ester appeared monoexponential with a mean half-life of 2.4 h and an apparent volume of distribution (Vd) of 50 l (0.87 l/kg).,Systemic bioavailability and pharmacokinetics of methylprednisolone in patients with rheumatoid arthritis following 'high-dose' pulse administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6626699/),h,2.4,15550,DB00860,Prednisolone
,6626699,apparent volume of distribution (Vd),The disposition of methylprednisolone from plasma following intravenous (i.v.) infusion of its succinate ester appeared monoexponential with a mean half-life of 2.4 h and an apparent volume of distribution (Vd) of 50 l (0.87 l/kg).,Systemic bioavailability and pharmacokinetics of methylprednisolone in patients with rheumatoid arthritis following 'high-dose' pulse administration. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6626699/),l,50,15551,DB00860,Prednisolone
,6626699,total body clearance (Cl),The total body clearance (Cl) averaged 15.12 l/h.,Systemic bioavailability and pharmacokinetics of methylprednisolone in patients with rheumatoid arthritis following 'high-dose' pulse administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6626699/),[l] / [h],15.12,15552,DB00860,Prednisolone
,6626699,systemic availability (f,"No significant difference (p greater than 0.2) was observed when systemic availability (f, expressed in per cent) following administration of drug in capsule (f = 49.35 per cent) was compared with that obtained following the administration of drug in a suspension (f = 58.26 per cent).",Systemic bioavailability and pharmacokinetics of methylprednisolone in patients with rheumatoid arthritis following 'high-dose' pulse administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6626699/),%,49.35,15553,DB00860,Prednisolone
,6626699,f,"No significant difference (p greater than 0.2) was observed when systemic availability (f, expressed in per cent) following administration of drug in capsule (f = 49.35 per cent) was compared with that obtained following the administration of drug in a suspension (f = 58.26 per cent).",Systemic bioavailability and pharmacokinetics of methylprednisolone in patients with rheumatoid arthritis following 'high-dose' pulse administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6626699/),%,49.35,15554,DB00860,Prednisolone
,6626699,f,"No significant difference (p greater than 0.2) was observed when systemic availability (f, expressed in per cent) following administration of drug in capsule (f = 49.35 per cent) was compared with that obtained following the administration of drug in a suspension (f = 58.26 per cent).",Systemic bioavailability and pharmacokinetics of methylprednisolone in patients with rheumatoid arthritis following 'high-dose' pulse administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6626699/),%,58.26,15555,DB00860,Prednisolone
,8105017,total body clearance,Interpatient variability in pharmacokinetic parameters of methylprednisolone was noted with a total body clearance of 240 +/- 112 mL/hr/Kg and half-life ranging from 2.2 to 3.9 hr.,CD4+/CD8+ lymphocyte patterns in renal transplant recipients receiving chronic methylprednisolone. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8105017/),[ml] / [h·kg],240,16313,DB00860,Prednisolone
,8105017,half-life,Interpatient variability in pharmacokinetic parameters of methylprednisolone was noted with a total body clearance of 240 +/- 112 mL/hr/Kg and half-life ranging from 2.2 to 3.9 hr.,CD4+/CD8+ lymphocyte patterns in renal transplant recipients receiving chronic methylprednisolone. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8105017/),h,2.2 to 3.9,16314,DB00860,Prednisolone
,6997330,elimination half-lives,The elimination half-lives were not significantly different in the noncushingoid and cushingoid patients (2.3 vs. 3.3 h).,Prednisolone disposition in cushingoid and noncushingoid kidney transplant patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6997330/),h,2.3,16591,DB00860,Prednisolone
,6997330,elimination half-lives,The elimination half-lives were not significantly different in the noncushingoid and cushingoid patients (2.3 vs. 3.3 h).,Prednisolone disposition in cushingoid and noncushingoid kidney transplant patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6997330/),h,3.3,16592,DB00860,Prednisolone
,6997330,plasma clearance,"However, other pharmacokinetic parameters were significantly lower in the cushingoid group: plasma clearance (147 vs. 82 ml/min) and volume of distribution (32 vs. 20 liters).",Prednisolone disposition in cushingoid and noncushingoid kidney transplant patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6997330/),[ml] / [min],147,16593,DB00860,Prednisolone
,6997330,plasma clearance,"However, other pharmacokinetic parameters were significantly lower in the cushingoid group: plasma clearance (147 vs. 82 ml/min) and volume of distribution (32 vs. 20 liters).",Prednisolone disposition in cushingoid and noncushingoid kidney transplant patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6997330/),[ml] / [min],82,16594,DB00860,Prednisolone
,6997330,volume of distribution,"However, other pharmacokinetic parameters were significantly lower in the cushingoid group: plasma clearance (147 vs. 82 ml/min) and volume of distribution (32 vs. 20 liters).",Prednisolone disposition in cushingoid and noncushingoid kidney transplant patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6997330/),l,32,16595,DB00860,Prednisolone
,6997330,volume of distribution,"However, other pharmacokinetic parameters were significantly lower in the cushingoid group: plasma clearance (147 vs. 82 ml/min) and volume of distribution (32 vs. 20 liters).",Prednisolone disposition in cushingoid and noncushingoid kidney transplant patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6997330/),l,20,16596,DB00860,Prednisolone
,6997330,availability,"In addition, the availability of prednisolone after oral prednisone administration was considerably variable (overall range, 27-108%) and was not significantly different between the two groups.",Prednisolone disposition in cushingoid and noncushingoid kidney transplant patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6997330/),%,27-108,16597,DB00860,Prednisolone
,17579865,peak plasma level,Mean peak plasma level after intravenous etoposide was significantly higher compared to oral administration (16.3+/-3.7 vs. 12.0+/-4.2 microg/ml; P=0.015).,Pharmacokinetic comparison of oral and intravenous etoposide in patients treated with the CHOEP-regimen for malignant lymphomas. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17579865/),[μg] / [ml],16.3,19185,DB00860,Prednisolone
,17579865,peak plasma level,Mean peak plasma level after intravenous etoposide was significantly higher compared to oral administration (16.3+/-3.7 vs. 12.0+/-4.2 microg/ml; P=0.015).,Pharmacokinetic comparison of oral and intravenous etoposide in patients treated with the CHOEP-regimen for malignant lymphomas. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17579865/),[μg] / [ml],12.0,19186,DB00860,Prednisolone
,17579865,bioavailability,The mean bioavailability of oral etoposide was 58+/-15% with an interpatient variability of 26%.,Pharmacokinetic comparison of oral and intravenous etoposide in patients treated with the CHOEP-regimen for malignant lymphomas. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17579865/),%,58,19187,DB00860,Prednisolone
,17579865,AUC,Mean AUC after a 100 mg/m2 intravenous and a 200 mg/m2 oral dose of etoposide were 74.0+/-18.3 and 84.9+/-29.6 microg h/ml (P=0.481).,Pharmacokinetic comparison of oral and intravenous etoposide in patients treated with the CHOEP-regimen for malignant lymphomas. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17579865/),[h·μg] / [ml],74.0,19188,DB00860,Prednisolone
,17579865,AUC,Mean AUC after a 100 mg/m2 intravenous and a 200 mg/m2 oral dose of etoposide were 74.0+/-18.3 and 84.9+/-29.6 microg h/ml (P=0.481).,Pharmacokinetic comparison of oral and intravenous etoposide in patients treated with the CHOEP-regimen for malignant lymphomas. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17579865/),[h·μg] / [ml],84.9,19189,DB00860,Prednisolone
,17579865,excretion,Urinary etoposide excretion as percentage of administered dose was 39.4+/-10.6% after intravenous infusion versus 35.4+/-9.4% after oral intake (P=0.422).,Pharmacokinetic comparison of oral and intravenous etoposide in patients treated with the CHOEP-regimen for malignant lymphomas. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17579865/),%,39.4,19190,DB00860,Prednisolone
,17579865,excretion,Urinary etoposide excretion as percentage of administered dose was 39.4+/-10.6% after intravenous infusion versus 35.4+/-9.4% after oral intake (P=0.422).,Pharmacokinetic comparison of oral and intravenous etoposide in patients treated with the CHOEP-regimen for malignant lymphomas. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17579865/),%,35.4,19191,DB00860,Prednisolone
,17579865,Renal clearance,Renal clearance was also very similar with intravenous and oral route (18.5+/-7.4 vs. 16.7+/-6.6 ml/min; P=0.546).,Pharmacokinetic comparison of oral and intravenous etoposide in patients treated with the CHOEP-regimen for malignant lymphomas. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17579865/),[ml] / [min],18.5,19192,DB00860,Prednisolone
,17579865,Renal clearance,Renal clearance was also very similar with intravenous and oral route (18.5+/-7.4 vs. 16.7+/-6.6 ml/min; P=0.546).,Pharmacokinetic comparison of oral and intravenous etoposide in patients treated with the CHOEP-regimen for malignant lymphomas. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17579865/),[ml] / [min],16.7,19193,DB00860,Prednisolone
,9115056,return AUC,"The return AUC of cortisol (425 +/- 357 ng.hr/mL [elderly] versus 854 +/- 216 ng.mL [young]) and the total AUC 764 +/- 340 ng.h/mL [elderly] versus 1,230 +/- 258 ng.hr/mL [young]) were significantly lower in the older men.",Cortisol pharmacodynamics after methylprednisolone administration in young and elderly males. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9115056/),[h·ng] / [ml],425,19357,DB00860,Prednisolone
,9115056,return AUC,"The return AUC of cortisol (425 +/- 357 ng.hr/mL [elderly] versus 854 +/- 216 ng.mL [young]) and the total AUC 764 +/- 340 ng.h/mL [elderly] versus 1,230 +/- 258 ng.hr/mL [young]) were significantly lower in the older men.",Cortisol pharmacodynamics after methylprednisolone administration in young and elderly males. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9115056/),ml·ng,854,19358,DB00860,Prednisolone
,9115056,total AUC,"The return AUC of cortisol (425 +/- 357 ng.hr/mL [elderly] versus 854 +/- 216 ng.mL [young]) and the total AUC 764 +/- 340 ng.h/mL [elderly] versus 1,230 +/- 258 ng.hr/mL [young]) were significantly lower in the older men.",Cortisol pharmacodynamics after methylprednisolone administration in young and elderly males. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9115056/),[h·ng] / [ml],764,19359,DB00860,Prednisolone
,9115056,total AUC,"The return AUC of cortisol (425 +/- 357 ng.hr/mL [elderly] versus 854 +/- 216 ng.mL [young]) and the total AUC 764 +/- 340 ng.h/mL [elderly] versus 1,230 +/- 258 ng.hr/mL [young]) were significantly lower in the older men.",Cortisol pharmacodynamics after methylprednisolone administration in young and elderly males. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9115056/),[h·ng] / [ml],"1,230",19360,DB00860,Prednisolone
,9115056,suppression ratio,"The suppression ratio was significantly greater in the elderly men (mean, 0.38 versus 0.58 in young), which indicates a greater degree of adrenal suppression after administration of methylprednisolone.",Cortisol pharmacodynamics after methylprednisolone administration in young and elderly males. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9115056/),,0.38,19361,DB00860,Prednisolone
,9115056,suppression ratio,"The suppression ratio was significantly greater in the elderly men (mean, 0.38 versus 0.58 in young), which indicates a greater degree of adrenal suppression after administration of methylprednisolone.",Cortisol pharmacodynamics after methylprednisolone administration in young and elderly males. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9115056/),,0.58,19362,DB00860,Prednisolone
,9115056,AUC,"Exposure to methylprednisolone, as measured by AUC, was 554 +/- 215 ng.hr/kg (elderly) and 389 +/- 102 ng.hr/kg (young).",Cortisol pharmacodynamics after methylprednisolone administration in young and elderly males. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9115056/),[h·ng] / [kg],554,19363,DB00860,Prednisolone
,9115056,AUC,"Exposure to methylprednisolone, as measured by AUC, was 554 +/- 215 ng.hr/kg (elderly) and 389 +/- 102 ng.hr/kg (young).",Cortisol pharmacodynamics after methylprednisolone administration in young and elderly males. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9115056/),[h·ng] / [kg],389,19364,DB00860,Prednisolone
,2967477,Peak serum concentrations,Peak serum concentrations of prednisolone obtained after dosing with prednisone occurred earlier and were higher (473 +/- 106 ng/ml) than those obtained after dosing with prednisolone methylsulfobenzoate (232 +/- 70 ng/ml; P less than 0.01).,[Comparative serum pharmacokinetics of prednisone and prednisolone methylsulfobenzoate after oral administration]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2967477/),[ng] / [ml],473,20095,DB00860,Prednisolone
,2967477,Peak serum concentrations,Peak serum concentrations of prednisolone obtained after dosing with prednisone occurred earlier and were higher (473 +/- 106 ng/ml) than those obtained after dosing with prednisolone methylsulfobenzoate (232 +/- 70 ng/ml; P less than 0.01).,[Comparative serum pharmacokinetics of prednisone and prednisolone methylsulfobenzoate after oral administration]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2967477/),[ng] / [ml],232,20096,DB00860,Prednisolone
,12560443,duration,"In addition, the mean duration of grade 4 neutropenia was similar in both groups (2.8 and 2.4 days, respectively).","Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12560443/),d,2.8,20431,DB00860,Prednisolone
,12560443,duration,"In addition, the mean duration of grade 4 neutropenia was similar in both groups (2.8 and 2.4 days, respectively).","Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12560443/),d,2.4,20432,DB00860,Prednisolone
,2778721,plasma clearance,Mean (S.D.) for prednisolone plasma clearance normalized for total body mass (TBM) was 2.3 (0.9) liters/hr/kg in normal rats and 2.7 (0.7) liters/hr/kg in obese rats.,Pharmacokinetics and pharmacodynamics of prednisolone in obese rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2778721/),[l] / [h·kg],2.3,21226,DB00860,Prednisolone
,2778721,plasma clearance,Mean (S.D.) for prednisolone plasma clearance normalized for total body mass (TBM) was 2.3 (0.9) liters/hr/kg in normal rats and 2.7 (0.7) liters/hr/kg in obese rats.,Pharmacokinetics and pharmacodynamics of prednisolone in obese rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2778721/),[l] / [h·kg],2.7,21227,DB00860,Prednisolone
,2778721,volume of distribution at steady-state,The volume of distribution at steady-state averaged 0.82 (0.46) liters/kg of TBM in normal rats vs. 1.08 (0.40) liters/kg of TBM in obese rats.,Pharmacokinetics and pharmacodynamics of prednisolone in obese rats. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2778721/),[l] / [kg],0.82,21228,DB00860,Prednisolone
,2778721,volume of distribution at steady-state,The volume of distribution at steady-state averaged 0.82 (0.46) liters/kg of TBM in normal rats vs. 1.08 (0.40) liters/kg of TBM in obese rats.,Pharmacokinetics and pharmacodynamics of prednisolone in obese rats. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2778721/),[l] / [kg],1.08,21229,DB00860,Prednisolone
,12174030,half-life,"There were no significant differences in methylprednisolone half-life (2.2 +/- 0.4 h), clearance (575 +/- 113 mL/min), volume of distribution (106 +/- 22 l), concentration producing the half-maximum effect on CD4+ T-cells (1.5 +/- 0.7 ng/mL), and Hill-coefficient (1.2 +/- 0.1), after single or divided dose.",Pharmacokinetics and pharmacodynamics of methylprednisolone after one bolus dose compared with two dose fractions. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12174030/),h,2.2,22137,DB00860,Prednisolone
,12174030,clearance,"There were no significant differences in methylprednisolone half-life (2.2 +/- 0.4 h), clearance (575 +/- 113 mL/min), volume of distribution (106 +/- 22 l), concentration producing the half-maximum effect on CD4+ T-cells (1.5 +/- 0.7 ng/mL), and Hill-coefficient (1.2 +/- 0.1), after single or divided dose.",Pharmacokinetics and pharmacodynamics of methylprednisolone after one bolus dose compared with two dose fractions. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12174030/),[ml] / [min],575,22138,DB00860,Prednisolone
,12174030,volume of distribution,"There were no significant differences in methylprednisolone half-life (2.2 +/- 0.4 h), clearance (575 +/- 113 mL/min), volume of distribution (106 +/- 22 l), concentration producing the half-maximum effect on CD4+ T-cells (1.5 +/- 0.7 ng/mL), and Hill-coefficient (1.2 +/- 0.1), after single or divided dose.",Pharmacokinetics and pharmacodynamics of methylprednisolone after one bolus dose compared with two dose fractions. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12174030/),l,106,22139,DB00860,Prednisolone
,12174030,concentration producing the half-maximum effect,"There were no significant differences in methylprednisolone half-life (2.2 +/- 0.4 h), clearance (575 +/- 113 mL/min), volume of distribution (106 +/- 22 l), concentration producing the half-maximum effect on CD4+ T-cells (1.5 +/- 0.7 ng/mL), and Hill-coefficient (1.2 +/- 0.1), after single or divided dose.",Pharmacokinetics and pharmacodynamics of methylprednisolone after one bolus dose compared with two dose fractions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12174030/),[ng] / [ml],1.5,22140,DB00860,Prednisolone
,12174030,Hill-coefficient,"There were no significant differences in methylprednisolone half-life (2.2 +/- 0.4 h), clearance (575 +/- 113 mL/min), volume of distribution (106 +/- 22 l), concentration producing the half-maximum effect on CD4+ T-cells (1.5 +/- 0.7 ng/mL), and Hill-coefficient (1.2 +/- 0.1), after single or divided dose.",Pharmacokinetics and pharmacodynamics of methylprednisolone after one bolus dose compared with two dose fractions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12174030/),,1.2,22141,DB00860,Prednisolone
,12174030,total 24 h effect area (AUETC),"However, the total 24 h effect area (AUETC) of lymphocytes, and mainly CD4+ T-cells was significantly more suppressed (P = 0.008) with the divided dosage regimen than after the single dose (8422 +/- 2163 vs. 11,545 +/- 3020 h cells/microL).",Pharmacokinetics and pharmacodynamics of methylprednisolone after one bolus dose compared with two dose fractions. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12174030/),[cells·h] / [μl],8422,22142,DB00860,Prednisolone
,12174030,total 24 h effect area (AUETC),"However, the total 24 h effect area (AUETC) of lymphocytes, and mainly CD4+ T-cells was significantly more suppressed (P = 0.008) with the divided dosage regimen than after the single dose (8422 +/- 2163 vs. 11,545 +/- 3020 h cells/microL).",Pharmacokinetics and pharmacodynamics of methylprednisolone after one bolus dose compared with two dose fractions. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12174030/),[cells·h] / [μl],"11,545",22143,DB00860,Prednisolone
,23673446,serum trough concentrations,"At this time, serum trough concentrations of sorafenib and M-2 were at 5.9 and 1.1 μg/ml, respectively.",Pharmacokinetic interaction between sorafenib and prednisolone in a patient with hepatocellular carcinoma. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23673446/),[μg] / [ml],5.9,22685,DB00860,Prednisolone
,23673446,serum trough concentrations,"At this time, serum trough concentrations of sorafenib and M-2 were at 5.9 and 1.1 μg/ml, respectively.",Pharmacokinetic interaction between sorafenib and prednisolone in a patient with hepatocellular carcinoma. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23673446/),[μg] / [ml],1.1,22686,DB00860,Prednisolone
,3235500,Peak serum methylprednisone concentrations,Peak serum methylprednisone concentrations of ca. 250 ng/ml occurred within 5 min of methylprednisolone administration and the average area under the curve ratio (methylprednisolone/methylprednisone) was 9.3.,"Analysis of methylprednisolone, methylprednisone and corticosterone for assessment of methylprednisolone disposition in the rat. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3235500/),[ng] / [ml],250,24265,DB00860,Prednisolone
,3235500,area under the curve ratio,Peak serum methylprednisone concentrations of ca. 250 ng/ml occurred within 5 min of methylprednisolone administration and the average area under the curve ratio (methylprednisolone/methylprednisone) was 9.3.,"Analysis of methylprednisolone, methylprednisone and corticosterone for assessment of methylprednisolone disposition in the rat. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3235500/),,9.3,24266,DB00860,Prednisolone
,7462536,apparent half-life,The mean (+/-SD) apparent half-life of prednisolone in these children was 2.5 +/- 0.5 hr.,Prednisolone disposition in steroid-dependent asthmatic children. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7462536/),h,2.5,24808,DB00860,Prednisolone
,7462536,total volume of distribution,The mean total volume of distribution was 52.8 +/- 14.5 L/1.73 m2 and mean plasma clearance was 246 +/- 62 ml/min/1.73 m2.,Prednisolone disposition in steroid-dependent asthmatic children. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7462536/),[l] / [1.73·m2],52.8,24809,DB00860,Prednisolone
,7462536,plasma clearance,The mean total volume of distribution was 52.8 +/- 14.5 L/1.73 m2 and mean plasma clearance was 246 +/- 62 ml/min/1.73 m2.,Prednisolone disposition in steroid-dependent asthmatic children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7462536/),[ml] / [1.73·m2·min],246,24810,DB00860,Prednisolone
,31625621,CLU /F,"Free prednisolone CLU /F and VU /F, scaled allometrically on lean body weight, were, respectively, 26.7 L/h and 94.3 L for 50 kg LBW.",Free prednisolone pharmacokinetics predicted from total concentrations in patients with inflammatory - immunonologic conditions. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31625621/),[l] / [h],26.7,29404,DB00860,Prednisolone
,31625621,VU /F,"Free prednisolone CLU /F and VU /F, scaled allometrically on lean body weight, were, respectively, 26.7 L/h and 94.3 L for 50 kg LBW.",Free prednisolone pharmacokinetics predicted from total concentrations in patients with inflammatory - immunonologic conditions. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31625621/),l,94.3,29405,DB00860,Prednisolone
,31625621,CLU /F,CLU /F interindividual variability was 0.20.,Free prednisolone pharmacokinetics predicted from total concentrations in patients with inflammatory - immunonologic conditions. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31625621/),,0.20,29406,DB00860,Prednisolone
,8633806,half-life,"Median half-life for MPA, as detected by HPLC, was 10.3 hours (range, 6.1 to 10.6) in the synovial space.","Plasma, urine, and synovial fluid disposition of methylprednisolone acetate and isoflupredone acetate after intra-articular administration in horses. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8633806/),h,10.3,29890,DB00860,Prednisolone
,8633806,half-life,"Median half-life for methylprednisolone, as detected by HPLC, was 10.4 (range, 9.9 to 32.1) hours.","Plasma, urine, and synovial fluid disposition of methylprednisolone acetate and isoflupredone acetate after intra-articular administration in horses. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8633806/),h,10.4,29891,DB00860,Prednisolone
,20430188,area-under-the-curve from 0 to 2 hours (AUC0-2),"The mean area-under-the-curve from 0 to 2 hours (AUC0-2) was 30.0+/-11.6 microg.h/mL (range, 7.8-60.7).",Pharmacokinetics of mycophenolic acid in living donor liver transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20430188/),[h·μg] / [ml],30.0,31279,DB00860,Prednisolone
,20430188,trough,"Of 114 pharmacokinetic profiles, 40 (35%) AUC and 7 (6.1%) trough values were within the target value (30-60 microg.h/mL and 1.7-4.0 microg/mL, respectively).",Pharmacokinetics of mycophenolic acid in living donor liver transplantation. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20430188/),[μg] / [ml],1.7-4.0,31280,DB00860,Prednisolone
,20430188,C0,"The C0, C1/2, and C2 concentrations showed large interindividual variability: C0 (0.01-4.46 microg/mL), C1/2 (0.14-36.86 microg/mL), and C2 (0.79-18.19 microg/mL).",Pharmacokinetics of mycophenolic acid in living donor liver transplantation. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20430188/),[μg] / [ml],0.01-4.46,31281,DB00860,Prednisolone
,20430188,C1/2,"The C0, C1/2, and C2 concentrations showed large interindividual variability: C0 (0.01-4.46 microg/mL), C1/2 (0.14-36.86 microg/mL), and C2 (0.79-18.19 microg/mL).",Pharmacokinetics of mycophenolic acid in living donor liver transplantation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20430188/),[μg] / [ml],0.14-36.86,31282,DB00860,Prednisolone
,20430188,C2,"The C0, C1/2, and C2 concentrations showed large interindividual variability: C0 (0.01-4.46 microg/mL), C1/2 (0.14-36.86 microg/mL), and C2 (0.79-18.19 microg/mL).",Pharmacokinetics of mycophenolic acid in living donor liver transplantation. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20430188/),[μg] / [ml],0.79-18.19,31283,DB00860,Prednisolone
<,17322623,AUC(0-12 h),"Two patients (man in his 30 s; woman in her 40 s) had acute rejection with a mycophenolic acid (MPA) AUC(0-12 h) <30 microg x h x ml(-1) and low CsA AUC (AUC(0-4 h); 2,408 ng x h x ml-1, 1,735 ng x h x ml-1).",Relationship between acute rejection and cyclosporine or mycophenolic acid levels in Japanese heart transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17322623/),[h·μg] / [ml],30,31388,DB00860,Prednisolone
,17322623,AUC (AUC(0-4 h),"Two patients (man in his 30 s; woman in her 40 s) had acute rejection with a mycophenolic acid (MPA) AUC(0-12 h) <30 microg x h x ml(-1) and low CsA AUC (AUC(0-4 h); 2,408 ng x h x ml-1, 1,735 ng x h x ml-1).",Relationship between acute rejection and cyclosporine or mycophenolic acid levels in Japanese heart transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17322623/),[h·ng] / [ml],"2,408",31389,DB00860,Prednisolone
,17322623,AUC (AUC(0-4 h),"Two patients (man in his 30 s; woman in her 40 s) had acute rejection with a mycophenolic acid (MPA) AUC(0-12 h) <30 microg x h x ml(-1) and low CsA AUC (AUC(0-4 h); 2,408 ng x h x ml-1, 1,735 ng x h x ml-1).",Relationship between acute rejection and cyclosporine or mycophenolic acid levels in Japanese heart transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17322623/),[h·ng] / [ml],"1,735",31390,DB00860,Prednisolone
,17322623,AUC(0-4 h),"However, 1 patient (man in his 30 s) with a high CsA AUC(0-4 h) (4,019 ng x h x ml-1) did not develop cardiac allograft rejection even if the MMF was temporarily stopped.",Relationship between acute rejection and cyclosporine or mycophenolic acid levels in Japanese heart transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17322623/),[h·ng] / [ml],"4,019",31391,DB00860,Prednisolone
,3732369,clearance,The mean plasma methylprednisolone clearance of 337 ml X h-1 X kg-1 was independent of dose.,Methylprednisolone versus prednisolone pharmacokinetics in relation to dose in adults. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3732369/),[ml] / [h·kg],337,31393,DB00860,Prednisolone
,3732369,volume of distribution,The steroid appears to moderately distribute into tissue spaces with a mean volume of distribution of 1.41 X kg-1.,Methylprednisolone versus prednisolone pharmacokinetics in relation to dose in adults. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3732369/),1/[kg],1.41,31394,DB00860,Prednisolone
,3665340,Plasma clearance,"Plasma clearance of prednisolone in subjects receiving phenobarbital, carbamazepine, and phenytoin and in control subjects was 302.7 +/- 74.6, 383.2 +/- 53.8, 378.9 +/- 50.7, and 214.0 +/- 28.8 ml/min/1.73 m2 (mean +/- 1 SD), whereas plasma clearance of methylprednisolone was 1179.1 +/- 519.4, 1687.0 +/- 109.9, 2209.5 +/- 473.8, and 381.7 +/- 98.4 ml/min/1.73 m2, respectively.",Prednisolone and methylprednisolone kinetics in children receiving anticonvulsant therapy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3665340/),[ml] / [1.73·m2·min],302.7,31407,DB00860,Prednisolone
,3665340,Plasma clearance,"Plasma clearance of prednisolone in subjects receiving phenobarbital, carbamazepine, and phenytoin and in control subjects was 302.7 +/- 74.6, 383.2 +/- 53.8, 378.9 +/- 50.7, and 214.0 +/- 28.8 ml/min/1.73 m2 (mean +/- 1 SD), whereas plasma clearance of methylprednisolone was 1179.1 +/- 519.4, 1687.0 +/- 109.9, 2209.5 +/- 473.8, and 381.7 +/- 98.4 ml/min/1.73 m2, respectively.",Prednisolone and methylprednisolone kinetics in children receiving anticonvulsant therapy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3665340/),[ml] / [1.73·m2·min],383.2,31408,DB00860,Prednisolone
,3665340,Plasma clearance,"Plasma clearance of prednisolone in subjects receiving phenobarbital, carbamazepine, and phenytoin and in control subjects was 302.7 +/- 74.6, 383.2 +/- 53.8, 378.9 +/- 50.7, and 214.0 +/- 28.8 ml/min/1.73 m2 (mean +/- 1 SD), whereas plasma clearance of methylprednisolone was 1179.1 +/- 519.4, 1687.0 +/- 109.9, 2209.5 +/- 473.8, and 381.7 +/- 98.4 ml/min/1.73 m2, respectively.",Prednisolone and methylprednisolone kinetics in children receiving anticonvulsant therapy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3665340/),[ml] / [1.73·m2·min],378.9,31409,DB00860,Prednisolone
,3665340,Plasma clearance,"Plasma clearance of prednisolone in subjects receiving phenobarbital, carbamazepine, and phenytoin and in control subjects was 302.7 +/- 74.6, 383.2 +/- 53.8, 378.9 +/- 50.7, and 214.0 +/- 28.8 ml/min/1.73 m2 (mean +/- 1 SD), whereas plasma clearance of methylprednisolone was 1179.1 +/- 519.4, 1687.0 +/- 109.9, 2209.5 +/- 473.8, and 381.7 +/- 98.4 ml/min/1.73 m2, respectively.",Prednisolone and methylprednisolone kinetics in children receiving anticonvulsant therapy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3665340/),[ml] / [1.73·m2·min],214.0,31410,DB00860,Prednisolone
,3665340,plasma clearance,"Plasma clearance of prednisolone in subjects receiving phenobarbital, carbamazepine, and phenytoin and in control subjects was 302.7 +/- 74.6, 383.2 +/- 53.8, 378.9 +/- 50.7, and 214.0 +/- 28.8 ml/min/1.73 m2 (mean +/- 1 SD), whereas plasma clearance of methylprednisolone was 1179.1 +/- 519.4, 1687.0 +/- 109.9, 2209.5 +/- 473.8, and 381.7 +/- 98.4 ml/min/1.73 m2, respectively.",Prednisolone and methylprednisolone kinetics in children receiving anticonvulsant therapy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3665340/),[ml] / [1.73·m2·min],1179.1,31411,DB00860,Prednisolone
,3665340,plasma clearance,"Plasma clearance of prednisolone in subjects receiving phenobarbital, carbamazepine, and phenytoin and in control subjects was 302.7 +/- 74.6, 383.2 +/- 53.8, 378.9 +/- 50.7, and 214.0 +/- 28.8 ml/min/1.73 m2 (mean +/- 1 SD), whereas plasma clearance of methylprednisolone was 1179.1 +/- 519.4, 1687.0 +/- 109.9, 2209.5 +/- 473.8, and 381.7 +/- 98.4 ml/min/1.73 m2, respectively.",Prednisolone and methylprednisolone kinetics in children receiving anticonvulsant therapy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3665340/),[ml] / [1.73·m2·min],1687.0,31412,DB00860,Prednisolone
,3665340,plasma clearance,"Plasma clearance of prednisolone in subjects receiving phenobarbital, carbamazepine, and phenytoin and in control subjects was 302.7 +/- 74.6, 383.2 +/- 53.8, 378.9 +/- 50.7, and 214.0 +/- 28.8 ml/min/1.73 m2 (mean +/- 1 SD), whereas plasma clearance of methylprednisolone was 1179.1 +/- 519.4, 1687.0 +/- 109.9, 2209.5 +/- 473.8, and 381.7 +/- 98.4 ml/min/1.73 m2, respectively.",Prednisolone and methylprednisolone kinetics in children receiving anticonvulsant therapy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3665340/),[ml] / [1.73·m2·min],2209.5,31413,DB00860,Prednisolone
,3665340,plasma clearance,"Plasma clearance of prednisolone in subjects receiving phenobarbital, carbamazepine, and phenytoin and in control subjects was 302.7 +/- 74.6, 383.2 +/- 53.8, 378.9 +/- 50.7, and 214.0 +/- 28.8 ml/min/1.73 m2 (mean +/- 1 SD), whereas plasma clearance of methylprednisolone was 1179.1 +/- 519.4, 1687.0 +/- 109.9, 2209.5 +/- 473.8, and 381.7 +/- 98.4 ml/min/1.73 m2, respectively.",Prednisolone and methylprednisolone kinetics in children receiving anticonvulsant therapy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3665340/),[ml] / [1.73·m2·min],381.7,31414,DB00860,Prednisolone
,3665340,Bioavailability,Bioavailability of prednisolone after the oral administration of prednisone and methylprednisolone ranged from 86% to 104% during anticonvulsant therapy.,Prednisolone and methylprednisolone kinetics in children receiving anticonvulsant therapy. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3665340/),%,86,31415,DB00860,Prednisolone
,3665340,Bioavailability,Bioavailability of prednisolone after the oral administration of prednisone and methylprednisolone ranged from 86% to 104% during anticonvulsant therapy.,Prednisolone and methylprednisolone kinetics in children receiving anticonvulsant therapy. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3665340/),%,104,31416,DB00860,Prednisolone
,7652760,clearance,The 7 patients with a rejection within the first 10 days had a methylprednisolone clearance of 437 ml/min (162-756) that was significantly higher than the 220 ml/min (121-604) in the 22 patients without a rejection episode (P = 0.04).,Pharmacokinetics of methylprednisolone and rejection episodes in kidney transplant patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7652760/),[ml] / [min],437,32175,DB00860,Prednisolone
,7652760,clearance,The 7 patients with a rejection within the first 10 days had a methylprednisolone clearance of 437 ml/min (162-756) that was significantly higher than the 220 ml/min (121-604) in the 22 patients without a rejection episode (P = 0.04).,Pharmacokinetics of methylprednisolone and rejection episodes in kidney transplant patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7652760/),[ml] / [min],220,32176,DB00860,Prednisolone
,7652760,elimination half-life,"In the complete group of 18 patients having a transplant rejection episode within 6 months, the methylprednisolone elimination half-life after oral dosage was 2.5 hr (1.6-3.9) and significantly shorter than 2.9 hr (1.7-4.0) in 22 patients without rejections (P = 0.03).",Pharmacokinetics of methylprednisolone and rejection episodes in kidney transplant patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7652760/),h,2.5,32177,DB00860,Prednisolone
shorter,7652760,elimination half-life,"In the complete group of 18 patients having a transplant rejection episode within 6 months, the methylprednisolone elimination half-life after oral dosage was 2.5 hr (1.6-3.9) and significantly shorter than 2.9 hr (1.7-4.0) in 22 patients without rejections (P = 0.03).",Pharmacokinetics of methylprednisolone and rejection episodes in kidney transplant patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7652760/),h,2.9,32178,DB00860,Prednisolone
,9190003,Total plasma prednisolone levels,Total plasma prednisolone levels declined over time from 597 +/- 174 ng/ml two hours post-dose to 422 +/- 106 ng/ml four hours post-dose and 250 +/- 85 ng/ml six hours post-dose.,Prednisolone concentrations in cerebrospinal fluid after oral prednisone. Preliminary data. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9190003/),[ng] / [ml],597,32364,DB00860,Prednisolone
,9190003,Total plasma prednisolone levels,Total plasma prednisolone levels declined over time from 597 +/- 174 ng/ml two hours post-dose to 422 +/- 106 ng/ml four hours post-dose and 250 +/- 85 ng/ml six hours post-dose.,Prednisolone concentrations in cerebrospinal fluid after oral prednisone. Preliminary data. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9190003/),[ng] / [ml],422,32365,DB00860,Prednisolone
,9190003,Total plasma prednisolone levels,Total plasma prednisolone levels declined over time from 597 +/- 174 ng/ml two hours post-dose to 422 +/- 106 ng/ml four hours post-dose and 250 +/- 85 ng/ml six hours post-dose.,Prednisolone concentrations in cerebrospinal fluid after oral prednisone. Preliminary data. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9190003/),[ng] / [ml],250,32366,DB00860,Prednisolone
,9190003,Plasma levels,"Plasma levels of free prednisolone were 95 +/- 21 ng/ml, 59 +/- 17 ng/ml, and 18 +/- 14 ng/ml, respectively, at the same time points.",Prednisolone concentrations in cerebrospinal fluid after oral prednisone. Preliminary data. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9190003/),[ng] / [ml],95,32367,DB00860,Prednisolone
,9190003,Plasma levels,"Plasma levels of free prednisolone were 95 +/- 21 ng/ml, 59 +/- 17 ng/ml, and 18 +/- 14 ng/ml, respectively, at the same time points.",Prednisolone concentrations in cerebrospinal fluid after oral prednisone. Preliminary data. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9190003/),[ng] / [ml],59,32368,DB00860,Prednisolone
,9190003,Plasma levels,"Plasma levels of free prednisolone were 95 +/- 21 ng/ml, 59 +/- 17 ng/ml, and 18 +/- 14 ng/ml, respectively, at the same time points.",Prednisolone concentrations in cerebrospinal fluid after oral prednisone. Preliminary data. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9190003/),[ng] / [ml],18,32369,DB00860,Prednisolone
,3886255,relative bioavailability,"When methylprednisolone (80 mg) was also taken by mouth, the relative bioavailability of the tablets was 99%.",Kinetics of methylprednisolone and its hemisuccinate ester. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3886255/),%,99,32753,DB00860,Prednisolone
,1578318,Bioavailability,Bioavailability averaged 88.4% +/- 20.1% of the administered dose.,Altered prednisolone pharmacokinetics in patients with cystic fibrosis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1578318/),%,88.4,32850,DB00860,Prednisolone
,8159595,suppression half-life,"After the drug was administered, cortisol declined in a linear fashion with a mean suppression half-life of 2.4 +/- 0.9 hours.",Cortisol pharmacodynamic response to long-term methylprednisolone in renal transplant recipients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8159595/),h,2.4,32908,DB00860,Prednisolone
,8159595,area under the curve (AUC-Cret),The return cortisol area under the curve (AUC-Cret) was noted in all patients and ranged from 57-987 ng.hr/ml.,Cortisol pharmacodynamic response to long-term methylprednisolone in renal transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8159595/),[h·ng] / [ml],57-987,32909,DB00860,Prednisolone
,8159595,area under the curve,The total cortisol area under the curve was greater in patients who had been transplanted for longer than 2 years (1676 +/- 252 vs 836 +/- 405 ng.hr/ml; p < 0.05) compared with more recently transplanted patients.,Cortisol pharmacodynamic response to long-term methylprednisolone in renal transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8159595/),[h·ng] / [ml],1676,32910,DB00860,Prednisolone
,8159595,area under the curve,The total cortisol area under the curve was greater in patients who had been transplanted for longer than 2 years (1676 +/- 252 vs 836 +/- 405 ng.hr/ml; p < 0.05) compared with more recently transplanted patients.,Cortisol pharmacodynamic response to long-term methylprednisolone in renal transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8159595/),[h·ng] / [ml],836,32911,DB00860,Prednisolone
,8159595,clearance,Methylprednisolone clearance ranged from 100-1181 ml/hr/kg with a mean volume of distribution of 1.3 +/- 0.6 L/kg.,Cortisol pharmacodynamic response to long-term methylprednisolone in renal transplant recipients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8159595/),[ml] / [h·kg],100-1181,32912,DB00860,Prednisolone
,8159595,volume of distribution,Methylprednisolone clearance ranged from 100-1181 ml/hr/kg with a mean volume of distribution of 1.3 +/- 0.6 L/kg.,Cortisol pharmacodynamic response to long-term methylprednisolone in renal transplant recipients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8159595/),[l] / [kg],1.3,32913,DB00860,Prednisolone
,8159595,half-life,The methylprednisolone half-life ranged from 1.2-4.7 hours.,Cortisol pharmacodynamic response to long-term methylprednisolone in renal transplant recipients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8159595/),h,1.2-4.7,32914,DB00860,Prednisolone
,19182395,clearances,"The theophylline clearances in males and females were 56.2+/-15.4 and 50.1+/-14.2 ml/h/kg for ages 0.5-<2 years, 58.7+/-18.8 and 48.3+/-6.5 ml/h/kg for ages 2-<4 years, and 65.7+/-12.0 and 52.1+/-16.8 ml/h/kg for ages 4-<9 years, respectively.",Effect of gender on theophylline clearance in the asthmatic acute phase in Japanese pediatric patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19182395/),[ml] / [h·kg],56.2,33222,DB00860,Prednisolone
,19182395,clearances,"The theophylline clearances in males and females were 56.2+/-15.4 and 50.1+/-14.2 ml/h/kg for ages 0.5-<2 years, 58.7+/-18.8 and 48.3+/-6.5 ml/h/kg for ages 2-<4 years, and 65.7+/-12.0 and 52.1+/-16.8 ml/h/kg for ages 4-<9 years, respectively.",Effect of gender on theophylline clearance in the asthmatic acute phase in Japanese pediatric patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19182395/),[ml] / [h·kg],50.1,33223,DB00860,Prednisolone
,19182395,clearances,"The theophylline clearances in males and females were 56.2+/-15.4 and 50.1+/-14.2 ml/h/kg for ages 0.5-<2 years, 58.7+/-18.8 and 48.3+/-6.5 ml/h/kg for ages 2-<4 years, and 65.7+/-12.0 and 52.1+/-16.8 ml/h/kg for ages 4-<9 years, respectively.",Effect of gender on theophylline clearance in the asthmatic acute phase in Japanese pediatric patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19182395/),[ml] / [h·kg],58.7,33224,DB00860,Prednisolone
,19182395,clearances,"The theophylline clearances in males and females were 56.2+/-15.4 and 50.1+/-14.2 ml/h/kg for ages 0.5-<2 years, 58.7+/-18.8 and 48.3+/-6.5 ml/h/kg for ages 2-<4 years, and 65.7+/-12.0 and 52.1+/-16.8 ml/h/kg for ages 4-<9 years, respectively.",Effect of gender on theophylline clearance in the asthmatic acute phase in Japanese pediatric patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19182395/),[ml] / [h·kg],48.3,33225,DB00860,Prednisolone
,19182395,clearances,"The theophylline clearances in males and females were 56.2+/-15.4 and 50.1+/-14.2 ml/h/kg for ages 0.5-<2 years, 58.7+/-18.8 and 48.3+/-6.5 ml/h/kg for ages 2-<4 years, and 65.7+/-12.0 and 52.1+/-16.8 ml/h/kg for ages 4-<9 years, respectively.",Effect of gender on theophylline clearance in the asthmatic acute phase in Japanese pediatric patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19182395/),[ml] / [h·kg],65.7,33226,DB00860,Prednisolone
,19182395,clearances,"The theophylline clearances in males and females were 56.2+/-15.4 and 50.1+/-14.2 ml/h/kg for ages 0.5-<2 years, 58.7+/-18.8 and 48.3+/-6.5 ml/h/kg for ages 2-<4 years, and 65.7+/-12.0 and 52.1+/-16.8 ml/h/kg for ages 4-<9 years, respectively.",Effect of gender on theophylline clearance in the asthmatic acute phase in Japanese pediatric patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19182395/),[ml] / [h·kg],52.1,33227,DB00860,Prednisolone
,29659758,half-life [T1/2],The estimated effective IFX half-life [T1/2] (median [range]) and clearance (median [range]) were 8.42 [3.94-22.03] days and 0.50 [0.19-1.41] L/day respectively.,Accelerated Clearance of Infliximab is Associated With Treatment Failure in Patients With Corticosteroid-Refractory Acute Ulcerative Colitis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29659758/),d,8.42,33648,DB00860,Prednisolone
,29659758,clearance,The estimated effective IFX half-life [T1/2] (median [range]) and clearance (median [range]) were 8.42 [3.94-22.03] days and 0.50 [0.19-1.41] L/day respectively.,Accelerated Clearance of Infliximab is Associated With Treatment Failure in Patients With Corticosteroid-Refractory Acute Ulcerative Colitis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29659758/),[l] / [d],0.50,33649,DB00860,Prednisolone
,28905613,absolute recovery rate,The absolute recovery rate was between 50.42% to 51.65%.,[LC-MS/MS method for determination of tripterine in plasma： pharmacokinetic study in Beagles]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28905613/),%,50.42,33933,DB00860,Prednisolone
,28905613,absolute recovery rate,The absolute recovery rate was between 50.42% to 51.65%.,[LC-MS/MS method for determination of tripterine in plasma： pharmacokinetic study in Beagles]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28905613/),%,51.65,33934,DB00860,Prednisolone
,28905613,Cmax,"The main pharmacokinetic parameters after a single dose were as follows： Cmax (35.64±9.540) μg •L⁻¹,Tmax(2.62±0.69) h,T1/2(2.93±0.29) h, CL (0.308±0.056) L•kg⁻¹•h⁻¹, AUC0-12 (131.16±31.94) μg•L•h⁻¹, AUC0-∞ (142.83±37.57) μg•L•h⁻¹.",[LC-MS/MS method for determination of tripterine in plasma： pharmacokinetic study in Beagles]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28905613/),l⁻¹·μg,35.64,33935,DB00860,Prednisolone
,28905613,Tmax,"The main pharmacokinetic parameters after a single dose were as follows： Cmax (35.64±9.540) μg •L⁻¹,Tmax(2.62±0.69) h,T1/2(2.93±0.29) h, CL (0.308±0.056) L•kg⁻¹•h⁻¹, AUC0-12 (131.16±31.94) μg•L•h⁻¹, AUC0-∞ (142.83±37.57) μg•L•h⁻¹.",[LC-MS/MS method for determination of tripterine in plasma： pharmacokinetic study in Beagles]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28905613/),h,2.62,33936,DB00860,Prednisolone
,28905613,T1/2,"The main pharmacokinetic parameters after a single dose were as follows： Cmax (35.64±9.540) μg •L⁻¹,Tmax(2.62±0.69) h,T1/2(2.93±0.29) h, CL (0.308±0.056) L•kg⁻¹•h⁻¹, AUC0-12 (131.16±31.94) μg•L•h⁻¹, AUC0-∞ (142.83±37.57) μg•L•h⁻¹.",[LC-MS/MS method for determination of tripterine in plasma： pharmacokinetic study in Beagles]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28905613/),h,2.93,33937,DB00860,Prednisolone
,28905613,CL,"The main pharmacokinetic parameters after a single dose were as follows： Cmax (35.64±9.540) μg •L⁻¹,Tmax(2.62±0.69) h,T1/2(2.93±0.29) h, CL (0.308±0.056) L•kg⁻¹•h⁻¹, AUC0-12 (131.16±31.94) μg•L•h⁻¹, AUC0-∞ (142.83±37.57) μg•L•h⁻¹.",[LC-MS/MS method for determination of tripterine in plasma： pharmacokinetic study in Beagles]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28905613/),h⁻¹·kg⁻¹·l,0.308,33938,DB00860,Prednisolone
,28905613,AUC0-12,"The main pharmacokinetic parameters after a single dose were as follows： Cmax (35.64±9.540) μg •L⁻¹,Tmax(2.62±0.69) h,T1/2(2.93±0.29) h, CL (0.308±0.056) L•kg⁻¹•h⁻¹, AUC0-12 (131.16±31.94) μg•L•h⁻¹, AUC0-∞ (142.83±37.57) μg•L•h⁻¹.",[LC-MS/MS method for determination of tripterine in plasma： pharmacokinetic study in Beagles]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28905613/),h⁻¹·l·μg,131.16,33939,DB00860,Prednisolone
,28905613,AUC0-∞,"The main pharmacokinetic parameters after a single dose were as follows： Cmax (35.64±9.540) μg •L⁻¹,Tmax(2.62±0.69) h,T1/2(2.93±0.29) h, CL (0.308±0.056) L•kg⁻¹•h⁻¹, AUC0-12 (131.16±31.94) μg•L•h⁻¹, AUC0-∞ (142.83±37.57) μg•L•h⁻¹.",[LC-MS/MS method for determination of tripterine in plasma： pharmacokinetic study in Beagles]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28905613/),h⁻¹·l·μg,142.83,33940,DB00860,Prednisolone
,2595785,total clearance,The mean total clearance of methylprednisolone was 379 ml/hr/kg (range 105-672) and the volume of distribution was 1.4 +/- 0.5 L/kg.,Methylprednisolone disposition in renal transplant recipients receiving triple-drug immunosuppression. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2595785/),[ml] / [h·kg],379,35683,DB00860,Prednisolone
,2595785,volume of distribution,The mean total clearance of methylprednisolone was 379 ml/hr/kg (range 105-672) and the volume of distribution was 1.4 +/- 0.5 L/kg.,Methylprednisolone disposition in renal transplant recipients receiving triple-drug immunosuppression. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2595785/),[l] / [kg],1.4,35684,DB00860,Prednisolone
,2595785,plasma half-life,The mean plasma half-life was 2.7 +/- 1.1 hr.,Methylprednisolone disposition in renal transplant recipients receiving triple-drug immunosuppression. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2595785/),h,2.7,35685,DB00860,Prednisolone
,2595785,peak concentration,"When normalized to a 1 mg dose of methylprednisolone, the mean peak concentration at 1 hr was 10.0 +/- 3.5 ng/ml with an 8 hr concentration ranging from 0.3 to 5.5 ng/ml.",Methylprednisolone disposition in renal transplant recipients receiving triple-drug immunosuppression. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2595785/),[ng] / [ml],10.0,35686,DB00860,Prednisolone
,2804250,elimination half-life,The average elimination half-life for the prodrug was 3.7 min indicating rapid hydrolysis.,Pharmacokinetics and dose linearity testing of methylprednisolone phosphate. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2804250/),min,3.7,35801,DB00860,Prednisolone
,2804250,total body clearance,"The total body clearance was 21 1h-1, the terminal half-life 2.8 h.",Pharmacokinetics and dose linearity testing of methylprednisolone phosphate. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2804250/),1/[1h],21,35802,DB00860,Prednisolone
,2804250,terminal half-life,"The total body clearance was 21 1h-1, the terminal half-life 2.8 h.",Pharmacokinetics and dose linearity testing of methylprednisolone phosphate. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2804250/),h,2.8,35803,DB00860,Prednisolone
,2804250,saliva/plasma ratio,The mean saliva/plasma ratio was 0.22.,Pharmacokinetics and dose linearity testing of methylprednisolone phosphate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2804250/),,0.22,35804,DB00860,Prednisolone
,3072558,saliva/plasma ratio,Methylprednisolone saliva levels paralleled plasma levels; the average saliva/plasma ratio was 0.22.,Comparative pharmacokinetics of methylprednisolone phosphate and hemisuccinate in high doses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3072558/),,0.22,36773,DB00860,Prednisolone
,3072558,Renal clearance,Renal clearance was 24 ml/min and not dose or prodrug dependent.,Comparative pharmacokinetics of methylprednisolone phosphate and hemisuccinate in high doses. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3072558/),[ml] / [min],24,36774,DB00860,Prednisolone
,8653994,clearance,"Methylprednisolone clearance was significantly decreased in the women who used OC steroids (0.298 versus 0.447 L/hr/kg), resulting in a longer elimination half-life (2.20 versus 1.72 hours).",Oral contraceptive effects on methylprednisolone pharmacokinetics and pharmacodynamics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8653994/),[l] / [h·kg],0.298,37033,DB00860,Prednisolone
,8653994,clearance,"Methylprednisolone clearance was significantly decreased in the women who used OC steroids (0.298 versus 0.447 L/hr/kg), resulting in a longer elimination half-life (2.20 versus 1.72 hours).",Oral contraceptive effects on methylprednisolone pharmacokinetics and pharmacodynamics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8653994/),[l] / [h·kg],0.447,37034,DB00860,Prednisolone
,8653994,elimination half-life,"Methylprednisolone clearance was significantly decreased in the women who used OC steroids (0.298 versus 0.447 L/hr/kg), resulting in a longer elimination half-life (2.20 versus 1.72 hours).",Oral contraceptive effects on methylprednisolone pharmacokinetics and pharmacodynamics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8653994/),h,2.20,37035,DB00860,Prednisolone
,8653994,elimination half-life,"Methylprednisolone clearance was significantly decreased in the women who used OC steroids (0.298 versus 0.447 L/hr/kg), resulting in a longer elimination half-life (2.20 versus 1.72 hours).",Oral contraceptive effects on methylprednisolone pharmacokinetics and pharmacodynamics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8653994/),h,1.72,37036,DB00860,Prednisolone
,8653994,area under the response curve,"Greater net suppression of basophils was observed in the users of OC steroids (area under the response curve, 694 versus 401 ng x hr/ml).",Oral contraceptive effects on methylprednisolone pharmacokinetics and pharmacodynamics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8653994/),[h·ng] / [ml],694,37037,DB00860,Prednisolone
,8653994,area under the response curve,"Greater net suppression of basophils was observed in the users of OC steroids (area under the response curve, 694 versus 401 ng x hr/ml).",Oral contraceptive effects on methylprednisolone pharmacokinetics and pharmacodynamics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8653994/),[h·ng] / [ml],401,37038,DB00860,Prednisolone
,7667198,apparent prednisolone clearance,Single administration of CBG decreased apparent prednisolone clearance by 56% (155 to 66 ml/min/kg) and reduced apparent VSS by 35% (4.1 to 2.7 L/kg) (p < 0.001).,Effect of corticosteroid binding globulin on the pharmacokinetics of prednisolone in rats. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7667198/),[ml] / [kg·min],155 to 66,39182,DB00860,Prednisolone
,2674406,limit of detection,"The limit of detection of both assays for PL and MP was 10 ng/mL in plasma and saliva and 25 ng/mL in urine, and of MPSS was 50 ng/mL in plasma.",Two chromatographic methods for the determination of corticosteroids in human biological fluids: pharmacokinetic applications. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2674406/),[ng] / [ml],10,39628,DB00860,Prednisolone
,2674406,limit of detection,"The limit of detection of both assays for PL and MP was 10 ng/mL in plasma and saliva and 25 ng/mL in urine, and of MPSS was 50 ng/mL in plasma.",Two chromatographic methods for the determination of corticosteroids in human biological fluids: pharmacokinetic applications. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2674406/),[ng] / [ml],25,39629,DB00860,Prednisolone
,2674406,limit of detection,"The limit of detection of both assays for PL and MP was 10 ng/mL in plasma and saliva and 25 ng/mL in urine, and of MPSS was 50 ng/mL in plasma.",Two chromatographic methods for the determination of corticosteroids in human biological fluids: pharmacokinetic applications. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2674406/),[ng] / [ml],50,39630,DB00860,Prednisolone
,19406953,elimination half-life (t(1/2)),"In the presence of topically instilled verapamil (1% w/v), elimination half-life (t(1/2)) (176 +/- 7 min), apparent elimination rate constant (lambda(z)) (0.0039 +/- 0.0001 min(-1)), and mean retention time (MRT) (143 +/- 30 min) of intravitreally administered quinidine were significantly different from those of the control (105 +/- 11 min, 0.0066 +/- 0.0007 min(-1), and 83 +/- 13 min, respectively).",Vitreal kinetics of quinidine in rabbits in the presence of topically coadministered P-glycoprotein substrates/modulators. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19406953/),min,176,40583,DB00860,Prednisolone
,19406953,apparent elimination rate constant (lambda(z)),"In the presence of topically instilled verapamil (1% w/v), elimination half-life (t(1/2)) (176 +/- 7 min), apparent elimination rate constant (lambda(z)) (0.0039 +/- 0.0001 min(-1)), and mean retention time (MRT) (143 +/- 30 min) of intravitreally administered quinidine were significantly different from those of the control (105 +/- 11 min, 0.0066 +/- 0.0007 min(-1), and 83 +/- 13 min, respectively).",Vitreal kinetics of quinidine in rabbits in the presence of topically coadministered P-glycoprotein substrates/modulators. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19406953/),1/[min],0.0039,40584,DB00860,Prednisolone
,19406953,mean retention time (MRT),"In the presence of topically instilled verapamil (1% w/v), elimination half-life (t(1/2)) (176 +/- 7 min), apparent elimination rate constant (lambda(z)) (0.0039 +/- 0.0001 min(-1)), and mean retention time (MRT) (143 +/- 30 min) of intravitreally administered quinidine were significantly different from those of the control (105 +/- 11 min, 0.0066 +/- 0.0007 min(-1), and 83 +/- 13 min, respectively).",Vitreal kinetics of quinidine in rabbits in the presence of topically coadministered P-glycoprotein substrates/modulators. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19406953/),min,143,40585,DB00860,Prednisolone
,19406953,mean retention time (MRT),"In the presence of topically instilled verapamil (1% w/v), elimination half-life (t(1/2)) (176 +/- 7 min), apparent elimination rate constant (lambda(z)) (0.0039 +/- 0.0001 min(-1)), and mean retention time (MRT) (143 +/- 30 min) of intravitreally administered quinidine were significantly different from those of the control (105 +/- 11 min, 0.0066 +/- 0.0007 min(-1), and 83 +/- 13 min, respectively).",Vitreal kinetics of quinidine in rabbits in the presence of topically coadministered P-glycoprotein substrates/modulators. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19406953/),min,105,40586,DB00860,Prednisolone
,19406953,mean retention time (MRT),"In the presence of topically instilled verapamil (1% w/v), elimination half-life (t(1/2)) (176 +/- 7 min), apparent elimination rate constant (lambda(z)) (0.0039 +/- 0.0001 min(-1)), and mean retention time (MRT) (143 +/- 30 min) of intravitreally administered quinidine were significantly different from those of the control (105 +/- 11 min, 0.0066 +/- 0.0007 min(-1), and 83 +/- 13 min, respectively).",Vitreal kinetics of quinidine in rabbits in the presence of topically coadministered P-glycoprotein substrates/modulators. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19406953/),min,83,40587,DB00860,Prednisolone
,19406953,t(1/2),Intravitreal coadministration of quinidine and verapamil resulted in a significant increase in t(1/2) (159 +/- 9 min) and a decrease in lambda(z) (0.0043 +/- 0.0002 min(-1)) of quinidine.,Vitreal kinetics of quinidine in rabbits in the presence of topically coadministered P-glycoprotein substrates/modulators. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19406953/),min,159,40588,DB00860,Prednisolone
,19406953,lambda(z),Intravitreal coadministration of quinidine and verapamil resulted in a significant increase in t(1/2) (159 +/- 9 min) and a decrease in lambda(z) (0.0043 +/- 0.0002 min(-1)) of quinidine.,Vitreal kinetics of quinidine in rabbits in the presence of topically coadministered P-glycoprotein substrates/modulators. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19406953/),1/[min],0.0043,40589,DB00860,Prednisolone
,25273387,total concentration,"In contrast, CS-GP maintained the total concentration in the range of 0.55-0.97 µg/g for 1-24 h, and maintained the free PD concentration at 0.06-0.16 µg/g for 1-24 h.",Chondroitin sulfate-glycyl-prednisolone conjugate as arthritis targeting system: localization and drug release in inflammatory joints. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25273387/),,0.55-0.97,41115,DB00860,Prednisolone
,1827622,clearance,"The addition of ketoconazole did not significantly change the clearance (96 +/- 11 versus 90 +/- 11 ml/hr/kg), mean residence time (4.29 +/- 0.43 versus 4.45 +/- 0.59 hours), volume of distribution (0.41 +/- 0.02 versus 0.40 +/- 0.02 L/kg), or plasma protein binding characteristics of prednisolone.",Lack of pharmacokinetic and pharmacodynamic interactions between ketoconazole and prednisolone. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1827622/),[ml] / [h·kg],96,42037,DB00860,Prednisolone
,1827622,clearance,"The addition of ketoconazole did not significantly change the clearance (96 +/- 11 versus 90 +/- 11 ml/hr/kg), mean residence time (4.29 +/- 0.43 versus 4.45 +/- 0.59 hours), volume of distribution (0.41 +/- 0.02 versus 0.40 +/- 0.02 L/kg), or plasma protein binding characteristics of prednisolone.",Lack of pharmacokinetic and pharmacodynamic interactions between ketoconazole and prednisolone. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1827622/),[ml] / [h·kg],90,42038,DB00860,Prednisolone
,1827622,mean residence time,"The addition of ketoconazole did not significantly change the clearance (96 +/- 11 versus 90 +/- 11 ml/hr/kg), mean residence time (4.29 +/- 0.43 versus 4.45 +/- 0.59 hours), volume of distribution (0.41 +/- 0.02 versus 0.40 +/- 0.02 L/kg), or plasma protein binding characteristics of prednisolone.",Lack of pharmacokinetic and pharmacodynamic interactions between ketoconazole and prednisolone. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1827622/),h,4.29,42039,DB00860,Prednisolone
,1827622,mean residence time,"The addition of ketoconazole did not significantly change the clearance (96 +/- 11 versus 90 +/- 11 ml/hr/kg), mean residence time (4.29 +/- 0.43 versus 4.45 +/- 0.59 hours), volume of distribution (0.41 +/- 0.02 versus 0.40 +/- 0.02 L/kg), or plasma protein binding characteristics of prednisolone.",Lack of pharmacokinetic and pharmacodynamic interactions between ketoconazole and prednisolone. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1827622/),h,4.45,42040,DB00860,Prednisolone
,1827622,volume of distribution,"The addition of ketoconazole did not significantly change the clearance (96 +/- 11 versus 90 +/- 11 ml/hr/kg), mean residence time (4.29 +/- 0.43 versus 4.45 +/- 0.59 hours), volume of distribution (0.41 +/- 0.02 versus 0.40 +/- 0.02 L/kg), or plasma protein binding characteristics of prednisolone.",Lack of pharmacokinetic and pharmacodynamic interactions between ketoconazole and prednisolone. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1827622/),[l] / [kg],0.41,42041,DB00860,Prednisolone
,1827622,volume of distribution,"The addition of ketoconazole did not significantly change the clearance (96 +/- 11 versus 90 +/- 11 ml/hr/kg), mean residence time (4.29 +/- 0.43 versus 4.45 +/- 0.59 hours), volume of distribution (0.41 +/- 0.02 versus 0.40 +/- 0.02 L/kg), or plasma protein binding characteristics of prednisolone.",Lack of pharmacokinetic and pharmacodynamic interactions between ketoconazole and prednisolone. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1827622/),[l] / [kg],0.40,42042,DB00860,Prednisolone
,3698167,terminal half-life,"The parent drug was eliminated in a biphasic manner, with a terminal half-life of 30-40 h.","Pharmacokinetic study in a phase I trial with an alkylating agent, diacetyldianhydrogalactitol (DADAG). ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3698167/),h,30-40,43394,DB00860,Prednisolone
,3698167,lag time,"Dianhydrogalactitol (DAG), the main, pharmacologically active metabolite, appeared after a lag time of about 0.2-0.6 h.","Pharmacokinetic study in a phase I trial with an alkylating agent, diacetyldianhydrogalactitol (DADAG). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3698167/),h,0.2-0.6,43395,DB00860,Prednisolone
,725320,t1/2,In vitro hydrolysis of methylprednisolone acetate at 37 degrees C in human whole blood is rapid (average t1/2 = 19 min).,Preliminary in vitro and in vivo investigations on methylprednisolone and its acetate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/725320/),min,19,43905,DB00860,Prednisolone
,725320,bioavailabilities,"In one cat, the bioavailabilities of methylprednisolone acetate rectally was 13% and of methylprednisolone (alcohol) rectally was 26%, relative to intravenous administration of methylprednisolone.",Preliminary in vitro and in vivo investigations on methylprednisolone and its acetate. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/725320/),%,13,43906,DB00860,Prednisolone
,725320,bioavailabilities,"In one cat, the bioavailabilities of methylprednisolone acetate rectally was 13% and of methylprednisolone (alcohol) rectally was 26%, relative to intravenous administration of methylprednisolone.",Preliminary in vitro and in vivo investigations on methylprednisolone and its acetate. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/725320/),%,26,43907,DB00860,Prednisolone
,725320,bioavailabilities,"In the same cat, the bioavailabilities of methylprednisolone acetate orally was 93% and of methylprednisolone was 82%, relative to intravenous administration of methylprednisolone.",Preliminary in vitro and in vivo investigations on methylprednisolone and its acetate. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/725320/),%,93,43908,DB00860,Prednisolone
,725320,bioavailabilities,"In the same cat, the bioavailabilities of methylprednisolone acetate orally was 93% and of methylprednisolone was 82%, relative to intravenous administration of methylprednisolone.",Preliminary in vitro and in vivo investigations on methylprednisolone and its acetate. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/725320/),%,82,43909,DB00860,Prednisolone
,14730102,time constant,"The first population is accumulated in the liver with a time constant of 50 s(-1) and a saturation level of 0.005 micromol/animal, whereas the second with 0.003 s(-1) and 50 micromol/animal, respectively.",Pharmacokinetics of liposomes designed to carry glucocorticoids. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14730102/),1/[s],50,44830,DB00860,Prednisolone
,14730102,saturation level,"The first population is accumulated in the liver with a time constant of 50 s(-1) and a saturation level of 0.005 micromol/animal, whereas the second with 0.003 s(-1) and 50 micromol/animal, respectively.",Pharmacokinetics of liposomes designed to carry glucocorticoids. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14730102/),[μM] / [animal],0.005,44831,DB00860,Prednisolone
,14730102,saturation level,"The first population is accumulated in the liver with a time constant of 50 s(-1) and a saturation level of 0.005 micromol/animal, whereas the second with 0.003 s(-1) and 50 micromol/animal, respectively.",Pharmacokinetics of liposomes designed to carry glucocorticoids. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14730102/),1/[s],0.003,44832,DB00860,Prednisolone
,14730102,saturation level,"The first population is accumulated in the liver with a time constant of 50 s(-1) and a saturation level of 0.005 micromol/animal, whereas the second with 0.003 s(-1) and 50 micromol/animal, respectively.",Pharmacokinetics of liposomes designed to carry glucocorticoids. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14730102/),[μM] / [animal],50,44833,DB00860,Prednisolone
,23089531,Trough levels,"Trough levels were fairly consistent at 7.9-18 ng·h/mL in all the patients included in this study, and this did not show variation with age or sex.",Pharmacokinetics of tacrolimus in adult renal transplant recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23089531/),[h·ng] / [ml],7.9-18,45100,DB00860,Prednisolone
,23089531,AUC0-6,"The AUC0-6 was higher [202-290 ng/mL at 3-8 mg bis-daily (b.d.) dosage] in patients who received kidneys from cadavers compared to recipients from live donors (60.5-171 ng/mL at 3-8 mg b.d. dosage), but the clinical significance of this is not known.",Pharmacokinetics of tacrolimus in adult renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23089531/),[ng] / [ml],202-290,45101,DB00860,Prednisolone
,23089531,AUC0-6,"The AUC0-6 was higher [202-290 ng/mL at 3-8 mg bis-daily (b.d.) dosage] in patients who received kidneys from cadavers compared to recipients from live donors (60.5-171 ng/mL at 3-8 mg b.d. dosage), but the clinical significance of this is not known.",Pharmacokinetics of tacrolimus in adult renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23089531/),[ng] / [ml],60.5-171,45102,DB00860,Prednisolone
,23089531,AUC0-6,"The highest AUC0-6 was 246 ng/mL, observed at 4.5 mg b.d. dosage.",Pharmacokinetics of tacrolimus in adult renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23089531/),[ng] / [ml],246,45103,DB00860,Prednisolone
,8620666,half-life (t1/2),"A slight but statistically significant increase in the mean half-life (t1/2) of prednisolone was detected with zileuton + prednisone administration compared with prednisone + placebo (from 2.8 to 2.9 hours); however, this change was of no clinical relevance.",Pharmacokinetic interactions between zileuton and prednisone. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8620666/),h,2.8,45223,DB00860,Prednisolone
,8620666,half-life (t1/2),"A slight but statistically significant increase in the mean half-life (t1/2) of prednisolone was detected with zileuton + prednisone administration compared with prednisone + placebo (from 2.8 to 2.9 hours); however, this change was of no clinical relevance.",Pharmacokinetic interactions between zileuton and prednisone. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8620666/),h,2.9,45224,DB00860,Prednisolone
,8620666,0 to 6 hours (AUC0-6),"While the single 40mg dose of prednisone resulted in a slight but statistically significant decrease in the mean zileuton AUC value from 0 to 6 hours (AUC0-6) [from 23 to 20 mg/L/h] and a reduction in tMAX (from 2.3 to 1.7 hours), these results were not considered to be clinically significant.",Pharmacokinetic interactions between zileuton and prednisone. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8620666/),[mg] / [h·l],23,45225,DB00860,Prednisolone
,8620666,0 to 6 hours (AUC0-6),"While the single 40mg dose of prednisone resulted in a slight but statistically significant decrease in the mean zileuton AUC value from 0 to 6 hours (AUC0-6) [from 23 to 20 mg/L/h] and a reduction in tMAX (from 2.3 to 1.7 hours), these results were not considered to be clinically significant.",Pharmacokinetic interactions between zileuton and prednisone. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8620666/),[mg] / [h·l],20,45226,DB00860,Prednisolone
,9205818,input rate constant,Population modelling indicated that the only difference in MP pharmacokinetics between MP suleptanate and MP succinate was in the input rate constant (66.0 h-1 vs 5.5 h-1 respectively).,A comparative population pharmacokinetic analysis for methylprednisolone following multiple dosing of two prodrugs in patients with acute asthma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9205818/),1/[h],66.0,46742,DB00860,Prednisolone
,9205818,input rate constant,Population modelling indicated that the only difference in MP pharmacokinetics between MP suleptanate and MP succinate was in the input rate constant (66.0 h-1 vs 5.5 h-1 respectively).,A comparative population pharmacokinetic analysis for methylprednisolone following multiple dosing of two prodrugs in patients with acute asthma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9205818/),1/[h],5.5,46743,DB00860,Prednisolone
,9205818,half-life,"Based on individual Bayesian estimates, the exposure of patients to MP was marginally lower for MP suleptanate although the parameter estimates were not significantly different for half-life (2.7 h vs 3.0 h), steady-state AUC (2007.0 ng ml-1 h vs 2321.0 ng ml-1 h) and steady-state Cmax (698.4 ng ml-1 vs 647.8 ng ml-1) for MP suleptanate and MP succinate respectively.",A comparative population pharmacokinetic analysis for methylprednisolone following multiple dosing of two prodrugs in patients with acute asthma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9205818/),h,2.7,46744,DB00860,Prednisolone
,9205818,half-life,"Based on individual Bayesian estimates, the exposure of patients to MP was marginally lower for MP suleptanate although the parameter estimates were not significantly different for half-life (2.7 h vs 3.0 h), steady-state AUC (2007.0 ng ml-1 h vs 2321.0 ng ml-1 h) and steady-state Cmax (698.4 ng ml-1 vs 647.8 ng ml-1) for MP suleptanate and MP succinate respectively.",A comparative population pharmacokinetic analysis for methylprednisolone following multiple dosing of two prodrugs in patients with acute asthma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9205818/),h,3.0,46745,DB00860,Prednisolone
,9205818,steady-state AUC,"Based on individual Bayesian estimates, the exposure of patients to MP was marginally lower for MP suleptanate although the parameter estimates were not significantly different for half-life (2.7 h vs 3.0 h), steady-state AUC (2007.0 ng ml-1 h vs 2321.0 ng ml-1 h) and steady-state Cmax (698.4 ng ml-1 vs 647.8 ng ml-1) for MP suleptanate and MP succinate respectively.",A comparative population pharmacokinetic analysis for methylprednisolone following multiple dosing of two prodrugs in patients with acute asthma. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9205818/),[h·ng] / [ml],2007.0,46746,DB00860,Prednisolone
,9205818,steady-state AUC,"Based on individual Bayesian estimates, the exposure of patients to MP was marginally lower for MP suleptanate although the parameter estimates were not significantly different for half-life (2.7 h vs 3.0 h), steady-state AUC (2007.0 ng ml-1 h vs 2321.0 ng ml-1 h) and steady-state Cmax (698.4 ng ml-1 vs 647.8 ng ml-1) for MP suleptanate and MP succinate respectively.",A comparative population pharmacokinetic analysis for methylprednisolone following multiple dosing of two prodrugs in patients with acute asthma. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9205818/),[h·ng] / [ml],2321.0,46747,DB00860,Prednisolone
,9205818,steady-state Cmax,"Based on individual Bayesian estimates, the exposure of patients to MP was marginally lower for MP suleptanate although the parameter estimates were not significantly different for half-life (2.7 h vs 3.0 h), steady-state AUC (2007.0 ng ml-1 h vs 2321.0 ng ml-1 h) and steady-state Cmax (698.4 ng ml-1 vs 647.8 ng ml-1) for MP suleptanate and MP succinate respectively.",A comparative population pharmacokinetic analysis for methylprednisolone following multiple dosing of two prodrugs in patients with acute asthma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9205818/),[ng] / [ml],698.4,46748,DB00860,Prednisolone
,9205818,steady-state Cmax,"Based on individual Bayesian estimates, the exposure of patients to MP was marginally lower for MP suleptanate although the parameter estimates were not significantly different for half-life (2.7 h vs 3.0 h), steady-state AUC (2007.0 ng ml-1 h vs 2321.0 ng ml-1 h) and steady-state Cmax (698.4 ng ml-1 vs 647.8 ng ml-1) for MP suleptanate and MP succinate respectively.",A comparative population pharmacokinetic analysis for methylprednisolone following multiple dosing of two prodrugs in patients with acute asthma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9205818/),[ng] / [ml],647.8,46749,DB00860,Prednisolone
,9205818,relative bioavailability,In addition the differences in the pharmacokinetics for the prodrugs resulted in only a small difference in the relative bioavailability of MP for MP suleptanate (0.94) compared with MP succinate.,A comparative population pharmacokinetic analysis for methylprednisolone following multiple dosing of two prodrugs in patients with acute asthma. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9205818/),,0.94,46750,DB00860,Prednisolone
,19774343,AUC(0-t) (area under the curve),"Iontophoretic delivery increased the AUC(0-t) (area under the curve) of drugs in the synovial fluid by 3-fold over passive delivery (0.86 +/- 0.04 and 2.0 +/- 0.06 microg.h/ml for diclofenac sodium and prednisolone sodium phosphate, respectively).","""ChilDrive"": a technique of combining regional cutaneous hypothermia with iontophoresis for the delivery of drugs to synovial fluid. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19774343/),[h·μg] / [ml],0.86,46767,DB00860,Prednisolone
,19774343,AUC(0-t) (area under the curve),"Iontophoretic delivery increased the AUC(0-t) (area under the curve) of drugs in the synovial fluid by 3-fold over passive delivery (0.86 +/- 0.04 and 2.0 +/- 0.06 microg.h/ml for diclofenac sodium and prednisolone sodium phosphate, respectively).","""ChilDrive"": a technique of combining regional cutaneous hypothermia with iontophoresis for the delivery of drugs to synovial fluid. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19774343/),[h·μg] / [ml],2.0,46768,DB00860,Prednisolone
,19774343,AUC(0-t),CD resulted in an AUC(0-t) of 5.2 +/- 0.69 and 24.6 +/- 1.97 microg.h/ml for diclofenac sodium and prednisolone sodium phosphate which was approximately 6-12-fold higher than the passive and 2-4-fold higher than iontophoresis.,"""ChilDrive"": a technique of combining regional cutaneous hypothermia with iontophoresis for the delivery of drugs to synovial fluid. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19774343/),[h·μg] / [ml],5.2,46769,DB00860,Prednisolone
,19774343,AUC(0-t),CD resulted in an AUC(0-t) of 5.2 +/- 0.69 and 24.6 +/- 1.97 microg.h/ml for diclofenac sodium and prednisolone sodium phosphate which was approximately 6-12-fold higher than the passive and 2-4-fold higher than iontophoresis.,"""ChilDrive"": a technique of combining regional cutaneous hypothermia with iontophoresis for the delivery of drugs to synovial fluid. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19774343/),[h·μg] / [ml],24.6,46770,DB00860,Prednisolone
,7273268,half-lives,"Chlorambucil, in contrast, was rapidly absorbed, peak levels (40 microM) occurring within 2 h, after which chlorambucil and phenyl acetic mustard plasma levels decreased with half-lives of 2.4 h and 2.9 h respectively.",The pharmacokinetics of prednimustine and chlorambucil in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7273268/),h,2.4,47184,DB00860,Prednisolone
,7273268,half-lives,"Chlorambucil, in contrast, was rapidly absorbed, peak levels (40 microM) occurring within 2 h, after which chlorambucil and phenyl acetic mustard plasma levels decreased with half-lives of 2.4 h and 2.9 h respectively.",The pharmacokinetics of prednimustine and chlorambucil in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7273268/),h,2.9,47185,DB00860,Prednisolone
,11604270,systemic clearance,The systemic clearance of DMP decreased approximately 5-fold (from 42.1+/-11.0 to 7.72+/-1.84 ml/h per kg) when the dose was increased from 2.5 to 30 mg/kg.,Dextran-methylprednisolone succinate as a prodrug of methylprednisolone: dose-dependent pharmacokinetics in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11604270/),[ml] / [h·kg],42.1,48132,DB00860,Prednisolone
,11604270,systemic clearance,The systemic clearance of DMP decreased approximately 5-fold (from 42.1+/-11.0 to 7.72+/-1.84 ml/h per kg) when the dose was increased from 2.5 to 30 mg/kg.,Dextran-methylprednisolone succinate as a prodrug of methylprednisolone: dose-dependent pharmacokinetics in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11604270/),[ml] / [h·kg],7.72,48133,DB00860,Prednisolone
,11604270,maximum velocity of elimination,The nonlinearity in the clearance of DMP could be adequately described by a Michaelis-Menten type elimination with a maximum velocity of elimination of 1.72 mg/h per kg and a constant of 24.9 microg/ml.,Dextran-methylprednisolone succinate as a prodrug of methylprednisolone: dose-dependent pharmacokinetics in rats. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11604270/),[mg] / [h·kg],1.72,48134,DB00860,Prednisolone
,11604270,constant,The nonlinearity in the clearance of DMP could be adequately described by a Michaelis-Menten type elimination with a maximum velocity of elimination of 1.72 mg/h per kg and a constant of 24.9 microg/ml.,Dextran-methylprednisolone succinate as a prodrug of methylprednisolone: dose-dependent pharmacokinetics in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11604270/),[μg] / [ml],24.9,48135,DB00860,Prednisolone
,2257862,time,"Withdrawal of prednisolone produced no significant change in the mean time and concentration of maximum blood cyclosporine (3.3 h and 1160 micrograms/l, respectively), the initial and terminal elimination half-life (3.5 h and 18.4 h, respectively) and the area under the blood concentration versus time curve (AUC) measured with either the specific or non-specific monoclonal antibody.",Effects of low-dose prednisolone on cyclosporine pharmacokinetics in liver transplant recipients: radioimmunoassay with specific and non-specific monoclonal antibodies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2257862/),h,3.3,49090,DB00860,Prednisolone
,2257862,time,"Withdrawal of prednisolone produced no significant change in the mean time and concentration of maximum blood cyclosporine (3.3 h and 1160 micrograms/l, respectively), the initial and terminal elimination half-life (3.5 h and 18.4 h, respectively) and the area under the blood concentration versus time curve (AUC) measured with either the specific or non-specific monoclonal antibody.",Effects of low-dose prednisolone on cyclosporine pharmacokinetics in liver transplant recipients: radioimmunoassay with specific and non-specific monoclonal antibodies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2257862/),[μg] / [l],116,49091,DB00860,Prednisolone
,2257862,initial,"Withdrawal of prednisolone produced no significant change in the mean time and concentration of maximum blood cyclosporine (3.3 h and 1160 micrograms/l, respectively), the initial and terminal elimination half-life (3.5 h and 18.4 h, respectively) and the area under the blood concentration versus time curve (AUC) measured with either the specific or non-specific monoclonal antibody.",Effects of low-dose prednisolone on cyclosporine pharmacokinetics in liver transplant recipients: radioimmunoassay with specific and non-specific monoclonal antibodies. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2257862/),h,3.5,49092,DB00860,Prednisolone
,2257862,terminal elimination half-life,"Withdrawal of prednisolone produced no significant change in the mean time and concentration of maximum blood cyclosporine (3.3 h and 1160 micrograms/l, respectively), the initial and terminal elimination half-life (3.5 h and 18.4 h, respectively) and the area under the blood concentration versus time curve (AUC) measured with either the specific or non-specific monoclonal antibody.",Effects of low-dose prednisolone on cyclosporine pharmacokinetics in liver transplant recipients: radioimmunoassay with specific and non-specific monoclonal antibodies. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2257862/),h,18.4,49093,DB00860,Prednisolone
,2257862,half-life,"Measurements with these two antibodies indicated that the terminal elimination of cyclosporine metabolites was more rapid than for the parent drug (half-life: 14.5 vs 18.4, respectively).",Effects of low-dose prednisolone on cyclosporine pharmacokinetics in liver transplant recipients: radioimmunoassay with specific and non-specific monoclonal antibodies. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2257862/),,14.5,49094,DB00860,Prednisolone
,2257862,half-life,"Measurements with these two antibodies indicated that the terminal elimination of cyclosporine metabolites was more rapid than for the parent drug (half-life: 14.5 vs 18.4, respectively).",Effects of low-dose prednisolone on cyclosporine pharmacokinetics in liver transplant recipients: radioimmunoassay with specific and non-specific monoclonal antibodies. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2257862/),,18.4,49095,DB00860,Prednisolone
,2015163,AUCs,"The AUCs of unbound prednisolone in plasma were higher after prednisolone phosphate, than after prednisolone phthalate (68.1 +/- 15.7 vs 19.0 +/- 5.2 micrograms ml-1 min, P less than 0.001).",Prednisolone concentrations in cerebrospinal fluid after different prednisolone prodrugs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2015163/),[min·μg] / [ml],68.1,49226,DB00860,Prednisolone
,2015163,AUCs,"The AUCs of unbound prednisolone in plasma were higher after prednisolone phosphate, than after prednisolone phthalate (68.1 +/- 15.7 vs 19.0 +/- 5.2 micrograms ml-1 min, P less than 0.001).",Prednisolone concentrations in cerebrospinal fluid after different prednisolone prodrugs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2015163/),[min·μg] / [ml],19.0,49227,DB00860,Prednisolone
,2015163,AUCs,"Similarly, the AUCs of prednisolone were higher in the CSF after prednisolone phosphate, than after prednisolone phthalate (17.6 +/- 2.8 vs 3.3 +/- 1.0 micrograms ml-1 min, P less than 0.0001).",Prednisolone concentrations in cerebrospinal fluid after different prednisolone prodrugs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2015163/),[min·μg] / [ml],17.6,49228,DB00860,Prednisolone
,2015163,AUCs,"Similarly, the AUCs of prednisolone were higher in the CSF after prednisolone phosphate, than after prednisolone phthalate (17.6 +/- 2.8 vs 3.3 +/- 1.0 micrograms ml-1 min, P less than 0.0001).",Prednisolone concentrations in cerebrospinal fluid after different prednisolone prodrugs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2015163/),[min·μg] / [ml],3.3,49229,DB00860,Prednisolone
,1855277,relative availability,"The median relative availability of the prednisolone and chlorambucil moiety in prednimustine was 19% and 16%, respectively.",A pharmacokinetic study of prednimustine as compared with prednisolone plus chlorambucil in cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1855277/),%,19,49802,DB00860,Prednisolone
,1855277,relative availability,"The median relative availability of the prednisolone and chlorambucil moiety in prednimustine was 19% and 16%, respectively.",A pharmacokinetic study of prednimustine as compared with prednisolone plus chlorambucil in cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1855277/),%,16,49803,DB00860,Prednisolone
,1837629,trough specific level,"The mean trough specific level was 121 +/- 14 micrograms/L following placebo, compared to 120 +/- 14 micrograms/L during isradipine.",Lack of effect of the calcium antagonist isradipine on cyclosporine pharmacokinetics in renal transplant patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1837629/),[μg] / [l],121,50560,DB00860,Prednisolone
,1837629,trough specific level,"The mean trough specific level was 121 +/- 14 micrograms/L following placebo, compared to 120 +/- 14 micrograms/L during isradipine.",Lack of effect of the calcium antagonist isradipine on cyclosporine pharmacokinetics in renal transplant patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1837629/),[μg] / [l],120,50561,DB00860,Prednisolone
,7516722,tissue-to-blood ratios,"Observed cecal and colonic tissue-to-blood ratios of 19:1 and 12:1, respectively, showed that this drug is extensively delivered to the large intestine even after subcutaneous administration.",Glucocorticoid-dextran conjugates as potential prodrugs for colon-specific delivery: steady-state pharmacokinetics in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7516722/),,12:1,51584,DB00860,Prednisolone
>,21976740,trough concentrations,"In 18 patients, mycophenolate mofetil (MMF) (adjusted to achieve blood mycophenolic acid trough concentrations > 2 μg/mL) was sequentially added, and 16 patients were converted to MMF monotherapy.",Sequential maintenance therapy with cyclosporin A and mycophenolate mofetil for sustained remission of childhood steroid-resistant nephrotic syndrome. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21976740/),[μg] / [ml],2,52509,DB00860,Prednisolone
,16236048,AUC((0-24 h)),"On day 6, the mean (95% confidence interval) whole blood sirolimus AUC((0-24 h)) was 1040 (846, 1234) ng ml(-1) and mean C(max) was 109 (88, 129) ng ml(-1).",Trimethoprim-sulphamethoxazole does not affect the pharmacokinetics of sirolimus in renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16236048/),[ng] / [ml],1040,52517,DB00860,Prednisolone
,16236048,C(max),"On day 6, the mean (95% confidence interval) whole blood sirolimus AUC((0-24 h)) was 1040 (846, 1234) ng ml(-1) and mean C(max) was 109 (88, 129) ng ml(-1).",Trimethoprim-sulphamethoxazole does not affect the pharmacokinetics of sirolimus in renal transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16236048/),[ng] / [ml],109,52518,DB00860,Prednisolone
,16236048,AUC((0-24 h)),"Corresponding values on day 7 were AUC((0-24 h)) 1060 (826, 1293) ng ml(-1) and C(max) mean 107 (87, 127) ng ml(-1).",Trimethoprim-sulphamethoxazole does not affect the pharmacokinetics of sirolimus in renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16236048/),[ng] / [ml],1060,52519,DB00860,Prednisolone
,16236048,C(max),"Corresponding values on day 7 were AUC((0-24 h)) 1060 (826, 1293) ng ml(-1) and C(max) mean 107 (87, 127) ng ml(-1).",Trimethoprim-sulphamethoxazole does not affect the pharmacokinetics of sirolimus in renal transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16236048/),[ng] / [ml],107,52520,DB00860,Prednisolone
,25809824,objective response rate,"In the efficacy population, two of 12 patients with measurable disease had partial response (objective response rate: 16.7 %), while 10 had stable disease.",Japanese phase I study of cabazitaxel in metastatic castration-resistant prostate cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25809824/),%,16.7,58310,DB00860,Prednisolone
,25809824,response rate,PSA response rate was 29.3 % (12/41 patients).,Japanese phase I study of cabazitaxel in metastatic castration-resistant prostate cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25809824/),%,29.3,58311,DB00860,Prednisolone
,25809824,time to PSA progression,Median time to PSA progression was 3.68 months (95 % confidence interval 1.35-4.63).,Japanese phase I study of cabazitaxel in metastatic castration-resistant prostate cancer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25809824/),month,3.68,58312,DB00860,Prednisolone
,14624194,area under the methylprednisolone concentration-time curve,"Following nefazodone administration, the mean (+/-SD) area under the methylprednisolone concentration-time curve was significantly higher (1393 +/- 343 vs. 2966 +/- 928 ug*h/L; P < 0.005), apparent clearance was lower (28.7 +/- 7.2 vs. 14.6 +/- 7.8 L/h; P < 0.02) and the terminal elimination half-life was longer (2.28 +/- 0.49 vs. 3.32 +/- 0.95 hours; P < 0.02).",Nefazodone inhibits methylprednisolone disposition and enhances its adrenal-suppressant effect. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14624194/),[h·ug] / [l],1393,60429,DB00860,Prednisolone
,14624194,area under the methylprednisolone concentration-time curve,"Following nefazodone administration, the mean (+/-SD) area under the methylprednisolone concentration-time curve was significantly higher (1393 +/- 343 vs. 2966 +/- 928 ug*h/L; P < 0.005), apparent clearance was lower (28.7 +/- 7.2 vs. 14.6 +/- 7.8 L/h; P < 0.02) and the terminal elimination half-life was longer (2.28 +/- 0.49 vs. 3.32 +/- 0.95 hours; P < 0.02).",Nefazodone inhibits methylprednisolone disposition and enhances its adrenal-suppressant effect. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14624194/),[h·ug] / [l],2966,60430,DB00860,Prednisolone
,14624194,apparent clearance,"Following nefazodone administration, the mean (+/-SD) area under the methylprednisolone concentration-time curve was significantly higher (1393 +/- 343 vs. 2966 +/- 928 ug*h/L; P < 0.005), apparent clearance was lower (28.7 +/- 7.2 vs. 14.6 +/- 7.8 L/h; P < 0.02) and the terminal elimination half-life was longer (2.28 +/- 0.49 vs. 3.32 +/- 0.95 hours; P < 0.02).",Nefazodone inhibits methylprednisolone disposition and enhances its adrenal-suppressant effect. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14624194/),[l] / [h],28.7,60431,DB00860,Prednisolone
,14624194,apparent clearance,"Following nefazodone administration, the mean (+/-SD) area under the methylprednisolone concentration-time curve was significantly higher (1393 +/- 343 vs. 2966 +/- 928 ug*h/L; P < 0.005), apparent clearance was lower (28.7 +/- 7.2 vs. 14.6 +/- 7.8 L/h; P < 0.02) and the terminal elimination half-life was longer (2.28 +/- 0.49 vs. 3.32 +/- 0.95 hours; P < 0.02).",Nefazodone inhibits methylprednisolone disposition and enhances its adrenal-suppressant effect. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14624194/),[l] / [h],14.6,60432,DB00860,Prednisolone
,14624194,terminal elimination half-life,"Following nefazodone administration, the mean (+/-SD) area under the methylprednisolone concentration-time curve was significantly higher (1393 +/- 343 vs. 2966 +/- 928 ug*h/L; P < 0.005), apparent clearance was lower (28.7 +/- 7.2 vs. 14.6 +/- 7.8 L/h; P < 0.02) and the terminal elimination half-life was longer (2.28 +/- 0.49 vs. 3.32 +/- 0.95 hours; P < 0.02).",Nefazodone inhibits methylprednisolone disposition and enhances its adrenal-suppressant effect. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14624194/),h,2.28,60433,DB00860,Prednisolone
,14624194,terminal elimination half-life,"Following nefazodone administration, the mean (+/-SD) area under the methylprednisolone concentration-time curve was significantly higher (1393 +/- 343 vs. 2966 +/- 928 ug*h/L; P < 0.005), apparent clearance was lower (28.7 +/- 7.2 vs. 14.6 +/- 7.8 L/h; P < 0.02) and the terminal elimination half-life was longer (2.28 +/- 0.49 vs. 3.32 +/- 0.95 hours; P < 0.02).",Nefazodone inhibits methylprednisolone disposition and enhances its adrenal-suppressant effect. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14624194/),h,3.32,60434,DB00860,Prednisolone
,8645883,drug clearance,A three-fold variation in drug clearance ranging from 174 to 638 ml/h/kg with a range in the volume of distribution of 0.83 to 2.24 l/kg and resultant half-lives ranging from 1.20 to 3.02 hours was noted.,Methylprednisolone and cortisol metabolism during the early post-renal transplant period. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8645883/),[ml] / [h·kg],174 to 638,60614,DB00860,Prednisolone
,8645883,volume of distribution,A three-fold variation in drug clearance ranging from 174 to 638 ml/h/kg with a range in the volume of distribution of 0.83 to 2.24 l/kg and resultant half-lives ranging from 1.20 to 3.02 hours was noted.,Methylprednisolone and cortisol metabolism during the early post-renal transplant period. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8645883/),l,0.83 to 2.24,60615,DB00860,Prednisolone
,8645883,half-lives,A three-fold variation in drug clearance ranging from 174 to 638 ml/h/kg with a range in the volume of distribution of 0.83 to 2.24 l/kg and resultant half-lives ranging from 1.20 to 3.02 hours was noted.,Methylprednisolone and cortisol metabolism during the early post-renal transplant period. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8645883/),h,1.20 to 3.02,60616,DB00860,Prednisolone
,8645883,C-AUC12,C-AUC12 ranged from 44.0 to 636 ng.h/ml.,Methylprednisolone and cortisol metabolism during the early post-renal transplant period. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8645883/),[h·ng] / [ml],44.0 to 636,60617,DB00860,Prednisolone
,17192769,Dose/trough concentration ratios,Dose/trough concentration ratios were 0.67+/-0.3 and 1.36+/-0.73 x 10(3) l (P<0.00001) for tacrolimus and 0.42+/-0.17 and 0.84+/-0.46 x 10(3) l (P=0.18) for sirolimus in CYP3A5 non-expressors and expressors.,CYP3A5 genotype markedly influences the pharmacokinetics of tacrolimus and sirolimus in kidney transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17192769/),l,0.67,60927,DB00860,Prednisolone
,17192769,Dose/trough concentration ratios,Dose/trough concentration ratios were 0.67+/-0.3 and 1.36+/-0.73 x 10(3) l (P<0.00001) for tacrolimus and 0.42+/-0.17 and 0.84+/-0.46 x 10(3) l (P=0.18) for sirolimus in CYP3A5 non-expressors and expressors.,CYP3A5 genotype markedly influences the pharmacokinetics of tacrolimus and sirolimus in kidney transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17192769/),l,1.36,60928,DB00860,Prednisolone
,17192769,Dose/trough concentration ratios,Dose/trough concentration ratios were 0.67+/-0.3 and 1.36+/-0.73 x 10(3) l (P<0.00001) for tacrolimus and 0.42+/-0.17 and 0.84+/-0.46 x 10(3) l (P=0.18) for sirolimus in CYP3A5 non-expressors and expressors.,CYP3A5 genotype markedly influences the pharmacokinetics of tacrolimus and sirolimus in kidney transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17192769/),10,0.42,60929,DB00860,Prednisolone
,17192769,Dose/trough concentration ratios,Dose/trough concentration ratios were 0.67+/-0.3 and 1.36+/-0.73 x 10(3) l (P<0.00001) for tacrolimus and 0.42+/-0.17 and 0.84+/-0.46 x 10(3) l (P=0.18) for sirolimus in CYP3A5 non-expressors and expressors.,CYP3A5 genotype markedly influences the pharmacokinetics of tacrolimus and sirolimus in kidney transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17192769/),l,0.84,60930,DB00860,Prednisolone
,17192769,area under curve (AUC)(0-12),The unadjusted tacrolimus area under curve (AUC)(0-12) was 106.8+/-17.5 ng/ml x h compared with 133.3+/-42.2 ng/ml x h (P=0.37) without affecting serum creatinine.,CYP3A5 genotype markedly influences the pharmacokinetics of tacrolimus and sirolimus in kidney transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17192769/),[ng] / [h·ml],106.8,60931,DB00860,Prednisolone
,17192769,area under curve (AUC)(0-12),The unadjusted tacrolimus area under curve (AUC)(0-12) was 106.8+/-17.5 ng/ml x h compared with 133.3+/-42.2 ng/ml x h (P=0.37) without affecting serum creatinine.,CYP3A5 genotype markedly influences the pharmacokinetics of tacrolimus and sirolimus in kidney transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17192769/),[ng] / [h·ml],133.3,60932,DB00860,Prednisolone
,29385232,plasma half-life,"2B3-201 was shown to have a plasma half-life between 24 and 37 h and caused a prolonged decrease in the lymphocyte count, adrenocorticotropic hormone and osteocalcin, and a rise in fasting glucose.",Glutathione-PEGylated liposomal methylprednisolone in comparison to free methylprednisolone: slow release characteristics and prolonged lymphocyte depression in a first-in-human study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29385232/),h,24 and 37,61204,DB00860,Prednisolone
,1827621,Total volume of distribution (Vss),"Total volume of distribution (Vss) of methylprednisolone was unchanged (about 120 L), but when normalized for total body weight, Vss per kilogram was less in obesity.",Pharmacokinetics and pharmacodynamics of methylprednisolone in obesity. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1827621/),l,120,61228,DB00860,Prednisolone
,3245858,terminal half-life,"The terminal half-life of 2.7 +/- 1.3 h and tmax of 1.9 +/- 0.5 h are in agreement with corresponding data of other glucocorticoids, whereas the normalized plasma concentration and the volume of distribution are different.",[Pharmacokinetics of triamcinolone following oral administration]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3245858/),h,2.7,61576,DB00860,Prednisolone
,3245858,tmax,"The terminal half-life of 2.7 +/- 1.3 h and tmax of 1.9 +/- 0.5 h are in agreement with corresponding data of other glucocorticoids, whereas the normalized plasma concentration and the volume of distribution are different.",[Pharmacokinetics of triamcinolone following oral administration]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3245858/),h,1.9,61577,DB00860,Prednisolone
,3987177,ratio,"Cimetidine reduced the mean (+/- SD) ratio of prednisone dose to the plasma prednisolone AUC (16.6 +/- 2.9 L/hr) below that ratio after ranitidine (19.2 +/- 4.2 L/hr) and placebo (19.3 +/- 2.8 L/hr), and resulted in the lowest fractional excretion of prednisolone in the urine (5.2% +/- 2.2%, 9.8% +/- 4.5%, and 12.4% +/- 4.9%, respectively).",Effects of cimetidine and ranitidine on the conversion of prednisone to prednisolone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3987177/),[l] / [h],16.6,62253,DB00860,Prednisolone
,3987177,ratio,"Cimetidine reduced the mean (+/- SD) ratio of prednisone dose to the plasma prednisolone AUC (16.6 +/- 2.9 L/hr) below that ratio after ranitidine (19.2 +/- 4.2 L/hr) and placebo (19.3 +/- 2.8 L/hr), and resulted in the lowest fractional excretion of prednisolone in the urine (5.2% +/- 2.2%, 9.8% +/- 4.5%, and 12.4% +/- 4.9%, respectively).",Effects of cimetidine and ranitidine on the conversion of prednisone to prednisolone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3987177/),[l] / [h],19.2,62254,DB00860,Prednisolone
,2347663,peak values,"Sham dialysis did not apparently influence serum MP levels, as shown by similar peak values in patients undergoing sham dialysis (203 micrograms/ml +/- SEM 33) and in patients off dialysis (177 micrograms/ml +/- 42).",Complement activated leucopenia during hemodialysis: effect of pulse methyl-prednisolone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2347663/),[μg] / [ml],203,62837,DB00860,Prednisolone
,2347663,peak values,"Sham dialysis did not apparently influence serum MP levels, as shown by similar peak values in patients undergoing sham dialysis (203 micrograms/ml +/- SEM 33) and in patients off dialysis (177 micrograms/ml +/- 42).",Complement activated leucopenia during hemodialysis: effect of pulse methyl-prednisolone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2347663/),[μg] / [ml],177,62838,DB00860,Prednisolone
,9013365,peak plasma concentration (Cmax),Mean pharmacokinetic values of prednisolone found before sirolimus administration were as follows: peak plasma concentration (Cmax) was 187 ng/mL; time to peak plasma concentration (tmax) was 2.03 hours; rate of reaching peak plasma concentration (Cmax divided by the area under the concentration-time curve [AUC]) was 0.149 hour-1; terminal half-life (t1/2) was 3.60 hours; AUC was 1206 ng.hour/mL; and apparent clearance (Cl/F) was 0.094 L/hour/kg.,Pharmacokinetics of prednisolone during administration of sirolimus in patients with renal transplants. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9013365/),[ng] / [ml],187,64277,DB00860,Prednisolone
,9013365,time to peak plasma concentration (tmax),Mean pharmacokinetic values of prednisolone found before sirolimus administration were as follows: peak plasma concentration (Cmax) was 187 ng/mL; time to peak plasma concentration (tmax) was 2.03 hours; rate of reaching peak plasma concentration (Cmax divided by the area under the concentration-time curve [AUC]) was 0.149 hour-1; terminal half-life (t1/2) was 3.60 hours; AUC was 1206 ng.hour/mL; and apparent clearance (Cl/F) was 0.094 L/hour/kg.,Pharmacokinetics of prednisolone during administration of sirolimus in patients with renal transplants. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9013365/),h,2.03,64278,DB00860,Prednisolone
,9013365,rate of reaching peak plasma concentration (Cmax divided by the area under the concentration-time curve [AUC]),Mean pharmacokinetic values of prednisolone found before sirolimus administration were as follows: peak plasma concentration (Cmax) was 187 ng/mL; time to peak plasma concentration (tmax) was 2.03 hours; rate of reaching peak plasma concentration (Cmax divided by the area under the concentration-time curve [AUC]) was 0.149 hour-1; terminal half-life (t1/2) was 3.60 hours; AUC was 1206 ng.hour/mL; and apparent clearance (Cl/F) was 0.094 L/hour/kg.,Pharmacokinetics of prednisolone during administration of sirolimus in patients with renal transplants. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9013365/),1/[h],0.149,64279,DB00860,Prednisolone
,9013365,terminal half-life (t1/2),Mean pharmacokinetic values of prednisolone found before sirolimus administration were as follows: peak plasma concentration (Cmax) was 187 ng/mL; time to peak plasma concentration (tmax) was 2.03 hours; rate of reaching peak plasma concentration (Cmax divided by the area under the concentration-time curve [AUC]) was 0.149 hour-1; terminal half-life (t1/2) was 3.60 hours; AUC was 1206 ng.hour/mL; and apparent clearance (Cl/F) was 0.094 L/hour/kg.,Pharmacokinetics of prednisolone during administration of sirolimus in patients with renal transplants. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9013365/),h,3.60,64280,DB00860,Prednisolone
,9013365,AUC,Mean pharmacokinetic values of prednisolone found before sirolimus administration were as follows: peak plasma concentration (Cmax) was 187 ng/mL; time to peak plasma concentration (tmax) was 2.03 hours; rate of reaching peak plasma concentration (Cmax divided by the area under the concentration-time curve [AUC]) was 0.149 hour-1; terminal half-life (t1/2) was 3.60 hours; AUC was 1206 ng.hour/mL; and apparent clearance (Cl/F) was 0.094 L/hour/kg.,Pharmacokinetics of prednisolone during administration of sirolimus in patients with renal transplants. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9013365/),[h·ng] / [ml],1206,64281,DB00860,Prednisolone
,9013365,apparent clearance (Cl/F),Mean pharmacokinetic values of prednisolone found before sirolimus administration were as follows: peak plasma concentration (Cmax) was 187 ng/mL; time to peak plasma concentration (tmax) was 2.03 hours; rate of reaching peak plasma concentration (Cmax divided by the area under the concentration-time curve [AUC]) was 0.149 hour-1; terminal half-life (t1/2) was 3.60 hours; AUC was 1206 ng.hour/mL; and apparent clearance (Cl/F) was 0.094 L/hour/kg.,Pharmacokinetics of prednisolone during administration of sirolimus in patients with renal transplants. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9013365/),[l] / [h·kg],0.094,64282,DB00860,Prednisolone
,8247916,clearance,"The drug's pharmacokinetics in black and white patients, respectively, were as follows: mean clearance 234 +/- 124 and 472 +/- 180 ml/hr/kg (p < 0.05); volume of distribution 0.3-2.0 and 0.8-2.0 L/kg; and elimination rate constant 0.13-0.41 and 0.27-0.42 hour-1 (p < 0.06).",Racial differences in the pharmacokinetics of methylprednisolone in black and white renal transplant recipients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8247916/),[ml] / [h·kg],234,64886,DB00860,Prednisolone
,8247916,clearance,"The drug's pharmacokinetics in black and white patients, respectively, were as follows: mean clearance 234 +/- 124 and 472 +/- 180 ml/hr/kg (p < 0.05); volume of distribution 0.3-2.0 and 0.8-2.0 L/kg; and elimination rate constant 0.13-0.41 and 0.27-0.42 hour-1 (p < 0.06).",Racial differences in the pharmacokinetics of methylprednisolone in black and white renal transplant recipients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8247916/),[ml] / [h·kg],472,64887,DB00860,Prednisolone
,8247916,volume of distribution,"The drug's pharmacokinetics in black and white patients, respectively, were as follows: mean clearance 234 +/- 124 and 472 +/- 180 ml/hr/kg (p < 0.05); volume of distribution 0.3-2.0 and 0.8-2.0 L/kg; and elimination rate constant 0.13-0.41 and 0.27-0.42 hour-1 (p < 0.06).",Racial differences in the pharmacokinetics of methylprednisolone in black and white renal transplant recipients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8247916/),[l] / [kg],0.3-2.0,64888,DB00860,Prednisolone
,8247916,volume of distribution,"The drug's pharmacokinetics in black and white patients, respectively, were as follows: mean clearance 234 +/- 124 and 472 +/- 180 ml/hr/kg (p < 0.05); volume of distribution 0.3-2.0 and 0.8-2.0 L/kg; and elimination rate constant 0.13-0.41 and 0.27-0.42 hour-1 (p < 0.06).",Racial differences in the pharmacokinetics of methylprednisolone in black and white renal transplant recipients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8247916/),[l] / [kg],0.8-2.0,64889,DB00860,Prednisolone
,8247916,elimination rate constant,"The drug's pharmacokinetics in black and white patients, respectively, were as follows: mean clearance 234 +/- 124 and 472 +/- 180 ml/hr/kg (p < 0.05); volume of distribution 0.3-2.0 and 0.8-2.0 L/kg; and elimination rate constant 0.13-0.41 and 0.27-0.42 hour-1 (p < 0.06).",Racial differences in the pharmacokinetics of methylprednisolone in black and white renal transplant recipients. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8247916/),1/[h],0.13-0.41,64890,DB00860,Prednisolone
,8247916,elimination rate constant,"The drug's pharmacokinetics in black and white patients, respectively, were as follows: mean clearance 234 +/- 124 and 472 +/- 180 ml/hr/kg (p < 0.05); volume of distribution 0.3-2.0 and 0.8-2.0 L/kg; and elimination rate constant 0.13-0.41 and 0.27-0.42 hour-1 (p < 0.06).",Racial differences in the pharmacokinetics of methylprednisolone in black and white renal transplant recipients. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8247916/),1/[h],0.27-0.42,64891,DB00860,Prednisolone
,8247916,half-life,The mean half-life of 3.4 +/- 1.4 hours in black patients compared with 2.1 +/- 0.3 hours in white patients approached statistical significance (p < 0.08).,Racial differences in the pharmacokinetics of methylprednisolone in black and white renal transplant recipients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8247916/),h,3.4,64892,DB00860,Prednisolone
,8247916,half-life,The mean half-life of 3.4 +/- 1.4 hours in black patients compared with 2.1 +/- 0.3 hours in white patients approached statistical significance (p < 0.08).,Racial differences in the pharmacokinetics of methylprednisolone in black and white renal transplant recipients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8247916/),h,2.1,64893,DB00860,Prednisolone
,26828453,zeta potentials,The drug-loaded nano-liposmes with average sizes of about 186 nm and zeta potentials of -20 mV were obtained.,Preparation and in vitro/pharmacokinetic/pharmacodynamic evaluation of a slow-release nano-liposomal form of prednisolone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26828453/),mv,-,65267,DB00860,Prednisolone
,26828453,zeta potentials,The drug-loaded nano-liposmes with average sizes of about 186 nm and zeta potentials of -20 mV were obtained.,Preparation and in vitro/pharmacokinetic/pharmacodynamic evaluation of a slow-release nano-liposomal form of prednisolone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26828453/),mv,20,65268,DB00860,Prednisolone
,1501110,elimination half-life,"After DEX at 8 hr, HC production was reduced instantaneously to a minimum level and HC disappeared rapidly from plasma with an elimination half-life of 1.32 +/- 0.28 hr (mean +/- S.D.).","Time-dependent effects of dexamethasone administration on the suppression of plasma hydrocortisone, assessed with a pharmacokinetic model. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1501110/),h,1.32,65491,DB00860,Prednisolone
,7026594,areas under the plasma concentration time curve,"Patients with cushingoid habitus more frequently exhibited peak hydrocortisone levels within the normal range (6 of 14 vs. 1 of 13) and had higher areas under the plasma concentration time curve of hydrocortisone (median, range), i.e. 2672 ng/ml.min (0-21, 637 ng/ml.min) vs. 308 ng/ml.min (0-12, 495 ng/ml.min) compared to those without cushingoid appearance (P less than 0.05).","Endogenous hydrocortisone, a possible factor contributing to the genesis of cushingoid habitus in patients on prednisone. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7026594/),[ng] / [min·ml],2672,65833,DB00860,Prednisolone
,7026594,areas under the plasma concentration time curve,"Patients with cushingoid habitus more frequently exhibited peak hydrocortisone levels within the normal range (6 of 14 vs. 1 of 13) and had higher areas under the plasma concentration time curve of hydrocortisone (median, range), i.e. 2672 ng/ml.min (0-21, 637 ng/ml.min) vs. 308 ng/ml.min (0-12, 495 ng/ml.min) compared to those without cushingoid appearance (P less than 0.05).","Endogenous hydrocortisone, a possible factor contributing to the genesis of cushingoid habitus in patients on prednisone. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7026594/),[ng] / [min·ml],308,65834,DB00860,Prednisolone
,31197020,plasma binding,The plasma binding of DEX and MPL was linear with moderate binding (60.5% and 82.5%) in male and female rats.,"Modeling Corticosteroid Pharmacokinetics and Pharmacodynamics, Part I: Determination and Prediction of Dexamethasone and Methylprednisolone Tissue Binding in the Rat. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31197020/),%,60.5,65927,DB00860,Prednisolone
,31197020,plasma binding,The plasma binding of DEX and MPL was linear with moderate binding (60.5% and 82.5%) in male and female rats.,"Modeling Corticosteroid Pharmacokinetics and Pharmacodynamics, Part I: Determination and Prediction of Dexamethasone and Methylprednisolone Tissue Binding in the Rat. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31197020/),%,82.5,65928,DB00860,Prednisolone
,21923441,absorption rate constant,"The absorption rate constant was fixed at 1.28 hour(-1), and the following population pharmacokinetic estimates were calculated: cyclosporine clearance 43.6 L/hour, apparent volume of distribution 1990 L, and interpatient variability for clearance (coefficient of variation) 17.69%.",Population pharmacokinetics of cyclosporine in Korean adults undergoing living-donor kidney transplantation. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21923441/),1/[hour],1.28,66359,DB00860,Prednisolone
,21923441,clearance,"The absorption rate constant was fixed at 1.28 hour(-1), and the following population pharmacokinetic estimates were calculated: cyclosporine clearance 43.6 L/hour, apparent volume of distribution 1990 L, and interpatient variability for clearance (coefficient of variation) 17.69%.",Population pharmacokinetics of cyclosporine in Korean adults undergoing living-donor kidney transplantation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21923441/),[l] / [h],43.6,66360,DB00860,Prednisolone
,21923441,apparent volume of distribution,"The absorption rate constant was fixed at 1.28 hour(-1), and the following population pharmacokinetic estimates were calculated: cyclosporine clearance 43.6 L/hour, apparent volume of distribution 1990 L, and interpatient variability for clearance (coefficient of variation) 17.69%.",Population pharmacokinetics of cyclosporine in Korean adults undergoing living-donor kidney transplantation. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21923441/),l,1990,66361,DB00860,Prednisolone
,16012079,Cmax,"The mean Cmax and AUC0-24 of (R)-lansoprazole compared to (S)-lansoprazole in renal transplant recipients were 12-fold (954+/-522 vs. 167+/-137 ngml(-1), respectively) and 6.9-fold (4787+/-3454 vs. 451+/-354 nghml(-1), respectively) greater, and its elimination half-life was 2.1-fold (2.3+/-1.0 vs. 1.2+/-0.6h, respectively) longer.",Comparison of enantioselective disposition of rabeprazole versus lansoprazole in renal-transplant recipients who are CYP2C19 extensive metabolizers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16012079/),1/[ngml],954,66805,DB00860,Prednisolone
,16012079,Cmax,"The mean Cmax and AUC0-24 of (R)-lansoprazole compared to (S)-lansoprazole in renal transplant recipients were 12-fold (954+/-522 vs. 167+/-137 ngml(-1), respectively) and 6.9-fold (4787+/-3454 vs. 451+/-354 nghml(-1), respectively) greater, and its elimination half-life was 2.1-fold (2.3+/-1.0 vs. 1.2+/-0.6h, respectively) longer.",Comparison of enantioselective disposition of rabeprazole versus lansoprazole in renal-transplant recipients who are CYP2C19 extensive metabolizers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16012079/),1/[ngml],167,66806,DB00860,Prednisolone
,16012079,AUC0-24,"The mean Cmax and AUC0-24 of (R)-lansoprazole compared to (S)-lansoprazole in renal transplant recipients were 12-fold (954+/-522 vs. 167+/-137 ngml(-1), respectively) and 6.9-fold (4787+/-3454 vs. 451+/-354 nghml(-1), respectively) greater, and its elimination half-life was 2.1-fold (2.3+/-1.0 vs. 1.2+/-0.6h, respectively) longer.",Comparison of enantioselective disposition of rabeprazole versus lansoprazole in renal-transplant recipients who are CYP2C19 extensive metabolizers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16012079/),1/[ngml],167,66807,DB00860,Prednisolone
,16012079,AUC0-24,"The mean Cmax and AUC0-24 of (R)-lansoprazole compared to (S)-lansoprazole in renal transplant recipients were 12-fold (954+/-522 vs. 167+/-137 ngml(-1), respectively) and 6.9-fold (4787+/-3454 vs. 451+/-354 nghml(-1), respectively) greater, and its elimination half-life was 2.1-fold (2.3+/-1.0 vs. 1.2+/-0.6h, respectively) longer.",Comparison of enantioselective disposition of rabeprazole versus lansoprazole in renal-transplant recipients who are CYP2C19 extensive metabolizers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16012079/),1/[nghml],4787,66808,DB00860,Prednisolone
,16012079,AUC0-24,"The mean Cmax and AUC0-24 of (R)-lansoprazole compared to (S)-lansoprazole in renal transplant recipients were 12-fold (954+/-522 vs. 167+/-137 ngml(-1), respectively) and 6.9-fold (4787+/-3454 vs. 451+/-354 nghml(-1), respectively) greater, and its elimination half-life was 2.1-fold (2.3+/-1.0 vs. 1.2+/-0.6h, respectively) longer.",Comparison of enantioselective disposition of rabeprazole versus lansoprazole in renal-transplant recipients who are CYP2C19 extensive metabolizers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16012079/),1/[nghml],451,66809,DB00860,Prednisolone
,16012079,elimination half-life,"The mean Cmax and AUC0-24 of (R)-lansoprazole compared to (S)-lansoprazole in renal transplant recipients were 12-fold (954+/-522 vs. 167+/-137 ngml(-1), respectively) and 6.9-fold (4787+/-3454 vs. 451+/-354 nghml(-1), respectively) greater, and its elimination half-life was 2.1-fold (2.3+/-1.0 vs. 1.2+/-0.6h, respectively) longer.",Comparison of enantioselective disposition of rabeprazole versus lansoprazole in renal-transplant recipients who are CYP2C19 extensive metabolizers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16012079/),h,2.3,66810,DB00860,Prednisolone
,16012079,elimination half-life,"The mean Cmax and AUC0-24 of (R)-lansoprazole compared to (S)-lansoprazole in renal transplant recipients were 12-fold (954+/-522 vs. 167+/-137 ngml(-1), respectively) and 6.9-fold (4787+/-3454 vs. 451+/-354 nghml(-1), respectively) greater, and its elimination half-life was 2.1-fold (2.3+/-1.0 vs. 1.2+/-0.6h, respectively) longer.",Comparison of enantioselective disposition of rabeprazole versus lansoprazole in renal-transplant recipients who are CYP2C19 extensive metabolizers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16012079/),h,1.2,66811,DB00860,Prednisolone
,16012079,elimination half-life,"In contrast, although the elimination half-life of (R)-rabeprazole was significantly longer than that of the (S)-enantiomer (2.1+/-0.5 vs. 1.3+/-0.9h, respectively; P<0.05), there was no difference in Cmax between the (R)- and (S)-enantiomer (186+/-40 vs. 200+/-92 ngml(-1), respectively).",Comparison of enantioselective disposition of rabeprazole versus lansoprazole in renal-transplant recipients who are CYP2C19 extensive metabolizers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16012079/),h,2.1,66812,DB00860,Prednisolone
,16012079,elimination half-life,"In contrast, although the elimination half-life of (R)-rabeprazole was significantly longer than that of the (S)-enantiomer (2.1+/-0.5 vs. 1.3+/-0.9h, respectively; P<0.05), there was no difference in Cmax between the (R)- and (S)-enantiomer (186+/-40 vs. 200+/-92 ngml(-1), respectively).",Comparison of enantioselective disposition of rabeprazole versus lansoprazole in renal-transplant recipients who are CYP2C19 extensive metabolizers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16012079/),h,1.3,66813,DB00860,Prednisolone
,16012079,Cmax,"In contrast, although the elimination half-life of (R)-rabeprazole was significantly longer than that of the (S)-enantiomer (2.1+/-0.5 vs. 1.3+/-0.9h, respectively; P<0.05), there was no difference in Cmax between the (R)- and (S)-enantiomer (186+/-40 vs. 200+/-92 ngml(-1), respectively).",Comparison of enantioselective disposition of rabeprazole versus lansoprazole in renal-transplant recipients who are CYP2C19 extensive metabolizers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16012079/),1/[ngml],186,66814,DB00860,Prednisolone
,16012079,Cmax,"In contrast, although the elimination half-life of (R)-rabeprazole was significantly longer than that of the (S)-enantiomer (2.1+/-0.5 vs. 1.3+/-0.9h, respectively; P<0.05), there was no difference in Cmax between the (R)- and (S)-enantiomer (186+/-40 vs. 200+/-92 ngml(-1), respectively).",Comparison of enantioselective disposition of rabeprazole versus lansoprazole in renal-transplant recipients who are CYP2C19 extensive metabolizers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16012079/),1/[ngml],200,66815,DB00860,Prednisolone
,1880717,availability,Incomplete availability of MP from iv MS (52-55%) and from the oral dose (10%) was found.,Disposition of methylprednisolone and its sodium succinate prodrug in vivo and in perfused liver of rats: nonlinear and sequential first-pass elimination. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1880717/),%,52-55,67771,DB00860,Prednisolone
,1880717,availability,Incomplete availability of MP from iv MS (52-55%) and from the oral dose (10%) was found.,Disposition of methylprednisolone and its sodium succinate prodrug in vivo and in perfused liver of rats: nonlinear and sequential first-pass elimination. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1880717/),%,10,67772,DB00860,Prednisolone
,1880717,hepatic extraction,"Extensive hepatic extraction of MP (84%) occurred at the low dose, but decreased to 48% at the high dose, supporting in vivo observations of high CL and nonlinearity.",Disposition of methylprednisolone and its sodium succinate prodrug in vivo and in perfused liver of rats: nonlinear and sequential first-pass elimination. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1880717/),%,84,67773,DB00860,Prednisolone
,1880717,hepatic extraction,"Extensive hepatic extraction of MP (84%) occurred at the low dose, but decreased to 48% at the high dose, supporting in vivo observations of high CL and nonlinearity.",Disposition of methylprednisolone and its sodium succinate prodrug in vivo and in perfused liver of rats: nonlinear and sequential first-pass elimination. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1880717/),%,48,67774,DB00860,Prednisolone
,1880717,Extraction,"Extraction of MS was also high (83%), but MP availability was slight (8%).",Disposition of methylprednisolone and its sodium succinate prodrug in vivo and in perfused liver of rats: nonlinear and sequential first-pass elimination. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1880717/),%,83,67775,DB00860,Prednisolone
,1880717,fraction of MS metabolized,The MS and MP data were fitted to a sequential first-pass model yielding an average fraction of MS metabolized-to-MP value of 0.22.,Disposition of methylprednisolone and its sodium succinate prodrug in vivo and in perfused liver of rats: nonlinear and sequential first-pass elimination. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1880717/),,0,67776,DB00860,Prednisolone
,15848557,AUC,"The percentage of patients with adequate therapeutic exposure (target AUC 30-60 microg.h/mL) of mycophenolic acid is 55%, 86%, and 100% at days 14, 90, and 180 postgrafting.",Standard dose enteric-coated mycophenolate sodium (myfortic) delivers rapid therapeutic mycophenolic acid exposure in kidney transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15848557/),[h·μg] / [ml],30-60,68914,DB00860,Prednisolone
,15848557,AUC0-12 h,The patients' mean +/- SD body weight was 48.1 +/- 8.8 kg; their mean (range) values of AUC0-12 h for MPA were 73.9 +/- 49.5 microg.h/ml (31.9-190) on day 1 and 74.3 +/- 44.3 (30.5-178) microg.h/ml on day 14.,Standard dose enteric-coated mycophenolate sodium (myfortic) delivers rapid therapeutic mycophenolic acid exposure in kidney transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15848557/),[h·μg] / [ml],73.9,68915,DB00860,Prednisolone
,15848557,AUC0-12 h,The patients' mean +/- SD body weight was 48.1 +/- 8.8 kg; their mean (range) values of AUC0-12 h for MPA were 73.9 +/- 49.5 microg.h/ml (31.9-190) on day 1 and 74.3 +/- 44.3 (30.5-178) microg.h/ml on day 14.,Standard dose enteric-coated mycophenolate sodium (myfortic) delivers rapid therapeutic mycophenolic acid exposure in kidney transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15848557/),[h·μg] / [ml],74.3,68916,DB00860,Prednisolone
,671172,half-life,Peak prednisolone levels occurred one to two hours after ingestion; half-life studies gave a mean value of 132 minutes in most children.,"Plasma levels, half-life values, and correlation with physiologic assays for growth and immunity. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/671172/),min,132,69593,DB00860,Prednisolone
,10228984,half-lives,"The in vitro half-lives of 8 and 9 in human serum were 18.2 and 43.8 hours, respectively.","Examination on biological activities and fates of new steroids, steroid-17-yl methyl glycolate derivatives. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10228984/),h,18.2,69622,DB00860,Prednisolone
,10228984,half-lives,"The in vitro half-lives of 8 and 9 in human serum were 18.2 and 43.8 hours, respectively.","Examination on biological activities and fates of new steroids, steroid-17-yl methyl glycolate derivatives. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10228984/),h,43.8,69623,DB00860,Prednisolone
,10228984,total body clearance,"The total body clearance of 8 was 1734 ml x hr(-1) x kg(-1), which was about 12 times larger than that of dexamethasone.","Examination on biological activities and fates of new steroids, steroid-17-yl methyl glycolate derivatives. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10228984/),[ml] / [hr·kg],1734,69624,DB00860,Prednisolone
,8406379,peak plasma levels,The plasma pharmacokinetics were described by a one-compartment open model with peak plasma levels of 6.9 +/- 2.5 micrograms/ml.,Pharmacokinetics of high dose methylprednisolone and use in hematological malignancies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8406379/),[μg] / [ml],6.9,69689,DB00860,Prednisolone
,8406379,relative oral bioavailability,Mean relative oral bioavailability was generally high (91 +/- 27 per cent).,Pharmacokinetics of high dose methylprednisolone and use in hematological malignancies. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8406379/),%,91,69690,DB00860,Prednisolone
,2596127,clearance,Prednisolone clearance before and after ketoconazole therapy was not significantly different (160 +/- 38 vs. 148 +/- 23 mL/h/kg).,Steroid-specific effects of ketoconazole on corticosteroid disposition: unaltered prednisolone elimination. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2596127/),[ml] / [h·kg],160,69779,DB00860,Prednisolone
,2596127,clearance,Prednisolone clearance before and after ketoconazole therapy was not significantly different (160 +/- 38 vs. 148 +/- 23 mL/h/kg).,Steroid-specific effects of ketoconazole on corticosteroid disposition: unaltered prednisolone elimination. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2596127/),[ml] / [h·kg],148,69780,DB00860,Prednisolone
,2596127,mean residence time,"In addition, no significant differences were found in mean residence time (5.03 +/- 0.69 vs. 6.18 +/- 1.77 h), terminal slope (0.23 +/- 0.03 vs. 0.19 +/- 0.05 h-1), or volume of distribution (0.79 +/- 0.11 vs. 0.84 +/- 0.12 L/kg).",Steroid-specific effects of ketoconazole on corticosteroid disposition: unaltered prednisolone elimination. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2596127/),h,5.03,69781,DB00860,Prednisolone
,2596127,mean residence time,"In addition, no significant differences were found in mean residence time (5.03 +/- 0.69 vs. 6.18 +/- 1.77 h), terminal slope (0.23 +/- 0.03 vs. 0.19 +/- 0.05 h-1), or volume of distribution (0.79 +/- 0.11 vs. 0.84 +/- 0.12 L/kg).",Steroid-specific effects of ketoconazole on corticosteroid disposition: unaltered prednisolone elimination. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2596127/),h,6.18,69782,DB00860,Prednisolone
,2596127,terminal slope,"In addition, no significant differences were found in mean residence time (5.03 +/- 0.69 vs. 6.18 +/- 1.77 h), terminal slope (0.23 +/- 0.03 vs. 0.19 +/- 0.05 h-1), or volume of distribution (0.79 +/- 0.11 vs. 0.84 +/- 0.12 L/kg).",Steroid-specific effects of ketoconazole on corticosteroid disposition: unaltered prednisolone elimination. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2596127/),1/[h],0.23,69783,DB00860,Prednisolone
,2596127,terminal slope,"In addition, no significant differences were found in mean residence time (5.03 +/- 0.69 vs. 6.18 +/- 1.77 h), terminal slope (0.23 +/- 0.03 vs. 0.19 +/- 0.05 h-1), or volume of distribution (0.79 +/- 0.11 vs. 0.84 +/- 0.12 L/kg).",Steroid-specific effects of ketoconazole on corticosteroid disposition: unaltered prednisolone elimination. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2596127/),1/[h],0.19,69784,DB00860,Prednisolone
,2596127,volume of distribution,"In addition, no significant differences were found in mean residence time (5.03 +/- 0.69 vs. 6.18 +/- 1.77 h), terminal slope (0.23 +/- 0.03 vs. 0.19 +/- 0.05 h-1), or volume of distribution (0.79 +/- 0.11 vs. 0.84 +/- 0.12 L/kg).",Steroid-specific effects of ketoconazole on corticosteroid disposition: unaltered prednisolone elimination. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2596127/),[l] / [kg],0.79,69785,DB00860,Prednisolone
,2596127,volume of distribution,"In addition, no significant differences were found in mean residence time (5.03 +/- 0.69 vs. 6.18 +/- 1.77 h), terminal slope (0.23 +/- 0.03 vs. 0.19 +/- 0.05 h-1), or volume of distribution (0.79 +/- 0.11 vs. 0.84 +/- 0.12 L/kg).",Steroid-specific effects of ketoconazole on corticosteroid disposition: unaltered prednisolone elimination. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2596127/),[l] / [kg],0.84,69786,DB00860,Prednisolone
,2179900,formation rate constant,The prodrug ester MPHS yields MP with an average formation rate constant of 0.70 +/- 0.29 hr-1.,Pharmacokinetics of methylprednisolone sodium succinate and methylprednisolone in patients undergoing cardiopulmonary bypass. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2179900/),1/[h],0.70,69912,DB00860,Prednisolone
,2285202,Maximum prednisolone concentrations,Maximum prednisolone concentrations measured after ingestion of prednisone are higher (535 +/- 32 ng/ml) and occur earlier than after taking prednisolone sodium metasulfobenzoate (198 +/- 114 ng/ml) (p less than 0.001).,[Pharmacokinetic parameters of prednisone and prednisolone in healthy volunteers]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2285202/),[ng] / [ml],535,71110,DB00860,Prednisolone
,2285202,Maximum prednisolone concentrations,Maximum prednisolone concentrations measured after ingestion of prednisone are higher (535 +/- 32 ng/ml) and occur earlier than after taking prednisolone sodium metasulfobenzoate (198 +/- 114 ng/ml) (p less than 0.001).,[Pharmacokinetic parameters of prednisone and prednisolone in healthy volunteers]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2285202/),[ng] / [ml],198,71111,DB00860,Prednisolone
,3691602,clearance,During prednisolone administration antipyrine clearance decreased from 54.9 +/- 14.8 to 51.7 +/- 14.6 ml/min (mean +/- SD; p less than 0.05).,Influence of prednisolone on antipyrine elimination in patients with obstructive lung disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3691602/),[ml] / [min],54.9,72209,DB00860,Prednisolone
,3691602,clearance,During prednisolone administration antipyrine clearance decreased from 54.9 +/- 14.8 to 51.7 +/- 14.6 ml/min (mean +/- SD; p less than 0.05).,Influence of prednisolone on antipyrine elimination in patients with obstructive lung disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3691602/),[ml] / [min],51.7,72210,DB00860,Prednisolone
,8583374,Area under the curves (AUC),"Area under the curves (AUC) of prednisolone before and after the treatment decreased from 0.94 to 0.78 mg h L-1 (P < 0.05) in the Sho-saiko-To group, increased from 0.92 to 1.06 mg h L-1 (P < 0.01) in the Saiboku-To group, and did not change in the Sairei-To group.",Different effects of traditional Chinese medicines containing similar herbal constituents on prednisolone pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8583374/),[h·mg] / [l],0.94,73046,DB00860,Prednisolone
,8583374,Area under the curves (AUC),"Area under the curves (AUC) of prednisolone before and after the treatment decreased from 0.94 to 0.78 mg h L-1 (P < 0.05) in the Sho-saiko-To group, increased from 0.92 to 1.06 mg h L-1 (P < 0.01) in the Saiboku-To group, and did not change in the Sairei-To group.",Different effects of traditional Chinese medicines containing similar herbal constituents on prednisolone pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8583374/),[h·mg] / [l],0,73047,DB00860,Prednisolone
,8583374,Area under the curves (AUC),"Area under the curves (AUC) of prednisolone before and after the treatment decreased from 0.94 to 0.78 mg h L-1 (P < 0.05) in the Sho-saiko-To group, increased from 0.92 to 1.06 mg h L-1 (P < 0.01) in the Saiboku-To group, and did not change in the Sairei-To group.",Different effects of traditional Chinese medicines containing similar herbal constituents on prednisolone pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8583374/),[h·mg] / [l],0.92,73048,DB00860,Prednisolone
,8583374,Area under the curves (AUC),"Area under the curves (AUC) of prednisolone before and after the treatment decreased from 0.94 to 0.78 mg h L-1 (P < 0.05) in the Sho-saiko-To group, increased from 0.92 to 1.06 mg h L-1 (P < 0.01) in the Saiboku-To group, and did not change in the Sairei-To group.",Different effects of traditional Chinese medicines containing similar herbal constituents on prednisolone pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8583374/),[h·mg] / [l],1,73049,DB00860,Prednisolone
,30963091,absorption half-life,"The absorption half-life into plasma was 1 h, while that into pericardial fluid was 9.4 h, which led to a median time-to-maximum concentration in plasma of 2.0 h versus 5.0 h in pericardial fluid [p = 0.048].","Detectable prednisolone is delayed in pericardial fluid, compared with plasma of patients with tuberculous pericarditis: A pilot study. ","t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30963091/),h,1,76480,DB00860,Prednisolone
,30963091,absorption half-life,"The absorption half-life into plasma was 1 h, while that into pericardial fluid was 9.4 h, which led to a median time-to-maximum concentration in plasma of 2.0 h versus 5.0 h in pericardial fluid [p = 0.048].","Detectable prednisolone is delayed in pericardial fluid, compared with plasma of patients with tuberculous pericarditis: A pilot study. ","t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30963091/),h,9.4,76481,DB00860,Prednisolone
,30963091,time-to-maximum concentration,"The absorption half-life into plasma was 1 h, while that into pericardial fluid was 9.4 h, which led to a median time-to-maximum concentration in plasma of 2.0 h versus 5.0 h in pericardial fluid [p = 0.048].","Detectable prednisolone is delayed in pericardial fluid, compared with plasma of patients with tuberculous pericarditis: A pilot study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30963091/),h,2.0,76482,DB00860,Prednisolone
,30963091,time-to-maximum concentration,"The absorption half-life into plasma was 1 h, while that into pericardial fluid was 9.4 h, which led to a median time-to-maximum concentration in plasma of 2.0 h versus 5.0 h in pericardial fluid [p = 0.048].","Detectable prednisolone is delayed in pericardial fluid, compared with plasma of patients with tuberculous pericarditis: A pilot study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30963091/),h,5.0,76483,DB00860,Prednisolone
,30963091,-to-plasma Cmax peak concentration ratio,"The pericardial fluid-to-plasma Cmax peak concentration ratio was 0.28 (p = 0.032), while the AUC0-24 ratio was 0.793.","Detectable prednisolone is delayed in pericardial fluid, compared with plasma of patients with tuberculous pericarditis: A pilot study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30963091/),,0.28,76484,DB00860,Prednisolone
,30963091,AUC0-24 ratio,"The pericardial fluid-to-plasma Cmax peak concentration ratio was 0.28 (p = 0.032), while the AUC0-24 ratio was 0.793.","Detectable prednisolone is delayed in pericardial fluid, compared with plasma of patients with tuberculous pericarditis: A pilot study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30963091/),,0.793,76485,DB00860,Prednisolone
,10707113,Vss,Male control rats cleared prednisolone faster [3.68 +/- 1.30 (males) vs 1.01 +/- 0.7 l/h/kg; p < 0.05] and had larger Vss (1.38 +/- 0.459 vs 0.394 +/- 0.500 l/kg; p < 0.05) than females both due largely to lesser plasma protein binding.,Pharmacokinetic and pharmacodynamic interactions between dehydroepiandrosterone and prednisolone in the rat. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10707113/),[l] / [kg],1.38,78561,DB00860,Prednisolone
,10707113,Vss,Male control rats cleared prednisolone faster [3.68 +/- 1.30 (males) vs 1.01 +/- 0.7 l/h/kg; p < 0.05] and had larger Vss (1.38 +/- 0.459 vs 0.394 +/- 0.500 l/kg; p < 0.05) than females both due largely to lesser plasma protein binding.,Pharmacokinetic and pharmacodynamic interactions between dehydroepiandrosterone and prednisolone in the rat. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10707113/),[l] / [kg],0.394,78562,DB00860,Prednisolone
,7119300,time-to-peak concentration,"Tablet data demonstrated a time-to-peak concentration of 1.23 +/- 0.68 hr (SD), mean residence time of 5.1 +/- 0.49 hr, and absolute bioavailability (tablet/i.v.) of 97.5% +/-- 17.5%.",Bioavailability assessment of a liquid prednisone preparation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7119300/),h,1.23,78781,DB00860,Prednisolone
,7119300,mean residence time,"Tablet data demonstrated a time-to-peak concentration of 1.23 +/- 0.68 hr (SD), mean residence time of 5.1 +/- 0.49 hr, and absolute bioavailability (tablet/i.v.) of 97.5% +/-- 17.5%.",Bioavailability assessment of a liquid prednisone preparation. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7119300/),h,5.1,78782,DB00860,Prednisolone
,7119300,absolute bioavailability,"Tablet data demonstrated a time-to-peak concentration of 1.23 +/- 0.68 hr (SD), mean residence time of 5.1 +/- 0.49 hr, and absolute bioavailability (tablet/i.v.) of 97.5% +/-- 17.5%.",Bioavailability assessment of a liquid prednisone preparation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7119300/),%,97.5,78783,DB00860,Prednisolone
,7119300,time-to-peak concentration,"Liquid data demonstrated a significantly (p less than 0.01) shorter time-to-peak concentration, 0.54 +/- 0.20 hr, and mean residence time 4.6 +/- 0.34 hr, with no significant difference in absolute bioavailability (liquid/i.v.), 88.2% +/- 15.8%.",Bioavailability assessment of a liquid prednisone preparation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7119300/),h,0.54,78784,DB00860,Prednisolone
,7119300,mean residence time,"Liquid data demonstrated a significantly (p less than 0.01) shorter time-to-peak concentration, 0.54 +/- 0.20 hr, and mean residence time 4.6 +/- 0.34 hr, with no significant difference in absolute bioavailability (liquid/i.v.), 88.2% +/- 15.8%.",Bioavailability assessment of a liquid prednisone preparation. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7119300/),h,4.6,78785,DB00860,Prednisolone
,7119300,absolute bioavailability,"Liquid data demonstrated a significantly (p less than 0.01) shorter time-to-peak concentration, 0.54 +/- 0.20 hr, and mean residence time 4.6 +/- 0.34 hr, with no significant difference in absolute bioavailability (liquid/i.v.), 88.2% +/- 15.8%.",Bioavailability assessment of a liquid prednisone preparation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7119300/),%,88.2,78786,DB00860,Prednisolone
,26103520,maximum dose,"The median maximum dose of MMF was 60 mg/kg/day (range, 34-107).",Mycophenolate mofetil for treatment of steroid-refractory acute graft-versus-host disease after pediatric hematopoietic stem cell transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26103520/),[mg] / [d·kg],60,80473,DB00860,Prednisolone
,12189539,plasma half-life,Pharmacokinetic parameters of melphalan were not significantly altered with its plasma half-life 1.5 h.,Successful allogeneic blood stem cell transplantation for aplastic anemia in a patient with renal insufficiency requiring dialysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12189539/),h,1.5,80474,DB00860,Prednisolone
,15964317,recovery ratios,"When Dx metabolites were added to rat serum containing Dx, the recovery ratios using Antiserum-I showed 100 to 110% and were remarkably lower than those using Antiserum-II.",Pharmacokinetic interaction with digoxin and glucocorticoids in rats detected by radio-immunoassay using a novel specific antiserum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15964317/),%,100 to 110,83406,DB00860,Prednisolone
,3806166,CSF to plasma ratios,"The CSF to plasma ratios of dexamethasone and prednisolone following IV bolus administration were 0.15 +/- 0.02 and 0.08 +/- 0.03, respectively.",Differences in cerebrospinal fluid penetration of corticosteroids: possible relationship to the prevention of meningeal leukemia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3806166/),,0.15,83936,DB00860,Prednisolone
,3806166,CSF to plasma ratios,"The CSF to plasma ratios of dexamethasone and prednisolone following IV bolus administration were 0.15 +/- 0.02 and 0.08 +/- 0.03, respectively.",Differences in cerebrospinal fluid penetration of corticosteroids: possible relationship to the prevention of meningeal leukemia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3806166/),,0.08,83937,DB00860,Prednisolone
,3806166,protein binding,"Dexamethasone was 70% protein bound over a wide concentration range, while the protein binding of prednisolone was concentration dependent, ranging from 60% at 10 mumol/L to 95% at 0.5 mumol/L and below.",Differences in cerebrospinal fluid penetration of corticosteroids: possible relationship to the prevention of meningeal leukemia. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3806166/),%,60,83938,DB00860,Prednisolone
,3806166,protein binding,"Dexamethasone was 70% protein bound over a wide concentration range, while the protein binding of prednisolone was concentration dependent, ranging from 60% at 10 mumol/L to 95% at 0.5 mumol/L and below.",Differences in cerebrospinal fluid penetration of corticosteroids: possible relationship to the prevention of meningeal leukemia. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3806166/),%,95,83939,DB00860,Prednisolone
,2966937,peak plasma levels,"Pharmacokinetic values varied considerably, with peak plasma levels ranging from 1.2 to 6.1 micrograms/ml between 20 and 120 minutes, and T 1/2 values of 77 to 648 minutes.",[Pharmacokinetics of prednisolone in children. Study of a correlation with tolerability and therapeutic effect in nephrosis]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2966937/),[μg] / [ml],1.2 to 6.1,84009,DB00860,Prednisolone
,2966937,T 1/2,"Pharmacokinetic values varied considerably, with peak plasma levels ranging from 1.2 to 6.1 micrograms/ml between 20 and 120 minutes, and T 1/2 values of 77 to 648 minutes.",[Pharmacokinetics of prednisolone in children. Study of a correlation with tolerability and therapeutic effect in nephrosis]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2966937/),min,77 to 648,84010,DB00860,Prednisolone
,2966937,T 1/2,"Within this scattering of values, some patients were clearly outside the mean T 1/2 value (3.1 +/- 1 hours) due to a particularly fast or slow metabolisation of the drug.",[Pharmacokinetics of prednisolone in children. Study of a correlation with tolerability and therapeutic effect in nephrosis]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2966937/),h,3.1,84011,DB00860,Prednisolone
over,17520809,Recovery,Recovery of LC-MS method for TP in plasma was over 75%.,[Pharmacokinetics of triptolide in Beagle dogs]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17520809/),%,75,84762,DB00860,Prednisolone
,17520809,T1/2beta,The T1/2beta was (2.5 +/- 0.8) h after intravenous administration of TP at the dose of 0.05 mg x kg(-1).,[Pharmacokinetics of triptolide in Beagle dogs]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17520809/),h,2.5,84763,DB00860,Prednisolone
,17520809,absolute bioavailability,The absolute bioavailability of TP after ig administration of 0.05 mg x kg(-1) was (75 +/- 17)%.,[Pharmacokinetics of triptolide in Beagle dogs]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17520809/),%,75,84764,DB00860,Prednisolone
,901703,peak plasma prednisolone concentration,"The mean peak plasma prednisolone concentration after the enteric-coated preparation, 199 ng ml-1, was significantly lower than after the plain tablet, 268 ng ml-1, and occurred later, at 4.69 h compared with 1.72 h.",Plasma prednisolone levels in man following administration in plain and enteric-coated forms. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/901703/),[ng] / [ml],199,85210,DB00860,Prednisolone
,901703,peak plasma prednisolone concentration,"The mean peak plasma prednisolone concentration after the enteric-coated preparation, 199 ng ml-1, was significantly lower than after the plain tablet, 268 ng ml-1, and occurred later, at 4.69 h compared with 1.72 h.",Plasma prednisolone levels in man following administration in plain and enteric-coated forms. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/901703/),[ng] / [ml],268,85211,DB00860,Prednisolone
,21982386,AUC(0-9),"Mean total prednisolone AUC(0-9), prednisone CL/F at steady state, and half-life were 1094 (range, 467-2404) ng/h/mL, 11 (range, 6.7-13.7) L/hr, and 2.6 (range, 1.3-3.9) hours.","Pharmacokinetics of prednisolone at steady state in young patients with systemic lupus erythematosus on prednisone therapy: an open-label, single-dose study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21982386/),[ng] / [h·ml],1094,85858,DB00860,Prednisolone
,21982386,CL/F at steady state,"Mean total prednisolone AUC(0-9), prednisone CL/F at steady state, and half-life were 1094 (range, 467-2404) ng/h/mL, 11 (range, 6.7-13.7) L/hr, and 2.6 (range, 1.3-3.9) hours.","Pharmacokinetics of prednisolone at steady state in young patients with systemic lupus erythematosus on prednisone therapy: an open-label, single-dose study. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21982386/),[l] / [h],11,85859,DB00860,Prednisolone
,21982386,half-life,"Mean total prednisolone AUC(0-9), prednisone CL/F at steady state, and half-life were 1094 (range, 467-2404) ng/h/mL, 11 (range, 6.7-13.7) L/hr, and 2.6 (range, 1.3-3.9) hours.","Pharmacokinetics of prednisolone at steady state in young patients with systemic lupus erythematosus on prednisone therapy: an open-label, single-dose study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21982386/),h,2.6,85860,DB00860,Prednisolone
,21982386,AUC(0-9),"Mean total prednisolone AUC(0-9) normalized to prednisone dose by weight was 4361 (range, 1136-9580) ng/h/mL/mg/kg.","Pharmacokinetics of prednisolone at steady state in young patients with systemic lupus erythematosus on prednisone therapy: an open-label, single-dose study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21982386/),[ng] / [h·kg·mg·ml],4361,85861,DB00860,Prednisolone
,21982386,C(max),"Mean total prednisolone C(max) normalized to prednisone dose by weight was 1097 (range, 301-2211) ng/mL/mg/kg at 1.84 (range, 0.48-4) hours (T(max)).","Pharmacokinetics of prednisolone at steady state in young patients with systemic lupus erythematosus on prednisone therapy: an open-label, single-dose study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21982386/),[ng] / [kg·mg·ml],1097,85862,DB00860,Prednisolone
,3909980,elimination half life,Results show important variability between patients: the elimination half life was 2.70 +/- 0.78 hr.; Tmax time to reach Cmax was 2.10 +/- 1.08 hr.; Maximal concentration (Cmax) was 474 +/- 153 ng/ml.,[Pharmacokinetics of prednisone after oral administration in children with renal grafts. Changes induced by phenobarbital and renal insufficiency]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3909980/),h,2.70,86144,DB00860,Prednisolone
,3909980,Tmax time to reach Cmax,Results show important variability between patients: the elimination half life was 2.70 +/- 0.78 hr.; Tmax time to reach Cmax was 2.10 +/- 1.08 hr.; Maximal concentration (Cmax) was 474 +/- 153 ng/ml.,[Pharmacokinetics of prednisone after oral administration in children with renal grafts. Changes induced by phenobarbital and renal insufficiency]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3909980/),h,2.10,86145,DB00860,Prednisolone
,3909980,Maximal concentration (Cmax),Results show important variability between patients: the elimination half life was 2.70 +/- 0.78 hr.; Tmax time to reach Cmax was 2.10 +/- 1.08 hr.; Maximal concentration (Cmax) was 474 +/- 153 ng/ml.,[Pharmacokinetics of prednisone after oral administration in children with renal grafts. Changes induced by phenobarbital and renal insufficiency]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3909980/),[ng] / [ml],474,86146,DB00860,Prednisolone
,3909980,urinary excretion,"With respect to the dose of steroid administered, the urinary excretion of corticosteroids: 17-hydroxycorticosteroids was 12.9 +/- 7.4% and that of unchanged prednisolone 2.8 +/- 3.1%.",[Pharmacokinetics of prednisone after oral administration in children with renal grafts. Changes induced by phenobarbital and renal insufficiency]. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3909980/),%,12.9,86147,DB00860,Prednisolone
,3909980,urinary excretion,"With respect to the dose of steroid administered, the urinary excretion of corticosteroids: 17-hydroxycorticosteroids was 12.9 +/- 7.4% and that of unchanged prednisolone 2.8 +/- 3.1%.",[Pharmacokinetics of prednisone after oral administration in children with renal grafts. Changes induced by phenobarbital and renal insufficiency]. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3909980/),%,2.8,86148,DB00860,Prednisolone
greater,7540071,time to an absolute neutrophil count of,The median time to an absolute neutrophil count of greater than 500/microL was 15 days for patients receiving FK506 alone or FK506 plus methylprednisolone and 23 days for FK506 plus short MTX.,Tacrolimus (FK506) alone or in combination with methotrexate or methylprednisolone for the prevention of acute graft-versus-host disease after marrow transplantation from HLA-matched siblings: a single-center study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7540071/),d,500,87809,DB00860,Prednisolone
,7540071,time to an absolute neutrophil count of,The median time to an absolute neutrophil count of greater than 500/microL was 15 days for patients receiving FK506 alone or FK506 plus methylprednisolone and 23 days for FK506 plus short MTX.,Tacrolimus (FK506) alone or in combination with methotrexate or methylprednisolone for the prevention of acute graft-versus-host disease after marrow transplantation from HLA-matched siblings: a single-center study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7540071/),d,15,87810,DB00860,Prednisolone
,7540071,time to an absolute neutrophil count of,The median time to an absolute neutrophil count of greater than 500/microL was 15 days for patients receiving FK506 alone or FK506 plus methylprednisolone and 23 days for FK506 plus short MTX.,Tacrolimus (FK506) alone or in combination with methotrexate or methylprednisolone for the prevention of acute graft-versus-host disease after marrow transplantation from HLA-matched siblings: a single-center study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7540071/),d,23,87811,DB00860,Prednisolone
,7540071,bioavailability,"The mean bioavailability after oral administration in these same three groups was 0.49 +/- 0.1, 0.27 +/- 0.12, and 0.16 +/- 0.08, respectively (P = .003).",Tacrolimus (FK506) alone or in combination with methotrexate or methylprednisolone for the prevention of acute graft-versus-host disease after marrow transplantation from HLA-matched siblings: a single-center study. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7540071/),,0.49,87812,DB00860,Prednisolone
,7540071,bioavailability,"The mean bioavailability after oral administration in these same three groups was 0.49 +/- 0.1, 0.27 +/- 0.12, and 0.16 +/- 0.08, respectively (P = .003).",Tacrolimus (FK506) alone or in combination with methotrexate or methylprednisolone for the prevention of acute graft-versus-host disease after marrow transplantation from HLA-matched siblings: a single-center study. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7540071/),,0.27,87813,DB00860,Prednisolone
,7540071,bioavailability,"The mean bioavailability after oral administration in these same three groups was 0.49 +/- 0.1, 0.27 +/- 0.12, and 0.16 +/- 0.08, respectively (P = .003).",Tacrolimus (FK506) alone or in combination with methotrexate or methylprednisolone for the prevention of acute graft-versus-host disease after marrow transplantation from HLA-matched siblings: a single-center study. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7540071/),,0.16,87814,DB00860,Prednisolone
,26638031,Recoveries,Recoveries of the analytes of interest in milk samples were in the ranges of 84.2-101.4%.,"Simultaneous detection and comparative pharmacokinetics of amoxicillin, clavulanic acid and prednisolone in cows' milk by UPLC-MS/MS. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26638031/),%,84.2-101.4,88594,DB00860,Prednisolone
,27721963,whole blood concentration,The mean±SD administered daily dose of tacrolimus during the first three weeks after transplantation was 0.085±0.024 mg/kg of IBW that resulted in a mean±SD whole blood concentration of 10.34±5.44 ng/mL.,Tacrolimus Dose Requirement in Iranian Kidney Transplant Recipients within the First Three Weeks after Transplantation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27721963/),ng,10,90701,DB00860,Prednisolone
,8227476,clearance (CL),MPHS clearance (CL) was significantly reduced in the CLD group (495 vs. 1389 mL/hr/kg) whereas volume of distribution (Vss) of MPHS (about 0.35 1/kg) did not differ.,Pharmacokinetics of methylprednisolone hemisuccinate and methylprednisolone in chronic liver disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8227476/),[ml] / [h·kg],495,91971,DB00860,Prednisolone
,8227476,clearance (CL),MPHS clearance (CL) was significantly reduced in the CLD group (495 vs. 1389 mL/hr/kg) whereas volume of distribution (Vss) of MPHS (about 0.35 1/kg) did not differ.,Pharmacokinetics of methylprednisolone hemisuccinate and methylprednisolone in chronic liver disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8227476/),[ml] / [h·kg],1389,91972,DB00860,Prednisolone
,8227476,volume of distribution (Vss),MPHS clearance (CL) was significantly reduced in the CLD group (495 vs. 1389 mL/hr/kg) whereas volume of distribution (Vss) of MPHS (about 0.35 1/kg) did not differ.,Pharmacokinetics of methylprednisolone hemisuccinate and methylprednisolone in chronic liver disease. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8227476/),[1] / [kg],0.35,91973,DB00860,Prednisolone
,8227476,"elimination half-life, t1/2 beta","The elimination half-life, t1/2 beta, was significantly longer in CLD (0.61 vs. 0.32 hr).",Pharmacokinetics of methylprednisolone hemisuccinate and methylprednisolone in chronic liver disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8227476/),h,0.61,91974,DB00860,Prednisolone
,8227476,"elimination half-life, t1/2 beta","The elimination half-life, t1/2 beta, was significantly longer in CLD (0.61 vs. 0.32 hr).",Pharmacokinetics of methylprednisolone hemisuccinate and methylprednisolone in chronic liver disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8227476/),h,0.32,91975,DB00860,Prednisolone
,8227476,percent recovery,The percent recovery of unchanged MPHS in urine was similar (about 9%) in both groups.,Pharmacokinetics of methylprednisolone hemisuccinate and methylprednisolone in chronic liver disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8227476/),%,9,91976,DB00860,Prednisolone
,8227476,clearance,"The kinetic parameters of MP did not differ between the two groups for: clearance (about 370 L/hr/kg IBW), Vss (about 1.3 L/kg), and t1/2 beta (about 3.0 hr).",Pharmacokinetics of methylprednisolone hemisuccinate and methylprednisolone in chronic liver disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8227476/),[l] / [h·kg],370,91977,DB00860,Prednisolone
,8227476,Vss,"The kinetic parameters of MP did not differ between the two groups for: clearance (about 370 L/hr/kg IBW), Vss (about 1.3 L/kg), and t1/2 beta (about 3.0 hr).",Pharmacokinetics of methylprednisolone hemisuccinate and methylprednisolone in chronic liver disease. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8227476/),[l] / [kg],1.3,91978,DB00860,Prednisolone
,8227476,t1/2 beta,"The kinetic parameters of MP did not differ between the two groups for: clearance (about 370 L/hr/kg IBW), Vss (about 1.3 L/kg), and t1/2 beta (about 3.0 hr).",Pharmacokinetics of methylprednisolone hemisuccinate and methylprednisolone in chronic liver disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8227476/),h,3.0,91979,DB00860,Prednisolone
,8227476,suppression t1/2,The suppression t1/2 of cortisol after MPHS was longer (3.9 vs. 1.9 hr) indicating metabolic pathways for cortisol and MP are affected differently in CLD.,Pharmacokinetics of methylprednisolone hemisuccinate and methylprednisolone in chronic liver disease. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8227476/),h,3.9,91980,DB00860,Prednisolone
,8227476,suppression t1/2,The suppression t1/2 of cortisol after MPHS was longer (3.9 vs. 1.9 hr) indicating metabolic pathways for cortisol and MP are affected differently in CLD.,Pharmacokinetics of methylprednisolone hemisuccinate and methylprednisolone in chronic liver disease. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8227476/),h,1.9,91981,DB00860,Prednisolone
,9806224,t(1/2),The t(1/2) of the dexamethasone pretreatment group (14.4+/-0.7 min) was significantly shorter than that of the prednisolone group (20.9+/-1.5 min).,Effects of glucocorticoids on pharmacokinetics and pharmacodynamics of midazolam in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9806224/),min,14.4,93713,DB00860,Prednisolone
,9806224,t(1/2),The t(1/2) of the dexamethasone pretreatment group (14.4+/-0.7 min) was significantly shorter than that of the prednisolone group (20.9+/-1.5 min).,Effects of glucocorticoids on pharmacokinetics and pharmacodynamics of midazolam in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9806224/),min,20.9,93714,DB00860,Prednisolone
,29331063,flow rate,The mobile phase was a mixture of 0.1% formic acid in water (A) and acetonitrile (B) and was used at a flow rate of 0.6 mL/min.,Simultaneous pharmacokinetics and stability studies of physalins in rat plasma and intestinal bacteria culture media using liquid chromatography with mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29331063/),[ml] / [min],0.6,93763,DB00860,Prednisolone
,6113924,total kidney clearance (CIT),The total kidney clearance (CIT) of Pn ranged from 0.39 to 1.24 ml/min/100 g of rat body weight with approximately half of the Pn dose unaccountable for as either Pn or prednisone.,Prednisolone metabolism and excretion in the isolated perfused rat kidney. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6113924/),[ml] / [100·g·min],0.39 to 1.24,95959,DB00860,Prednisolone
,6113924,apparent percentage,The apparent percentage of the Pn dose excreted unchanged in the urine ranged from 1.9 to 6.4% and was not related to Pn dose.,Prednisolone metabolism and excretion in the isolated perfused rat kidney. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6113924/),%,1.9 to 6.4,95960,DB00860,Prednisolone
,1941630,mean residence time,The mean residence time decreased from 0.60 +/- 0.15 (control) to 0.43 +/- 0.10 hr with ketoconazole (P less than .05) after 5 mg/kg of MPL (free alcohol).,Effect of ketoconazole on methylprednisolone pharmacokinetics and receptor/gene-mediated pharmacodynamics. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1941630/),h,0.60,96350,DB00860,Prednisolone
,1941630,mean residence time,The mean residence time decreased from 0.60 +/- 0.15 (control) to 0.43 +/- 0.10 hr with ketoconazole (P less than .05) after 5 mg/kg of MPL (free alcohol).,Effect of ketoconazole on methylprednisolone pharmacokinetics and receptor/gene-mediated pharmacodynamics. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1941630/),h,0.43,96351,DB00860,Prednisolone
,1941630,area under the curve ratio,The methylprednisone to MPL area under the curve ratio decreased from 0.19 +/- 0.04 in control to 0.14 +/- 0.03 in ketoconazole-treated rats (P less than .05) due to altered interconversion between these steroids.,Effect of ketoconazole on methylprednisolone pharmacokinetics and receptor/gene-mediated pharmacodynamics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1941630/),,0.19,96352,DB00860,Prednisolone
,1941630,area under the curve ratio,The methylprednisone to MPL area under the curve ratio decreased from 0.19 +/- 0.04 in control to 0.14 +/- 0.03 in ketoconazole-treated rats (P less than .05) due to altered interconversion between these steroids.,Effect of ketoconazole on methylprednisolone pharmacokinetics and receptor/gene-mediated pharmacodynamics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1941630/),,0.14,96353,DB00860,Prednisolone
,8222483,clearance,Women (luteal phase) exhibited a greater methylprednisolone clearance (0.45 versus 0.29 L/hr/kg) and shorter elimination half-life (1.7 versus 2.6 hours) than men.,Gender-based effects on methylprednisolone pharmacokinetics and pharmacodynamics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8222483/),[l] / [h·kg],0.45,96565,DB00860,Prednisolone
,8222483,clearance,Women (luteal phase) exhibited a greater methylprednisolone clearance (0.45 versus 0.29 L/hr/kg) and shorter elimination half-life (1.7 versus 2.6 hours) than men.,Gender-based effects on methylprednisolone pharmacokinetics and pharmacodynamics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8222483/),[l] / [h·kg],0.29,96566,DB00860,Prednisolone
,8222483,elimination half-life,Women (luteal phase) exhibited a greater methylprednisolone clearance (0.45 versus 0.29 L/hr/kg) and shorter elimination half-life (1.7 versus 2.6 hours) than men.,Gender-based effects on methylprednisolone pharmacokinetics and pharmacodynamics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8222483/),h,1.7,96567,DB00860,Prednisolone
,8222483,elimination half-life,Women (luteal phase) exhibited a greater methylprednisolone clearance (0.45 versus 0.29 L/hr/kg) and shorter elimination half-life (1.7 versus 2.6 hours) than men.,Gender-based effects on methylprednisolone pharmacokinetics and pharmacodynamics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8222483/),h,2.6,96568,DB00860,Prednisolone
,8222483,50% inhibitory concentration (IC50),"A significantly smaller 50% inhibitory concentration (IC50) value (0.1 versus 1.7 ng/ml) was seen in the women for suppression of cortisol secretion, indicating increased sensitivity.",Gender-based effects on methylprednisolone pharmacokinetics and pharmacodynamics. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8222483/),[ng] / [ml],0.1,96569,DB00860,Prednisolone
,8222483,50% inhibitory concentration (IC50),"A significantly smaller 50% inhibitory concentration (IC50) value (0.1 versus 1.7 ng/ml) was seen in the women for suppression of cortisol secretion, indicating increased sensitivity.",Gender-based effects on methylprednisolone pharmacokinetics and pharmacodynamics. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8222483/),[ng] / [ml],1.7,96570,DB00860,Prednisolone
,3806371,plasma clearance,"Dose, however, had a marked effect on prednisolone pharmacokinetics, with mean plasma clearance decreasing from 6.18 to 3.07 L/h per kg and mean steady-state volume of distribution decreasing from 2.14 to 1.05 L/kg from the lower to higher steroid dose.",Dose-dependent pharmacokinetics of prednisolone in normal and adrenalectomized rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3806371/),[l] / [h·kg],6.18 to 3.07,97656,DB00860,Prednisolone
,3806371,steady-state volume of distribution,"Dose, however, had a marked effect on prednisolone pharmacokinetics, with mean plasma clearance decreasing from 6.18 to 3.07 L/h per kg and mean steady-state volume of distribution decreasing from 2.14 to 1.05 L/kg from the lower to higher steroid dose.",Dose-dependent pharmacokinetics of prednisolone in normal and adrenalectomized rats. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3806371/),[l] / [kg],2.14 to 1.05,97657,DB00860,Prednisolone
,3806371,Half-life,Half-life (0.50 hr) and mean residence time (0.35 hr) were unaffected by dose.,Dose-dependent pharmacokinetics of prednisolone in normal and adrenalectomized rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3806371/),h,0.50,97658,DB00860,Prednisolone
,3806371,mean residence time,Half-life (0.50 hr) and mean residence time (0.35 hr) were unaffected by dose.,Dose-dependent pharmacokinetics of prednisolone in normal and adrenalectomized rats. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3806371/),h,0.35,97659,DB00860,Prednisolone
,9865456,clearance,"A slower clearance of methylprednisolone was noted in the elderly (mean: 256 mL/hr/Kg) than in the young men (mean: 359 mL/hr/Kg; p < 0.05) during Phase II with no significant difference found between groups for volume of distribution, elimination rate constant or half-life.",CD4+ and CD8+ lymphocyte and cortisol response patterns in elderly and young males after methylprednisolone exposure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9865456/),[ml] / [h·kg],256,97722,DB00860,Prednisolone
,9865456,clearance,"A slower clearance of methylprednisolone was noted in the elderly (mean: 256 mL/hr/Kg) than in the young men (mean: 359 mL/hr/Kg; p < 0.05) during Phase II with no significant difference found between groups for volume of distribution, elimination rate constant or half-life.",CD4+ and CD8+ lymphocyte and cortisol response patterns in elderly and young males after methylprednisolone exposure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9865456/),[ml] / [h·kg],359,97723,DB00860,Prednisolone
,9865456,co,"A significantly smaller cortisol suppression ratio [0.36+/-0.11 (elderly) versus 0.58+/-0.11 (young), p = 0.01] which indicates a more profound cortisol suppression was noted.",CD4+ and CD8+ lymphocyte and cortisol response patterns in elderly and young males after methylprednisolone exposure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9865456/),,0.36,97724,DB00860,Prednisolone
,9865456,co,"A significantly smaller cortisol suppression ratio [0.36+/-0.11 (elderly) versus 0.58+/-0.11 (young), p = 0.01] which indicates a more profound cortisol suppression was noted.",CD4+ and CD8+ lymphocyte and cortisol response patterns in elderly and young males after methylprednisolone exposure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9865456/),,0.58,97725,DB00860,Prednisolone
,9865456,suppression ratio,"A significantly smaller cortisol suppression ratio [0.36+/-0.11 (elderly) versus 0.58+/-0.11 (young), p = 0.01] which indicates a more profound cortisol suppression was noted.",CD4+ and CD8+ lymphocyte and cortisol response patterns in elderly and young males after methylprednisolone exposure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9865456/),,0.36,97726,DB00860,Prednisolone
,9865456,suppression ratio,"A significantly smaller cortisol suppression ratio [0.36+/-0.11 (elderly) versus 0.58+/-0.11 (young), p = 0.01] which indicates a more profound cortisol suppression was noted.",CD4+ and CD8+ lymphocyte and cortisol response patterns in elderly and young males after methylprednisolone exposure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9865456/),,0.58,97727,DB00860,Prednisolone
,3972231,peak serum interferon concentration,The mean peak serum interferon concentration ranged from 93 U/ml on day 1 in the first group to 1271 U/ml on day 28 in the fourth group.,"Recombinant leukocyte a interferon treatment in patients with chronic hepatitis B virus infection. Pharmacokinetics, tolerance, and biologic effects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3972231/),[u] / [ml],93,98273,DB00860,Prednisolone
,3972231,peak serum interferon concentration,The mean peak serum interferon concentration ranged from 93 U/ml on day 1 in the first group to 1271 U/ml on day 28 in the fourth group.,"Recombinant leukocyte a interferon treatment in patients with chronic hepatitis B virus infection. Pharmacokinetics, tolerance, and biologic effects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3972231/),[u] / [ml],1271,98274,DB00860,Prednisolone
,8549229,half-life,"The pharmacokinetic parameters tested and their means were a half-life of 1.150 +/- 0.233 (+/- SEM) hours, an excretion constant of 0.686 +/- 0.018 Ke/hr, a volume of distribution of 607 +/- 109 ml/kg, and a clearance rate of 374 +/- 47 ml/hr/kg.",Pharmacokinetics of intravenously administration of prednisolone in the horse as determined by radioimmunoassay. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8549229/),h,1.150,98700,DB00860,Prednisolone
,8549229,excretion constant,"The pharmacokinetic parameters tested and their means were a half-life of 1.150 +/- 0.233 (+/- SEM) hours, an excretion constant of 0.686 +/- 0.018 Ke/hr, a volume of distribution of 607 +/- 109 ml/kg, and a clearance rate of 374 +/- 47 ml/hr/kg.",Pharmacokinetics of intravenously administration of prednisolone in the horse as determined by radioimmunoassay. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8549229/),[ke] / [h],0.686,98701,DB00860,Prednisolone
,8549229,volume of distribution,"The pharmacokinetic parameters tested and their means were a half-life of 1.150 +/- 0.233 (+/- SEM) hours, an excretion constant of 0.686 +/- 0.018 Ke/hr, a volume of distribution of 607 +/- 109 ml/kg, and a clearance rate of 374 +/- 47 ml/hr/kg.",Pharmacokinetics of intravenously administration of prednisolone in the horse as determined by radioimmunoassay. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8549229/),[ml] / [kg],607,98702,DB00860,Prednisolone
,8549229,clearance rate,"The pharmacokinetic parameters tested and their means were a half-life of 1.150 +/- 0.233 (+/- SEM) hours, an excretion constant of 0.686 +/- 0.018 Ke/hr, a volume of distribution of 607 +/- 109 ml/kg, and a clearance rate of 374 +/- 47 ml/hr/kg.",Pharmacokinetics of intravenously administration of prednisolone in the horse as determined by radioimmunoassay. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8549229/),[ml] / [h·kg],374,98703,DB00860,Prednisolone
,6213074,EC50,"The mean EC50 (+/- SD) for total prednisolone concentration following the oral and the i.v. dosing was 66.3 +/- 26.7 and 86.5 +/- 30.9 ng/ml, respectively; for free prednisolone concentration the corresponding values were 10.0 +/- 5.0 and 12.4 +/- 12.6 ng/ml.",Prednisolone pharmacodynamics assessed by inhibition of the mixed lymphocyte reaction. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6213074/),[ng] / [ml],66.3,99281,DB00860,Prednisolone
,6213074,EC50,"The mean EC50 (+/- SD) for total prednisolone concentration following the oral and the i.v. dosing was 66.3 +/- 26.7 and 86.5 +/- 30.9 ng/ml, respectively; for free prednisolone concentration the corresponding values were 10.0 +/- 5.0 and 12.4 +/- 12.6 ng/ml.",Prednisolone pharmacodynamics assessed by inhibition of the mixed lymphocyte reaction. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6213074/),[ng] / [ml],86.5,99282,DB00860,Prednisolone
,6213074,EC50,"The mean EC50 (+/- SD) for total prednisolone concentration following the oral and the i.v. dosing was 66.3 +/- 26.7 and 86.5 +/- 30.9 ng/ml, respectively; for free prednisolone concentration the corresponding values were 10.0 +/- 5.0 and 12.4 +/- 12.6 ng/ml.",Prednisolone pharmacodynamics assessed by inhibition of the mixed lymphocyte reaction. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6213074/),[ng] / [ml],10.0,99283,DB00860,Prednisolone
,6213074,EC50,"The mean EC50 (+/- SD) for total prednisolone concentration following the oral and the i.v. dosing was 66.3 +/- 26.7 and 86.5 +/- 30.9 ng/ml, respectively; for free prednisolone concentration the corresponding values were 10.0 +/- 5.0 and 12.4 +/- 12.6 ng/ml.",Prednisolone pharmacodynamics assessed by inhibition of the mixed lymphocyte reaction. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6213074/),[ng] / [ml],12.4,99284,DB00860,Prednisolone
,7440853,apparent half-lifes,The apparent half-lifes of prednisolone in the asthmatics and normals were 3.33 +/- 0.71 and 3.25 +/- 0.58 hr (mean +/- SD).,Prednisolone disposition in steroid-dependent asthmatics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7440853/),h,3.33,100047,DB00860,Prednisolone
,7440853,apparent half-lifes,The apparent half-lifes of prednisolone in the asthmatics and normals were 3.33 +/- 0.71 and 3.25 +/- 0.58 hr (mean +/- SD).,Prednisolone disposition in steroid-dependent asthmatics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7440853/),h,3.25,100048,DB00860,Prednisolone
,7440853,apparent plasma clearances,"The apparent plasma clearances of prednisolone were 201 +/- 54 and 198 +/- 38 ml/min/1.73 m2 and the apparent volumes of distribution were 50.8 +/- 11.7 and 53.5 +/- 13.5 L/1.73 m2 for the asthmatic and normal groups, respectively.",Prednisolone disposition in steroid-dependent asthmatics. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7440853/),[ml] / [1.73·m2·min],201,100049,DB00860,Prednisolone
,7440853,apparent plasma clearances,"The apparent plasma clearances of prednisolone were 201 +/- 54 and 198 +/- 38 ml/min/1.73 m2 and the apparent volumes of distribution were 50.8 +/- 11.7 and 53.5 +/- 13.5 L/1.73 m2 for the asthmatic and normal groups, respectively.",Prednisolone disposition in steroid-dependent asthmatics. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7440853/),[ml] / [1.73·m2·min],198,100050,DB00860,Prednisolone
,7440853,apparent volumes of distribution,"The apparent plasma clearances of prednisolone were 201 +/- 54 and 198 +/- 38 ml/min/1.73 m2 and the apparent volumes of distribution were 50.8 +/- 11.7 and 53.5 +/- 13.5 L/1.73 m2 for the asthmatic and normal groups, respectively.",Prednisolone disposition in steroid-dependent asthmatics. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7440853/),[l] / [1.73·m2],50.8,100051,DB00860,Prednisolone
,7440853,apparent volumes of distribution,"The apparent plasma clearances of prednisolone were 201 +/- 54 and 198 +/- 38 ml/min/1.73 m2 and the apparent volumes of distribution were 50.8 +/- 11.7 and 53.5 +/- 13.5 L/1.73 m2 for the asthmatic and normal groups, respectively.",Prednisolone disposition in steroid-dependent asthmatics. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7440853/),[l] / [1.73·m2],53.5,100052,DB00860,Prednisolone
,8061359,AUC (0-6 h),"On the 1st study, the dose-adjusted Aza AUC (0-6 h) ranged from 8.4 to 129.1 ngh*ml-1/mg*kg-1, mean 41.4 (+/- 37.6) ngh*ml-1/mg*kg-1.",Day-to-day variability in azathioprine pharmacokinetics in renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8061359/),[ngh] / [kg·mg·ml],8.4 to 129.1,100723,DB00860,Prednisolone
,8061359,AUC (0-6 h),"On the 1st study, the dose-adjusted Aza AUC (0-6 h) ranged from 8.4 to 129.1 ngh*ml-1/mg*kg-1, mean 41.4 (+/- 37.6) ngh*ml-1/mg*kg-1.",Day-to-day variability in azathioprine pharmacokinetics in renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8061359/),[ngh] / [kg·mg·ml],41.4,100724,DB00860,Prednisolone
,8061359,AUC (0-6 h),"The corresponding values for the dose-adjusted 6-MP AUC (0-6 h) ranged from 37.9 to 172.0 ngh*ml-1/mg*kg-1, mean 91.7 (+/- 50.7) ngh*ml-1/mg*kg-1.",Day-to-day variability in azathioprine pharmacokinetics in renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8061359/),[ngh] / [kg·mg·ml],37.9 to 172.0,100725,DB00860,Prednisolone
,8061359,AUC (0-6 h),"The corresponding values for the dose-adjusted 6-MP AUC (0-6 h) ranged from 37.9 to 172.0 ngh*ml-1/mg*kg-1, mean 91.7 (+/- 50.7) ngh*ml-1/mg*kg-1.",Day-to-day variability in azathioprine pharmacokinetics in renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8061359/),[ngh] / [kg·mg·ml],91.7,100726,DB00860,Prednisolone
,8061359,half-life,The mean half-life of Aza was 1.7 h and of 6-MP 1.2 h.,Day-to-day variability in azathioprine pharmacokinetics in renal transplant recipients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8061359/),h,1.7,100727,DB00860,Prednisolone
,8061359,half-life,The mean half-life of Aza was 1.7 h and of 6-MP 1.2 h.,Day-to-day variability in azathioprine pharmacokinetics in renal transplant recipients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8061359/),h,1.2,100728,DB00860,Prednisolone
,7324480,morning level,Cortisone showed a mean morning level of 440 nmol/l +/- 165 nmol/l and a half life of 4.8 hours.,"[The metabolism of hydrocortisone, prednisolone and fluocortolone (author's transl)]. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7324480/),[nM] / [l],440,101953,DB00860,Prednisolone
,7324480,half life,Cortisone showed a mean morning level of 440 nmol/l +/- 165 nmol/l and a half life of 4.8 hours.,"[The metabolism of hydrocortisone, prednisolone and fluocortolone (author's transl)]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7324480/),h,4.8,101954,DB00860,Prednisolone
,7324480,half life,"The half life of prednisolone was determined after intravenous injection of 25 mg and found to be 2.4 hours and that of fluocortolone, after oral administration of 60 mg, was calculated to be 1.7 hours.","[The metabolism of hydrocortisone, prednisolone and fluocortolone (author's transl)]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7324480/),h,2.4,101955,DB00860,Prednisolone
,7324480,half life,"The half life of prednisolone was determined after intravenous injection of 25 mg and found to be 2.4 hours and that of fluocortolone, after oral administration of 60 mg, was calculated to be 1.7 hours.","[The metabolism of hydrocortisone, prednisolone and fluocortolone (author's transl)]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7324480/),h,1.7,101956,DB00860,Prednisolone
,26403249,area under the plasma concentration-time curve,"Mean area under the plasma concentration-time curve was 2390 nmol h/L (±580) (SD) and 175 nmol h/L (±78) for total and free prednisolone, respectively.","Exploratory study of total and free prednisolone plasma exposure and cushingoid appearance, quality of life and biochemical toxicity in adult male kidney transplant recipients. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26403249/),[h·nM] / [l],2390,102244,DB00860,Prednisolone
,26403249,area under the plasma concentration-time curve,"Mean area under the plasma concentration-time curve was 2390 nmol h/L (±580) (SD) and 175 nmol h/L (±78) for total and free prednisolone, respectively.","Exploratory study of total and free prednisolone plasma exposure and cushingoid appearance, quality of life and biochemical toxicity in adult male kidney transplant recipients. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26403249/),[h·nM] / [l],175,102245,DB00860,Prednisolone
,30952111,Cmax,"Results Vaginal administration of PN suppositories was not bioequivalent to rectal administration: Cmax and AUC0-360 were significantly lower after vaginal compared to rectal administration: 22 ng/mL (109%) vs 161 ng/mL (28%), P < 0.001; 4390 ng/mL * min (116%) vs 40,302 ng/mL * min (26%), P < 0.001; (mean (coefficient of variation), respectively).",Emergency treatment of adrenal crisis with prednisone suppositories: a bioequivalence study in female patients with Addison's disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30952111/),[ng] / [ml],22,103741,DB00860,Prednisolone
,30952111,Cmax,"Results Vaginal administration of PN suppositories was not bioequivalent to rectal administration: Cmax and AUC0-360 were significantly lower after vaginal compared to rectal administration: 22 ng/mL (109%) vs 161 ng/mL (28%), P < 0.001; 4390 ng/mL * min (116%) vs 40,302 ng/mL * min (26%), P < 0.001; (mean (coefficient of variation), respectively).",Emergency treatment of adrenal crisis with prednisone suppositories: a bioequivalence study in female patients with Addison's disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30952111/),[ng] / [ml],161,103742,DB00860,Prednisolone
,30952111,Cmax,"Results Vaginal administration of PN suppositories was not bioequivalent to rectal administration: Cmax and AUC0-360 were significantly lower after vaginal compared to rectal administration: 22 ng/mL (109%) vs 161 ng/mL (28%), P < 0.001; 4390 ng/mL * min (116%) vs 40,302 ng/mL * min (26%), P < 0.001; (mean (coefficient of variation), respectively).",Emergency treatment of adrenal crisis with prednisone suppositories: a bioequivalence study in female patients with Addison's disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30952111/),[ng] / [min·ml],4390,103743,DB00860,Prednisolone
,30952111,AUC0-360,"Results Vaginal administration of PN suppositories was not bioequivalent to rectal administration: Cmax and AUC0-360 were significantly lower after vaginal compared to rectal administration: 22 ng/mL (109%) vs 161 ng/mL (28%), P < 0.001; 4390 ng/mL * min (116%) vs 40,302 ng/mL * min (26%), P < 0.001; (mean (coefficient of variation), respectively).",Emergency treatment of adrenal crisis with prednisone suppositories: a bioequivalence study in female patients with Addison's disease. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30952111/),[ng] / [min·ml],4390,103744,DB00860,Prednisolone
,30952111,AUC0-360,"Results Vaginal administration of PN suppositories was not bioequivalent to rectal administration: Cmax and AUC0-360 were significantly lower after vaginal compared to rectal administration: 22 ng/mL (109%) vs 161 ng/mL (28%), P < 0.001; 4390 ng/mL * min (116%) vs 40,302 ng/mL * min (26%), P < 0.001; (mean (coefficient of variation), respectively).",Emergency treatment of adrenal crisis with prednisone suppositories: a bioequivalence study in female patients with Addison's disease. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30952111/),[ng] / [min·ml],"40,302",103745,DB00860,Prednisolone
,2225699,clearance,"Eleven patients had unusually rapid methylprednisolone elimination (clearance, 565 to 837 ml/min/1.73 m2; population mean, [+/- SD] 380 +/- 100 ml/min/1.73 m2) without an identifiable cause.",Monitoring glucocorticoid therapy: a pharmacokinetic approach. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2225699/),[ml] / [1.73·m2·min],565 to 837,104355,DB00860,Prednisolone
,2225699,clearance,"Eleven patients had unusually rapid methylprednisolone elimination (clearance, 565 to 837 ml/min/1.73 m2; population mean, [+/- SD] 380 +/- 100 ml/min/1.73 m2) without an identifiable cause.",Monitoring glucocorticoid therapy: a pharmacokinetic approach. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2225699/),[ml] / [1.73·m2·min],380,104356,DB00860,Prednisolone
,17408218,bioavailability,The bioavailability studies in rats indicated that the carvedilol transdermal patches provided steady-state plasma concentrations with minimal fluctuations and improved bioavailability of 71% (for F3) and 62% (for F6) in comparison with oral administration.,Transdermal therapeutic system of carvedilol: effect of hydrophilic and hydrophobic matrix on in vitro and in vivo characteristics. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17408218/),%,71,107350,DB00860,Prednisolone
,17408218,bioavailability,The bioavailability studies in rats indicated that the carvedilol transdermal patches provided steady-state plasma concentrations with minimal fluctuations and improved bioavailability of 71% (for F3) and 62% (for F6) in comparison with oral administration.,Transdermal therapeutic system of carvedilol: effect of hydrophilic and hydrophobic matrix on in vitro and in vivo characteristics. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17408218/),%,62,107351,DB00860,Prednisolone
,3350994,systemic availability,"Using IV PN as reference, approximately 70% systemic availability was observed from both tablets, whereas using IV PL as reference, systemic availability was greater than unity.",Relative and absolute bioavailability of prednisone and prednisolone after separate oral and intravenous doses. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3350994/),%,70,107519,DB00860,Prednisolone
,19203724,relative bioavailability,"Whereas systemic exposure to budesonide was markedly lower in healthy subjects after the mouthwash compared to oral dosing (mean relative bioavailability 18%-36%), the systemic concentrations thereafter in patients were as high as those after the identical dose of oral budesonide.",Pharmacokinetics and pharmacodynamic action of budesonide after buccal administration in healthy subjects and patients with oral chronic graft-versus-host disease. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19203724/),%,18,109370,DB00860,Prednisolone
,19203724,relative bioavailability,"Whereas systemic exposure to budesonide was markedly lower in healthy subjects after the mouthwash compared to oral dosing (mean relative bioavailability 18%-36%), the systemic concentrations thereafter in patients were as high as those after the identical dose of oral budesonide.",Pharmacokinetics and pharmacodynamic action of budesonide after buccal administration in healthy subjects and patients with oral chronic graft-versus-host disease. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19203724/),%,36,109371,DB00860,Prednisolone
,25279405,whole blood clearance/bioavailability,"Tacrolimus whole blood clearance/bioavailability standardized to haematocrit of 45% and fat free mass of 60 kg was estimated to be 16.1 l h−1 [95% CI 12.6, 18.0 l h−1].",Improved prediction of tacrolimus concentrations early after kidney transplantation using theory-based pharmacokinetic modelling. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25279405/),[l] / [h],16.1,109434,DB00860,Prednisolone
,3361533,Vd,"Pharmacokinetic variables for methylprednisolone were Vd of 69.9 l, t1/2 of 2.96 h, total plasma clearance of 17.5 l/h.",Comparison of methylprednisolone (1 g i.v.) with prednisolone (1 g orally) in rheumatoid arthritis: a pharmacokinetic and clinical study. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3361533/),l,69.9,110205,DB00860,Prednisolone
,3361533,t1/2,"Pharmacokinetic variables for methylprednisolone were Vd of 69.9 l, t1/2 of 2.96 h, total plasma clearance of 17.5 l/h.",Comparison of methylprednisolone (1 g i.v.) with prednisolone (1 g orally) in rheumatoid arthritis: a pharmacokinetic and clinical study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3361533/),h,2.96,110206,DB00860,Prednisolone
,3361533,total plasma clearance,"Pharmacokinetic variables for methylprednisolone were Vd of 69.9 l, t1/2 of 2.96 h, total plasma clearance of 17.5 l/h.",Comparison of methylprednisolone (1 g i.v.) with prednisolone (1 g orally) in rheumatoid arthritis: a pharmacokinetic and clinical study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3361533/),[l] / [h],17.5,110207,DB00860,Prednisolone
,3361533,Vd,"Pharmacokinetic variables for prednisolone were Vd of 47.5 l, t1/2 of 3.08 h and total plasma clearance of 11.3 l/h.",Comparison of methylprednisolone (1 g i.v.) with prednisolone (1 g orally) in rheumatoid arthritis: a pharmacokinetic and clinical study. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3361533/),l,47.5,110208,DB00860,Prednisolone
,3361533,t1/2,"Pharmacokinetic variables for prednisolone were Vd of 47.5 l, t1/2 of 3.08 h and total plasma clearance of 11.3 l/h.",Comparison of methylprednisolone (1 g i.v.) with prednisolone (1 g orally) in rheumatoid arthritis: a pharmacokinetic and clinical study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3361533/),h,3.08,110209,DB00860,Prednisolone
,3361533,total plasma clearance,"Pharmacokinetic variables for prednisolone were Vd of 47.5 l, t1/2 of 3.08 h and total plasma clearance of 11.3 l/h.",Comparison of methylprednisolone (1 g i.v.) with prednisolone (1 g orally) in rheumatoid arthritis: a pharmacokinetic and clinical study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3361533/),[l] / [h],11.3,110210,DB00860,Prednisolone
,21256961,AUC,"However, in vivo bioavailability studies in rats showed the same plasma concentration-time profiles when dosing 10mg/kg halofantrine at two dose levels of F6H8, MCT or F6H8:MCT (1:1) (AUC ranged from 3058 to 3447hng/ml, T(max)∼6.0h, C(max) ranged from 168 to 265mg/ml).","A novel excipient, 1-perfluorohexyloctane shows limited utility for the oral delivery of poorly water-soluble drugs. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21256961/),[hng] / [ml],3058 to 3447,110524,DB00860,Prednisolone
,21256961,T(max),"However, in vivo bioavailability studies in rats showed the same plasma concentration-time profiles when dosing 10mg/kg halofantrine at two dose levels of F6H8, MCT or F6H8:MCT (1:1) (AUC ranged from 3058 to 3447hng/ml, T(max)∼6.0h, C(max) ranged from 168 to 265mg/ml).","A novel excipient, 1-perfluorohexyloctane shows limited utility for the oral delivery of poorly water-soluble drugs. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21256961/),h,∼6,110525,DB00860,Prednisolone
,21256961,T(max),"However, in vivo bioavailability studies in rats showed the same plasma concentration-time profiles when dosing 10mg/kg halofantrine at two dose levels of F6H8, MCT or F6H8:MCT (1:1) (AUC ranged from 3058 to 3447hng/ml, T(max)∼6.0h, C(max) ranged from 168 to 265mg/ml).","A novel excipient, 1-perfluorohexyloctane shows limited utility for the oral delivery of poorly water-soluble drugs. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21256961/),h,.0,110526,DB00860,Prednisolone
,21256961,C(max),"However, in vivo bioavailability studies in rats showed the same plasma concentration-time profiles when dosing 10mg/kg halofantrine at two dose levels of F6H8, MCT or F6H8:MCT (1:1) (AUC ranged from 3058 to 3447hng/ml, T(max)∼6.0h, C(max) ranged from 168 to 265mg/ml).","A novel excipient, 1-perfluorohexyloctane shows limited utility for the oral delivery of poorly water-soluble drugs. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21256961/),[mg] / [ml],168 to 265,110527,DB00860,Prednisolone
,21256961,T(max),"Generally, the addition of polysorbate 80 shortened the time to reach C(max) (T(max) ranged 1.3-4.5h), but had limited effect on the bioavailability from F6H8 or MCT in combination with polysorbate 80 (4:1) (AUC ranged from 3807 to 4403 (hng/ml)).","A novel excipient, 1-perfluorohexyloctane shows limited utility for the oral delivery of poorly water-soluble drugs. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21256961/),h,1.3-4.5,110528,DB00860,Prednisolone
,21256961,AUC,"Generally, the addition of polysorbate 80 shortened the time to reach C(max) (T(max) ranged 1.3-4.5h), but had limited effect on the bioavailability from F6H8 or MCT in combination with polysorbate 80 (4:1) (AUC ranged from 3807 to 4403 (hng/ml)).","A novel excipient, 1-perfluorohexyloctane shows limited utility for the oral delivery of poorly water-soluble drugs. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21256961/),[hng] / [ml],3807 to 4403,110529,DB00860,Prednisolone
,21256961,AUC,"Although a synergistic effect was obtained with halofantrine in F6H8:MCT:polysorbate 80 (2:2:1) (AUC 5574±675hng/ml; mean±SEM), it was not superior to dosing halofantrine in pure polysorbarte 80 (AUC 7370±579hng/ml; mean±SEM).","A novel excipient, 1-perfluorohexyloctane shows limited utility for the oral delivery of poorly water-soluble drugs. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21256961/),[hng] / [ml],5574,110530,DB00860,Prednisolone
,21256961,AUC,"Although a synergistic effect was obtained with halofantrine in F6H8:MCT:polysorbate 80 (2:2:1) (AUC 5574±675hng/ml; mean±SEM), it was not superior to dosing halofantrine in pure polysorbarte 80 (AUC 7370±579hng/ml; mean±SEM).","A novel excipient, 1-perfluorohexyloctane shows limited utility for the oral delivery of poorly water-soluble drugs. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21256961/),[hng] / [ml],7370,110531,DB00860,Prednisolone
,21998684,t(1/2),"These principles allow fabrication of formulations that exhibit either a fast, second-order (t(1/2) ~1 h), or a slow, zero-order release rate (t(1/2) ~ 50 h) kinetics.",Fabrication principles and their contribution to the superior in vivo therapeutic efficacy of nano-liposomes remote loaded with glucocorticoids. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21998684/),h,1,110829,DB00860,Prednisolone
,26242764,time to neutrophil engraftment,"Median (range) time to neutrophil engraftment (>500 cells/µL) and platelet engraftment (>20,000/mm(3) ) were 15 (12-28) and 25 (17-30) days, respectively.",Unrelated donor hematopoietic stem cell transplantation for the treatment of non-malignant genetic diseases: An alemtuzumab based regimen is associated with cure of clinical disease; earlier clearance of alemtuzumab may be associated with graft rejection. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26242764/),d,15,111482,DB00860,Prednisolone
,26242764,time to neutrophil engraftment,"Median (range) time to neutrophil engraftment (>500 cells/µL) and platelet engraftment (>20,000/mm(3) ) were 15 (12-28) and 25 (17-30) days, respectively.",Unrelated donor hematopoietic stem cell transplantation for the treatment of non-malignant genetic diseases: An alemtuzumab based regimen is associated with cure of clinical disease; earlier clearance of alemtuzumab may be associated with graft rejection. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26242764/),d,25,111483,DB00860,Prednisolone
,18664204,flow rate,"The analyte was isocratically eluted on a Venusil XBP C8 column (200 mm x 3.9 mm ID, 5 microm) with methanol-water mol x L(-1) ammonium formate) (80:20) at a flow rate of 0.4 mL x min(-1), and detected (containing 5 mmol x L(-1) ammonium formate) (80:20) at a flow rate of 0.4 mL x min(-1), and detected with a triple quad LC-MS/MS using ESI with positive ionization.",Determination of betamethasone in human plasma by liquid chromatography with tandem mass. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18664204/),[ml] / [min],0.4,111928,DB00860,Prednisolone
,18664204,m/,Ions monitored in the multiple reaction monitoring (MRM) mode were m/z 393.3-->355.2 for betamethasone and m/z 361.3-->343.2 for prednisolone (IS).,Determination of betamethasone in human plasma by liquid chromatography with tandem mass. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18664204/),,393.3,111929,DB00860,Prednisolone
,18664204,m/z,Ions monitored in the multiple reaction monitoring (MRM) mode were m/z 393.3-->355.2 for betamethasone and m/z 361.3-->343.2 for prednisolone (IS).,Determination of betamethasone in human plasma by liquid chromatography with tandem mass. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18664204/),,361.3,111930,DB00860,Prednisolone
,18664204,m/z,Ions monitored in the multiple reaction monitoring (MRM) mode were m/z 393.3-->355.2 for betamethasone and m/z 361.3-->343.2 for prednisolone (IS).,Determination of betamethasone in human plasma by liquid chromatography with tandem mass. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18664204/),,343.2,111931,DB00860,Prednisolone
,18664204,recovery,The average recovery is 88.24% and the low limit of quantitation (LLOQ) was 0.5 ng x mL(-1).,Determination of betamethasone in human plasma by liquid chromatography with tandem mass. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18664204/),%,88.24,111932,DB00860,Prednisolone
,6861855,bioavailability,The bioavailability after oral administration was 84.5% after 10 mg and 77.6% after 20 mg (p greater than 0.05).,Pharmacokinetics and protein binding of prednisolone after oral and intravenous administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6861855/),%,84.5,112071,DB00860,Prednisolone
,6861855,bioavailability,The bioavailability after oral administration was 84.5% after 10 mg and 77.6% after 20 mg (p greater than 0.05).,Pharmacokinetics and protein binding of prednisolone after oral and intravenous administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6861855/),%,77.6,112072,DB00860,Prednisolone
,11304898,CLo,"Population mean estimates (+/- SE) of parameters in the model were as follows: CLo = 13.2 +/- 2.4 L/h, CLmax = 25.0 +/- 3.6 L/h, time of half-maximal increase in CL (T50) = 41.1 +/- 8.2 h, gamma (Hill coefficient) = 3.8 +/- 0.6, and volume of distribution (Vd) = 137 +/- 30.2 L.",Time-variant increase in methylprednisolone clearance in patients with acute respiratory distress syndrome: a population pharmacokinetic study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11304898/),[l] / [h],13.2,112437,DB00860,Prednisolone
,11304898,CLmax,"Population mean estimates (+/- SE) of parameters in the model were as follows: CLo = 13.2 +/- 2.4 L/h, CLmax = 25.0 +/- 3.6 L/h, time of half-maximal increase in CL (T50) = 41.1 +/- 8.2 h, gamma (Hill coefficient) = 3.8 +/- 0.6, and volume of distribution (Vd) = 137 +/- 30.2 L.",Time-variant increase in methylprednisolone clearance in patients with acute respiratory distress syndrome: a population pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11304898/),[l] / [h],25.0,112438,DB00860,Prednisolone
,11304898,time of half-maximal increase in CL (T50),"Population mean estimates (+/- SE) of parameters in the model were as follows: CLo = 13.2 +/- 2.4 L/h, CLmax = 25.0 +/- 3.6 L/h, time of half-maximal increase in CL (T50) = 41.1 +/- 8.2 h, gamma (Hill coefficient) = 3.8 +/- 0.6, and volume of distribution (Vd) = 137 +/- 30.2 L.",Time-variant increase in methylprednisolone clearance in patients with acute respiratory distress syndrome: a population pharmacokinetic study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11304898/),h,41.1,112439,DB00860,Prednisolone
,11304898,gamma (Hill coefficient),"Population mean estimates (+/- SE) of parameters in the model were as follows: CLo = 13.2 +/- 2.4 L/h, CLmax = 25.0 +/- 3.6 L/h, time of half-maximal increase in CL (T50) = 41.1 +/- 8.2 h, gamma (Hill coefficient) = 3.8 +/- 0.6, and volume of distribution (Vd) = 137 +/- 30.2 L.",Time-variant increase in methylprednisolone clearance in patients with acute respiratory distress syndrome: a population pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11304898/),,3.8,112440,DB00860,Prednisolone
,11304898,volume of distribution (Vd),"Population mean estimates (+/- SE) of parameters in the model were as follows: CLo = 13.2 +/- 2.4 L/h, CLmax = 25.0 +/- 3.6 L/h, time of half-maximal increase in CL (T50) = 41.1 +/- 8.2 h, gamma (Hill coefficient) = 3.8 +/- 0.6, and volume of distribution (Vd) = 137 +/- 30.2 L.",Time-variant increase in methylprednisolone clearance in patients with acute respiratory distress syndrome: a population pharmacokinetic study. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11304898/),l,137,112441,DB00860,Prednisolone
,27783276,C max,"Meanwhile, there was a significant difference in C max between groups 1 and 2 (mean ± SD: 1.20 ± 0.52 vs. 0.76 ± 0.39 μg/mL, p = 0.04), and C max levels in CR cases were significantly higher than those in non-CR cases.",Mizoribine therapy combined with steroids and mizoribine blood concentration monitoring for idiopathic membranous nephropathy with steroid-resistant nephrotic syndrome. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27783276/),[μg] / [ml],1.20,113052,DB00860,Prednisolone
,27783276,C max,"Meanwhile, there was a significant difference in C max between groups 1 and 2 (mean ± SD: 1.20 ± 0.52 vs. 0.76 ± 0.39 μg/mL, p = 0.04), and C max levels in CR cases were significantly higher than those in non-CR cases.",Mizoribine therapy combined with steroids and mizoribine blood concentration monitoring for idiopathic membranous nephropathy with steroid-resistant nephrotic syndrome. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27783276/),[μg] / [ml],0.76,113053,DB00860,Prednisolone
more,27783276,C max,Receiver operating characteristic analysis showed that C max more than 1.1 µg/mL was necessary for CR in once-a-day administration.,Mizoribine therapy combined with steroids and mizoribine blood concentration monitoring for idiopathic membranous nephropathy with steroid-resistant nephrotic syndrome. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27783276/),[μg] / [ml],1.1,113054,DB00860,Prednisolone
more,27783276,C max,"In addition, it is important to assay the serum concentration of MZR and to determine C max, and more than 1.1 µg/mL of C max is necessary for CR.",Mizoribine therapy combined with steroids and mizoribine blood concentration monitoring for idiopathic membranous nephropathy with steroid-resistant nephrotic syndrome. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27783276/),[μg] / [ml],1.1,113055,DB00860,Prednisolone
,8616954,elimination half-life (t0.5e),"The washout phase of ATG elimination was analysed over 0-300 days; results were well-fitted by a single exponential decay (r2 > 0.95) giving a mean elimination half-life (t0.5e) of 29.8 days (range 14.3-45.0, n = 9).",The pharmacokinetics of anti-thymocyte globulin (ATG) following intravenous infusion in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8616954/),d,29.8,113057,DB00860,Prednisolone
,8616954,apparent volume of distribution of ATG (Vd),"Data for the first 4 days of treatment were analysed with linear regression to obtain a mean value for the apparent volume of distribution of ATG (Vd) of 0.12 l/kg body weight (range 0.07 to 0.17, n = 5).",The pharmacokinetics of anti-thymocyte globulin (ATG) following intravenous infusion in man. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8616954/),[l] / [body·kg·weight],0.12,113058,DB00860,Prednisolone
,30083083,Cmax,"The obtained values for test and reference products were 683.00 ± 94.54 ng/mL and 635.16 ± 125.57 ng/mL for Cmax; 2716.54 ± 196.28 ng·h/mL and 2780.5 ± 119.73 ng·h/mL for AUC0-12; 3284.36 ± 138.12 ng·h/mL and 3317.96 ± 133.95 ng·h/mL for AUC0-∞, respectively.",Pharmacokinetics and Bioavailability Study of a Prednisolone Tablet as a Single Oral Dose in Bangladeshi Healthy Volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30083083/),[ng] / [ml],635.16,113840,DB00860,Prednisolone
,30083083,AUC0-12,"The obtained values for test and reference products were 683.00 ± 94.54 ng/mL and 635.16 ± 125.57 ng/mL for Cmax; 2716.54 ± 196.28 ng·h/mL and 2780.5 ± 119.73 ng·h/mL for AUC0-12; 3284.36 ± 138.12 ng·h/mL and 3317.96 ± 133.95 ng·h/mL for AUC0-∞, respectively.",Pharmacokinetics and Bioavailability Study of a Prednisolone Tablet as a Single Oral Dose in Bangladeshi Healthy Volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30083083/),[h·ng] / [ml],2716.54,113841,DB00860,Prednisolone
,30083083,AUC0-12,"The obtained values for test and reference products were 683.00 ± 94.54 ng/mL and 635.16 ± 125.57 ng/mL for Cmax; 2716.54 ± 196.28 ng·h/mL and 2780.5 ± 119.73 ng·h/mL for AUC0-12; 3284.36 ± 138.12 ng·h/mL and 3317.96 ± 133.95 ng·h/mL for AUC0-∞, respectively.",Pharmacokinetics and Bioavailability Study of a Prednisolone Tablet as a Single Oral Dose in Bangladeshi Healthy Volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30083083/),[h·ng] / [ml],2780.5,113842,DB00860,Prednisolone
,30083083,AUC0-∞,"The obtained values for test and reference products were 683.00 ± 94.54 ng/mL and 635.16 ± 125.57 ng/mL for Cmax; 2716.54 ± 196.28 ng·h/mL and 2780.5 ± 119.73 ng·h/mL for AUC0-12; 3284.36 ± 138.12 ng·h/mL and 3317.96 ± 133.95 ng·h/mL for AUC0-∞, respectively.",Pharmacokinetics and Bioavailability Study of a Prednisolone Tablet as a Single Oral Dose in Bangladeshi Healthy Volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30083083/),[h·ng] / [ml],3284.36,113843,DB00860,Prednisolone
,30083083,AUC0-∞,"The obtained values for test and reference products were 683.00 ± 94.54 ng/mL and 635.16 ± 125.57 ng/mL for Cmax; 2716.54 ± 196.28 ng·h/mL and 2780.5 ± 119.73 ng·h/mL for AUC0-12; 3284.36 ± 138.12 ng·h/mL and 3317.96 ± 133.95 ng·h/mL for AUC0-∞, respectively.",Pharmacokinetics and Bioavailability Study of a Prednisolone Tablet as a Single Oral Dose in Bangladeshi Healthy Volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30083083/),[h·ng] / [ml],3317.96,113844,DB00860,Prednisolone
,8011967,bioavailability,"After an oral prednisone dose of 0.8 mg kg-1 and an intravenous prednisolone dose of 0.66 mg kg-1, the bioavailability was found to be about 62%.",Bioavailability and reversible metabolism of prednisone and prednisolone in man. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8011967/),%,62,114265,DB00860,Prednisolone
,22624503,area under the blood concentration-time curve from time zero to 12 hours (AUC(12)),Everolimus blood concentrations were analysed in whole blood using liquid chromatography-tandem mass spectrometry during routine therapeutic drug monitoring targeting an area under the blood concentration-time curve from time zero to 12 hours (AUC(12)) of 120 μg · h/L.,Population pharmacokinetics and pharmacogenetics of everolimus in renal transplant patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22624503/),[h·μg] / [l],120,114932,DB00860,Prednisolone
,22624503,AUC(12),Maintaining everolimus systemic exposure at an AUC(12) of 120 μg · h/L resulted in low rejection rates but considerable numbers of adverse events and toxicity.,Population pharmacokinetics and pharmacogenetics of everolimus in renal transplant patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22624503/),[h·μg] / [l],120,114933,DB00860,Prednisolone
,22624503,oral clearance,Everolimus pharmacokinetics were best described by a two-compartment model with lag-time (oral clearance = 17.9 L/h; volume of distribution of the central compartment after oral administration [V(1)/F] = 148 L and first-order absorption rate constant [k(a)] = 7.36 h-1).,Population pharmacokinetics and pharmacogenetics of everolimus in renal transplant patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22624503/),[l] / [h],17.9,114934,DB00860,Prednisolone
,22624503,volume of distribution of the central compartment after oral administration [V(1)/F],Everolimus pharmacokinetics were best described by a two-compartment model with lag-time (oral clearance = 17.9 L/h; volume of distribution of the central compartment after oral administration [V(1)/F] = 148 L and first-order absorption rate constant [k(a)] = 7.36 h-1).,Population pharmacokinetics and pharmacogenetics of everolimus in renal transplant patients. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22624503/),l,148,114935,DB00860,Prednisolone
,22624503,first-order absorption rate constant [k(a)],Everolimus pharmacokinetics were best described by a two-compartment model with lag-time (oral clearance = 17.9 L/h; volume of distribution of the central compartment after oral administration [V(1)/F] = 148 L and first-order absorption rate constant [k(a)] = 7.36 h-1).,Population pharmacokinetics and pharmacogenetics of everolimus in renal transplant patients. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22624503/),1/[h],7.36,114936,DB00860,Prednisolone
,3207561,renal clearance,2. The mean (+/- s.e. mean) renal clearance of sulphadimidine was increased from 0.03 +/- 0.01 to 0.07 +/- 0.02 ml min-1 kg-1 (P = 0.01) following the administration of intra-articular steroid.,Effect of intra-articular glucocorticoids on the disposition of sulphadimidine in chronic osteoarthritis patients. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3207561/),[ml] / [kg·min],0.03,115005,DB00860,Prednisolone
,3207561,renal clearance,2. The mean (+/- s.e. mean) renal clearance of sulphadimidine was increased from 0.03 +/- 0.01 to 0.07 +/- 0.02 ml min-1 kg-1 (P = 0.01) following the administration of intra-articular steroid.,Effect of intra-articular glucocorticoids on the disposition of sulphadimidine in chronic osteoarthritis patients. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3207561/),[ml] / [kg·min],0.07,115006,DB00860,Prednisolone
,10354967,Cmax,"The Cmax values were about 3 ng/mL, while the tmax occurred at 7 to 9 hours.",Pharmacokinetic and adrenal interactions of IL-10 and prednisone in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10354967/),[ng] / [ml],3,116749,DB00860,Prednisolone
,10354967,tmax,"The Cmax values were about 3 ng/mL, while the tmax occurred at 7 to 9 hours.",Pharmacokinetic and adrenal interactions of IL-10 and prednisone in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10354967/),h,7 to 9,116750,DB00860,Prednisolone
,10354967,Cmax,"Prednisolone exhibited rapid systemic kinetics with a Cmax of 235 ng/mL, tmax at 1.11 hours, and t1/2 of 2.54 hours with no significant alterations owing to IL-10.",Pharmacokinetic and adrenal interactions of IL-10 and prednisone in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10354967/),[ng] / [ml],235,116751,DB00860,Prednisolone
,10354967,tmax,"Prednisolone exhibited rapid systemic kinetics with a Cmax of 235 ng/mL, tmax at 1.11 hours, and t1/2 of 2.54 hours with no significant alterations owing to IL-10.",Pharmacokinetic and adrenal interactions of IL-10 and prednisone in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10354967/),h,1.11,116752,DB00860,Prednisolone
,10354967,t1/2,"Prednisolone exhibited rapid systemic kinetics with a Cmax of 235 ng/mL, tmax at 1.11 hours, and t1/2 of 2.54 hours with no significant alterations owing to IL-10.",Pharmacokinetic and adrenal interactions of IL-10 and prednisone in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10354967/),h,2.54,116753,DB00860,Prednisolone
,10935703,trough concentration,"The mean Mycophenolic acid (MPA) trough concentration was 4.0 +/- 2.0 microg/ml, range 1.4-7.9 microg/ml.",Effect of adding Mycophenolate mofetil in paediatric renal transplant recipients with chronical cyclosporine nephrotoxicity. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10935703/),[μg] / [ml],4.0,117816,DB00860,Prednisolone
,10935703,AUC,Mean 12 h MPA AUC was 70.6 +/- 28.1 (range 31.9-127) microg x h/ml.,Effect of adding Mycophenolate mofetil in paediatric renal transplant recipients with chronical cyclosporine nephrotoxicity. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10935703/),[h·μg] / [ml],70.6,117817,DB00860,Prednisolone
,2715934,limit of detection,The limit of detection of the assay for all tested steroids is 10-20 ng/mL.,High-performance liquid chromatographic determination of prednisolone and its steroid 21-oate ester derivatives in rat plasma: pharmacokinetic applications. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2715934/),[ng] / [ml],10-20,119402,DB00860,Prednisolone
,19274604,V(max),"V(max) and K(m) values of MMF hydrolysis in pooled human liver microsomes were 1368 +/- 44 nmol min(-1) mg(-1) protein and 1030 +/- 65 microM, respectively.",Influence of carboxylesterase 2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19274604/),[nM] / [mg·min],1368,121494,DB00860,Prednisolone
,19274604,K(m),"V(max) and K(m) values of MMF hydrolysis in pooled human liver microsomes were 1368 +/- 44 nmol min(-1) mg(-1) protein and 1030 +/- 65 microM, respectively.",Influence of carboxylesterase 2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19274604/),μM,1030,121495,DB00860,Prednisolone
,19274604,IC(50),"Hydrolytic activity was inhibited by the CES inhibitors phenylmethylsulfonylfluoride, bis-p-nitorophenylphosphate and diisopropylfluorophosphate, with IC(50) values of 77.1, 3.59 and 0.0312 microM, respectively.",Influence of carboxylesterase 2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19274604/),μM,77.1,121496,DB00860,Prednisolone
,19274604,IC(50),"Hydrolytic activity was inhibited by the CES inhibitors phenylmethylsulfonylfluoride, bis-p-nitorophenylphosphate and diisopropylfluorophosphate, with IC(50) values of 77.1, 3.59 and 0.0312 microM, respectively.",Influence of carboxylesterase 2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19274604/),μM,3.59,121497,DB00860,Prednisolone
,19274604,IC(50),"Hydrolytic activity was inhibited by the CES inhibitors phenylmethylsulfonylfluoride, bis-p-nitorophenylphosphate and diisopropylfluorophosphate, with IC(50) values of 77.1, 3.59 and 0.0312 microM, respectively.",Influence of carboxylesterase 2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19274604/),μM,0.0312,121498,DB00860,Prednisolone
,4051860,half-life,"The half-life as determined by HPLC was 1.6 days, the level at 13 days postinjection was 66 +/- 19 micrograms, and no drug was detectable by HPLC analysis at 21 days in five of six eyes.",Clearance of triamcinolone from vitreous. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4051860/),d,1.6,121703,DB00860,Prednisolone
,4051860,half-life,"The half-life as determined by HPLC was 1.6 days, the level at 13 days postinjection was 66 +/- 19 micrograms, and no drug was detectable by HPLC analysis at 21 days in five of six eyes.",Clearance of triamcinolone from vitreous. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4051860/),μg,66,121704,DB00860,Prednisolone
,9300138,trough levels,"In clinical adaptation for renal transplant patients, the steady-state concentration of CsA (Css) based on the AUC0-8 predictive model was significantly decreased during acute gastroenteritis or before acute rejection, whereas nephrotoxicity was increased, even though CsA trough levels were within a normal therapeutic range (100-200 ng/ml).",A predictive model for area under the concentration versus time curve of cyclosporin A using several routine monitoring results in renal transplant patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9300138/),[ng] / [ml],100-200,122470,DB00860,Prednisolone
,30713247,milk/plasma concentration ratio,"5) In breastfeeding women, the median milk/plasma concentration ratio of amlodipine was 0.85.",Optimization of Individual Pharmacotherapy Based on Multiple Evaluations of Patient Data. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30713247/),,0.85,123684,DB00860,Prednisolone
,8513854,AUCs,"From the data on PO, the active molecule, the systemic availability of PO-MS was significantly smaller than of PN, with the respective mean AUCs being 1.71 and 3.60 mg.h-1.",Comparative study of availability of prednisolone after intestinal infusion of prednisolone metasulfobenzoate and prednisone. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8513854/),[mg] / [h],1.71,123716,DB00860,Prednisolone
,8513854,AUCs,"From the data on PO, the active molecule, the systemic availability of PO-MS was significantly smaller than of PN, with the respective mean AUCs being 1.71 and 3.60 mg.h-1.",Comparative study of availability of prednisolone after intestinal infusion of prednisolone metasulfobenzoate and prednisone. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8513854/),[mg] / [h],3.60,123717,DB00860,Prednisolone
,8513854,Cmax,"The difference was associated with smaller mean Cmax, 0.20 vs 0.64 mg.l-1, higher mean tmax, 2.94 vs 2.06 h and lower mean ka, 0.98 vs 2.18 l/h after PO-MS.",Comparative study of availability of prednisolone after intestinal infusion of prednisolone metasulfobenzoate and prednisone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8513854/),[mg] / [l],0.20,123718,DB00860,Prednisolone
,8513854,Cmax,"The difference was associated with smaller mean Cmax, 0.20 vs 0.64 mg.l-1, higher mean tmax, 2.94 vs 2.06 h and lower mean ka, 0.98 vs 2.18 l/h after PO-MS.",Comparative study of availability of prednisolone after intestinal infusion of prednisolone metasulfobenzoate and prednisone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8513854/),[mg] / [l],0.64,123719,DB00860,Prednisolone
,8513854,tmax,"The difference was associated with smaller mean Cmax, 0.20 vs 0.64 mg.l-1, higher mean tmax, 2.94 vs 2.06 h and lower mean ka, 0.98 vs 2.18 l/h after PO-MS.",Comparative study of availability of prednisolone after intestinal infusion of prednisolone metasulfobenzoate and prednisone. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8513854/),h,2.94,123720,DB00860,Prednisolone
,8513854,tmax,"The difference was associated with smaller mean Cmax, 0.20 vs 0.64 mg.l-1, higher mean tmax, 2.94 vs 2.06 h and lower mean ka, 0.98 vs 2.18 l/h after PO-MS.",Comparative study of availability of prednisolone after intestinal infusion of prednisolone metasulfobenzoate and prednisone. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8513854/),h,2.06,123721,DB00860,Prednisolone
,8513854,ka,"The difference was associated with smaller mean Cmax, 0.20 vs 0.64 mg.l-1, higher mean tmax, 2.94 vs 2.06 h and lower mean ka, 0.98 vs 2.18 l/h after PO-MS.",Comparative study of availability of prednisolone after intestinal infusion of prednisolone metasulfobenzoate and prednisone. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8513854/),[l] / [h],0.98,123722,DB00860,Prednisolone
,8513854,ka,"The difference was associated with smaller mean Cmax, 0.20 vs 0.64 mg.l-1, higher mean tmax, 2.94 vs 2.06 h and lower mean ka, 0.98 vs 2.18 l/h after PO-MS.",Comparative study of availability of prednisolone after intestinal infusion of prednisolone metasulfobenzoate and prednisone. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8513854/),[l] / [h],2.18,123723,DB00860,Prednisolone
,8513854,MRT,"The mean MRT was significantly increased after PO-MS, 6.82 vs 5.30 h.",Comparative study of availability of prednisolone after intestinal infusion of prednisolone metasulfobenzoate and prednisone. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8513854/),h,6.82,123724,DB00860,Prednisolone
,8513854,MRT,"The mean MRT was significantly increased after PO-MS, 6.82 vs 5.30 h.",Comparative study of availability of prednisolone after intestinal infusion of prednisolone metasulfobenzoate and prednisone. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8513854/),h,5.30,123725,DB00860,Prednisolone
,8513854,absorption,The mean absorption in the test segment of PO-MS was significantly smaller at 17.4 vs 85.5% for PN.,Comparative study of availability of prednisolone after intestinal infusion of prednisolone metasulfobenzoate and prednisone. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8513854/),%,17.4,123726,DB00860,Prednisolone
,8513854,absorption,The mean absorption in the test segment of PO-MS was significantly smaller at 17.4 vs 85.5% for PN.,Comparative study of availability of prednisolone after intestinal infusion of prednisolone metasulfobenzoate and prednisone. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8513854/),%,85.5,123727,DB00860,Prednisolone
,10096263,IC50,"The steroid caused monocytopenia, lymphocytopenia, and neutrophilia, with IC50 or SC50 values of 10 to 20 ng/mL.",Pharmacoimmunodynamic interactions of interleukin-10 and prednisone in healthy volunteers. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10096263/),[ng] / [ml],10 to 20,126013,DB00860,Prednisolone
,10096263,IC50,"Interleukin-10 elevated monocytes and neutrophils and lowered lymphocyte counts, with IC50 or SC50 values of 0.7 to 1.3 ng/mL.",Pharmacoimmunodynamic interactions of interleukin-10 and prednisone in healthy volunteers. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10096263/),[ng] / [ml],0.7 to 1.3,126014,DB00860,Prednisolone
,11271216,trough level,"The mean trough level of FK 506 in whole blood and the mean serum creatinine level in year 2 were 7.9 ng/ml and 1.9 mg/dl, respectively.",Two-year follow-up study of the efficacy and safety of FK 506 in kidney transplant patients. Japanese FK 506 Study Group. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11271216/),[ng] / [ml],7.9,126169,DB00860,Prednisolone
,11271216,trough level,"The mean trough level of FK 506 in whole blood and the mean serum creatinine level in year 2 were 7.9 ng/ml and 1.9 mg/dl, respectively.",Two-year follow-up study of the efficacy and safety of FK 506 in kidney transplant patients. Japanese FK 506 Study Group. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11271216/),mg,1.9,126170,DB00860,Prednisolone
,9884251,duration of,"The median duration of the initial episode of i.v. cyclosporine was 4.0 days for Neoral, compared to 6.5 days for Sandimmun (P<0.001).",Randomized trial of cyclosporine microemulsion (neoral) versus conventional cyclosporine in liver transplantation: MILTON study. Multicentre International Study in Liver Transplantation of Neoral. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9884251/),d,4.0,126663,DB00860,Prednisolone
,9884251,duration of,"The median duration of the initial episode of i.v. cyclosporine was 4.0 days for Neoral, compared to 6.5 days for Sandimmun (P<0.001).",Randomized trial of cyclosporine microemulsion (neoral) versus conventional cyclosporine in liver transplantation: MILTON study. Multicentre International Study in Liver Transplantation of Neoral. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9884251/),d,6.5,126664,DB00860,Prednisolone
>,17326777,Cmax,"While only 2 (28.6%) of seven pigs with Cmax > 3 microg/ml during the first 2 weeks had AMR, 7 (87.5%) of eight pigs with Cmax < 3 microg/ml elicited anti-donor Abs and experienced AMR (P = 0.0406).",Prophylactic treatment of antibody-mediated rejection with high-dose mizoribine and pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17326777/),[μg] / [ml],3,127304,DB00860,Prednisolone
<,17326777,Cmax,"While only 2 (28.6%) of seven pigs with Cmax > 3 microg/ml during the first 2 weeks had AMR, 7 (87.5%) of eight pigs with Cmax < 3 microg/ml elicited anti-donor Abs and experienced AMR (P = 0.0406).",Prophylactic treatment of antibody-mediated rejection with high-dose mizoribine and pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17326777/),[μg] / [ml],3,127305,DB00860,Prednisolone
over,17326777,Cmax,Effective Cmax seemed to be over 3 microg/ml at minimum.,Prophylactic treatment of antibody-mediated rejection with high-dose mizoribine and pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17326777/),[μg] / [ml],3,127306,DB00860,Prednisolone
,19533049,half-life,"Pharmacokinetic half-life of prednisolone is 2-3 h, indicating short pharmacodynamic effect duration.",Twice daily fractionated dose administration of prednisolone compared to standard once daily administration to patients with glomerulonephritis or with kidney transplants. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19533049/),h,2-3,128507,DB00860,Prednisolone
,30215770,C1,"C1, C2 and C12 were 8.3 ± 6.6 , 7.2 ± 5.2 and 2.0 ± 1.4 mg/L and all correlated with the 12-h area under the curve (AUC0-12; r = 0.51, 0.85 and 0.73; P = 0.02, <0.001 and <0.001, respectively).",Pharmacokinetics and pharmacogenomics of mycophenolic acid and its clinical correlations in maintenance immunosuppression for lupus nephritis. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30215770/),[mg] / [l],8.3,128963,DB00860,Prednisolone
,30215770,C2,"C1, C2 and C12 were 8.3 ± 6.6 , 7.2 ± 5.2 and 2.0 ± 1.4 mg/L and all correlated with the 12-h area under the curve (AUC0-12; r = 0.51, 0.85 and 0.73; P = 0.02, <0.001 and <0.001, respectively).",Pharmacokinetics and pharmacogenomics of mycophenolic acid and its clinical correlations in maintenance immunosuppression for lupus nephritis. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30215770/),[mg] / [l],7.2,128964,DB00860,Prednisolone
,30215770,C12,"C1, C2 and C12 were 8.3 ± 6.6 , 7.2 ± 5.2 and 2.0 ± 1.4 mg/L and all correlated with the 12-h area under the curve (AUC0-12; r = 0.51, 0.85 and 0.73; P = 0.02, <0.001 and <0.001, respectively).",Pharmacokinetics and pharmacogenomics of mycophenolic acid and its clinical correlations in maintenance immunosuppression for lupus nephritis. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30215770/),[mg] / [l],2.0,128965,DB00860,Prednisolone
,30215770,C12,"Five renal flares, 11 episodes of infection and 10 episodes of anemia (hemoglobin <10 g/dL) occurred over 96 weeks, with a corresponding C12 of 1.3 ± 0.5, 4.3 ± 2.6 and 2.9 ± 1.5 mg/L, respectively (versus 2.4 ± 1.2, 1.8 ± 1.2 and 1.7 ± 1.1 mg/L in patients without these complications; P = 0.041, <0.001 and 0.004).",Pharmacokinetics and pharmacogenomics of mycophenolic acid and its clinical correlations in maintenance immunosuppression for lupus nephritis. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30215770/),[mg] / [l],1.3,128966,DB00860,Prednisolone
,30215770,C12,"Five renal flares, 11 episodes of infection and 10 episodes of anemia (hemoglobin <10 g/dL) occurred over 96 weeks, with a corresponding C12 of 1.3 ± 0.5, 4.3 ± 2.6 and 2.9 ± 1.5 mg/L, respectively (versus 2.4 ± 1.2, 1.8 ± 1.2 and 1.7 ± 1.1 mg/L in patients without these complications; P = 0.041, <0.001 and 0.004).",Pharmacokinetics and pharmacogenomics of mycophenolic acid and its clinical correlations in maintenance immunosuppression for lupus nephritis. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30215770/),[mg] / [l],4.3,128967,DB00860,Prednisolone
,30215770,C12,"Five renal flares, 11 episodes of infection and 10 episodes of anemia (hemoglobin <10 g/dL) occurred over 96 weeks, with a corresponding C12 of 1.3 ± 0.5, 4.3 ± 2.6 and 2.9 ± 1.5 mg/L, respectively (versus 2.4 ± 1.2, 1.8 ± 1.2 and 1.7 ± 1.1 mg/L in patients without these complications; P = 0.041, <0.001 and 0.004).",Pharmacokinetics and pharmacogenomics of mycophenolic acid and its clinical correlations in maintenance immunosuppression for lupus nephritis. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30215770/),[mg] / [l],2.9,128968,DB00860,Prednisolone
,30215770,C12,"Five renal flares, 11 episodes of infection and 10 episodes of anemia (hemoglobin <10 g/dL) occurred over 96 weeks, with a corresponding C12 of 1.3 ± 0.5, 4.3 ± 2.6 and 2.9 ± 1.5 mg/L, respectively (versus 2.4 ± 1.2, 1.8 ± 1.2 and 1.7 ± 1.1 mg/L in patients without these complications; P = 0.041, <0.001 and 0.004).",Pharmacokinetics and pharmacogenomics of mycophenolic acid and its clinical correlations in maintenance immunosuppression for lupus nephritis. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30215770/),[mg] / [l],2.4,128969,DB00860,Prednisolone
,30215770,C12,"Five renal flares, 11 episodes of infection and 10 episodes of anemia (hemoglobin <10 g/dL) occurred over 96 weeks, with a corresponding C12 of 1.3 ± 0.5, 4.3 ± 2.6 and 2.9 ± 1.5 mg/L, respectively (versus 2.4 ± 1.2, 1.8 ± 1.2 and 1.7 ± 1.1 mg/L in patients without these complications; P = 0.041, <0.001 and 0.004).",Pharmacokinetics and pharmacogenomics of mycophenolic acid and its clinical correlations in maintenance immunosuppression for lupus nephritis. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30215770/),[mg] / [l],1.8,128970,DB00860,Prednisolone
,30215770,C12,"Five renal flares, 11 episodes of infection and 10 episodes of anemia (hemoglobin <10 g/dL) occurred over 96 weeks, with a corresponding C12 of 1.3 ± 0.5, 4.3 ± 2.6 and 2.9 ± 1.5 mg/L, respectively (versus 2.4 ± 1.2, 1.8 ± 1.2 and 1.7 ± 1.1 mg/L in patients without these complications; P = 0.041, <0.001 and 0.004).",Pharmacokinetics and pharmacogenomics of mycophenolic acid and its clinical correlations in maintenance immunosuppression for lupus nephritis. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30215770/),[mg] / [l],1.7,128971,DB00860,Prednisolone
,3994138,half-life of elimination,"After IV administration of prednisolone 21-sodium succinate, the half-life of elimination was 3.6 +/- 1.177 hours.",Prednisolone succinate and prednisolone acetate in cattle: pharmacokinetics and action on the adrenal gland. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3994138/),h,3.6,129144,DB00860,Prednisolone
,3994138,absorption half-life,"After IM administration of prednisolone acetate, absorption was very slow with an absorption half-life of 48 hours, but was still complete.",Prednisolone succinate and prednisolone acetate in cattle: pharmacokinetics and action on the adrenal gland. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3994138/),h,48,129145,DB00860,Prednisolone
,7494809,Maximum concentrations,Maximum concentrations of 21-desacetyldeflazacort averaged 116 ng/ml and were observed after 1.3 h.,Pharmacokinetic/pharmacodynamic evaluation of deflazacort in comparison to methylprednisolone and prednisolone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7494809/),[ng] / [ml],116,129146,DB00860,Prednisolone
,7494809,area under the curve,"The average area under the curve was 280 ng/ml.h, and the terminal half-life was 1.3 h.",Pharmacokinetic/pharmacodynamic evaluation of deflazacort in comparison to methylprednisolone and prednisolone. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7494809/),[ng] / [h·ml],280,129147,DB00860,Prednisolone
,7494809,terminal half-life,"The average area under the curve was 280 ng/ml.h, and the terminal half-life was 1.3 h.",Pharmacokinetic/pharmacodynamic evaluation of deflazacort in comparison to methylprednisolone and prednisolone. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7494809/),h,1.3,129148,DB00860,Prednisolone
,6726655,Kp,"The small intestine (Kp = 6.65), heart (2.92), kidney (2.91), lung (2.86), skeletal muscle (1.54) and spleen (1.16) exhibited linear Kp values and percentage of tissue binding.",Tissue distribution of prednisolone in the rabbit. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6726655/),,6.65,130378,DB00860,Prednisolone
,6726655,Kp,"The small intestine (Kp = 6.65), heart (2.92), kidney (2.91), lung (2.86), skeletal muscle (1.54) and spleen (1.16) exhibited linear Kp values and percentage of tissue binding.",Tissue distribution of prednisolone in the rabbit. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6726655/),,2.92,130379,DB00860,Prednisolone
,6726655,Kp,"The small intestine (Kp = 6.65), heart (2.92), kidney (2.91), lung (2.86), skeletal muscle (1.54) and spleen (1.16) exhibited linear Kp values and percentage of tissue binding.",Tissue distribution of prednisolone in the rabbit. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6726655/),,2.91,130380,DB00860,Prednisolone
,6726655,Kp,"The small intestine (Kp = 6.65), heart (2.92), kidney (2.91), lung (2.86), skeletal muscle (1.54) and spleen (1.16) exhibited linear Kp values and percentage of tissue binding.",Tissue distribution of prednisolone in the rabbit. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6726655/),,2.86,130381,DB00860,Prednisolone
,6726655,Kp,"The small intestine (Kp = 6.65), heart (2.92), kidney (2.91), lung (2.86), skeletal muscle (1.54) and spleen (1.16) exhibited linear Kp values and percentage of tissue binding.",Tissue distribution of prednisolone in the rabbit. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6726655/),,1.54,130382,DB00860,Prednisolone
,6726655,Kp,"The small intestine (Kp = 6.65), heart (2.92), kidney (2.91), lung (2.86), skeletal muscle (1.54) and spleen (1.16) exhibited linear Kp values and percentage of tissue binding.",Tissue distribution of prednisolone in the rabbit. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6726655/),,1.16,130383,DB00860,Prednisolone
,6726655,Kp,Liver uptake (Kp = 0.38-4.47) was nonlinear with apparent tissue binding ranging from less than 59 to 84%.,Tissue distribution of prednisolone in the rabbit. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6726655/),,0.38-4.47,130384,DB00860,Prednisolone
less,6726655,apparent tissue binding,Liver uptake (Kp = 0.38-4.47) was nonlinear with apparent tissue binding ranging from less than 59 to 84%.,Tissue distribution of prednisolone in the rabbit. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6726655/),%,59 to 84,130385,DB00860,Prednisolone
,7876403,clearance,"After first-dose administration, mean clearance increased from 19.5 L/hr for 40-mg doses to 27.7 L/hr after 500-mg doses of the sodium succinate ester, and from 20.1 to 31.7 L/hr after the suleptanate ester.",Pilot study of the pharmacokinetics of methylprednisolone after single and multiple intravenous doses of methylprednisolone sodium succinate and methylprednisolone suleptanate to healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7876403/),[l] / [h],19.5,130407,DB00860,Prednisolone
,7876403,clearance,"After first-dose administration, mean clearance increased from 19.5 L/hr for 40-mg doses to 27.7 L/hr after 500-mg doses of the sodium succinate ester, and from 20.1 to 31.7 L/hr after the suleptanate ester.",Pilot study of the pharmacokinetics of methylprednisolone after single and multiple intravenous doses of methylprednisolone sodium succinate and methylprednisolone suleptanate to healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7876403/),[l] / [h],27.7,130408,DB00860,Prednisolone
,7876403,clearance,"After first-dose administration, mean clearance increased from 19.5 L/hr for 40-mg doses to 27.7 L/hr after 500-mg doses of the sodium succinate ester, and from 20.1 to 31.7 L/hr after the suleptanate ester.",Pilot study of the pharmacokinetics of methylprednisolone after single and multiple intravenous doses of methylprednisolone sodium succinate and methylprednisolone suleptanate to healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7876403/),[l] / [h],20,130409,DB00860,Prednisolone
,7876403,clearance,"After first-dose administration, mean clearance increased from 19.5 L/hr for 40-mg doses to 27.7 L/hr after 500-mg doses of the sodium succinate ester, and from 20.1 to 31.7 L/hr after the suleptanate ester.",Pilot study of the pharmacokinetics of methylprednisolone after single and multiple intravenous doses of methylprednisolone sodium succinate and methylprednisolone suleptanate to healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7876403/),[l] / [h],31,130410,DB00860,Prednisolone
,7876403,clearance,"After multiple dosing, mean clearance values increased from 31.1 to 44.7 L/hr for sodium succinate dosing, and from 31.5 to 46.0 L/hr for suleptanate dosing.",Pilot study of the pharmacokinetics of methylprednisolone after single and multiple intravenous doses of methylprednisolone sodium succinate and methylprednisolone suleptanate to healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7876403/),[l] / [h],31.1 to 44.7,130411,DB00860,Prednisolone
,7876403,clearance,"After multiple dosing, mean clearance values increased from 31.1 to 44.7 L/hr for sodium succinate dosing, and from 31.5 to 46.0 L/hr for suleptanate dosing.",Pilot study of the pharmacokinetics of methylprednisolone after single and multiple intravenous doses of methylprednisolone sodium succinate and methylprednisolone suleptanate to healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7876403/),[l] / [h],31.5 to 46.0,130412,DB00860,Prednisolone
,19258929,clearance,"TRL clearance was 1.5-fold higher for patients with the CYP3A5*1/*3 genotype compared with the CYP3A5*3/*3 genotype (5.5 +/- 0.5 L/h versus 3.7 +/- 0.3 L/h, respectively).",Explaining variability in tacrolimus pharmacokinetics to optimize early exposure in adult kidney transplant recipients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19258929/),[l] / [h],5.5,131131,DB00860,Prednisolone
,19258929,clearance,"TRL clearance was 1.5-fold higher for patients with the CYP3A5*1/*3 genotype compared with the CYP3A5*3/*3 genotype (5.5 +/- 0.5 L/h versus 3.7 +/- 0.3 L/h, respectively).",Explaining variability in tacrolimus pharmacokinetics to optimize early exposure in adult kidney transplant recipients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19258929/),[l] / [h],3.7,131132,DB00860,Prednisolone
,19258929,clearance,"Also, a relationship between the pregnane X receptor A+7635G genotype and TRL clearance was identified with a clearance of 3.9 +/- 0.3 L/h in the A allele carriers versus 5.4 +/- 0.6 L/h in the GG genotype.",Explaining variability in tacrolimus pharmacokinetics to optimize early exposure in adult kidney transplant recipients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19258929/),[l] / [h],3.9,131133,DB00860,Prednisolone
,19258929,clearance,"Also, a relationship between the pregnane X receptor A+7635G genotype and TRL clearance was identified with a clearance of 3.9 +/- 0.3 L/h in the A allele carriers versus 5.4 +/- 0.6 L/h in the GG genotype.",Explaining variability in tacrolimus pharmacokinetics to optimize early exposure in adult kidney transplant recipients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19258929/),[l] / [h],5.4,131134,DB00860,Prednisolone
,20595378,apparent elimination rate constant (λ(z)),"The vitreal pharmacokinetic parameters of quinidine in the presence of verapamil [apparent elimination rate constant (λ(z)), 0.0027 ± 0.0002 min(-1); clearance (CL_F), 131 ± 21 ml/min; area under the curve (AUC(0-∞)), 39 ± 7.0 μg · min/ml; and mean residence time, 435 ± 20 min] were significantly different from those of the control (0.0058 ± 0.0006 min(-1), 296 ± 46 ml/min, 17 ± 3 μg · min/ml, and 232 ± 20 min, respectively).",Interaction between topically and systemically coadministered P-glycoprotein substrates/inhibitors: effect on vitreal kinetics. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20595378/),1/[min],0.0027,131299,DB00860,Prednisolone
,20595378,clearance (CL_F),"The vitreal pharmacokinetic parameters of quinidine in the presence of verapamil [apparent elimination rate constant (λ(z)), 0.0027 ± 0.0002 min(-1); clearance (CL_F), 131 ± 21 ml/min; area under the curve (AUC(0-∞)), 39 ± 7.0 μg · min/ml; and mean residence time, 435 ± 20 min] were significantly different from those of the control (0.0058 ± 0.0006 min(-1), 296 ± 46 ml/min, 17 ± 3 μg · min/ml, and 232 ± 20 min, respectively).",Interaction between topically and systemically coadministered P-glycoprotein substrates/inhibitors: effect on vitreal kinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20595378/),[ml] / [min],131,131300,DB00860,Prednisolone
,20595378,area under the curve (AUC(0-∞)),"The vitreal pharmacokinetic parameters of quinidine in the presence of verapamil [apparent elimination rate constant (λ(z)), 0.0027 ± 0.0002 min(-1); clearance (CL_F), 131 ± 21 ml/min; area under the curve (AUC(0-∞)), 39 ± 7.0 μg · min/ml; and mean residence time, 435 ± 20 min] were significantly different from those of the control (0.0058 ± 0.0006 min(-1), 296 ± 46 ml/min, 17 ± 3 μg · min/ml, and 232 ± 20 min, respectively).",Interaction between topically and systemically coadministered P-glycoprotein substrates/inhibitors: effect on vitreal kinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20595378/),[min·μg] / [ml],39,131301,DB00860,Prednisolone
,20595378,area under the curve (AUC(0-∞)),"The vitreal pharmacokinetic parameters of quinidine in the presence of verapamil [apparent elimination rate constant (λ(z)), 0.0027 ± 0.0002 min(-1); clearance (CL_F), 131 ± 21 ml/min; area under the curve (AUC(0-∞)), 39 ± 7.0 μg · min/ml; and mean residence time, 435 ± 20 min] were significantly different from those of the control (0.0058 ± 0.0006 min(-1), 296 ± 46 ml/min, 17 ± 3 μg · min/ml, and 232 ± 20 min, respectively).",Interaction between topically and systemically coadministered P-glycoprotein substrates/inhibitors: effect on vitreal kinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20595378/),1/[min],0.0058,131302,DB00860,Prednisolone
,20595378,mean residence time,"The vitreal pharmacokinetic parameters of quinidine in the presence of verapamil [apparent elimination rate constant (λ(z)), 0.0027 ± 0.0002 min(-1); clearance (CL_F), 131 ± 21 ml/min; area under the curve (AUC(0-∞)), 39 ± 7.0 μg · min/ml; and mean residence time, 435 ± 20 min] were significantly different from those of the control (0.0058 ± 0.0006 min(-1), 296 ± 46 ml/min, 17 ± 3 μg · min/ml, and 232 ± 20 min, respectively).",Interaction between topically and systemically coadministered P-glycoprotein substrates/inhibitors: effect on vitreal kinetics. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20595378/),min,435,131303,DB00860,Prednisolone
,20595378,mean residence time,"The vitreal pharmacokinetic parameters of quinidine in the presence of verapamil [apparent elimination rate constant (λ(z)), 0.0027 ± 0.0002 min(-1); clearance (CL_F), 131 ± 21 ml/min; area under the curve (AUC(0-∞)), 39 ± 7.0 μg · min/ml; and mean residence time, 435 ± 20 min] were significantly different from those of the control (0.0058 ± 0.0006 min(-1), 296 ± 46 ml/min, 17 ± 3 μg · min/ml, and 232 ± 20 min, respectively).",Interaction between topically and systemically coadministered P-glycoprotein substrates/inhibitors: effect on vitreal kinetics. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20595378/),1/[min],0.0058,131304,DB00860,Prednisolone
,20595378,mean residence time,"The vitreal pharmacokinetic parameters of quinidine in the presence of verapamil [apparent elimination rate constant (λ(z)), 0.0027 ± 0.0002 min(-1); clearance (CL_F), 131 ± 21 ml/min; area under the curve (AUC(0-∞)), 39 ± 7.0 μg · min/ml; and mean residence time, 435 ± 20 min] were significantly different from those of the control (0.0058 ± 0.0006 min(-1), 296 ± 46 ml/min, 17 ± 3 μg · min/ml, and 232 ± 20 min, respectively).",Interaction between topically and systemically coadministered P-glycoprotein substrates/inhibitors: effect on vitreal kinetics. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20595378/),[ml] / [min],296,131305,DB00860,Prednisolone
,20595378,mean residence time,"The vitreal pharmacokinetic parameters of quinidine in the presence of verapamil [apparent elimination rate constant (λ(z)), 0.0027 ± 0.0002 min(-1); clearance (CL_F), 131 ± 21 ml/min; area under the curve (AUC(0-∞)), 39 ± 7.0 μg · min/ml; and mean residence time, 435 ± 20 min] were significantly different from those of the control (0.0058 ± 0.0006 min(-1), 296 ± 46 ml/min, 17 ± 3 μg · min/ml, and 232 ± 20 min, respectively).",Interaction between topically and systemically coadministered P-glycoprotein substrates/inhibitors: effect on vitreal kinetics. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20595378/),min,232,131306,DB00860,Prednisolone
,15518751,AUC,The median MPA AUC was 34.3 ug.h/mL (range 14.1-65.4).,The pharmacokinetics of mycophenolate mofetil in Thai kidney transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15518751/),[h·ug] / [ml],34.3,131352,DB00860,Prednisolone
,15518751,AUC,"Thirty-one of 45 (68.9%) patients had a MPA AUC within 20 to 40 ug.h/mL, which is the most reasonable risk: benefit ratio in terms of preventing acute rejection episodes.",The pharmacokinetics of mycophenolate mofetil in Thai kidney transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15518751/),[h·ug] / [ml],20 to 40,131353,DB00860,Prednisolone
,15518751,AUC,"Forty-one of 45 (91.1%) patients had MPA AUC within 20 to 60 ug.h/mL, which is the MPA therapeutic range.",The pharmacokinetics of mycophenolate mofetil in Thai kidney transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15518751/),[h·ug] / [ml],20 to 60,131354,DB00860,Prednisolone
,7047863,bioavailability,"Since prednisolone exhibits dose-dependent pharmacokinetics because of nonlinear plasma protein binding, bioavailability from oral prednisone and oral prednisolone, compared to the intravenous dose, was 84.5 +/- 17.8% and 95.5 +/- 17.6% using unbound drug concentrations.",Prednisone and prednisolone bioavailability in renal transplant patients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7047863/),%,84.5,132221,DB00860,Prednisolone
,7047863,bioavailability,"Since prednisolone exhibits dose-dependent pharmacokinetics because of nonlinear plasma protein binding, bioavailability from oral prednisone and oral prednisolone, compared to the intravenous dose, was 84.5 +/- 17.8% and 95.5 +/- 17.6% using unbound drug concentrations.",Prednisone and prednisolone bioavailability in renal transplant patients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7047863/),%,95.5,132222,DB00860,Prednisolone
,8274287,half life,PRED-17-EC was further metabolized with a half life of 1.6 h to prednisolone.,Studies on the pharmacokinetics and metabolism of prednicarbate after cutaneous and oral administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8274287/),h,1.6,133438,DB00860,Prednisolone
,1880318,clearance,"Theophylline clearance decreased an average of 19% in patients randomized to receive MTX, from 48.0 +/- 2.0 ml/hr/kg to 38.9 +/- 3.6 ml/hr/kg (p less than 0.05).",Effect of low-dose methotrexate on the disposition of glucocorticoids and theophylline. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1880318/),[ml] / [h·kg],48.0,134416,DB00860,Prednisolone
,1880318,clearance,"Theophylline clearance decreased an average of 19% in patients randomized to receive MTX, from 48.0 +/- 2.0 ml/hr/kg to 38.9 +/- 3.6 ml/hr/kg (p less than 0.05).",Effect of low-dose methotrexate on the disposition of glucocorticoids and theophylline. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1880318/),[ml] / [h·kg],38.9,134417,DB00860,Prednisolone
,17990084,solubility,"Being formulated with 6% PM, MP had higher solubility (219.6 +/- 3.6 microg/ml) and release rate (11.1 +/- 0.4 ng min(1/2)) at 37 degrees C.",Bioavailability effect of methylprednisolone by polymeric micelles. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17990084/),[μg] / [ml],219.6,135300,DB00860,Prednisolone
,17990084,release rate,"Being formulated with 6% PM, MP had higher solubility (219.6 +/- 3.6 microg/ml) and release rate (11.1 +/- 0.4 ng min(1/2)) at 37 degrees C.",Bioavailability effect of methylprednisolone by polymeric micelles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17990084/),[min(1·ng] / [2],11.1,135301,DB00860,Prednisolone
,17990084,plasma half-lives (t (1/2)),PM formulation markedly increased (7-fold) the plasma half-lives (t (1/2)) of MP (from 76.1 +/- 8.0 to 514.3 +/- 70.0 min).,Bioavailability effect of methylprednisolone by polymeric micelles. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17990084/),min,76.1,135302,DB00860,Prednisolone
,17990084,plasma half-lives (t (1/2)),PM formulation markedly increased (7-fold) the plasma half-lives (t (1/2)) of MP (from 76.1 +/- 8.0 to 514.3 +/- 70.0 min).,Bioavailability effect of methylprednisolone by polymeric micelles. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17990084/),min,514.3,135303,DB00860,Prednisolone
,17990084,SC t (1/2),"In addition, the SC t (1/2) of MP/PM also increased from 278 to 528 min.",Bioavailability effect of methylprednisolone by polymeric micelles. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17990084/),min,278,135304,DB00860,Prednisolone
,17990084,SC t (1/2),"In addition, the SC t (1/2) of MP/PM also increased from 278 to 528 min.",Bioavailability effect of methylprednisolone by polymeric micelles. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17990084/),min,528,135305,DB00860,Prednisolone
,21517926,plasma concentrations,"Median predose plasma concentrations of MPA and MPAG were 1·95 and 26·2μg/mL (interquartile ranges, 0·94-2·96 and 18·6-53·7 μg/mL).",Effective plasma concentrations of mycophenolic acid and its glucuronide in systemic lupus erythematosus patients in the remission-maintenance phase. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21517926/),[μg] / [ml],1·95,137794,DB00860,Prednisolone
,21517926,plasma concentrations,"Median predose plasma concentrations of MPA and MPAG were 1·95 and 26·2μg/mL (interquartile ranges, 0·94-2·96 and 18·6-53·7 μg/mL).",Effective plasma concentrations of mycophenolic acid and its glucuronide in systemic lupus erythematosus patients in the remission-maintenance phase. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21517926/),[μg] / [ml],26·2,137795,DB00860,Prednisolone
,3899153,area under curve (AUCu),Free prednisolone area under curve (AUCu) ranged from 101 to 436 ng ml-1 h and was 6.3 to 15.0% of total prednisolone AUC.,Prednisolone protein binding in renal transplant patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3899153/),[h·ng] / [ml],101 to 436,139028,DB00860,Prednisolone
,2864155,elimination half-life,Sulphasalazine itself is poorly absorbed (3 to 12%) and its elimination half-life of about 5 to 10 hours is probably affected by the absorption process.,"Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2864155/),h,5 to 10,139123,DB00860,Prednisolone
,2864155,elimination half-life,"Depending on the genetic phenotype, the elimination half-life and apparent oral clearance of sulphapyridine are approximately 14 hours and 40 ml/min (slow acetylators) or 6 hours and 150 ml/min (fast acetylators), respectively.","Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2864155/),h,14,139124,DB00860,Prednisolone
,2864155,elimination half-life,"Depending on the genetic phenotype, the elimination half-life and apparent oral clearance of sulphapyridine are approximately 14 hours and 40 ml/min (slow acetylators) or 6 hours and 150 ml/min (fast acetylators), respectively.","Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2864155/),h,6,139125,DB00860,Prednisolone
,2864155,apparent oral clearance,"Depending on the genetic phenotype, the elimination half-life and apparent oral clearance of sulphapyridine are approximately 14 hours and 40 ml/min (slow acetylators) or 6 hours and 150 ml/min (fast acetylators), respectively.","Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2864155/),[ml] / [min],40,139126,DB00860,Prednisolone
,2864155,apparent oral clearance,"Depending on the genetic phenotype, the elimination half-life and apparent oral clearance of sulphapyridine are approximately 14 hours and 40 ml/min (slow acetylators) or 6 hours and 150 ml/min (fast acetylators), respectively.","Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2864155/),[ml] / [min],150,139127,DB00860,Prednisolone
,2864155,elimination half-life,"While the elimination half-life of 5-ASA is short (0.5 to 1.5 h), its major acetylated metabolite (which may be active) exhibits a half-life of 5 to 10 hours.","Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2864155/),h,0.5 to 1.5,139128,DB00860,Prednisolone
,2864155,half-life,"While the elimination half-life of 5-ASA is short (0.5 to 1.5 h), its major acetylated metabolite (which may be active) exhibits a half-life of 5 to 10 hours.","Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2864155/),h,5 to 10,139129,DB00860,Prednisolone
less,2864155,steady-state plasma concentrations,"During therapy with sulphasalazine or 5-ASA, steady-state plasma concentrations of 5-ASA are relatively low (less than or equal to 2 micrograms/ml); thus its mode of action appears to be topically rather than systemically.","Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2864155/),[μg] / [ml],2,139130,DB00860,Prednisolone
,8776613,trough concentration,The smaller dosage of tacrolimus led to a higher trough concentration of 14.1 +/- 1.6 ng/mL in the three-times-a-day regimen compared with 12.7 +/- 1.9 ng/ml in twice-a-day therapy (P < 0.01).,Three-times-daily monotherapy with tacrolimus (FK 506) in kidney transplantation. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8776613/),[ng] / [ml],14.1,139202,DB00860,Prednisolone
,8776613,trough concentration,The smaller dosage of tacrolimus led to a higher trough concentration of 14.1 +/- 1.6 ng/mL in the three-times-a-day regimen compared with 12.7 +/- 1.9 ng/ml in twice-a-day therapy (P < 0.01).,Three-times-daily monotherapy with tacrolimus (FK 506) in kidney transplantation. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8776613/),[ng] / [ml],12.7,139203,DB00860,Prednisolone
<,8776613,trough concentration,Our target trough concentration was decreased finally to < 5 ng/mL.,Three-times-daily monotherapy with tacrolimus (FK 506) in kidney transplantation. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8776613/),[ng] / [ml],5,139204,DB00860,Prednisolone
,24069591,maximum plasma prednisolone concentration,Mean ± standard error (SE) of maximum plasma prednisolone concentration (300.8 ± 67.3 ng/mL) was reached at 1 h after administration.,Plasma and ocular prednisolone disposition after oral treatment in cats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24069591/),[ng] / [ml],300.8,139559,DB00860,Prednisolone
,24069591,peak concentration,Prednisolone was distributed to the aqueous humor reaching a mean peak concentration of 100.9 ± 25.5 ng/mL at 1.25 h after administration.,Plasma and ocular prednisolone disposition after oral treatment in cats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24069591/),[ng] / [ml],100.9,139560,DB00860,Prednisolone
,24069591,exposure,"The mean ± SE systemic and aqueous humor exposure (AUC) was 553.3 ± 120.0 ng h/mL and 378.8 ± 64.9 ng h/mL, respectively.",Plasma and ocular prednisolone disposition after oral treatment in cats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24069591/),[h·ng] / [ml],553.3,139561,DB00860,Prednisolone
,24069591,(,"The mean ± SE systemic and aqueous humor exposure (AUC) was 553.3 ± 120.0 ng h/mL and 378.8 ± 64.9 ng h/mL, respectively.",Plasma and ocular prednisolone disposition after oral treatment in cats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24069591/),[h·ng] / [ml],553.3,139562,DB00860,Prednisolone
,24069591,AUC),"The mean ± SE systemic and aqueous humor exposure (AUC) was 553.3 ± 120.0 ng h/mL and 378.8 ± 64.9 ng h/mL, respectively.",Plasma and ocular prednisolone disposition after oral treatment in cats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24069591/),[h·ng] / [ml],553.3,139563,DB00860,Prednisolone
,24069591,AUC),"The mean ± SE systemic and aqueous humor exposure (AUC) was 553.3 ± 120.0 ng h/mL and 378.8 ± 64.9 ng h/mL, respectively.",Plasma and ocular prednisolone disposition after oral treatment in cats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24069591/),[h·ng] / [ml],378.8,139564,DB00860,Prednisolone
,24069591,AUC,A high AUC(aqueous humor)/AUC(plasma) ratio was observed (0.68 ± 0.13).,Plasma and ocular prednisolone disposition after oral treatment in cats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24069591/),,0.68,139565,DB00860,Prednisolone
,24069591,half-life time of elimination,"The mean half-life time of elimination in plasma and aqueous humor was 0.87 ± 0.16 h and 2.25 ± 0.44 h, respectively.",Plasma and ocular prednisolone disposition after oral treatment in cats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24069591/),h,0.87,139566,DB00860,Prednisolone
,24069591,half-life time of elimination,"The mean half-life time of elimination in plasma and aqueous humor was 0.87 ± 0.16 h and 2.25 ± 0.44 h, respectively.",Plasma and ocular prednisolone disposition after oral treatment in cats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24069591/),h,2.25,139567,DB00860,Prednisolone
,3512355,elimination capacity,"The systemic availability of total prednisone and unbound prednisolone, and the urinary excretion of 6 beta-hydroxyprednisolone, were measured after an oral dose of prednisone and an i.v. dose of prednisolone in 22 patients covering a wide range of liver function (galactose elimination capacity ranging from 3.3 mg/min X kg body wt to 9.2 mg/min X kg body wt).",Effect of liver function on the metabolism of prednisone and prednisolone in humans. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3512355/),[mg] / [body·kg·min·wt],3.3,142587,DB00860,Prednisolone
,3512355,elimination capacity,"The systemic availability of total prednisone and unbound prednisolone, and the urinary excretion of 6 beta-hydroxyprednisolone, were measured after an oral dose of prednisone and an i.v. dose of prednisolone in 22 patients covering a wide range of liver function (galactose elimination capacity ranging from 3.3 mg/min X kg body wt to 9.2 mg/min X kg body wt).",Effect of liver function on the metabolism of prednisone and prednisolone in humans. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3512355/),[mg] / [kg·min],9.2,142588,DB00860,Prednisolone
,12006542,time required to reach the maximum plasma drug concentration (t(max)),"Our findings indicate that LFM-A13 is quickly absorbed, with the time required to reach the maximum plasma drug concentration (t(max)) being 10-18 min after i.p. administration with nearly complete bioavailability.","In vivo pharmacokinetic features, toxicity profile, and chemosensitizing activity of alpha-cyano-beta-hydroxy-beta- methyl-N-(2,5-dibromophenyl)propenamide (LFM-A13), a novel antileukemic agent targeting Bruton's tyrosine kinase. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12006542/),min,10-18,143386,DB00860,Prednisolone
,12006542,elimination half-life,LFM-A13 had an elimination half-life of 17-32 min after i.p. administration at dose levels of 10-50 mg/kg.,"In vivo pharmacokinetic features, toxicity profile, and chemosensitizing activity of alpha-cyano-beta-hydroxy-beta- methyl-N-(2,5-dibromophenyl)propenamide (LFM-A13), a novel antileukemic agent targeting Bruton's tyrosine kinase. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12006542/),min,17-32,143387,DB00860,Prednisolone
,12006542,survival time,LFM-A13 prolonged the median survival time of VPL-treated mice from 37 to 58 days.,"In vivo pharmacokinetic features, toxicity profile, and chemosensitizing activity of alpha-cyano-beta-hydroxy-beta- methyl-N-(2,5-dibromophenyl)propenamide (LFM-A13), a novel antileukemic agent targeting Bruton's tyrosine kinase. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12006542/),d,37 to 58,143388,DB00860,Prednisolone
,15795639,absorption rate constants,The absorption rate constants were fixed at 0.25 L/h for Sandimmune and 1.35 L/h for Neoral formulations.,Population pharmacokinetics of cyclosporine in cardiopulmonary transplant recipients. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15795639/),[l] / [h],0.25,143668,DB00860,Prednisolone
,15795639,absorption rate constants,The absorption rate constants were fixed at 0.25 L/h for Sandimmune and 1.35 L/h for Neoral formulations.,Population pharmacokinetics of cyclosporine in cardiopulmonary transplant recipients. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15795639/),[l] / [h],1.35,143669,DB00860,Prednisolone
,15795639,Oral clearance (CL/F),Oral clearance (CL/F) was estimated to be 22.1 L/h (95% confidence intervals [CI] 19.5-24.7 L/h).,Population pharmacokinetics of cyclosporine in cardiopulmonary transplant recipients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15795639/),[l] / [h],22.1,143670,DB00860,Prednisolone
,15795639,relative oral bioavailability,The relative oral bioavailability of Sandimmune to Neoral was 0.82.,Population pharmacokinetics of cyclosporine in cardiopulmonary transplant recipients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15795639/),,0.82,143671,DB00860,Prednisolone
,22777155,Area under the time-concentration curve,Area under the time-concentration curve of prednisolone was 3-13 μg·h·mL·mg·kg with maximum concentrations (Cmax) between 0.37 and 2.5 μg·mL·mg·kg and trough concentrations (C0) between 0.13 and 1.1 μg·mL·mg·kg.,The pharmacokinetics of prednisolone and prednisone in adult liver transplant recipients early after transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22777155/),h·kg·mg·ml·μg,3-13,143749,DB00860,Prednisolone
,22777155,maximum concentrations (Cmax),Area under the time-concentration curve of prednisolone was 3-13 μg·h·mL·mg·kg with maximum concentrations (Cmax) between 0.37 and 2.5 μg·mL·mg·kg and trough concentrations (C0) between 0.13 and 1.1 μg·mL·mg·kg.,The pharmacokinetics of prednisolone and prednisone in adult liver transplant recipients early after transplantation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22777155/),kg·mg·ml·μg,0.37 and 2.5,143750,DB00860,Prednisolone
,22777155,trough concentrations (C0),Area under the time-concentration curve of prednisolone was 3-13 μg·h·mL·mg·kg with maximum concentrations (Cmax) between 0.37 and 2.5 μg·mL·mg·kg and trough concentrations (C0) between 0.13 and 1.1 μg·mL·mg·kg.,The pharmacokinetics of prednisolone and prednisone in adult liver transplant recipients early after transplantation. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22777155/),kg·mg·ml·μg,0.13 and 1.1,143751,DB00860,Prednisolone
,22777155,elimination half-lives,The elimination half-lives were 1.9-10.3 hours.,The pharmacokinetics of prednisolone and prednisone in adult liver transplant recipients early after transplantation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22777155/),h,1.9-10.3,143752,DB00860,Prednisolone
,22777155,Apparent volume of distribution (VD/F),"Apparent volume of distribution (VD/F) and apparent clearance (Cl/F) were 23-159 L and 4.7-28.7 L/h, respectively.",The pharmacokinetics of prednisolone and prednisone in adult liver transplant recipients early after transplantation. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22777155/),l,23-159,143753,DB00860,Prednisolone
,22777155,apparent clearance (Cl/F),"Apparent volume of distribution (VD/F) and apparent clearance (Cl/F) were 23-159 L and 4.7-28.7 L/h, respectively.",The pharmacokinetics of prednisolone and prednisone in adult liver transplant recipients early after transplantation. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22777155/),[l] / [h],4.7-28.7,143754,DB00860,Prednisolone
,3517294,availability,"After intravenous methylprednisolone sodium succinate administration, methylprednisolone was released rapidly but the extent of availability was rather low (43.6%).","Pharmacokinetics of methylprednisolone, methylprednisolone sodium succinate, and methylprednisolone acetate in dogs. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3517294/),%,43.6,143995,DB00860,Prednisolone
,3517294,half-time of absorption,"After intramuscular administration of methylprednisolone acetate, its absorption was slow (half-time of absorption, 69.04 h) and the availability of the released methylprednisolone was low (42.7%).","Pharmacokinetics of methylprednisolone, methylprednisolone sodium succinate, and methylprednisolone acetate in dogs. ","t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3517294/),h,69.04,143996,DB00860,Prednisolone
,7229914,systemic availability,"There were no statistically significant differences between smokers and nonsmokers in the systemic availability of prednisolone (75 versus 84%), oral dose clearance of prednisone (29 verus 27 ml/min/kg), systemic prednisolone clearance (2.8 versus 2.9 ml/min/kg), or in the interconversion rates, volumes of distribution, or urinary recoveries of prednisone and prednisolone.","Effect of smoking on prednisone, prednisolone, and dexamethasone pharmacokinetics. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7229914/),%,75,144191,DB00860,Prednisolone
,7229914,systemic availability,"There were no statistically significant differences between smokers and nonsmokers in the systemic availability of prednisolone (75 versus 84%), oral dose clearance of prednisone (29 verus 27 ml/min/kg), systemic prednisolone clearance (2.8 versus 2.9 ml/min/kg), or in the interconversion rates, volumes of distribution, or urinary recoveries of prednisone and prednisolone.","Effect of smoking on prednisone, prednisolone, and dexamethasone pharmacokinetics. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7229914/),%,84,144192,DB00860,Prednisolone
,7229914,oral dose clearance,"There were no statistically significant differences between smokers and nonsmokers in the systemic availability of prednisolone (75 versus 84%), oral dose clearance of prednisone (29 verus 27 ml/min/kg), systemic prednisolone clearance (2.8 versus 2.9 ml/min/kg), or in the interconversion rates, volumes of distribution, or urinary recoveries of prednisone and prednisolone.","Effect of smoking on prednisone, prednisolone, and dexamethasone pharmacokinetics. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7229914/),[ml] / [kg·min],29,144193,DB00860,Prednisolone
,7229914,oral dose clearance,"There were no statistically significant differences between smokers and nonsmokers in the systemic availability of prednisolone (75 versus 84%), oral dose clearance of prednisone (29 verus 27 ml/min/kg), systemic prednisolone clearance (2.8 versus 2.9 ml/min/kg), or in the interconversion rates, volumes of distribution, or urinary recoveries of prednisone and prednisolone.","Effect of smoking on prednisone, prednisolone, and dexamethasone pharmacokinetics. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7229914/),[ml] / [kg·min],27,144194,DB00860,Prednisolone
,7229914,systemic prednisolone clearance,"There were no statistically significant differences between smokers and nonsmokers in the systemic availability of prednisolone (75 versus 84%), oral dose clearance of prednisone (29 verus 27 ml/min/kg), systemic prednisolone clearance (2.8 versus 2.9 ml/min/kg), or in the interconversion rates, volumes of distribution, or urinary recoveries of prednisone and prednisolone.","Effect of smoking on prednisone, prednisolone, and dexamethasone pharmacokinetics. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7229914/),[ml] / [kg·min],2.8,144195,DB00860,Prednisolone
,7229914,systemic prednisolone clearance,"There were no statistically significant differences between smokers and nonsmokers in the systemic availability of prednisolone (75 versus 84%), oral dose clearance of prednisone (29 verus 27 ml/min/kg), systemic prednisolone clearance (2.8 versus 2.9 ml/min/kg), or in the interconversion rates, volumes of distribution, or urinary recoveries of prednisone and prednisolone.","Effect of smoking on prednisone, prednisolone, and dexamethasone pharmacokinetics. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7229914/),[ml] / [kg·min],2.9,144196,DB00860,Prednisolone
,7229914,oral dose clearances,A limited correlation (r = 0.55) was found between the high oral dose clearances of prednisone and the lower values of dexamethasone (6.73 and 5.71 ml/min/kg in smokers and nonsmokers).,"Effect of smoking on prednisone, prednisolone, and dexamethasone pharmacokinetics. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7229914/),[ml] / [kg·min],6.73,144197,DB00860,Prednisolone
,7229914,oral dose clearances,A limited correlation (r = 0.55) was found between the high oral dose clearances of prednisone and the lower values of dexamethasone (6.73 and 5.71 ml/min/kg in smokers and nonsmokers).,"Effect of smoking on prednisone, prednisolone, and dexamethasone pharmacokinetics. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7229914/),[ml] / [kg·min],5.71,144198,DB00860,Prednisolone
,2863117,clearance,"The ranges of clearance values at low and high rates of infusion were 2.51-4.08 and 6.08-10.98 ml/min/kg, respectively.",Pharmacokinetics of prednisone and prednisolone at steady state in the rabbit. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2863117/),[ml] / [kg·min],2.51-4.08,145000,DB00860,Prednisolone
,2863117,clearance,"The ranges of clearance values at low and high rates of infusion were 2.51-4.08 and 6.08-10.98 ml/min/kg, respectively.",Pharmacokinetics of prednisone and prednisolone at steady state in the rabbit. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2863117/),[ml] / [kg·min],6.08-10.98,145001,DB00860,Prednisolone
,2863117,unbound plasma prednisolone clearance,"The ranges of unbound plasma prednisolone clearance at low and high rates of infusions were 30.3-67.7 and 50.6-110.2 ml/min/kg, respectively.",Pharmacokinetics of prednisone and prednisolone at steady state in the rabbit. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2863117/),[ml] / [kg·min],30.3-67.7,145002,DB00860,Prednisolone
,2863117,unbound plasma prednisolone clearance,"The ranges of unbound plasma prednisolone clearance at low and high rates of infusions were 30.3-67.7 and 50.6-110.2 ml/min/kg, respectively.",Pharmacokinetics of prednisone and prednisolone at steady state in the rabbit. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2863117/),[ml] / [kg·min],50.6-110.2,145003,DB00860,Prednisolone
,25404561,m/z,"Electrospray ionization in positive ion mode and multiple reaction monitoring were used to monitor the ion transitions at m/z 375.4/160.8 for methylprednisolone, and m/z 361.2/147.0 for prednisolone.",An Economical Online Solid-Phase Extraction LC-MS/MS Method for Quantifying Methylprednisolone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25404561/),,375.4,145039,DB00860,Prednisolone
,25404561,m/z,"Electrospray ionization in positive ion mode and multiple reaction monitoring were used to monitor the ion transitions at m/z 375.4/160.8 for methylprednisolone, and m/z 361.2/147.0 for prednisolone.",An Economical Online Solid-Phase Extraction LC-MS/MS Method for Quantifying Methylprednisolone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25404561/),,160.8,145040,DB00860,Prednisolone
,25404561,m/z,"Electrospray ionization in positive ion mode and multiple reaction monitoring were used to monitor the ion transitions at m/z 375.4/160.8 for methylprednisolone, and m/z 361.2/147.0 for prednisolone.",An Economical Online Solid-Phase Extraction LC-MS/MS Method for Quantifying Methylprednisolone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25404561/),,361.2,145041,DB00860,Prednisolone
,25404561,m/z,"Electrospray ionization in positive ion mode and multiple reaction monitoring were used to monitor the ion transitions at m/z 375.4/160.8 for methylprednisolone, and m/z 361.2/147.0 for prednisolone.",An Economical Online Solid-Phase Extraction LC-MS/MS Method for Quantifying Methylprednisolone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25404561/),,147.0,145042,DB00860,Prednisolone
,21372831,overall response rate (ORR),"The overall response rate (ORR) was 45.5%, and the CR rate was 27.3%.",Pharmacodynamic and pharmacokinetic study of pegylated liposomal doxorubicin combination (CCOP) chemotherapy in patients with peripheral T-cell lymphomas. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21372831/),%,45.5,147623,DB00860,Prednisolone
,21372831,CR rate,"The overall response rate (ORR) was 45.5%, and the CR rate was 27.3%.",Pharmacodynamic and pharmacokinetic study of pegylated liposomal doxorubicin combination (CCOP) chemotherapy in patients with peripheral T-cell lymphomas. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21372831/),%,27,147624,DB00860,Prednisolone
,21372831,progression-free survival (PFS) rate,"The 1-year overall survival rate was 45.5%, and the median progression-free survival (PFS) rate was 6.5 [95% confidence interval (95% CI) 3.17-19.02] with a survival rate of 11.5 months (95% CI 6.65-16.36).",Pharmacodynamic and pharmacokinetic study of pegylated liposomal doxorubicin combination (CCOP) chemotherapy in patients with peripheral T-cell lymphomas. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21372831/),,6.5,147625,DB00860,Prednisolone
,21372831,survival rate,"The 1-year overall survival rate was 45.5%, and the median progression-free survival (PFS) rate was 6.5 [95% confidence interval (95% CI) 3.17-19.02] with a survival rate of 11.5 months (95% CI 6.65-16.36).",Pharmacodynamic and pharmacokinetic study of pegylated liposomal doxorubicin combination (CCOP) chemotherapy in patients with peripheral T-cell lymphomas. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21372831/),,11,147626,DB00860,Prednisolone
,21372831,plasma concentration,The PLD plasma concentration from nine patients ranged from 1.7036 to 9.2207 mg·L(-1) after administration of the CCOP regimen (0-168 h).,Pharmacodynamic and pharmacokinetic study of pegylated liposomal doxorubicin combination (CCOP) chemotherapy in patients with peripheral T-cell lymphomas. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21372831/),[mg] / [l],1.7036 to 9.2207,147627,DB00860,Prednisolone
,21372831,AUC(0-∞),"The pharmacokinetic parameters AUC(0-∞), CL, t(1/2), and V(d) were 910.76 mg/L·h, 0.043 L·h(-1)·m(-2), 68.40 h, and 3.56 L/m(2), respectively.",Pharmacodynamic and pharmacokinetic study of pegylated liposomal doxorubicin combination (CCOP) chemotherapy in patients with peripheral T-cell lymphomas. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21372831/),[mg] / [h·l],910.76,147628,DB00860,Prednisolone
,21372831,CL,"The pharmacokinetic parameters AUC(0-∞), CL, t(1/2), and V(d) were 910.76 mg/L·h, 0.043 L·h(-1)·m(-2), 68.40 h, and 3.56 L/m(2), respectively.",Pharmacodynamic and pharmacokinetic study of pegylated liposomal doxorubicin combination (CCOP) chemotherapy in patients with peripheral T-cell lymphomas. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21372831/),[l] / [(m)^2·h],0.043,147629,DB00860,Prednisolone
,21372831,CL,"The pharmacokinetic parameters AUC(0-∞), CL, t(1/2), and V(d) were 910.76 mg/L·h, 0.043 L·h(-1)·m(-2), 68.40 h, and 3.56 L/m(2), respectively.",Pharmacodynamic and pharmacokinetic study of pegylated liposomal doxorubicin combination (CCOP) chemotherapy in patients with peripheral T-cell lymphomas. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21372831/),h,68.40,147630,DB00860,Prednisolone
,21372831,t(1/2),"The pharmacokinetic parameters AUC(0-∞), CL, t(1/2), and V(d) were 910.76 mg/L·h, 0.043 L·h(-1)·m(-2), 68.40 h, and 3.56 L/m(2), respectively.",Pharmacodynamic and pharmacokinetic study of pegylated liposomal doxorubicin combination (CCOP) chemotherapy in patients with peripheral T-cell lymphomas. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21372831/),[l] / [(m)^2·h],0.043,147631,DB00860,Prednisolone
,21372831,t(1/2),"The pharmacokinetic parameters AUC(0-∞), CL, t(1/2), and V(d) were 910.76 mg/L·h, 0.043 L·h(-1)·m(-2), 68.40 h, and 3.56 L/m(2), respectively.",Pharmacodynamic and pharmacokinetic study of pegylated liposomal doxorubicin combination (CCOP) chemotherapy in patients with peripheral T-cell lymphomas. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21372831/),h,68.40,147632,DB00860,Prednisolone
,21372831,V(d),"The pharmacokinetic parameters AUC(0-∞), CL, t(1/2), and V(d) were 910.76 mg/L·h, 0.043 L·h(-1)·m(-2), 68.40 h, and 3.56 L/m(2), respectively.",Pharmacodynamic and pharmacokinetic study of pegylated liposomal doxorubicin combination (CCOP) chemotherapy in patients with peripheral T-cell lymphomas. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21372831/),[l] / [m(2],3.56,147633,DB00860,Prednisolone
,1184723,MCR,"The MCR, half-life, and volume of distribution were, respectively, 383 +/- 72 (SD) liters/day, 165 +/- 49 minutes, and 61 +/- 12 liters for MP, and 234 +/- 37, 160 +/- 19, and 41 +/- 6 for MPHS.","Effects of diphenylhydantoin, phenobarbital, and diazepam on the metabolism of methylprednisolone and its sodium succinate. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1184723/),[l] / [d],383,149337,DB00860,Prednisolone
,1184723,volume of distribution,"The MCR, half-life, and volume of distribution were, respectively, 383 +/- 72 (SD) liters/day, 165 +/- 49 minutes, and 61 +/- 12 liters for MP, and 234 +/- 37, 160 +/- 19, and 41 +/- 6 for MPHS.","Effects of diphenylhydantoin, phenobarbital, and diazepam on the metabolism of methylprednisolone and its sodium succinate. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1184723/),l,61,149338,DB00860,Prednisolone
,1184723,MCR,"Diphenylhydantoin (DPH) administered to 4 subjects increased the MCR of MP from 424 +/- 71 to 977 +/- 132 (P less than 0.01), and decreased the half-life from 149 +/- 44 to 69 +/- 7 (P less than 0.001).","Effects of diphenylhydantoin, phenobarbital, and diazepam on the metabolism of methylprednisolone and its sodium succinate. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1184723/),,424,149339,DB00860,Prednisolone
,1184723,MCR,"Diphenylhydantoin (DPH) administered to 4 subjects increased the MCR of MP from 424 +/- 71 to 977 +/- 132 (P less than 0.01), and decreased the half-life from 149 +/- 44 to 69 +/- 7 (P less than 0.001).","Effects of diphenylhydantoin, phenobarbital, and diazepam on the metabolism of methylprednisolone and its sodium succinate. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1184723/),,977,149340,DB00860,Prednisolone
,1184723,half-life,"Diphenylhydantoin (DPH) administered to 4 subjects increased the MCR of MP from 424 +/- 71 to 977 +/- 132 (P less than 0.01), and decreased the half-life from 149 +/- 44 to 69 +/- 7 (P less than 0.001).","Effects of diphenylhydantoin, phenobarbital, and diazepam on the metabolism of methylprednisolone and its sodium succinate. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1184723/),,149,149341,DB00860,Prednisolone
,1184723,half-life,"Diphenylhydantoin (DPH) administered to 4 subjects increased the MCR of MP from 424 +/- 71 to 977 +/- 132 (P less than 0.01), and decreased the half-life from 149 +/- 44 to 69 +/- 7 (P less than 0.001).","Effects of diphenylhydantoin, phenobarbital, and diazepam on the metabolism of methylprednisolone and its sodium succinate. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1184723/),,69,149342,DB00860,Prednisolone
,30717564,flow rate,"After the plasma samples were processed by precipitation protein method, the constituents and internal standards were gradient eluted by using a Zorbax SB-18 column with a mobile phase of acetonitrile(A) and 0.1% formic acid aqueous solution(B) using a gradient elution of 0-2.5 min, 15%-30% A; 2.5-3.5 min, 30%-35% A; 3.5-5.0 min, 35%-40% A; 5.0-9.0 min, 40%-60% A; 9.0-11.0 min, 60%-15% A, and the flow rate was 0.4 mL·min⁻¹.",[Pharmacokinetic characteristics of fourteen main components of Gegen Qinlian Decoction in rats]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30717564/),min⁻¹·ml,0.4,149520,DB00860,Prednisolone
,30717564,MRT0-t,"The results showed that the MRT0-t of the isoflavones and flavonoids was 7.5-11.8 h, T1/2z were mainly in 11.0-29.7 h, and the AUC0-t flavonoids were larger than the isoflavones.",[Pharmacokinetic characteristics of fourteen main components of Gegen Qinlian Decoction in rats]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30717564/),h,7.5-11.8,149521,DB00860,Prednisolone
,30717564,T1/2z,"The results showed that the MRT0-t of the isoflavones and flavonoids was 7.5-11.8 h, T1/2z were mainly in 11.0-29.7 h, and the AUC0-t flavonoids were larger than the isoflavones.",[Pharmacokinetic characteristics of fourteen main components of Gegen Qinlian Decoction in rats]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30717564/),h,11.0-29.7,149522,DB00860,Prednisolone
,30717564,MRT0-t,"The MRT0-t of alkaloids were between 4.3-7.2 h, T1/2z were 1.0-5.0 h, AUC0-t were less than flavonoids and isoflavones.",[Pharmacokinetic characteristics of fourteen main components of Gegen Qinlian Decoction in rats]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30717564/),h,4.3-7.2,149523,DB00860,Prednisolone
,30717564,T1/2z,"The MRT0-t of alkaloids were between 4.3-7.2 h, T1/2z were 1.0-5.0 h, AUC0-t were less than flavonoids and isoflavones.",[Pharmacokinetic characteristics of fourteen main components of Gegen Qinlian Decoction in rats]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30717564/),h,1.0-5.0,149524,DB00860,Prednisolone
,10426160,elimination half-life,The mean elimination half-life of methylprednisolone was increased from 2.1+/-0.3 hr to 4.8+/-0.8 hr (P<0.001) by itraconazole.,Itraconazole decreases the clearance and enhances the effects of intravenously administered methylprednisolone in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10426160/),h,2.1,150097,DB00860,Prednisolone
,10426160,elimination half-life,The mean elimination half-life of methylprednisolone was increased from 2.1+/-0.3 hr to 4.8+/-0.8 hr (P<0.001) by itraconazole.,Itraconazole decreases the clearance and enhances the effects of intravenously administered methylprednisolone in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10426160/),h,4.8,150098,DB00860,Prednisolone
,10426160,plasma cortisol concentration,"The mean morning plasma cortisol concentration during the itraconazole phase, measured 24 hr after the administration of methylprednisolone, was only about 9% of that during the placebo phase (11.0+/-9.0 ng/ml versus 117+/-49.2 ng/ml; P<0.001).",Itraconazole decreases the clearance and enhances the effects of intravenously administered methylprednisolone in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10426160/),[ng] / [ml],11.0,150099,DB00860,Prednisolone
,10426160,plasma cortisol concentration,"The mean morning plasma cortisol concentration during the itraconazole phase, measured 24 hr after the administration of methylprednisolone, was only about 9% of that during the placebo phase (11.0+/-9.0 ng/ml versus 117+/-49.2 ng/ml; P<0.001).",Itraconazole decreases the clearance and enhances the effects of intravenously administered methylprednisolone in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10426160/),[ng] / [ml],117,150100,DB00860,Prednisolone
,1543815,peak plasma prednisolone concentrations,"Plasma and urine prednisolone profiles in 6 healthy volunteers confirmed minimal absorption from Eudragit S-coated prednisolone metasulphabenzoate compared to prednisolone acetate: peak plasma prednisolone concentrations 29 +/- 21 ng/ml vs. 570 +/- 185 ng/ml (P less than 0.01), area under curve measurements 204 +/- 214 vs. 2724 +/- 1236 ng.h/ml (P less than 0.01).",An Eudragit-coated prednisolone preparation for ulcerative colitis: pharmacokinetics and preliminary therapeutic use. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1543815/),[ng] / [ml],29,153129,DB00860,Prednisolone
,1543815,peak plasma prednisolone concentrations,"Plasma and urine prednisolone profiles in 6 healthy volunteers confirmed minimal absorption from Eudragit S-coated prednisolone metasulphabenzoate compared to prednisolone acetate: peak plasma prednisolone concentrations 29 +/- 21 ng/ml vs. 570 +/- 185 ng/ml (P less than 0.01), area under curve measurements 204 +/- 214 vs. 2724 +/- 1236 ng.h/ml (P less than 0.01).",An Eudragit-coated prednisolone preparation for ulcerative colitis: pharmacokinetics and preliminary therapeutic use. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1543815/),[ng] / [ml],570,153130,DB00860,Prednisolone
,1543815,area under curve,"Plasma and urine prednisolone profiles in 6 healthy volunteers confirmed minimal absorption from Eudragit S-coated prednisolone metasulphabenzoate compared to prednisolone acetate: peak plasma prednisolone concentrations 29 +/- 21 ng/ml vs. 570 +/- 185 ng/ml (P less than 0.01), area under curve measurements 204 +/- 214 vs. 2724 +/- 1236 ng.h/ml (P less than 0.01).",An Eudragit-coated prednisolone preparation for ulcerative colitis: pharmacokinetics and preliminary therapeutic use. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1543815/),[h·ng] / [ml],204,153131,DB00860,Prednisolone
,1543815,area under curve,"Plasma and urine prednisolone profiles in 6 healthy volunteers confirmed minimal absorption from Eudragit S-coated prednisolone metasulphabenzoate compared to prednisolone acetate: peak plasma prednisolone concentrations 29 +/- 21 ng/ml vs. 570 +/- 185 ng/ml (P less than 0.01), area under curve measurements 204 +/- 214 vs. 2724 +/- 1236 ng.h/ml (P less than 0.01).",An Eudragit-coated prednisolone preparation for ulcerative colitis: pharmacokinetics and preliminary therapeutic use. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1543815/),[h·ng] / [ml],2724,153132,DB00860,Prednisolone
,31744668,flow rate,"Using testosterone as internal standard, the plasma samples were prepared by precipitation with acetonitrile and separated using an ACQUITY UPLC BEH C18 column (100 mm × 2.1 mm, 1.7 μm) with a mobile phase composed of acetonitrile and 0.1 % (v/v) formic acid aqueous solution by gradient elution at a flow rate of 0.3 mL/min.",Development and validation of a LC-MS/MS method for simultaneous determination of six glucocorticoids and its application to a pharmacokinetic study in nude mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31744668/),[ml] / [min],0.3,155222,DB00860,Prednisolone
,32883831,blood-to-plasma ratio,The blood-to-plasma ratio of PNL was 0.71 with similar red blood cell and unbound-plasma concentrations.,Physiologically Based Pharmacokinetic Modeling Involving Nonlinear Plasma and Tissue Binding: Application to Prednisolone and Prednisone in Rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32883831/),,0.71,156520,DB00860,Prednisolone
,32883831,Plasma protein binding,Plasma protein binding (60%-90%) was related to corticosteroid-binding globulin (CBG) saturation.,Physiologically Based Pharmacokinetic Modeling Involving Nonlinear Plasma and Tissue Binding: Application to Prednisolone and Prednisone in Rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32883831/),%,60,156521,DB00860,Prednisolone
,32883831,equilibrium dissociation constant (K d ),"The equilibrium dissociation constant (K d ) of PNL shared by all tissues was 3.01 ng/ml, with the highest binding in muscle, followed by liver, heart, intestine, and bone and the lowest binding in skin, spleen, fat, kidney, lung, and brain.",Physiologically Based Pharmacokinetic Modeling Involving Nonlinear Plasma and Tissue Binding: Application to Prednisolone and Prednisone in Rats. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32883831/),[ng] / [ml],3.01,156522,DB00860,Prednisolone
,32883831,Clearances,Clearances of CBG-free PNL were 1789 from liver and 191.2 ml/h from kidney.,Physiologically Based Pharmacokinetic Modeling Involving Nonlinear Plasma and Tissue Binding: Application to Prednisolone and Prednisone in Rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32883831/),[ml] / [h],1789,156523,DB00860,Prednisolone
,32883831,Clearances,Clearances of CBG-free PNL were 1789 from liver and 191.2 ml/h from kidney.,Physiologically Based Pharmacokinetic Modeling Involving Nonlinear Plasma and Tissue Binding: Application to Prednisolone and Prednisone in Rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32883831/),[ml] / [h],191.2,156524,DB00860,Prednisolone
,1932610,unbound fraction,The unbound fraction of POH ranged between 3 and 15 per cent from tracer to total concentrations of 2000 micrograms-1.,Prednisone and prednisolone interconversion in the rabbit utilizing unbound concentrations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1932610/),%,3 and 15,156863,DB00860,Prednisolone
,1932610,total concentrations,The unbound fraction of POH ranged between 3 and 15 per cent from tracer to total concentrations of 2000 micrograms-1.,Prednisone and prednisolone interconversion in the rabbit utilizing unbound concentrations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1932610/),1/[μg],2000,156864,DB00860,Prednisolone
,1932610,unbound fraction,The unbound fraction of PO ranged between 23 and 34 per cent and appeared nonlinear for four of the rabbits.,Prednisone and prednisolone interconversion in the rabbit utilizing unbound concentrations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1932610/),%,23 and 34,156865,DB00860,Prednisolone
,1932610,apparent unbound clearances,"The mean apparent unbound clearances of POH ranged from 4.4 to 6.1 lh-1kg-1 and from 4.1 to 5.9 lh-1kg-1 for PO, and were dose-independent for both compounds.",Prednisone and prednisolone interconversion in the rabbit utilizing unbound concentrations. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1932610/),1/[lh],4.4 to 6.1,156866,DB00860,Prednisolone
,1932610,apparent unbound clearances,"The mean apparent unbound clearances of POH ranged from 4.4 to 6.1 lh-1kg-1 and from 4.1 to 5.9 lh-1kg-1 for PO, and were dose-independent for both compounds.",Prednisone and prednisolone interconversion in the rabbit utilizing unbound concentrations. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1932610/),1/[lh],4.1 to 5.9,156867,DB00860,Prednisolone
,1932610,available fraction,The available fraction of POH from PO was 50 to 70 per cent and independent of dose.,Prednisone and prednisolone interconversion in the rabbit utilizing unbound concentrations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1932610/),%,50 to 70,156868,DB00860,Prednisolone
,1932610,available fraction,The available fraction of PO from POH averaged 44 per cent at the low infusion rate decreasing to 16 and 20 per cent at the medium and high infusion rates.,Prednisone and prednisolone interconversion in the rabbit utilizing unbound concentrations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1932610/),%,44,156869,DB00860,Prednisolone
,1932610,available fraction,The available fraction of PO from POH averaged 44 per cent at the low infusion rate decreasing to 16 and 20 per cent at the medium and high infusion rates.,Prednisone and prednisolone interconversion in the rabbit utilizing unbound concentrations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1932610/),%,16,156870,DB00860,Prednisolone
,1932610,available fraction,The available fraction of PO from POH averaged 44 per cent at the low infusion rate decreasing to 16 and 20 per cent at the medium and high infusion rates.,Prednisone and prednisolone interconversion in the rabbit utilizing unbound concentrations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1932610/),%,20,156871,DB00860,Prednisolone
,6826099,oral/intravenous availability ratio,The oral/intravenous availability ratio was 0.61 +/- 0.14 in Crohn's patients and 0.89 +/- 0.07 in the normal group.,Absorption of prednisolone in patients with Crohn's disease. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6826099/),,0.61,159397,DB00860,Prednisolone
,6826099,oral/intravenous availability ratio,The oral/intravenous availability ratio was 0.61 +/- 0.14 in Crohn's patients and 0.89 +/- 0.07 in the normal group.,Absorption of prednisolone in patients with Crohn's disease. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6826099/),,0.89,159398,DB00860,Prednisolone
,6826099,Areas under plasma concentration-time curves,Areas under plasma concentration-time curves were lower in patients than normal subjects and the oral/intravenous ratios were 0.6 +/- 0.2 and 0.86 +/- 0.09 respectively.,Absorption of prednisolone in patients with Crohn's disease. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6826099/),,0.6,159399,DB00860,Prednisolone
,6826099,Areas under plasma concentration-time curves,Areas under plasma concentration-time curves were lower in patients than normal subjects and the oral/intravenous ratios were 0.6 +/- 0.2 and 0.86 +/- 0.09 respectively.,Absorption of prednisolone in patients with Crohn's disease. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6826099/),,0.86,159400,DB00860,Prednisolone
,6826099,ratios,Areas under plasma concentration-time curves were lower in patients than normal subjects and the oral/intravenous ratios were 0.6 +/- 0.2 and 0.86 +/- 0.09 respectively.,Absorption of prednisolone in patients with Crohn's disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6826099/),,0.6,159401,DB00860,Prednisolone
,6826099,ratios,Areas under plasma concentration-time curves were lower in patients than normal subjects and the oral/intravenous ratios were 0.6 +/- 0.2 and 0.86 +/- 0.09 respectively.,Absorption of prednisolone in patients with Crohn's disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6826099/),,0.86,159402,DB00860,Prednisolone
,6826099,Faecal excretion,"Faecal excretion of radioactivity after oral ingestion was greater in Crohn's patients (19.3 +/- 2.5%, n = 3) than in normal subjects (7 +/- 2.8%, n = 4).",Absorption of prednisolone in patients with Crohn's disease. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6826099/),%,19.3,159403,DB00860,Prednisolone
,6826099,Faecal excretion,"Faecal excretion of radioactivity after oral ingestion was greater in Crohn's patients (19.3 +/- 2.5%, n = 3) than in normal subjects (7 +/- 2.8%, n = 4).",Absorption of prednisolone in patients with Crohn's disease. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6826099/),%,7,159404,DB00860,Prednisolone
,9263380,blood/ plasma ratio,Blood and plasma sirolimus concentrations were analyzed by an electrospray-high performance liquid/mass spectrophotometric (ESP-HPLC/MS) method Sirolimus showed an extensive red blood cell distribution with a mean blood/ plasma ratio of 49.1.,Kinetics and dynamics of single oral doses of sirolimus in sixteen renal transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9263380/),,49.1,160379,DB00860,Prednisolone
,9263380,elimination half-life,The elimination half-life ranged from 43.8 to 86.5 hours (mean 56.9 hours).,Kinetics and dynamics of single oral doses of sirolimus in sixteen renal transplant recipients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9263380/),h,56.9,160380,DB00860,Prednisolone
,9263380,oral dose clearance,The oral dose clearance ranged from 42 to 339 ml/h.kg.,Kinetics and dynamics of single oral doses of sirolimus in sixteen renal transplant recipients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9263380/),[ml] / [h·kg],42 to 339,160381,DB00860,Prednisolone
,7441495,steady-state levels,Six dogs were given four different zero-order infusions of prednisolone resulting in steady-state levels from 23 to 5884 ng/ml.,Prednisolone clearance at steady state in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7441495/),[ng] / [ml],23 to 5884,160555,DB00860,Prednisolone
,7441495,Km,"The conversion of prednisolone to prednisone, defined by the prednisolone/prednisone ratio, exhibited saturable characteristics which, when data for all dogs was fitted to a Michaelis-Menten type equation (r2 = 0.938), gave a Km of 658 ng/ml, i.e., total prednisolone concentration at half-maximal saturation.",Prednisolone clearance at steady state in dogs. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7441495/),[ng] / [ml],658,160556,DB00860,Prednisolone
,6374250,half-life,"Pharmacokinetic analysis showed that the half-life of prednisolone was shorter in the anticonvulsant group compared to the controls, based on both total (2.3 +/- 0.4 vs. 3.4 +/- 0.2 hr (SD), P less than 0.01) and unbound (1.7 +/- 0.3 vs. 2.4 +/- 0.2 hr, P less than 0.01) concentrations.",Disposition of total and unbound prednisolone in renal transplant patients receiving anticonvulsants. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6374250/),h,2.3,160807,DB00860,Prednisolone
,6374250,half-life,"Pharmacokinetic analysis showed that the half-life of prednisolone was shorter in the anticonvulsant group compared to the controls, based on both total (2.3 +/- 0.4 vs. 3.4 +/- 0.2 hr (SD), P less than 0.01) and unbound (1.7 +/- 0.3 vs. 2.4 +/- 0.2 hr, P less than 0.01) concentrations.",Disposition of total and unbound prednisolone in renal transplant patients receiving anticonvulsants. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6374250/),h,3.4,160808,DB00860,Prednisolone
,6374250,unbound,"Pharmacokinetic analysis showed that the half-life of prednisolone was shorter in the anticonvulsant group compared to the controls, based on both total (2.3 +/- 0.4 vs. 3.4 +/- 0.2 hr (SD), P less than 0.01) and unbound (1.7 +/- 0.3 vs. 2.4 +/- 0.2 hr, P less than 0.01) concentrations.",Disposition of total and unbound prednisolone in renal transplant patients receiving anticonvulsants. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6374250/),h,1.7,160809,DB00860,Prednisolone
,6374250,unbound,"Pharmacokinetic analysis showed that the half-life of prednisolone was shorter in the anticonvulsant group compared to the controls, based on both total (2.3 +/- 0.4 vs. 3.4 +/- 0.2 hr (SD), P less than 0.01) and unbound (1.7 +/- 0.3 vs. 2.4 +/- 0.2 hr, P less than 0.01) concentrations.",Disposition of total and unbound prednisolone in renal transplant patients receiving anticonvulsants. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6374250/),h,2.4,160810,DB00860,Prednisolone
,6374250,Total drug clearance,Total drug clearance was 10.4 +/- 2.8 liters/hr (0.171 +/- 0.087 liters/hr X kg) in the anticonvulsant group versus 7.2 +/- 1.2 liters/hr (0.100 +/- 0.014 liters/hr X kg) in the controls (P less than 0.05).,Disposition of total and unbound prednisolone in renal transplant patients receiving anticonvulsants. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6374250/),[l] / [h],10.4,160811,DB00860,Prednisolone
,6374250,Total drug clearance,Total drug clearance was 10.4 +/- 2.8 liters/hr (0.171 +/- 0.087 liters/hr X kg) in the anticonvulsant group versus 7.2 +/- 1.2 liters/hr (0.100 +/- 0.014 liters/hr X kg) in the controls (P less than 0.05).,Disposition of total and unbound prednisolone in renal transplant patients receiving anticonvulsants. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6374250/),[l] / [h·kg],0.171,160812,DB00860,Prednisolone
,6374250,Total drug clearance,Total drug clearance was 10.4 +/- 2.8 liters/hr (0.171 +/- 0.087 liters/hr X kg) in the anticonvulsant group versus 7.2 +/- 1.2 liters/hr (0.100 +/- 0.014 liters/hr X kg) in the controls (P less than 0.05).,Disposition of total and unbound prednisolone in renal transplant patients receiving anticonvulsants. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6374250/),[l] / [h],7.2,160813,DB00860,Prednisolone
,6374250,Total drug clearance,Total drug clearance was 10.4 +/- 2.8 liters/hr (0.171 +/- 0.087 liters/hr X kg) in the anticonvulsant group versus 7.2 +/- 1.2 liters/hr (0.100 +/- 0.014 liters/hr X kg) in the controls (P less than 0.05).,Disposition of total and unbound prednisolone in renal transplant patients receiving anticonvulsants. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6374250/),[l] / [h·kg],0.100,160814,DB00860,Prednisolone
,6374250,Unbound prednisolone clearance,"Unbound prednisolone clearance was 57.2 +/- 12.1 versus 46.4 +/- 8.7 liters/hr (P greater than 0.05) and for weight-corrected estimates 0.886 +/- 0.224 liters/hr X kg versus 0.644 +/- 0.115 liters/hr X kg (P less than 0.05) in the two groups, respectively.",Disposition of total and unbound prednisolone in renal transplant patients receiving anticonvulsants. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6374250/),[l] / [h],57.2,160815,DB00860,Prednisolone
,6374250,Unbound prednisolone clearance,"Unbound prednisolone clearance was 57.2 +/- 12.1 versus 46.4 +/- 8.7 liters/hr (P greater than 0.05) and for weight-corrected estimates 0.886 +/- 0.224 liters/hr X kg versus 0.644 +/- 0.115 liters/hr X kg (P less than 0.05) in the two groups, respectively.",Disposition of total and unbound prednisolone in renal transplant patients receiving anticonvulsants. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6374250/),[l] / [h],46.4,160816,DB00860,Prednisolone
,6374250,Unbound prednisolone clearance,"Unbound prednisolone clearance was 57.2 +/- 12.1 versus 46.4 +/- 8.7 liters/hr (P greater than 0.05) and for weight-corrected estimates 0.886 +/- 0.224 liters/hr X kg versus 0.644 +/- 0.115 liters/hr X kg (P less than 0.05) in the two groups, respectively.",Disposition of total and unbound prednisolone in renal transplant patients receiving anticonvulsants. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6374250/),[l] / [h·kg],0.886,160817,DB00860,Prednisolone
,6374250,Unbound prednisolone clearance,"Unbound prednisolone clearance was 57.2 +/- 12.1 versus 46.4 +/- 8.7 liters/hr (P greater than 0.05) and for weight-corrected estimates 0.886 +/- 0.224 liters/hr X kg versus 0.644 +/- 0.115 liters/hr X kg (P less than 0.05) in the two groups, respectively.",Disposition of total and unbound prednisolone in renal transplant patients receiving anticonvulsants. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6374250/),[l] / [h·kg],0.644,160818,DB00860,Prednisolone
,23447478,Total concentrations,"Total concentrations of teriflunomide varied between 5.2 and 23.2 mg/L, while unbound concentrations varied between 0.0306 and 0.1468 mg/L. The unbound fraction varied between 0.367% and 0.71%.",Leflunomide for inflammatory arthritis in end-stage renal disease on peritoneal dialysis: a pharmacokinetic and pharmacogenetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23447478/),[mg] / [l],5.2 and 23.2,161228,DB00860,Prednisolone
,23447478,unbound concentrations,"Total concentrations of teriflunomide varied between 5.2 and 23.2 mg/L, while unbound concentrations varied between 0.0306 and 0.1468 mg/L. The unbound fraction varied between 0.367% and 0.71%.",Leflunomide for inflammatory arthritis in end-stage renal disease on peritoneal dialysis: a pharmacokinetic and pharmacogenetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23447478/),[mg] / [l],0.0306 and 0.1468,161229,DB00860,Prednisolone
,23447478,unbound fraction,"Total concentrations of teriflunomide varied between 5.2 and 23.2 mg/L, while unbound concentrations varied between 0.0306 and 0.1468 mg/L. The unbound fraction varied between 0.367% and 0.71%.",Leflunomide for inflammatory arthritis in end-stage renal disease on peritoneal dialysis: a pharmacokinetic and pharmacogenetic study. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23447478/),%,0.367,161230,DB00860,Prednisolone
,23447478,unbound fraction,"Total concentrations of teriflunomide varied between 5.2 and 23.2 mg/L, while unbound concentrations varied between 0.0306 and 0.1468 mg/L. The unbound fraction varied between 0.367% and 0.71%.",Leflunomide for inflammatory arthritis in end-stage renal disease on peritoneal dialysis: a pharmacokinetic and pharmacogenetic study. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23447478/),%,0.71,161231,DB00860,Prednisolone
,23447478,Health Assessment Questionnaire-Disability Index,Health Assessment Questionnaire-Disability Index improved from 0.5 to 0.125 at 7 months.,Leflunomide for inflammatory arthritis in end-stage renal disease on peritoneal dialysis: a pharmacokinetic and pharmacogenetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23447478/),,0.5,161232,DB00860,Prednisolone
,23447478,Health Assessment Questionnaire-Disability Index,Health Assessment Questionnaire-Disability Index improved from 0.5 to 0.125 at 7 months.,Leflunomide for inflammatory arthritis in end-stage renal disease on peritoneal dialysis: a pharmacokinetic and pharmacogenetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23447478/),,0.125,161233,DB00860,Prednisolone
,4018307,t 1/2,"The mean values of t 1/2 of cortisol, prednisolone and dexamethasone in patients with collagen diseases under RFP therapy were 1.8 +/- 0.3 (Mean +/- SD) (p less than 0.05), 1.4 +/- 0.2 (p less than 0.001) and 1.3 +/- 0.3 hours (p less than 0.001), respectively, which were significantly shortened when compared with normal subjects (cortisol, 2.1 +/- 0.2; prednisolone, 2.5 +/- 0.7; dexamethasone, 3.5 +/- 1.0 hours).","[A comparative study of the accelerated metabolism of cortisol, prednisolone and dexamethasone in patients under rifampicin therapy]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4018307/),h,1.8,161897,DB00860,Prednisolone
,4018307,t 1/2,"The mean values of t 1/2 of cortisol, prednisolone and dexamethasone in patients with collagen diseases under RFP therapy were 1.8 +/- 0.3 (Mean +/- SD) (p less than 0.05), 1.4 +/- 0.2 (p less than 0.001) and 1.3 +/- 0.3 hours (p less than 0.001), respectively, which were significantly shortened when compared with normal subjects (cortisol, 2.1 +/- 0.2; prednisolone, 2.5 +/- 0.7; dexamethasone, 3.5 +/- 1.0 hours).","[A comparative study of the accelerated metabolism of cortisol, prednisolone and dexamethasone in patients under rifampicin therapy]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4018307/),h,1.4,161898,DB00860,Prednisolone
,4018307,t 1/2,"The mean values of t 1/2 of cortisol, prednisolone and dexamethasone in patients with collagen diseases under RFP therapy were 1.8 +/- 0.3 (Mean +/- SD) (p less than 0.05), 1.4 +/- 0.2 (p less than 0.001) and 1.3 +/- 0.3 hours (p less than 0.001), respectively, which were significantly shortened when compared with normal subjects (cortisol, 2.1 +/- 0.2; prednisolone, 2.5 +/- 0.7; dexamethasone, 3.5 +/- 1.0 hours).","[A comparative study of the accelerated metabolism of cortisol, prednisolone and dexamethasone in patients under rifampicin therapy]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4018307/),h,1.3,161899,DB00860,Prednisolone
,4018307,t 1/2,"The mean values of t 1/2 of cortisol, prednisolone and dexamethasone in patients with collagen diseases under RFP therapy were 1.8 +/- 0.3 (Mean +/- SD) (p less than 0.05), 1.4 +/- 0.2 (p less than 0.001) and 1.3 +/- 0.3 hours (p less than 0.001), respectively, which were significantly shortened when compared with normal subjects (cortisol, 2.1 +/- 0.2; prednisolone, 2.5 +/- 0.7; dexamethasone, 3.5 +/- 1.0 hours).","[A comparative study of the accelerated metabolism of cortisol, prednisolone and dexamethasone in patients under rifampicin therapy]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4018307/),h,2.1,161900,DB00860,Prednisolone
,4018307,t 1/2,"The mean values of t 1/2 of cortisol, prednisolone and dexamethasone in patients with collagen diseases under RFP therapy were 1.8 +/- 0.3 (Mean +/- SD) (p less than 0.05), 1.4 +/- 0.2 (p less than 0.001) and 1.3 +/- 0.3 hours (p less than 0.001), respectively, which were significantly shortened when compared with normal subjects (cortisol, 2.1 +/- 0.2; prednisolone, 2.5 +/- 0.7; dexamethasone, 3.5 +/- 1.0 hours).","[A comparative study of the accelerated metabolism of cortisol, prednisolone and dexamethasone in patients under rifampicin therapy]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4018307/),h,2.5,161901,DB00860,Prednisolone
,4018307,t 1/2,"The mean values of t 1/2 of cortisol, prednisolone and dexamethasone in patients with collagen diseases under RFP therapy were 1.8 +/- 0.3 (Mean +/- SD) (p less than 0.05), 1.4 +/- 0.2 (p less than 0.001) and 1.3 +/- 0.3 hours (p less than 0.001), respectively, which were significantly shortened when compared with normal subjects (cortisol, 2.1 +/- 0.2; prednisolone, 2.5 +/- 0.7; dexamethasone, 3.5 +/- 1.0 hours).","[A comparative study of the accelerated metabolism of cortisol, prednisolone and dexamethasone in patients under rifampicin therapy]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4018307/),h,3.5,161902,DB00860,Prednisolone
,4018307,MCR,"The MCR of cortisol, prednisolone and dexamethasone in these patients were 139 +/- 57, 141 +/- 53 (p less than 0.01) and 722 +/- 137 l/day/m2 (p less than 0.001), respectively, which were increased when compared with normal subjects (cortisol, 114 +/- 20; prednisolone, 75 +/- 25; dexamethasone, 153 +/- 45 l/day/m2).","[A comparative study of the accelerated metabolism of cortisol, prednisolone and dexamethasone in patients under rifampicin therapy]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4018307/),[l] / [d·m2],139,161903,DB00860,Prednisolone
,4018307,MCR,"The MCR of cortisol, prednisolone and dexamethasone in these patients were 139 +/- 57, 141 +/- 53 (p less than 0.01) and 722 +/- 137 l/day/m2 (p less than 0.001), respectively, which were increased when compared with normal subjects (cortisol, 114 +/- 20; prednisolone, 75 +/- 25; dexamethasone, 153 +/- 45 l/day/m2).","[A comparative study of the accelerated metabolism of cortisol, prednisolone and dexamethasone in patients under rifampicin therapy]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4018307/),[l] / [d·m2],141,161904,DB00860,Prednisolone
,4018307,MCR,"The MCR of cortisol, prednisolone and dexamethasone in these patients were 139 +/- 57, 141 +/- 53 (p less than 0.01) and 722 +/- 137 l/day/m2 (p less than 0.001), respectively, which were increased when compared with normal subjects (cortisol, 114 +/- 20; prednisolone, 75 +/- 25; dexamethasone, 153 +/- 45 l/day/m2).","[A comparative study of the accelerated metabolism of cortisol, prednisolone and dexamethasone in patients under rifampicin therapy]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4018307/),[l] / [d·m2],722,161905,DB00860,Prednisolone
,4018307,MCR,"The MCR of cortisol, prednisolone and dexamethasone in these patients were 139 +/- 57, 141 +/- 53 (p less than 0.01) and 722 +/- 137 l/day/m2 (p less than 0.001), respectively, which were increased when compared with normal subjects (cortisol, 114 +/- 20; prednisolone, 75 +/- 25; dexamethasone, 153 +/- 45 l/day/m2).","[A comparative study of the accelerated metabolism of cortisol, prednisolone and dexamethasone in patients under rifampicin therapy]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4018307/),[l] / [d·m2],114,161906,DB00860,Prednisolone
,4018307,MCR,"The MCR of cortisol, prednisolone and dexamethasone in these patients were 139 +/- 57, 141 +/- 53 (p less than 0.01) and 722 +/- 137 l/day/m2 (p less than 0.001), respectively, which were increased when compared with normal subjects (cortisol, 114 +/- 20; prednisolone, 75 +/- 25; dexamethasone, 153 +/- 45 l/day/m2).","[A comparative study of the accelerated metabolism of cortisol, prednisolone and dexamethasone in patients under rifampicin therapy]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4018307/),[l] / [d·m2],75,161907,DB00860,Prednisolone
,4018307,MCR,"The MCR of cortisol, prednisolone and dexamethasone in these patients were 139 +/- 57, 141 +/- 53 (p less than 0.01) and 722 +/- 137 l/day/m2 (p less than 0.001), respectively, which were increased when compared with normal subjects (cortisol, 114 +/- 20; prednisolone, 75 +/- 25; dexamethasone, 153 +/- 45 l/day/m2).","[A comparative study of the accelerated metabolism of cortisol, prednisolone and dexamethasone in patients under rifampicin therapy]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4018307/),[l] / [d·m2],153,161908,DB00860,Prednisolone
,4018307,t 1/2,"The t 1/2 of cortisol, prednisolone and dexamethasone in patients with tuberculosis alone under RFP therapy were 1.3 +/- 0.3 (p less than 0.001), 1.4 +/- 0.5 (p less than 0.01) and 1.2 +/- 0.3 hours (p less than 0.001), respectively, which were significantly shortened when compared with normal subjects.","[A comparative study of the accelerated metabolism of cortisol, prednisolone and dexamethasone in patients under rifampicin therapy]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4018307/),h,1.3,161909,DB00860,Prednisolone
,4018307,t 1/2,"The t 1/2 of cortisol, prednisolone and dexamethasone in patients with tuberculosis alone under RFP therapy were 1.3 +/- 0.3 (p less than 0.001), 1.4 +/- 0.5 (p less than 0.01) and 1.2 +/- 0.3 hours (p less than 0.001), respectively, which were significantly shortened when compared with normal subjects.","[A comparative study of the accelerated metabolism of cortisol, prednisolone and dexamethasone in patients under rifampicin therapy]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4018307/),h,1.4,161910,DB00860,Prednisolone
,4018307,t 1/2,"The t 1/2 of cortisol, prednisolone and dexamethasone in patients with tuberculosis alone under RFP therapy were 1.3 +/- 0.3 (p less than 0.001), 1.4 +/- 0.5 (p less than 0.01) and 1.2 +/- 0.3 hours (p less than 0.001), respectively, which were significantly shortened when compared with normal subjects.","[A comparative study of the accelerated metabolism of cortisol, prednisolone and dexamethasone in patients under rifampicin therapy]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4018307/),h,1.2,161911,DB00860,Prednisolone
,16678035,AUC,Only 9 of 52 LTx patients had a prednisolone AUC within the previously reported reference range for healthy adult control subjects (170 to 260 nmol x hr/liter/milligram prednisolone).,Therapeutic drug monitoring of prednisolone after lung transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16678035/),[h·nM] / [l·milligram],170 to 260,162032,DB00860,Prednisolone
,16678035,AUC,"Prednisolone AUC was higher in patients with CF compared with non-CF patients (511 +/- 82 vs 349 +/- 27 nmol x hr/liter/milligram, p < 0.02) and 70% of LTx recipients had measurable prednisolone levels at baseline (26.5 +/- 4.5 nmol/liter), unlike normal controls.",Therapeutic drug monitoring of prednisolone after lung transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16678035/),[h·nM] / [l·milligram],511,162033,DB00860,Prednisolone
,16678035,AUC,"Prednisolone AUC was higher in patients with CF compared with non-CF patients (511 +/- 82 vs 349 +/- 27 nmol x hr/liter/milligram, p < 0.02) and 70% of LTx recipients had measurable prednisolone levels at baseline (26.5 +/- 4.5 nmol/liter), unlike normal controls.",Therapeutic drug monitoring of prednisolone after lung transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16678035/),[h·nM] / [l·milligram],349,162034,DB00860,Prednisolone
,3994116,Volume of the central compartment,"Volume of the central compartment of prednisolone before and after hemorrhage was 165 ml/kg of body weight and 110 ml/kg, respectively; and the difference was significant (P less than 0.05).",Pharmacokinetics of prednisolone sodium succinate and its metabolites in normovolemic and hypovolemic dogs. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3994116/),[ml] / [kg],165,162761,DB00860,Prednisolone
,3994116,Volume of the central compartment,"Volume of the central compartment of prednisolone before and after hemorrhage was 165 ml/kg of body weight and 110 ml/kg, respectively; and the difference was significant (P less than 0.05).",Pharmacokinetics of prednisolone sodium succinate and its metabolites in normovolemic and hypovolemic dogs. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3994116/),[ml] / [kg],110,162762,DB00860,Prednisolone
,3994116,rate of total body clearance,"The rate of total body clearance of prednisolone before and after hemorrhage was 3.96 ml/min/kg and 2.53 ml/min/kg, respectively; the difference was significant.",Pharmacokinetics of prednisolone sodium succinate and its metabolites in normovolemic and hypovolemic dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3994116/),[ml] / [kg·min],3.96,162763,DB00860,Prednisolone
,3994116,rate of total body clearance,"The rate of total body clearance of prednisolone before and after hemorrhage was 3.96 ml/min/kg and 2.53 ml/min/kg, respectively; the difference was significant.",Pharmacokinetics of prednisolone sodium succinate and its metabolites in normovolemic and hypovolemic dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3994116/),[ml] / [kg·min],2.53,162764,DB00860,Prednisolone
,3994116,plasma half-lives,"The mean plasma half-lives for prednisolone sodium succinate and its metabolites, before and after hemorrhage, were 166 and 197 minutes, respectively; the difference was not significant.",Pharmacokinetics of prednisolone sodium succinate and its metabolites in normovolemic and hypovolemic dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3994116/),min,166,162765,DB00860,Prednisolone
,3994116,plasma half-lives,"The mean plasma half-lives for prednisolone sodium succinate and its metabolites, before and after hemorrhage, were 166 and 197 minutes, respectively; the difference was not significant.",Pharmacokinetics of prednisolone sodium succinate and its metabolites in normovolemic and hypovolemic dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3994116/),min,197,162766,DB00860,Prednisolone
,17593325,bioavailability,The pharmacokinetics of MPL showed bi-exponential disposition with two first-order absorption components from the injection site and bioavailability was 21%.,Modeling receptor/gene-mediated effects of corticosteroids on hepatic tyrosine aminotransferase dynamics in rats: dual regulation by endogenous and exogenous corticosteroids. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17593325/),%,21,165032,DB00860,Prednisolone
,16579759,transfer half-life (t(1/2t)),"The median transfer half-life (t(1/2t)) of methylprednisolone from the joint to plasma and elimination half-life (t(1/2e)) from plasma were 1.7 and 19.2 hours, respectively.",Pharmacokinetics of methylprednisolone acetate after intra-articular administration and its effect on endogenous hydrocortisone and cortisone secretion in horses. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16579759/),h,1.7,165762,DB00860,Prednisolone
,16579759,elimination half-life (t(1/2e)),"The median transfer half-life (t(1/2t)) of methylprednisolone from the joint to plasma and elimination half-life (t(1/2e)) from plasma were 1.7 and 19.2 hours, respectively.",Pharmacokinetics of methylprednisolone acetate after intra-articular administration and its effect on endogenous hydrocortisone and cortisone secretion in horses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16579759/),h,19.2,165763,DB00860,Prednisolone
,16579759,Maximum plasma concentration,"Maximum plasma concentration of methylprednisolone was 7.26 +/- 3.3 ng/mL at 8 hours, which decreased to 0.11 +/- 0.08 ng/mL at 144 hours after injection.",Pharmacokinetics of methylprednisolone acetate after intra-articular administration and its effect on endogenous hydrocortisone and cortisone secretion in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16579759/),[ng] / [ml],7.26,165764,DB00860,Prednisolone
,16579759,Maximum plasma concentration,"Maximum plasma concentration of methylprednisolone was 7.26 +/- 3.3 ng/mL at 8 hours, which decreased to 0.11 +/- 0.08 ng/mL at 144 hours after injection.",Pharmacokinetics of methylprednisolone acetate after intra-articular administration and its effect on endogenous hydrocortisone and cortisone secretion in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16579759/),[ng] / [ml],0.11,165765,DB00860,Prednisolone
,21850665,peak level (C(max),"Different pharmacokinetic profiles were observed in the two formulations, and a lower peak level (C(max) = 13.7 ± 4.3 ng · mL(-1)) and AUC(0-72 h) (198 ± 45 ng · mL(-1) · h) were observed for MP-PLGA MS than MPA (C(max) = 18.4 ± 2.7 ng · mL(-1)) and AUC(0-72 h) (943 ± 249 ng · mL(-1) · h).",Methylprednisolone-loaded PLGA microspheres: a new formulation for sustained release via intra-articular administration. A comparison study with methylprednisolone acetate in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21850665/),[ng] / [ml],13.7,166590,DB00860,Prednisolone
,21850665,AUC(0-72 h),"Different pharmacokinetic profiles were observed in the two formulations, and a lower peak level (C(max) = 13.7 ± 4.3 ng · mL(-1)) and AUC(0-72 h) (198 ± 45 ng · mL(-1) · h) were observed for MP-PLGA MS than MPA (C(max) = 18.4 ± 2.7 ng · mL(-1)) and AUC(0-72 h) (943 ± 249 ng · mL(-1) · h).",Methylprednisolone-loaded PLGA microspheres: a new formulation for sustained release via intra-articular administration. A comparison study with methylprednisolone acetate in rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21850665/),[h·ng] / [ml],198,166591,DB00860,Prednisolone
,21850665,C(max),"Different pharmacokinetic profiles were observed in the two formulations, and a lower peak level (C(max) = 13.7 ± 4.3 ng · mL(-1)) and AUC(0-72 h) (198 ± 45 ng · mL(-1) · h) were observed for MP-PLGA MS than MPA (C(max) = 18.4 ± 2.7 ng · mL(-1)) and AUC(0-72 h) (943 ± 249 ng · mL(-1) · h).",Methylprednisolone-loaded PLGA microspheres: a new formulation for sustained release via intra-articular administration. A comparison study with methylprednisolone acetate in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21850665/),[ng] / [ml],18.4,166592,DB00860,Prednisolone
,21850665,AUC(0-72 h),"Different pharmacokinetic profiles were observed in the two formulations, and a lower peak level (C(max) = 13.7 ± 4.3 ng · mL(-1)) and AUC(0-72 h) (198 ± 45 ng · mL(-1) · h) were observed for MP-PLGA MS than MPA (C(max) = 18.4 ± 2.7 ng · mL(-1)) and AUC(0-72 h) (943 ± 249 ng · mL(-1) · h).",Methylprednisolone-loaded PLGA microspheres: a new formulation for sustained release via intra-articular administration. A comparison study with methylprednisolone acetate in rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21850665/),[h·ng] / [ml],943,166593,DB00860,Prednisolone
,21850665,t(max),"The administration of MP-PLGA MS resulted in a rapid increase in the MP concentration at 30 min, with a t(max) at 0.8 ± 0.3 h.",Methylprednisolone-loaded PLGA microspheres: a new formulation for sustained release via intra-articular administration. A comparison study with methylprednisolone acetate in rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21850665/),h,0.8,166594,DB00860,Prednisolone
,21850665,t(max),"Instead, for the MPA suspension the t(max) was 32.0 ± 13.9 h.",Methylprednisolone-loaded PLGA microspheres: a new formulation for sustained release via intra-articular administration. A comparison study with methylprednisolone acetate in rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21850665/),h,32.0,166595,DB00860,Prednisolone
,848546,Peak drug concentration,"Peak drug concentration in aqueous humor was 1.13 mug/ml, which occurred 30 to 45 minutes after instillation of the medication.",Penetration of topically administered prednisolone acetate into the human aqueous humor. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/848546/),[μg] / [ml],1.13,167984,DB00860,Prednisolone
,848546,area under the drug concentration in aqueous humor-vs-time curve,"The area under the drug concentration in aqueous humor-vs-time curve (a measure of the drug's bioavailability in aqueous humor) was 88 mug min/ml, and its half-life in human aqueous humor was 28 minutes.",Penetration of topically administered prednisolone acetate into the human aqueous humor. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/848546/),[min·μg] / [ml],88,167985,DB00860,Prednisolone
,848546,half-life,"The area under the drug concentration in aqueous humor-vs-time curve (a measure of the drug's bioavailability in aqueous humor) was 88 mug min/ml, and its half-life in human aqueous humor was 28 minutes.",Penetration of topically administered prednisolone acetate into the human aqueous humor. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/848546/),min,28,167986,DB00860,Prednisolone
,2655680,half-life,"2. The mean values (+/- s.d.) of half-life, mean residence time (MRT), systemic clearance (CL) and volume of distribution at steady state (Vss) of MP following intravenous administration were 1.93 +/- 0.35 h, 3.50 +/- 1.01 h, 0.45 +/- 0.12 lh-1 kg-1 and 1.5 +/- 0.63 1 kg-1, respectively.",Methylprednisolone pharmacokinetics after intravenous and oral administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2655680/),h,1.93,168300,DB00860,Prednisolone
,2655680,mean residence time (MRT),"2. The mean values (+/- s.d.) of half-life, mean residence time (MRT), systemic clearance (CL) and volume of distribution at steady state (Vss) of MP following intravenous administration were 1.93 +/- 0.35 h, 3.50 +/- 1.01 h, 0.45 +/- 0.12 lh-1 kg-1 and 1.5 +/- 0.63 1 kg-1, respectively.",Methylprednisolone pharmacokinetics after intravenous and oral administration. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2655680/),h,3.50,168301,DB00860,Prednisolone
,2655680,mean residence time (MRT),"2. The mean values (+/- s.d.) of half-life, mean residence time (MRT), systemic clearance (CL) and volume of distribution at steady state (Vss) of MP following intravenous administration were 1.93 +/- 0.35 h, 3.50 +/- 1.01 h, 0.45 +/- 0.12 lh-1 kg-1 and 1.5 +/- 0.63 1 kg-1, respectively.",Methylprednisolone pharmacokinetics after intravenous and oral administration. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2655680/),1/[kg·lh],0.45,168302,DB00860,Prednisolone
,2655680,volume of distribution at steady state (Vss),"2. The mean values (+/- s.d.) of half-life, mean residence time (MRT), systemic clearance (CL) and volume of distribution at steady state (Vss) of MP following intravenous administration were 1.93 +/- 0.35 h, 3.50 +/- 1.01 h, 0.45 +/- 0.12 lh-1 kg-1 and 1.5 +/- 0.63 1 kg-1, respectively.",Methylprednisolone pharmacokinetics after intravenous and oral administration. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2655680/),[1] / [kg],1.5,168303,DB00860,Prednisolone
,2655680,bioavailability,3. The bioavailability of methylprednisolone from the 20 mg tablet was 0.82 +/- 0.11 (s.d.).,Methylprednisolone pharmacokinetics after intravenous and oral administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2655680/),,0.82,168304,DB00860,Prednisolone
,2655680,half-life,"4. In vivo hydrolysis of MPSS was rapid with a half-life of 4.14 +/- 1.62 (s.d.) min, and was independent of dose.",Methylprednisolone pharmacokinetics after intravenous and oral administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2655680/),min,4.14,168305,DB00860,Prednisolone
,23876165,Maximum measured plasma MPA concentrations,"Maximum measured plasma MPA concentrations were 6.06 ± 1.57 at 0.271 days (6.5 h; range: 5.0-7.92 h) and 6.27 ± 1.29 ng/mL at 0.276 days (6.6 h; range: 4.03-12.0 h) for horses that had synovial fluid collected (group 1) and those that did not (group 2), respectively.","Disposition of methylprednisolone acetate in plasma, urine, and synovial fluid following intra-articular administration to exercised thoroughbred horses. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23876165/),,6.06,169094,DB00860,Prednisolone
,23876165,Maximum measured plasma MPA concentrations,"Maximum measured plasma MPA concentrations were 6.06 ± 1.57 at 0.271 days (6.5 h; range: 5.0-7.92 h) and 6.27 ± 1.29 ng/mL at 0.276 days (6.6 h; range: 4.03-12.0 h) for horses that had synovial fluid collected (group 1) and those that did not (group 2), respectively.","Disposition of methylprednisolone acetate in plasma, urine, and synovial fluid following intra-articular administration to exercised thoroughbred horses. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23876165/),[ng] / [ml],6.27,169095,DB00860,Prednisolone
,23876165,plasma terminal half-life,"The plasma terminal half-life was 1.33 ± 0.80 and 0.843 ± 0.414 days for groups 1 and 2, respectively.","Disposition of methylprednisolone acetate in plasma, urine, and synovial fluid following intra-articular administration to exercised thoroughbred horses. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23876165/),d,1.33,169096,DB00860,Prednisolone
,23876165,plasma terminal half-life,"The plasma terminal half-life was 1.33 ± 0.80 and 0.843 ± 0.414 days for groups 1 and 2, respectively.","Disposition of methylprednisolone acetate in plasma, urine, and synovial fluid following intra-articular administration to exercised thoroughbred horses. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23876165/),d,0.843,169097,DB00860,Prednisolone
,6878255,total body clearance,The total body clearance of prednisolone increased from 73.5 +/- 14.6ml/min to 142.7 +/- 35.8ml/min (p less than 0.01).,Changes in prednisolone pharmacokinetics and protein binding during treatment with rifampicin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6878255/),[ml] / [min],73.5,171021,DB00860,Prednisolone
,6878255,total body clearance,The total body clearance of prednisolone increased from 73.5 +/- 14.6ml/min to 142.7 +/- 35.8ml/min (p less than 0.01).,Changes in prednisolone pharmacokinetics and protein binding during treatment with rifampicin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6878255/),[ml] / [min],142.7,171022,DB00860,Prednisolone
exceeded,7870352,fractional renal clearance,"The fractional renal clearance of unbound prednisolone during the high, but not during the low infusion rate exceeded 1.",Renal handling of prednisolone/prednisone: effect of steroid dose and 11 beta-hydroxysteroid dehydrogenase. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7870352/),,1,171300,DB00860,Prednisolone
,1673428,Hepatic extraction,Hepatic extraction of POH averaged 0.49 and that of PO was nearly complete at 0.96.,Prednisolone and prednisone exhibit linear extraction in the perfused rabbit liver. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1673428/),,0.49,171380,DB00860,Prednisolone
,1673428,Hepatic extraction,Hepatic extraction of POH averaged 0.49 and that of PO was nearly complete at 0.96.,Prednisolone and prednisone exhibit linear extraction in the perfused rabbit liver. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1673428/),,0,171381,DB00860,Prednisolone
,1673428,apparent hepatic blood clearance,"The apparent hepatic blood clearance of POH was about 16 ml/min and that of PO approximated liver blood flow, at 30 ml/min.",Prednisolone and prednisone exhibit linear extraction in the perfused rabbit liver. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1673428/),[ml] / [min],16,171382,DB00860,Prednisolone
,1673428,apparent hepatic blood clearance,"The apparent hepatic blood clearance of POH was about 16 ml/min and that of PO approximated liver blood flow, at 30 ml/min.",Prednisolone and prednisone exhibit linear extraction in the perfused rabbit liver. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1673428/),[ml] / [min],30,171383,DB00860,Prednisolone
,25540593,AUC,"The mean AUC was 39.49 mg-h/L (28.39-89.58 mg-h/L), which was in the therapeutic range.",Mycophenolic acid AUC in Thai kidney transplant recipients receiving low dose mycophenolate and its association with UGT2B7 polymorphisms. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25540593/),[mg-h] / [l],39.49,173022,DB00860,Prednisolone
,33181621,AUC0-24,"In renal Tx recipients (n = 28), our results indicated a relatively high PL exposure [median, range AUC0-24 = 3821 (2232-5382) mcg h/L], paralleled by strong suppression of endogenous CL profile, demonstrated by a low CL evening-to-morning ratio [median, range 11 (3-47)%].",Prednisolone and Prednisone Pharmacokinetics in Adult Renal Transplant Recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33181621/),[h·mcg] / [l],3821,174699,DB00860,Prednisolone
,33181621,evening-to-morning ratio,"In renal Tx recipients (n = 28), our results indicated a relatively high PL exposure [median, range AUC0-24 = 3821 (2232-5382) mcg h/L], paralleled by strong suppression of endogenous CL profile, demonstrated by a low CL evening-to-morning ratio [median, range 11 (3-47)%].",Prednisolone and Prednisone Pharmacokinetics in Adult Renal Transplant Recipients. ,CL ratio-Q31,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33181621/),%,11,174700,DB00860,Prednisolone
≤,21441467,maximal concentration,"Systemic exposure to mapracorat was low after a single administration, with an average maximal concentration of ≤2.0 ng/ml at the highest dose tested (3000 μg/eye).","Ocular pharmacokinetics of mapracorat, a novel, selective glucocorticoid receptor agonist, in rabbits and monkeys. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21441467/),[ng] / [ml],2.0,176309,DB00860,Prednisolone
,3313841,clearance,In 38 patients on Aza-Po treatment the mean clearance for prednisolone was 0.17 +/- 0.04 1/kg/hr (range 0.11-0.27) and in 39 patients on CsA-Po the mean prednisolone clearance was 0.12 +/- 0.02 (0.07-0.17) (P less than 0.001).,Impairment of prednisolone metabolism by cyclosporine treatment in renal graft recipients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3313841/),[1] / [h·kg],0.17,176633,DB00860,Prednisolone
,3313841,clearance,In 38 patients on Aza-Po treatment the mean clearance for prednisolone was 0.17 +/- 0.04 1/kg/hr (range 0.11-0.27) and in 39 patients on CsA-Po the mean prednisolone clearance was 0.12 +/- 0.02 (0.07-0.17) (P less than 0.001).,Impairment of prednisolone metabolism by cyclosporine treatment in renal graft recipients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3313841/),,0.12,176634,DB00860,Prednisolone
,3313841,clearance,"Eight patients on CsA-Po were tested on three occasions; prednisolone clearance at 2-4 weeks was 0.13 +/- 0.02 (range 0.11-0.17), at 3-6 months 0.11 +/- 0.01 (0.10-0.12) and at 2-5 years 0.11 +/- 0.02 (0.09-0.14).",Impairment of prednisolone metabolism by cyclosporine treatment in renal graft recipients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3313841/),,0.13,176635,DB00860,Prednisolone
,3313841,clearance,"Eight patients on CsA-Po were tested on three occasions; prednisolone clearance at 2-4 weeks was 0.13 +/- 0.02 (range 0.11-0.17), at 3-6 months 0.11 +/- 0.01 (0.10-0.12) and at 2-5 years 0.11 +/- 0.02 (0.09-0.14).",Impairment of prednisolone metabolism by cyclosporine treatment in renal graft recipients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3313841/),,0.11,176636,DB00860,Prednisolone
,3313841,clearance,"Eight patients on CsA-Po were tested on three occasions; prednisolone clearance at 2-4 weeks was 0.13 +/- 0.02 (range 0.11-0.17), at 3-6 months 0.11 +/- 0.01 (0.10-0.12) and at 2-5 years 0.11 +/- 0.02 (0.09-0.14).",Impairment of prednisolone metabolism by cyclosporine treatment in renal graft recipients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3313841/),,0.11,176637,DB00860,Prednisolone
,3313841,clearance,The prednisolone clearance then decreased from 0.18 +/- 0.05 1/kg/hr (range 0.13-0.27) to 0.12 +/- 0.03 (0.10-0.16) (P less than 0.001).,Impairment of prednisolone metabolism by cyclosporine treatment in renal graft recipients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3313841/),[1] / [h·kg],0.18,176638,DB00860,Prednisolone
,3313841,clearance,The prednisolone clearance then decreased from 0.18 +/- 0.05 1/kg/hr (range 0.13-0.27) to 0.12 +/- 0.03 (0.10-0.16) (P less than 0.001).,Impairment of prednisolone metabolism by cyclosporine treatment in renal graft recipients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3313841/),[1] / [h·kg],0.12,176639,DB00860,Prednisolone
,3313841,clearance,"When the treatment was changed from CsA-Po to Aza-Po in 2 patients the prednisolone clearance increased from 0.12 and 0.10 to 0.17 and 0.12 1/kg/hr, respectively.",Impairment of prednisolone metabolism by cyclosporine treatment in renal graft recipients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3313841/),[1] / [h·kg],0.12,176640,DB00860,Prednisolone
,3313841,clearance,"When the treatment was changed from CsA-Po to Aza-Po in 2 patients the prednisolone clearance increased from 0.12 and 0.10 to 0.17 and 0.12 1/kg/hr, respectively.",Impairment of prednisolone metabolism by cyclosporine treatment in renal graft recipients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3313841/),[1] / [h·kg],0.10,176641,DB00860,Prednisolone
,3313841,clearance,"When the treatment was changed from CsA-Po to Aza-Po in 2 patients the prednisolone clearance increased from 0.12 and 0.10 to 0.17 and 0.12 1/kg/hr, respectively.",Impairment of prednisolone metabolism by cyclosporine treatment in renal graft recipients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3313841/),[1] / [h·kg],0.17,176642,DB00860,Prednisolone
,3356080,renal,"7.7 +/- 1.6 ml/min/kg, mean +/- SD; P less than 0.001) and renal (0.9 +/- 0.3 vs. 2.9 +/- 0.7 ml/min/kg; P less than 0.001) clearances of unbound prednisolone were lower in the elderly.",Kinetics of prednisolone and endogenous cortisol suppression in the elderly. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3356080/),[ml] / [kg·min],0.9,177087,DB00860,Prednisolone
,3356080,renal,"7.7 +/- 1.6 ml/min/kg, mean +/- SD; P less than 0.001) and renal (0.9 +/- 0.3 vs. 2.9 +/- 0.7 ml/min/kg; P less than 0.001) clearances of unbound prednisolone were lower in the elderly.",Kinetics of prednisolone and endogenous cortisol suppression in the elderly. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3356080/),[ml] / [kg·min],2.9,177088,DB00860,Prednisolone
,6497132,half-life of elimination,"After dexamethasone alcohol (IV) or dexamethasone 21-isonicotinate (IV), the half-life of elimination was similar (53 minutes) for both formulations.",Dexamethasone and prednisolone in the horse: pharmacokinetics and action on the adrenal gland. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6497132/),min,53,177901,DB00860,Prednisolone
,6497132,half-life of elimination,"After prednisolone 21-sodium succinate (IV), the half-life of elimination (99.5 minutes) was significantly (P less than 0.01) longer than that for dexamethasone.",Dexamethasone and prednisolone in the horse: pharmacokinetics and action on the adrenal gland. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6497132/),min,99.5,177902,DB00860,Prednisolone
higher,6497132,bioavailability,"Due to the nonlinearity of prednisolone kinetics, a bioavailability higher than 100% was obtained.",Dexamethasone and prednisolone in the horse: pharmacokinetics and action on the adrenal gland. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6497132/),%,100,177903,DB00860,Prednisolone
,2324964,dose turnover rate,"At 1 min after the dose administration, drug was eluted from the donor chamber at a dose turnover rate of 12%/min.",A corneal perfusion device for estimating ocular bioavailability in vitro. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2324964/),[%] / [min],12,179037,DB00860,Prednisolone
,2324964,ocular bioavailability,"Using this chamber device, the ocular bioavailability via corneal absorption ranged between 5 and 16% for solution formulations, whereas the ocular bioavailability for the suspension formulations was less than 0.3%.",A corneal perfusion device for estimating ocular bioavailability in vitro. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2324964/),%,5 and 16,179038,DB00860,Prednisolone
less,2324964,ocular bioavailability,"Using this chamber device, the ocular bioavailability via corneal absorption ranged between 5 and 16% for solution formulations, whereas the ocular bioavailability for the suspension formulations was less than 0.3%.",A corneal perfusion device for estimating ocular bioavailability in vitro. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2324964/),%,0.3,179039,DB00860,Prednisolone
,11049012,time to the Cmax,Grapefruit juice delayed the time to the Cmax from 2.0 h to 3.0 h (P < 0.05).,Grapefruit juice can increase the plasma concentrations of oral methylprednisolone. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11049012/),h,2.0,181196,DB00860,Prednisolone
,11049012,time to the Cmax,Grapefruit juice delayed the time to the Cmax from 2.0 h to 3.0 h (P < 0.05).,Grapefruit juice can increase the plasma concentrations of oral methylprednisolone. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11049012/),h,3.0,181197,DB00860,Prednisolone
,7139852,plasma half-life,The mean plasma half-life of unchanged melphalan was 0.9 +/- 0.5 (SD) h.,Plasma melphalan and prednisolone concentrations during oral therapy for multiple myeloma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7139852/),h,0.9,181486,DB00860,Prednisolone
,7139852,',"The 'lag-time' before melphalan was detected in the plasma varied from 1 to 4 h, the mean peak concentration was 96 +/- 21 ng/ml, and the mean area under the plasma concentration by time curve was 160 +/- 78 ng h/ml.",Plasma melphalan and prednisolone concentrations during oral therapy for multiple myeloma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7139852/),h,1 to 4,181487,DB00860,Prednisolone
,7139852,lag-time,"The 'lag-time' before melphalan was detected in the plasma varied from 1 to 4 h, the mean peak concentration was 96 +/- 21 ng/ml, and the mean area under the plasma concentration by time curve was 160 +/- 78 ng h/ml.",Plasma melphalan and prednisolone concentrations during oral therapy for multiple myeloma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7139852/),h,1 to 4,181488,DB00860,Prednisolone
,7139852,peak concentration,"The 'lag-time' before melphalan was detected in the plasma varied from 1 to 4 h, the mean peak concentration was 96 +/- 21 ng/ml, and the mean area under the plasma concentration by time curve was 160 +/- 78 ng h/ml.",Plasma melphalan and prednisolone concentrations during oral therapy for multiple myeloma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7139852/),[ng] / [ml],96,181489,DB00860,Prednisolone
,7139852,area under the plasma concentration by time curve,"The 'lag-time' before melphalan was detected in the plasma varied from 1 to 4 h, the mean peak concentration was 96 +/- 21 ng/ml, and the mean area under the plasma concentration by time curve was 160 +/- 78 ng h/ml.",Plasma melphalan and prednisolone concentrations during oral therapy for multiple myeloma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7139852/),[h·ng] / [ml],160,181490,DB00860,Prednisolone
,8347899,clearances,Mean methylprednisolone clearances were similar in both groups: 405 +/- 205 (double-drug) and 373 +/- 365 mL/h/kg (triple-drug) (p > 0.05).,Comparative methylprednisolone pharmacokinetics in renal transplant patients receiving double- or triple-drug immunosuppression. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8347899/),[ml] / [h·kg],405,181655,DB00860,Prednisolone
,8347899,clearances,Mean methylprednisolone clearances were similar in both groups: 405 +/- 205 (double-drug) and 373 +/- 365 mL/h/kg (triple-drug) (p > 0.05).,Comparative methylprednisolone pharmacokinetics in renal transplant patients receiving double- or triple-drug immunosuppression. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8347899/),[ml] / [h·kg],373,181656,DB00860,Prednisolone
,8347899,steady-state volume of distribution,Mean steady-state volume of distribution was 1.5 +/- 0.8 L/kg in the double-drug group and 1.3 +/- 0.8 L/kg in the triple-drug group (p > 0.05).,Comparative methylprednisolone pharmacokinetics in renal transplant patients receiving double- or triple-drug immunosuppression. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8347899/),[l] / [kg],1.5,181657,DB00860,Prednisolone
,8347899,steady-state volume of distribution,Mean steady-state volume of distribution was 1.5 +/- 0.8 L/kg in the double-drug group and 1.3 +/- 0.8 L/kg in the triple-drug group (p > 0.05).,Comparative methylprednisolone pharmacokinetics in renal transplant patients receiving double- or triple-drug immunosuppression. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8347899/),[l] / [kg],1.3,181658,DB00860,Prednisolone
,8347899,Plasma half-life,Plasma half-life ranged from 1.7 to 4.3 h (mean 2.7) in the double-drug group versus 1.4 to 3.4 h (mean 2.6) in the triple-drug group (p > 0.05).,Comparative methylprednisolone pharmacokinetics in renal transplant patients receiving double- or triple-drug immunosuppression. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8347899/),h,2.7,181659,DB00860,Prednisolone
,8347899,Plasma half-life,Plasma half-life ranged from 1.7 to 4.3 h (mean 2.7) in the double-drug group versus 1.4 to 3.4 h (mean 2.6) in the triple-drug group (p > 0.05).,Comparative methylprednisolone pharmacokinetics in renal transplant patients receiving double- or triple-drug immunosuppression. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8347899/),h,2.6,181660,DB00860,Prednisolone
,9892474,terminal half-life,Pred terminal half-life and clearance were 1.1 hr and 0.72 l/hr/kg with no difference after Sir.,Pharmacokinetic and pharmacoimmunodynamic interactions between prednisolone and sirolimus in rabbits. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9892474/),h,1.1,181881,DB00860,Prednisolone
,9892474,clearance,Pred terminal half-life and clearance were 1.1 hr and 0.72 l/hr/kg with no difference after Sir.,Pharmacokinetic and pharmacoimmunodynamic interactions between prednisolone and sirolimus in rabbits. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9892474/),[l] / [h·kg],0.72,181882,DB00860,Prednisolone
,9892474,Sir,Sir values were 13 hr and 0.16 l/hr/kg and Pred produced no changes.,Pharmacokinetic and pharmacoimmunodynamic interactions between prednisolone and sirolimus in rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9892474/),h,13,181883,DB00860,Prednisolone
,9892474,Sir,Sir values were 13 hr and 0.16 l/hr/kg and Pred produced no changes.,Pharmacokinetic and pharmacoimmunodynamic interactions between prednisolone and sirolimus in rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9892474/),[l] / [h·kg],0.16,181884,DB00860,Prednisolone
,23425382,Apparent total clearance,Apparent total clearance of HCQ from blood was 316 (± 319) mL/min (mean (± standard deviation).,A cross-sectional study of hydroxychloroquine concentrations and effects in people with systemic lupus erythematosus. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23425382/),[ml] / [min],316,181982,DB00860,Prednisolone
,8828722,bioavailability,The bioavailability in 0-12 h for prednisolone acetate in Leogel and fusidic acid 1% to conjunctiva was significantly higher (p = 0.003) than for prednisolone acetate in aqueous and sulfacetamide sodium 10%.,A bioavailability comparison in rabbits after a single topical ocular application of prednisolone acetate formulated as a high-viscosity gel and as an aqueous suspension. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8828722/),%,10,183770,DB00860,Prednisolone
,8828722,bioavailability,The bioavailability (0-6 h) for conjunctiva was significantly higher for the Leogel preparation than for the aqueous suspension (p < 0.001).,A bioavailability comparison in rabbits after a single topical ocular application of prednisolone acetate formulated as a high-viscosity gel and as an aqueous suspension. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8828722/),h,0,183771,DB00860,Prednisolone
,7599405,clearance,"During rejection episodes, the methylprednisolone clearance values were 523 +/- 154 ml/h/kg with a corresponding mean volume of distribution of 1.89 +/- 0.72 l/kg.",Pharmacokinetics of methylprednisolone during acute renal allograft rejection. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7599405/),[ml] / [h·kg],523,183935,DB00860,Prednisolone
,7599405,volume of distribution,"During rejection episodes, the methylprednisolone clearance values were 523 +/- 154 ml/h/kg with a corresponding mean volume of distribution of 1.89 +/- 0.72 l/kg.",Pharmacokinetics of methylprednisolone during acute renal allograft rejection. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7599405/),[l] / [kg],1.89,183936,DB00860,Prednisolone
,7599405,half-life,The mean methylprednisolone half-life was 2.61 +/- 0.62 h.,Pharmacokinetics of methylprednisolone during acute renal allograft rejection. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7599405/),h,2.61,183937,DB00860,Prednisolone
,7599405,clearance,"During Phase II, the methylprednisolone clearance was 358 +/- 95 ml/h/kg with a half-life of 3.05 h.",Pharmacokinetics of methylprednisolone during acute renal allograft rejection. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7599405/),[ml] / [h·kg],358,183938,DB00860,Prednisolone
,7599405,half-life,"During Phase II, the methylprednisolone clearance was 358 +/- 95 ml/h/kg with a half-life of 3.05 h.",Pharmacokinetics of methylprednisolone during acute renal allograft rejection. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7599405/),h,3.05,183939,DB00860,Prednisolone
,17325899,Overall response rate,"Overall response rate was 58%, with 37% complete and 21% partial responses.","A phase I/II trial of pixantrone (BBR2778), methylprednisolone, cisplatin, and cytosine arabinoside (PSHAP) in relapsed/refractory aggressive non-Hodgkin's lymphoma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17325899/),%,58,184793,DB00860,Prednisolone
,17325899,time to progression,"Median time to progression and overall median survival were 5.7 months and 14.5 months, respectively.","A phase I/II trial of pixantrone (BBR2778), methylprednisolone, cisplatin, and cytosine arabinoside (PSHAP) in relapsed/refractory aggressive non-Hodgkin's lymphoma. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17325899/),month,5.7,184794,DB00860,Prednisolone
,17325899,overall median survival,"Median time to progression and overall median survival were 5.7 months and 14.5 months, respectively.","A phase I/II trial of pixantrone (BBR2778), methylprednisolone, cisplatin, and cytosine arabinoside (PSHAP) in relapsed/refractory aggressive non-Hodgkin's lymphoma. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17325899/),month,14.5,184795,DB00860,Prednisolone
,24892626,steady state flux,The steady state flux of prednisolone across the buccal mucosa was found to be 105.33 ± 32.07 µg/cm(2)/h.,Buccal films of prednisolone with enhanced bioavailability. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24892626/),[μg] / [cm(2)·h],105.33,185022,DB00860,Prednisolone
,24892626,AUC0-α,In vivo data of buccal film show greater bioavailability (AUC0-α: 24.26 ± 4.06 µg.h/ml versus 10.65 ± 2.15 µg.h/ml) and higher Cmax (2.70 ± 0.38 µg/ml versus 2.29 ± 0.32 µg/ml) value when compared to oral suspension.,Buccal films of prednisolone with enhanced bioavailability. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24892626/),[h·μg] / [ml],24.26,185023,DB00860,Prednisolone
,24892626,AUC0-α,In vivo data of buccal film show greater bioavailability (AUC0-α: 24.26 ± 4.06 µg.h/ml versus 10.65 ± 2.15 µg.h/ml) and higher Cmax (2.70 ± 0.38 µg/ml versus 2.29 ± 0.32 µg/ml) value when compared to oral suspension.,Buccal films of prednisolone with enhanced bioavailability. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24892626/),[h·μg] / [ml],10.65,185024,DB00860,Prednisolone
,24892626,Cmax,In vivo data of buccal film show greater bioavailability (AUC0-α: 24.26 ± 4.06 µg.h/ml versus 10.65 ± 2.15 µg.h/ml) and higher Cmax (2.70 ± 0.38 µg/ml versus 2.29 ± 0.32 µg/ml) value when compared to oral suspension.,Buccal films of prednisolone with enhanced bioavailability. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24892626/),[μg] / [ml],2.70,185025,DB00860,Prednisolone
,24892626,Cmax,In vivo data of buccal film show greater bioavailability (AUC0-α: 24.26 ± 4.06 µg.h/ml versus 10.65 ± 2.15 µg.h/ml) and higher Cmax (2.70 ± 0.38 µg/ml versus 2.29 ± 0.32 µg/ml) value when compared to oral suspension.,Buccal films of prednisolone with enhanced bioavailability. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24892626/),[μg] / [ml],2.29,185026,DB00860,Prednisolone
,16979996,levels,"Mean CsA levels (ng/mL) during the first month were 1419.1 +/- 213.6 and 1460.5 +/- 290.7 and at 3 months, 1296.3 +/- 227.8 and 1342.4 +/- 303.4 in the two groups, respectively (P = NS).",Comparison of generic cyclosporine microemulsion versus neoral in de novo renal transplant recipients managed by 2-hour postdose monitoring. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16979996/),[ng] / [ml],1419.1,186526,DB00860,Prednisolone
,16979996,levels,"Mean CsA levels (ng/mL) during the first month were 1419.1 +/- 213.6 and 1460.5 +/- 290.7 and at 3 months, 1296.3 +/- 227.8 and 1342.4 +/- 303.4 in the two groups, respectively (P = NS).",Comparison of generic cyclosporine microemulsion versus neoral in de novo renal transplant recipients managed by 2-hour postdose monitoring. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16979996/),[ng] / [ml],1460.5,186527,DB00860,Prednisolone
,16979996,levels,"Mean CsA levels (ng/mL) during the first month were 1419.1 +/- 213.6 and 1460.5 +/- 290.7 and at 3 months, 1296.3 +/- 227.8 and 1342.4 +/- 303.4 in the two groups, respectively (P = NS).",Comparison of generic cyclosporine microemulsion versus neoral in de novo renal transplant recipients managed by 2-hour postdose monitoring. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16979996/),[ng] / [ml],129,186528,DB00860,Prednisolone
,16979996,levels,"Mean CsA levels (ng/mL) during the first month were 1419.1 +/- 213.6 and 1460.5 +/- 290.7 and at 3 months, 1296.3 +/- 227.8 and 1342.4 +/- 303.4 in the two groups, respectively (P = NS).",Comparison of generic cyclosporine microemulsion versus neoral in de novo renal transplant recipients managed by 2-hour postdose monitoring. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16979996/),[ng] / [ml],1342,186529,DB00860,Prednisolone
,14756266,AUC(0-8),"The concomitant administration of daclizumab and MMF had no effect on the pharmacokinetics of MPA: AUC(0-8) values (microg h/mL +/- SD) on day 28 were 30.1 +/- 13.3 for daclizumab-treat patients vs. 31.1 +/- 12.4 for placebo and on day 56, 37.7 +/- 18.2 for daclizumab-treated patients vs. 35.7 +/- 14.0 for placebo.",Pharmacokinetics of daclizumab and mycophenolate mofetil with cyclosporine and steroids in renal transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14756266/),[h·μg] / [ml],30.1,186660,DB00860,Prednisolone
,14756266,AUC(0-8),"The concomitant administration of daclizumab and MMF had no effect on the pharmacokinetics of MPA: AUC(0-8) values (microg h/mL +/- SD) on day 28 were 30.1 +/- 13.3 for daclizumab-treat patients vs. 31.1 +/- 12.4 for placebo and on day 56, 37.7 +/- 18.2 for daclizumab-treated patients vs. 35.7 +/- 14.0 for placebo.",Pharmacokinetics of daclizumab and mycophenolate mofetil with cyclosporine and steroids in renal transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14756266/),[h·μg] / [ml],31.1,186661,DB00860,Prednisolone
,14756266,AUC(0-8),"The concomitant administration of daclizumab and MMF had no effect on the pharmacokinetics of MPA: AUC(0-8) values (microg h/mL +/- SD) on day 28 were 30.1 +/- 13.3 for daclizumab-treat patients vs. 31.1 +/- 12.4 for placebo and on day 56, 37.7 +/- 18.2 for daclizumab-treated patients vs. 35.7 +/- 14.0 for placebo.",Pharmacokinetics of daclizumab and mycophenolate mofetil with cyclosporine and steroids in renal transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14756266/),[h·μg] / [ml],37.7,186662,DB00860,Prednisolone
,14756266,AUC(0-8),"The concomitant administration of daclizumab and MMF had no effect on the pharmacokinetics of MPA: AUC(0-8) values (microg h/mL +/- SD) on day 28 were 30.1 +/- 13.3 for daclizumab-treat patients vs. 31.1 +/- 12.4 for placebo and on day 56, 37.7 +/- 18.2 for daclizumab-treated patients vs. 35.7 +/- 14.0 for placebo.",Pharmacokinetics of daclizumab and mycophenolate mofetil with cyclosporine and steroids in renal transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14756266/),[h·μg] / [ml],35.7,186663,DB00860,Prednisolone
,15317828,total clearance,The total clearance of methylprednisolone for the female subjects was 15.6 +/- 5.99 L/h compared to the males with 21.5 +/- 8.67 L/h (P <.05).,Pharmacokinetics and pharmacodynamic response of methylprednisolone in premenopausal renal transplant recipients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15317828/),[l] / [h],15.6,187089,DB00860,Prednisolone
,15317828,total clearance,The total clearance of methylprednisolone for the female subjects was 15.6 +/- 5.99 L/h compared to the males with 21.5 +/- 8.67 L/h (P <.05).,Pharmacokinetics and pharmacodynamic response of methylprednisolone in premenopausal renal transplant recipients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15317828/),[l] / [h],21.5,187090,DB00860,Prednisolone
,15317828,a,Dose-normalized methylprednisolone a AUC was greater in women (66.1 +/- 19.8 ng*h/mL) than men (46.4 +/- 19.7 ng*h/mL) (P =.174).,Pharmacokinetics and pharmacodynamic response of methylprednisolone in premenopausal renal transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15317828/),[h·ng] / [ml],66.1,187091,DB00860,Prednisolone
,15317828,AUC,Dose-normalized methylprednisolone a AUC was greater in women (66.1 +/- 19.8 ng*h/mL) than men (46.4 +/- 19.7 ng*h/mL) (P =.174).,Pharmacokinetics and pharmacodynamic response of methylprednisolone in premenopausal renal transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15317828/),[h·ng] / [ml],66.1,187092,DB00860,Prednisolone
,15317828,AUC,Dose-normalized methylprednisolone a AUC was greater in women (66.1 +/- 19.8 ng*h/mL) than men (46.4 +/- 19.7 ng*h/mL) (P =.174).,Pharmacokinetics and pharmacodynamic response of methylprednisolone in premenopausal renal transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15317828/),[h·ng] / [ml],46.4,187093,DB00860,Prednisolone
,15317828,AUC,"Despite chronic steroid therapy, 9 of 13 women had a normal cortisol profile and an ACTH AUC of 299 +/- 102 pg*h/mL.",Pharmacokinetics and pharmacodynamic response of methylprednisolone in premenopausal renal transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15317828/),[h·pg] / [ml],299,187094,DB00860,Prednisolone
,27191538,apparent clearance (CL/F),"The population estimate of tacrolimus apparent clearance (CL/F) and apparent volume of distribution (V/F) in the final population model was 21·5 L/h (95% CI; 18·38, 24·34) and 333 L (95% CI; 222·66, 484·35), respectively.",Population pharmacokinetics of tacrolimus in Thai kidney transplant patients: comparison with similar data from other populations. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27191538/),[l] / [h],21·5,187218,DB00860,Prednisolone
,27191538,apparent volume of distribution (V/F),"The population estimate of tacrolimus apparent clearance (CL/F) and apparent volume of distribution (V/F) in the final population model was 21·5 L/h (95% CI; 18·38, 24·34) and 333 L (95% CI; 222·66, 484·35), respectively.",Population pharmacokinetics of tacrolimus in Thai kidney transplant patients: comparison with similar data from other populations. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27191538/),l,333,187219,DB00860,Prednisolone
,1541321,relative oral bioavailability,The relative oral bioavailability of the sterol was 69.2%.,High dose oral methylprednisolone in patients with rheumatoid arthritis: pharmacokinetics and clinical response. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1541321/),%,69.2,187427,DB00860,Prednisolone
,1541321,mean residence times,"Elimination of methylprednisolone was prolonged when given orally; the mean residence times were 7.23 h and 3.94 h for oral and i.v. administrations, respectively.",High dose oral methylprednisolone in patients with rheumatoid arthritis: pharmacokinetics and clinical response. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1541321/),h,7.23,187428,DB00860,Prednisolone
,1541321,mean residence times,"Elimination of methylprednisolone was prolonged when given orally; the mean residence times were 7.23 h and 3.94 h for oral and i.v. administrations, respectively.",High dose oral methylprednisolone in patients with rheumatoid arthritis: pharmacokinetics and clinical response. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1541321/),h,3.94,187429,DB00860,Prednisolone
,6833459,Plasma clearance,"Plasma clearance of total prednisolone in females on OC was 96 +/- 9 (SD) ml/min X 1.73 m2, significantly (P less than 0.001) lower than those in both male and female controls (205 +/- 46 and 187 +/- 22 ml/min X 1.73 m2).",Prednisolone disposition and protein binding in oral contraceptive users. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6833459/),[ml] / [1.73·m2·min],96,188806,DB00860,Prednisolone
,6833459,Plasma clearance,"Plasma clearance of total prednisolone in females on OC was 96 +/- 9 (SD) ml/min X 1.73 m2, significantly (P less than 0.001) lower than those in both male and female controls (205 +/- 46 and 187 +/- 22 ml/min X 1.73 m2).",Prednisolone disposition and protein binding in oral contraceptive users. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6833459/),[ml] / [1.73·m2·min],205,188807,DB00860,Prednisolone
,6833459,Plasma clearance,"Plasma clearance of total prednisolone in females on OC was 96 +/- 9 (SD) ml/min X 1.73 m2, significantly (P less than 0.001) lower than those in both male and female controls (205 +/- 46 and 187 +/- 22 ml/min X 1.73 m2).",Prednisolone disposition and protein binding in oral contraceptive users. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6833459/),[ml] / [1.73·m2·min],187,188808,DB00860,Prednisolone
,6698661,half-lives,After intravenous injection the plasma levels of fluocortolone decreased biexponentially with half-lives of 9 +/- 5 min and 1.3 +/- 0.3 h.,The pharmacokinetics of fluocortolone and prednisolone after intravenous and oral administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6698661/),min,9,190201,DB00860,Prednisolone
,6698661,half-lives,After intravenous injection the plasma levels of fluocortolone decreased biexponentially with half-lives of 9 +/- 5 min and 1.3 +/- 0.3 h.,The pharmacokinetics of fluocortolone and prednisolone after intravenous and oral administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6698661/),h,1.3,190202,DB00860,Prednisolone
,6698661,Total plasma clearance,Total plasma clearance of fluocortolone was calculated to be 7.0 +/- 1.5 ml/min/kg.,The pharmacokinetics of fluocortolone and prednisolone after intravenous and oral administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6698661/),[ml] / [kg·min],7.0,190203,DB00860,Prednisolone
,6698661,maximum plasma levels,Oral administrations of fluocortolone revealed maximum plasma levels of 86 +/- 12 ng/ml (10-mg dose) and 174 +/- 34 ng/ml (20-mg dose) after 1.4 +/- 0.2 h.,The pharmacokinetics of fluocortolone and prednisolone after intravenous and oral administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6698661/),[ng] / [ml],86,190204,DB00860,Prednisolone
,6698661,maximum plasma levels,Oral administrations of fluocortolone revealed maximum plasma levels of 86 +/- 12 ng/ml (10-mg dose) and 174 +/- 34 ng/ml (20-mg dose) after 1.4 +/- 0.2 h.,The pharmacokinetics of fluocortolone and prednisolone after intravenous and oral administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6698661/),[ng] / [ml],174,190205,DB00860,Prednisolone
,6698661,t 1/2 alpha,Intravenously administered prednisolone was rapidly distributed (t 1/2 alpha = 5 +/- 3 min) but more slowly eliminated from plasma than fluocortolone (t1/2 beta = 3.1 +/- 0.8 h).,The pharmacokinetics of fluocortolone and prednisolone after intravenous and oral administration. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6698661/),min,5,190206,DB00860,Prednisolone
,6698661,t1/2 beta,Intravenously administered prednisolone was rapidly distributed (t 1/2 alpha = 5 +/- 3 min) but more slowly eliminated from plasma than fluocortolone (t1/2 beta = 3.1 +/- 0.8 h).,The pharmacokinetics of fluocortolone and prednisolone after intravenous and oral administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6698661/),h,3.1,190207,DB00860,Prednisolone
,6698661,total plasma clearance,Correspondingly a total plasma clearance of 2.2 +/- 0.2 ml/min/kg was calculated.,The pharmacokinetics of fluocortolone and prednisolone after intravenous and oral administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6698661/),[ml] / [kg·min],2.2,190208,DB00860,Prednisolone
,6698661,maximum prednisolone plasma levels,Oral administrations revealed maximum prednisolone plasma levels of 172 +/- 25 ng/ml (10-mg dose) and 278 ng/ml (20-mg dose) after 1.6 +/- 0.7 h.,The pharmacokinetics of fluocortolone and prednisolone after intravenous and oral administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6698661/),[ng] / [ml],172,190209,DB00860,Prednisolone
,6698661,maximum prednisolone plasma levels,Oral administrations revealed maximum prednisolone plasma levels of 172 +/- 25 ng/ml (10-mg dose) and 278 ng/ml (20-mg dose) after 1.6 +/- 0.7 h.,The pharmacokinetics of fluocortolone and prednisolone after intravenous and oral administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6698661/),[ng] / [ml],278,190210,DB00860,Prednisolone
higher,6698661,absolute bioavailability,The absolute bioavailability of both corticosteroids was higher than 80% and independent of both dose levels investigated.,The pharmacokinetics of fluocortolone and prednisolone after intravenous and oral administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6698661/),%,80,190211,DB00860,Prednisolone
<,17154474,Mw,Amphiphilic chitosan-based polymers (Mw < 20 kDa) self-assemble in aqueous media at low micromolar concentrations to give previously unknown micellar clusters of 100-300 nm in size.,Carbohydrate-based micelle clusters which enhance hydrophobic drug bioavailability by up to 1 order of magnitude. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17154474/),kda,20,190969,DB00860,Prednisolone
,9832298,systemic clearance,"During the acute phase, the systemic clearance of methylprednisolone was 0.98 (1 kg(-1) x h(-1)) and the elimination half-life was 1.67 h.",Pharmacokinetics of intravenous methylprednisolone and oral prednisone in paediatric patients with inflammatory bowel disease during the acute phase and in remission. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9832298/),[1] / [h·kg],0.98,191717,DB00860,Prednisolone
,9832298,elimination half-life,"During the acute phase, the systemic clearance of methylprednisolone was 0.98 (1 kg(-1) x h(-1)) and the elimination half-life was 1.67 h.",Pharmacokinetics of intravenous methylprednisolone and oral prednisone in paediatric patients with inflammatory bowel disease during the acute phase and in remission. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9832298/),h,1.67,191718,DB00860,Prednisolone
,9832298,area under the plasma concentration-versus-time curve,"The area under the plasma concentration-versus-time curve of prednisolone was 4.00 and 3.20 x mg x h x l(-1) respectively during the active disease and remission, while its elimination half-life was 3.51 h during the acute phase and 2.42 h in remission.",Pharmacokinetics of intravenous methylprednisolone and oral prednisone in paediatric patients with inflammatory bowel disease during the acute phase and in remission. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9832298/),[h·mg] / [l],4.00,191719,DB00860,Prednisolone
,9832298,area under the plasma concentration-versus-time curve,"The area under the plasma concentration-versus-time curve of prednisolone was 4.00 and 3.20 x mg x h x l(-1) respectively during the active disease and remission, while its elimination half-life was 3.51 h during the acute phase and 2.42 h in remission.",Pharmacokinetics of intravenous methylprednisolone and oral prednisone in paediatric patients with inflammatory bowel disease during the acute phase and in remission. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9832298/),[h·mg] / [l],3.20,191720,DB00860,Prednisolone
,9832298,elimination half-life,"The area under the plasma concentration-versus-time curve of prednisolone was 4.00 and 3.20 x mg x h x l(-1) respectively during the active disease and remission, while its elimination half-life was 3.51 h during the acute phase and 2.42 h in remission.",Pharmacokinetics of intravenous methylprednisolone and oral prednisone in paediatric patients with inflammatory bowel disease during the acute phase and in remission. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9832298/),h,3.51,191721,DB00860,Prednisolone
,9832298,elimination half-life,"The area under the plasma concentration-versus-time curve of prednisolone was 4.00 and 3.20 x mg x h x l(-1) respectively during the active disease and remission, while its elimination half-life was 3.51 h during the acute phase and 2.42 h in remission.",Pharmacokinetics of intravenous methylprednisolone and oral prednisone in paediatric patients with inflammatory bowel disease during the acute phase and in remission. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9832298/),h,2.42,191722,DB00860,Prednisolone
,17921190,EC(50),"An exposure-response relationship was demonstrated, with an estimated EC(50) of 391 nM (total) and 17 nM (free).","Demonstration of proof of mechanism and pharmacokinetics and pharmacodynamic relationship with 4'-cyano-biphenyl-4-sulfonic acid (6-amino-pyridin-2-yl)-amide (PF-915275), an inhibitor of 11 -hydroxysteroid dehydrogenase type 1, in cynomolgus monkeys. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17921190/),nM,391,193001,DB00860,Prednisolone
,17921190,EC(50),"An exposure-response relationship was demonstrated, with an estimated EC(50) of 391 nM (total) and 17 nM (free).","Demonstration of proof of mechanism and pharmacokinetics and pharmacodynamic relationship with 4'-cyano-biphenyl-4-sulfonic acid (6-amino-pyridin-2-yl)-amide (PF-915275), an inhibitor of 11 -hydroxysteroid dehydrogenase type 1, in cynomolgus monkeys. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17921190/),nM,17,193002,DB00860,Prednisolone
,12386639,clearance,"The clearance of methylprednisolone was significantly reduced in the presence of diltiazem (25.2 L/h versus 16.8 L/h), resulting in a longer half-life (2.28 hours versus 3.12 hours) and increased area under the plasma concentration-time curve (AUC) (871 ng x h/mL versus 1299 ng x h/mL).",Pharmacokinetic and pharmacodynamic interactions between diltiazem and methylprednisolone in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12386639/),[l] / [h],25.2,193169,DB00860,Prednisolone
,12386639,clearance,"The clearance of methylprednisolone was significantly reduced in the presence of diltiazem (25.2 L/h versus 16.8 L/h), resulting in a longer half-life (2.28 hours versus 3.12 hours) and increased area under the plasma concentration-time curve (AUC) (871 ng x h/mL versus 1299 ng x h/mL).",Pharmacokinetic and pharmacodynamic interactions between diltiazem and methylprednisolone in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12386639/),[l] / [h],16.8,193170,DB00860,Prednisolone
,12386639,half-life,"The clearance of methylprednisolone was significantly reduced in the presence of diltiazem (25.2 L/h versus 16.8 L/h), resulting in a longer half-life (2.28 hours versus 3.12 hours) and increased area under the plasma concentration-time curve (AUC) (871 ng x h/mL versus 1299 ng x h/mL).",Pharmacokinetic and pharmacodynamic interactions between diltiazem and methylprednisolone in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12386639/),h,2.28,193171,DB00860,Prednisolone
,12386639,half-life,"The clearance of methylprednisolone was significantly reduced in the presence of diltiazem (25.2 L/h versus 16.8 L/h), resulting in a longer half-life (2.28 hours versus 3.12 hours) and increased area under the plasma concentration-time curve (AUC) (871 ng x h/mL versus 1299 ng x h/mL).",Pharmacokinetic and pharmacodynamic interactions between diltiazem and methylprednisolone in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12386639/),h,3.12,193172,DB00860,Prednisolone
,12386639,area under the plasma concentration-time curve (AUC),"The clearance of methylprednisolone was significantly reduced in the presence of diltiazem (25.2 L/h versus 16.8 L/h), resulting in a longer half-life (2.28 hours versus 3.12 hours) and increased area under the plasma concentration-time curve (AUC) (871 ng x h/mL versus 1299 ng x h/mL).",Pharmacokinetic and pharmacodynamic interactions between diltiazem and methylprednisolone in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12386639/),[h·ng] / [ml],871,193173,DB00860,Prednisolone
,12386639,area under the plasma concentration-time curve (AUC),"The clearance of methylprednisolone was significantly reduced in the presence of diltiazem (25.2 L/h versus 16.8 L/h), resulting in a longer half-life (2.28 hours versus 3.12 hours) and increased area under the plasma concentration-time curve (AUC) (871 ng x h/mL versus 1299 ng x h/mL).",Pharmacokinetic and pharmacodynamic interactions between diltiazem and methylprednisolone in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12386639/),[h·ng] / [ml],1299,193174,DB00860,Prednisolone
,12386639,50% inhibitory concentration,"The 50% inhibitory concentration values were 0.446 ng/mL versus 0.780 ng/mL for cortisol, 9.20 ng/mL versus 10.7 ng/mL for T-helper cells, and 18.5 ng/mL versus 20.9 ng/mL for T-suppressor cells (P >.05).",Pharmacokinetic and pharmacodynamic interactions between diltiazem and methylprednisolone in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12386639/),[ng] / [ml],0.446,193175,DB00860,Prednisolone
,12386639,50% inhibitory concentration,"The 50% inhibitory concentration values were 0.446 ng/mL versus 0.780 ng/mL for cortisol, 9.20 ng/mL versus 10.7 ng/mL for T-helper cells, and 18.5 ng/mL versus 20.9 ng/mL for T-suppressor cells (P >.05).",Pharmacokinetic and pharmacodynamic interactions between diltiazem and methylprednisolone in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12386639/),[ng] / [ml],0.780,193176,DB00860,Prednisolone
,12386639,50% inhibitory concentration,"The 50% inhibitory concentration values were 0.446 ng/mL versus 0.780 ng/mL for cortisol, 9.20 ng/mL versus 10.7 ng/mL for T-helper cells, and 18.5 ng/mL versus 20.9 ng/mL for T-suppressor cells (P >.05).",Pharmacokinetic and pharmacodynamic interactions between diltiazem and methylprednisolone in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12386639/),[ng] / [ml],9.20,193177,DB00860,Prednisolone
,12386639,50% inhibitory concentration,"The 50% inhibitory concentration values were 0.446 ng/mL versus 0.780 ng/mL for cortisol, 9.20 ng/mL versus 10.7 ng/mL for T-helper cells, and 18.5 ng/mL versus 20.9 ng/mL for T-suppressor cells (P >.05).",Pharmacokinetic and pharmacodynamic interactions between diltiazem and methylprednisolone in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12386639/),[ng] / [ml],10.7,193178,DB00860,Prednisolone
,12386639,50% inhibitory concentration,"The 50% inhibitory concentration values were 0.446 ng/mL versus 0.780 ng/mL for cortisol, 9.20 ng/mL versus 10.7 ng/mL for T-helper cells, and 18.5 ng/mL versus 20.9 ng/mL for T-suppressor cells (P >.05).",Pharmacokinetic and pharmacodynamic interactions between diltiazem and methylprednisolone in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12386639/),[ng] / [ml],18.5,193179,DB00860,Prednisolone
,12386639,50% inhibitory concentration,"The 50% inhibitory concentration values were 0.446 ng/mL versus 0.780 ng/mL for cortisol, 9.20 ng/mL versus 10.7 ng/mL for T-helper cells, and 18.5 ng/mL versus 20.9 ng/mL for T-suppressor cells (P >.05).",Pharmacokinetic and pharmacodynamic interactions between diltiazem and methylprednisolone in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12386639/),[ng] / [ml],20.9,193180,DB00860,Prednisolone
,29687456,extent of,"This study reveals that MPA is highly bound to plasma proteins (>90%) in dogs and cats, mean extent of binding of MPA at 15 μg/ml to plasma proteins being 96% (range, 95%-97%) and 92% (range, 90%-93%) for dogs and cats, respectively.",Ex vivo binding of the immunosuppressant mycophenolic acid to dog and cat plasma proteins and the effect of co-incubated dexamethasone and prednisolone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29687456/),%,96,194559,DB00860,Prednisolone
,29687456,extent of,"This study reveals that MPA is highly bound to plasma proteins (>90%) in dogs and cats, mean extent of binding of MPA at 15 μg/ml to plasma proteins being 96% (range, 95%-97%) and 92% (range, 90%-93%) for dogs and cats, respectively.",Ex vivo binding of the immunosuppressant mycophenolic acid to dog and cat plasma proteins and the effect of co-incubated dexamethasone and prednisolone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29687456/),%,92,194560,DB00860,Prednisolone
,2324584,penetration,Pharmacokinetic study revealed high peaks of Ara-C concentration in plasma (6.2 microM immediately after the end of the infusion) and high degree of its penetration into the CNS (5.6 microM at 3 hr after the end of the infusion) suggesting the effective and perhaps a uniform level of Ara-C is achieved throughout the CNS by this therapy.,[Clinical effect and pharmacokinetics of intermediate dose Ara-C therapy in a patient with acute non-lymphocytic leukemia with two CNS recurrences]. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2324584/),μM,5.6,194604,DB00860,Prednisolone
,1938000,AUC,"In responder patients, PO AUC values were 6,225.5 +/- 575.5 ngh/ml, range 3,933-9,080.5 on day 1 and 5,687 +/- 535 ngh/ml, range 4,513.5-9,828.5 on day Y.",Pharmacokinetics of prednisone and prednisolone in bullous pemphigoid patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1938000/),[ngh] / [ml],"6,225.5",196103,DB00860,Prednisolone
,1938000,AUC,"In responder patients, PO AUC values were 6,225.5 +/- 575.5 ngh/ml, range 3,933-9,080.5 on day 1 and 5,687 +/- 535 ngh/ml, range 4,513.5-9,828.5 on day Y.",Pharmacokinetics of prednisone and prednisolone in bullous pemphigoid patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1938000/),[ngh] / [ml],"5,687",196104,DB00860,Prednisolone
,18835342,T(max),The results of plasma pharmacokinetic studies in Sprague-Dawley rats showed that the developed system provided a significant delay (T(max) 9.3 h) in the absorption profile of PDS compared with simple enteric-coated (T(max) 4 h) or powder (T(max) 1 h) formulation that was taken as proof for the colon-targeted delivery.,Studies of chitosan/organic acid/Eudragit RS/RL-coated system for colonic delivery. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18835342/),h,9.3,196229,DB00860,Prednisolone
,18835342,T(max),The results of plasma pharmacokinetic studies in Sprague-Dawley rats showed that the developed system provided a significant delay (T(max) 9.3 h) in the absorption profile of PDS compared with simple enteric-coated (T(max) 4 h) or powder (T(max) 1 h) formulation that was taken as proof for the colon-targeted delivery.,Studies of chitosan/organic acid/Eudragit RS/RL-coated system for colonic delivery. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18835342/),h,4,196230,DB00860,Prednisolone
,18835342,T(max),The results of plasma pharmacokinetic studies in Sprague-Dawley rats showed that the developed system provided a significant delay (T(max) 9.3 h) in the absorption profile of PDS compared with simple enteric-coated (T(max) 4 h) or powder (T(max) 1 h) formulation that was taken as proof for the colon-targeted delivery.,Studies of chitosan/organic acid/Eudragit RS/RL-coated system for colonic delivery. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18835342/),h,1,196231,DB00860,Prednisolone
,18401017,clearance (CL,"Population estimates (typical value +/- standard error) were obtained from the final covariate model: clearance (CL: 0.273 +/- 0.007 L/day), volume of distribution in the central compartment (V(1): 3.06 +/- 0.057 L), intercompartment clearance (Q: 1.72 +/- 0.48 L/day), and volume of distribution in the peripheral compartment (V(2): 2.94 +/- 0.17 L).",Population pharmacokinetics of infliximab in patients with ankylosing spondylitis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18401017/),[l] / [d],0.273,196260,DB00860,Prednisolone
,18401017,volume of distribution in the central compartment (V(1),"Population estimates (typical value +/- standard error) were obtained from the final covariate model: clearance (CL: 0.273 +/- 0.007 L/day), volume of distribution in the central compartment (V(1): 3.06 +/- 0.057 L), intercompartment clearance (Q: 1.72 +/- 0.48 L/day), and volume of distribution in the peripheral compartment (V(2): 2.94 +/- 0.17 L).",Population pharmacokinetics of infliximab in patients with ankylosing spondylitis. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18401017/),l,3.06,196261,DB00860,Prednisolone
,18401017,intercompartment clearance (Q,"Population estimates (typical value +/- standard error) were obtained from the final covariate model: clearance (CL: 0.273 +/- 0.007 L/day), volume of distribution in the central compartment (V(1): 3.06 +/- 0.057 L), intercompartment clearance (Q: 1.72 +/- 0.48 L/day), and volume of distribution in the peripheral compartment (V(2): 2.94 +/- 0.17 L).",Population pharmacokinetics of infliximab in patients with ankylosing spondylitis. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18401017/),[l] / [d],1.72,196262,DB00860,Prednisolone
,18401017,volume of distribution in the peripheral compartment (V(2),"Population estimates (typical value +/- standard error) were obtained from the final covariate model: clearance (CL: 0.273 +/- 0.007 L/day), volume of distribution in the central compartment (V(1): 3.06 +/- 0.057 L), intercompartment clearance (Q: 1.72 +/- 0.48 L/day), and volume of distribution in the peripheral compartment (V(2): 2.94 +/- 0.17 L).",Population pharmacokinetics of infliximab in patients with ankylosing spondylitis. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18401017/),l,2.94,196263,DB00860,Prednisolone
,7310640,oral dose plasma clearances,The mean oral dose plasma clearances of prednisone ranged from 572 ml/min/1.73 m 2 for the 5 mg dose to 2271 ml/min/1.73 m 2 for the 50 mg dose.,Dose dependent pharmacokinetics of prednisone and prednisolone in man. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7310640/),[ml] / [1.73·2·m·min],572,196705,DB00860,Prednisolone
,7310640,oral dose plasma clearances,The mean oral dose plasma clearances of prednisone ranged from 572 ml/min/1.73 m 2 for the 5 mg dose to 2271 ml/min/1.73 m 2 for the 50 mg dose.,Dose dependent pharmacokinetics of prednisone and prednisolone in man. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7310640/),[ml] / [1.73·2·m·min],2271,196706,DB00860,Prednisolone
,7310640,systemic plasma clearance,The systemic plasma clearance of i.v. prednisolone was dose-dependent and increased from 111 to 194 ml/min/1.73 m 2 over the 5 to 40 mg i.v. dosage range.,Dose dependent pharmacokinetics of prednisone and prednisolone in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7310640/),[ml] / [1.73·2·m·min],111 to 194,196707,DB00860,Prednisolone
,6376143,clearance,Intrinsic prednisolone clearance differed less than three-fold (range 0.10-0.27 l/kg X h) between the patients and was relatively stable at different times in each of them.,Clinical value of assessing prednisolone pharmacokinetics before and after renal transplantation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6376143/),[l] / [h·kg],0.10-0.27,197981,DB00860,Prednisolone
greater,6376143,clearance,"If rejection occurred, however, a high clearance (greater than or equal to 0.20 l/kg X h) appeared to be deleterious for the outcome (p less than 0.05).",Clinical value of assessing prednisolone pharmacokinetics before and after renal transplantation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6376143/),[l] / [h·kg],0.20,197982,DB00860,Prednisolone
lower,6376143,clearance,"7 out of 8 cases of steroid-related complications (steroid diabetes, psychosis, duodenal ulcer, perforation of the colon and osteonecrosis) occurred in patients with a clearance lower than 0.16 l/kg X h (ns).",Clinical value of assessing prednisolone pharmacokinetics before and after renal transplantation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6376143/),[l] / [h·kg],0.16,197983,DB00860,Prednisolone
greater,6376143,clearance,"The one-year graft survival rate was 67% in patients with a clearance greater than or equal to 0.16 l/kg X h, compared to 85% in patients with a lower clearance (ns).",Clinical value of assessing prednisolone pharmacokinetics before and after renal transplantation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6376143/),[l] / [h·kg],0.16,197984,DB00860,Prednisolone
,28438492,Maximum blood concentrations,"Maximum blood concentrations were 1.6 and 1.4μg D4 or D5/g blood at 24h post-dosing, with elimination half-lives of 39h (D4) and 70h (D5).",Metabolism of 14C-octamethylcyclotetrasiloxane ([14C]D4) or 14C-decamethylcyclopentasiloxane ([14C]D5) orally gavaged in rainbow trout (Oncorhynchus mykiss). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28438492/),μg,1.6,198860,DB00860,Prednisolone
,28438492,Maximum blood concentrations,"Maximum blood concentrations were 1.6 and 1.4μg D4 or D5/g blood at 24h post-dosing, with elimination half-lives of 39h (D4) and 70h (D5).",Metabolism of 14C-octamethylcyclotetrasiloxane ([14C]D4) or 14C-decamethylcyclopentasiloxane ([14C]D5) orally gavaged in rainbow trout (Oncorhynchus mykiss). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28438492/),μg,1.4,198861,DB00860,Prednisolone
,28438492,elimination half-lives,"Maximum blood concentrations were 1.6 and 1.4μg D4 or D5/g blood at 24h post-dosing, with elimination half-lives of 39h (D4) and 70h (D5).",Metabolism of 14C-octamethylcyclotetrasiloxane ([14C]D4) or 14C-decamethylcyclopentasiloxane ([14C]D5) orally gavaged in rainbow trout (Oncorhynchus mykiss). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28438492/),h,39,198862,DB00860,Prednisolone
,28438492,elimination half-lives,"Maximum blood concentrations were 1.6 and 1.4μg D4 or D5/g blood at 24h post-dosing, with elimination half-lives of 39h (D4) and 70h (D5).",Metabolism of 14C-octamethylcyclotetrasiloxane ([14C]D4) or 14C-decamethylcyclopentasiloxane ([14C]D5) orally gavaged in rainbow trout (Oncorhynchus mykiss). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28438492/),h,70,198863,DB00860,Prednisolone
,28438492,metabolism rate constants (km(blood)),Modeling of parent and metabolite blood concentrations resulted in estimated metabolism rate constants (km(blood)) of 0.15 (D4) and 0.17day-1(D5).,Metabolism of 14C-octamethylcyclotetrasiloxane ([14C]D4) or 14C-decamethylcyclopentasiloxane ([14C]D5) orally gavaged in rainbow trout (Oncorhynchus mykiss). ,km-Q51,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28438492/),1/[d],0.15,198864,DB00860,Prednisolone
,28438492,metabolism rate constants (km(blood)),Modeling of parent and metabolite blood concentrations resulted in estimated metabolism rate constants (km(blood)) of 0.15 (D4) and 0.17day-1(D5).,Metabolism of 14C-octamethylcyclotetrasiloxane ([14C]D4) or 14C-decamethylcyclopentasiloxane ([14C]D5) orally gavaged in rainbow trout (Oncorhynchus mykiss). ,km-Q51,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28438492/),1/[d],0.17,198865,DB00860,Prednisolone
,33626793,maximal serum concentration (Cmax),The overall mean maximal serum concentration (Cmax) was 114.0 μg/L and was achieved at an average time to maximal concentration (Tmax) of 1.43 h.,Prednisolone Replacement Therapy Mimics the Circadian Rhythm More Closely Than Other Glucocorticoids. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33626793/),[μg] / [l],114.0,199429,DB00860,Prednisolone
,33626793,time to maximal concentration (Tmax),The overall mean maximal serum concentration (Cmax) was 114.0 μg/L and was achieved at an average time to maximal concentration (Tmax) of 1.43 h.,Prednisolone Replacement Therapy Mimics the Circadian Rhythm More Closely Than Other Glucocorticoids. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33626793/),h,1.43,199430,DB00860,Prednisolone
,33626793,area under the curve to 24 h (AUC0-24h),"Total glucocorticoid exposure was represented by the mean area under the curve to 24 h (AUC0-24h), which was 518.2 μg|·|h/L.",Prednisolone Replacement Therapy Mimics the Circadian Rhythm More Closely Than Other Glucocorticoids. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33626793/),[|h·μg|] / [l],518.2,199431,DB00860,Prednisolone
,429520,MCR2,"In subjects with normal gastrointestinal function, MCR0 was consistently lower than MCR2 (mean MCR2 = 0.175 liters/h.kg; MCR0 = 0.145 liters/h.kg).","Studies comparing the metabolic clearance rate of 11 beta,17,21-trihydroxypregn-1,4-diene-3,20-dione (prednisolone) after oral 17,21-dihydroxypregn-1,4-diene-3,11,20-trione and intravenous prednisolone. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/429520/),[l] / [h·kg],0.175,199453,DB00860,Prednisolone
,429520,MCR0,"In subjects with normal gastrointestinal function, MCR0 was consistently lower than MCR2 (mean MCR2 = 0.175 liters/h.kg; MCR0 = 0.145 liters/h.kg).","Studies comparing the metabolic clearance rate of 11 beta,17,21-trihydroxypregn-1,4-diene-3,20-dione (prednisolone) after oral 17,21-dihydroxypregn-1,4-diene-3,11,20-trione and intravenous prednisolone. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/429520/),[l] / [h·kg],0.145,199454,DB00860,Prednisolone
,7513355,Clearances,Clearances of MP were 0.45 liters/hr/kg after given alone and 0.48 liter/hr/kg after tracrolimus.,Pharmacokinetic and pharmacodynamic effects of coadministration of methylprednisolone and tacrolimus in rabbits. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7513355/),[l] / [h·kg],0.45,200562,DB00860,Prednisolone
,7513355,Clearances,Clearances of MP were 0.45 liters/hr/kg after given alone and 0.48 liter/hr/kg after tracrolimus.,Pharmacokinetic and pharmacodynamic effects of coadministration of methylprednisolone and tacrolimus in rabbits. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7513355/),[l] / [h·kg],0.48,200563,DB00860,Prednisolone
,7513355,plasma,The plasma and whole blood clearances of tacrolimus were 2.18 and 0.21 and 2.35 and 0.19 liters/hr/kg after separate and joint administration with the steroid.,Pharmacokinetic and pharmacodynamic effects of coadministration of methylprednisolone and tacrolimus in rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7513355/),[l] / [h·kg],2.18,200564,DB00860,Prednisolone
,7513355,plasma,The plasma and whole blood clearances of tacrolimus were 2.18 and 0.21 and 2.35 and 0.19 liters/hr/kg after separate and joint administration with the steroid.,Pharmacokinetic and pharmacodynamic effects of coadministration of methylprednisolone and tacrolimus in rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7513355/),[l] / [h·kg],0.21,200565,DB00860,Prednisolone
,7513355,plasma,The plasma and whole blood clearances of tacrolimus were 2.18 and 0.21 and 2.35 and 0.19 liters/hr/kg after separate and joint administration with the steroid.,Pharmacokinetic and pharmacodynamic effects of coadministration of methylprednisolone and tacrolimus in rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7513355/),[l] / [h·kg],2.35,200566,DB00860,Prednisolone
,7513355,whole blood clearances,The plasma and whole blood clearances of tacrolimus were 2.18 and 0.21 and 2.35 and 0.19 liters/hr/kg after separate and joint administration with the steroid.,Pharmacokinetic and pharmacodynamic effects of coadministration of methylprednisolone and tacrolimus in rabbits. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7513355/),[l] / [h·kg],0.21,200567,DB00860,Prednisolone
,7513355,whole blood clearances,The plasma and whole blood clearances of tacrolimus were 2.18 and 0.21 and 2.35 and 0.19 liters/hr/kg after separate and joint administration with the steroid.,Pharmacokinetic and pharmacodynamic effects of coadministration of methylprednisolone and tacrolimus in rabbits. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7513355/),[l] / [h·kg],2.35,200568,DB00860,Prednisolone
,7513355,whole blood clearances,The plasma and whole blood clearances of tacrolimus were 2.18 and 0.21 and 2.35 and 0.19 liters/hr/kg after separate and joint administration with the steroid.,Pharmacokinetic and pharmacodynamic effects of coadministration of methylprednisolone and tacrolimus in rabbits. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7513355/),[l] / [h·kg],0.19,200569,DB00860,Prednisolone
,7513355,IC50,MP and tacrolimus decreased the number of circulating helper-T cells with IC50 values of 23 ng/ml for MP and 6.7 ng/ml for tacrolimus.,Pharmacokinetic and pharmacodynamic effects of coadministration of methylprednisolone and tacrolimus in rabbits. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7513355/),[ng] / [ml],23,200570,DB00860,Prednisolone
,7513355,IC50,MP and tacrolimus decreased the number of circulating helper-T cells with IC50 values of 23 ng/ml for MP and 6.7 ng/ml for tacrolimus.,Pharmacokinetic and pharmacodynamic effects of coadministration of methylprednisolone and tacrolimus in rabbits. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7513355/),[ng] / [ml],6.7,200571,DB00860,Prednisolone
,7513355,IC50,The IC50 of tacrolimus for in vitro inhibition of lymphocyte proliferation was 0.39 ng/ml (0.47 nM) and 1.02 ng/ml (2.73 nM) for MP.,Pharmacokinetic and pharmacodynamic effects of coadministration of methylprednisolone and tacrolimus in rabbits. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7513355/),[ng] / [ml],0.39,200572,DB00860,Prednisolone
,7513355,IC50,The IC50 of tacrolimus for in vitro inhibition of lymphocyte proliferation was 0.39 ng/ml (0.47 nM) and 1.02 ng/ml (2.73 nM) for MP.,Pharmacokinetic and pharmacodynamic effects of coadministration of methylprednisolone and tacrolimus in rabbits. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7513355/),[ng] / [ml],1.02,200573,DB00860,Prednisolone
,7513355,maximum percentage of inhibition,The maximum percentage of inhibition was 94.6% for tacrolimus and 64.9% for MP.,Pharmacokinetic and pharmacodynamic effects of coadministration of methylprednisolone and tacrolimus in rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7513355/),%,94.6,200574,DB00860,Prednisolone
,7513355,maximum percentage of inhibition,The maximum percentage of inhibition was 94.6% for tacrolimus and 64.9% for MP.,Pharmacokinetic and pharmacodynamic effects of coadministration of methylprednisolone and tacrolimus in rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7513355/),%,64.9,200575,DB00860,Prednisolone
,15099443,half-life,The difference between the in-vivo and in-vitro inhibitory behaviours of MP was attributed to the rapid elimination of MP after biotransformation from MPS because the plasma MP concentration decreased with a half-life of 15 min immediately after reaching a level close to the inhibition constant for the triazolam 4-hydroxylation reaction (32.4 microM).,Influence of intravenous methylprednisolone pulse treatment on the disposition of ciclosporin and hepatic CYP3A activity in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15099443/),min,15,200702,DB00860,Prednisolone
,15099443,inhibition constant,The difference between the in-vivo and in-vitro inhibitory behaviours of MP was attributed to the rapid elimination of MP after biotransformation from MPS because the plasma MP concentration decreased with a half-life of 15 min immediately after reaching a level close to the inhibition constant for the triazolam 4-hydroxylation reaction (32.4 microM).,Influence of intravenous methylprednisolone pulse treatment on the disposition of ciclosporin and hepatic CYP3A activity in rats. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15099443/),μM,32.4,200703,DB00860,Prednisolone
,7781199,clearance,"The clearance was about 280 ml/hr/kg, volume of distribution was 1.1 l/kg, t1/2 was 2.7 hr, and fraction unbound was 0.2.",Methylprednisolone pharmacokinetics and pharmacodynamics in chronic renal failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7781199/),[ml] / [h·kg],280,201017,DB00860,Prednisolone
,7781199,volume of distribution,"The clearance was about 280 ml/hr/kg, volume of distribution was 1.1 l/kg, t1/2 was 2.7 hr, and fraction unbound was 0.2.",Methylprednisolone pharmacokinetics and pharmacodynamics in chronic renal failure. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7781199/),[l] / [kg],1.1,201018,DB00860,Prednisolone
,7781199,t1/2,"The clearance was about 280 ml/hr/kg, volume of distribution was 1.1 l/kg, t1/2 was 2.7 hr, and fraction unbound was 0.2.",Methylprednisolone pharmacokinetics and pharmacodynamics in chronic renal failure. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7781199/),h,2.7,201019,DB00860,Prednisolone
,7781199,fraction unbound,"The clearance was about 280 ml/hr/kg, volume of distribution was 1.1 l/kg, t1/2 was 2.7 hr, and fraction unbound was 0.2.",Methylprednisolone pharmacokinetics and pharmacodynamics in chronic renal failure. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7781199/),,0.2,201020,DB00860,Prednisolone
,6662164,half-life,Betamethasone phosphate disappeared rapidly from plasma (mean half-life = 4.7 min) as betamethasone levels rose.,Pharmacokinetics of betamethasone in healthy adults after intravenous administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6662164/),min,4.7,201240,DB00860,Prednisolone
,6662164,half-life,The terminal slow disposition phase had a mean half-life of 6.5 h.,Pharmacokinetics of betamethasone in healthy adults after intravenous administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6662164/),h,6.5,201241,DB00860,Prednisolone
,28806969,AUC0-inf,"Based on the plasma pharmacokinetics and urinary profiles, 20β-dihydroprednisolone was confirmed as the main prednisolone-derived metabolite, being detected in the biological fluids of all 12 bovines (plasma AUC0-inf of 121 h μg L-1 and urinary concentration > 0.695 μg L-1).",Pharmacokinetic and urinary profiling reveals the prednisolone/cortisol ratio as a valid biomarker for prednisolone administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28806969/),[h·μg] / [l],121,203536,DB00860,Prednisolone
,2306790,log octanol:water partition coefficients (log P values),The esters were lipophilic and possessed log octanol:water partition coefficients (log P values) that ranged from 4.05 to greater than 8.0.,Physicochemical and pharmacokinetic parameters of seven lipophilic chlorambucil esters designed for brain penetration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2306790/),,4.05 to greater,205104,DB00860,Prednisolone
,17139160,flow-rate,A flow-rate of 0.5 ml/min was used at ambient temperature and sample detection was carried out at 254 nm.,Quantification and 24-hour monitoring of mycophenolic acid by high-performance liquid chromatography in Japanese renal transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17139160/),[ml] / [min],0.5,205472,DB00860,Prednisolone
,17139160,time to reach the maximum,"The time to reach the maximum (11.7 microg/ml) and second peak (4.5 microg/ml) of MPA after morning 0.75 g MMF administration was 2.6 h and 9.0 h, and time to reach maximum (10.5 microg/ml) after evening 0.75 g administration was 4.0 h.",Quantification and 24-hour monitoring of mycophenolic acid by high-performance liquid chromatography in Japanese renal transplant recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17139160/),[μg] / [ml],11.7,205473,DB00860,Prednisolone
,17139160,second peak,"The time to reach the maximum (11.7 microg/ml) and second peak (4.5 microg/ml) of MPA after morning 0.75 g MMF administration was 2.6 h and 9.0 h, and time to reach maximum (10.5 microg/ml) after evening 0.75 g administration was 4.0 h.",Quantification and 24-hour monitoring of mycophenolic acid by high-performance liquid chromatography in Japanese renal transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17139160/),[μg] / [ml],4.5,205474,DB00860,Prednisolone
,17139160,second peak,"The time to reach the maximum (11.7 microg/ml) and second peak (4.5 microg/ml) of MPA after morning 0.75 g MMF administration was 2.6 h and 9.0 h, and time to reach maximum (10.5 microg/ml) after evening 0.75 g administration was 4.0 h.",Quantification and 24-hour monitoring of mycophenolic acid by high-performance liquid chromatography in Japanese renal transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17139160/),h,2.6,205475,DB00860,Prednisolone
,17139160,second peak,"The time to reach the maximum (11.7 microg/ml) and second peak (4.5 microg/ml) of MPA after morning 0.75 g MMF administration was 2.6 h and 9.0 h, and time to reach maximum (10.5 microg/ml) after evening 0.75 g administration was 4.0 h.",Quantification and 24-hour monitoring of mycophenolic acid by high-performance liquid chromatography in Japanese renal transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17139160/),h,9.0,205476,DB00860,Prednisolone
,17139160,time to reach maximum,"The time to reach the maximum (11.7 microg/ml) and second peak (4.5 microg/ml) of MPA after morning 0.75 g MMF administration was 2.6 h and 9.0 h, and time to reach maximum (10.5 microg/ml) after evening 0.75 g administration was 4.0 h.",Quantification and 24-hour monitoring of mycophenolic acid by high-performance liquid chromatography in Japanese renal transplant recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17139160/),[μg] / [ml],10.5,205477,DB00860,Prednisolone
,17139160,time to reach maximum,"The time to reach the maximum (11.7 microg/ml) and second peak (4.5 microg/ml) of MPA after morning 0.75 g MMF administration was 2.6 h and 9.0 h, and time to reach maximum (10.5 microg/ml) after evening 0.75 g administration was 4.0 h.",Quantification and 24-hour monitoring of mycophenolic acid by high-performance liquid chromatography in Japanese renal transplant recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17139160/),h,4.0,205478,DB00860,Prednisolone
,7915309,clearance,"The clearance and apparent volume of distribution of prednisolone in the control and indomethacin-treated animals were similar, averaging 4.71 versus 4.05 L/h/kg and 1.37 versus 1.33 L/kg, respectively.",Effects of indomethacin on the pharmacokinetics and pharmacodynamics of prednisolone in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7915309/),[l] / [h·kg],4.71,205750,DB00860,Prednisolone
,7915309,clearance,"The clearance and apparent volume of distribution of prednisolone in the control and indomethacin-treated animals were similar, averaging 4.71 versus 4.05 L/h/kg and 1.37 versus 1.33 L/kg, respectively.",Effects of indomethacin on the pharmacokinetics and pharmacodynamics of prednisolone in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7915309/),[l] / [h·kg],4.05,205751,DB00860,Prednisolone
,7915309,apparent volume of distribution,"The clearance and apparent volume of distribution of prednisolone in the control and indomethacin-treated animals were similar, averaging 4.71 versus 4.05 L/h/kg and 1.37 versus 1.33 L/kg, respectively.",Effects of indomethacin on the pharmacokinetics and pharmacodynamics of prednisolone in rats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7915309/),[l] / [kg],1.37,205752,DB00860,Prednisolone
,7915309,apparent volume of distribution,"The clearance and apparent volume of distribution of prednisolone in the control and indomethacin-treated animals were similar, averaging 4.71 versus 4.05 L/h/kg and 1.37 versus 1.33 L/kg, respectively.",Effects of indomethacin on the pharmacokinetics and pharmacodynamics of prednisolone in rats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7915309/),[l] / [kg],1.33,205753,DB00860,Prednisolone
,7915309,elimination half-life,The elimination half-life was 0.48 h in both groups.,Effects of indomethacin on the pharmacokinetics and pharmacodynamics of prednisolone in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7915309/),h,0.48,205754,DB00860,Prednisolone
,3883592,peak concentrations,"The mean (+/- SD) peak concentrations of unbound prednisolone were higher after i.v. prednisolone phosphate (18.5 +/- 3.4 micrograms/ml) than after i.v. prednisolone phthalate (2.9 +/- 0.5 micrograms/ml) or after oral prednisone (3.1 +/- 0.8 micrograms/ml), (P less than 0.001).",Pharmacokinetics of 3 prednisolone prodrugs. Evidence of therapeutic inequivalence in renal transplant patients with rejection. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3883592/),[μg] / [ml],18.5,206638,DB00860,Prednisolone
,3883592,peak concentrations,"The mean (+/- SD) peak concentrations of unbound prednisolone were higher after i.v. prednisolone phosphate (18.5 +/- 3.4 micrograms/ml) than after i.v. prednisolone phthalate (2.9 +/- 0.5 micrograms/ml) or after oral prednisone (3.1 +/- 0.8 micrograms/ml), (P less than 0.001).",Pharmacokinetics of 3 prednisolone prodrugs. Evidence of therapeutic inequivalence in renal transplant patients with rejection. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3883592/),[μg] / [ml],2.9,206639,DB00860,Prednisolone
,3883592,peak concentrations,"The mean (+/- SD) peak concentrations of unbound prednisolone were higher after i.v. prednisolone phosphate (18.5 +/- 3.4 micrograms/ml) than after i.v. prednisolone phthalate (2.9 +/- 0.5 micrograms/ml) or after oral prednisone (3.1 +/- 0.8 micrograms/ml), (P less than 0.001).",Pharmacokinetics of 3 prednisolone prodrugs. Evidence of therapeutic inequivalence in renal transplant patients with rejection. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3883592/),[μg] / [ml],3.1,206640,DB00860,Prednisolone
,3883592,AUCs,"The mean AUCs of unbound prednisolone were 2324 +/- 683 micrograms/ml/min from prednisolone phosphate, 1209 +/- 324 micrograms/ml/min from prednisolone phthalate, and 1584 +/- 556 micrograms/ml/min from oral prednisone.",Pharmacokinetics of 3 prednisolone prodrugs. Evidence of therapeutic inequivalence in renal transplant patients with rejection. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3883592/),[μg] / [min·ml],2324,206641,DB00860,Prednisolone
,3883592,AUCs,"The mean AUCs of unbound prednisolone were 2324 +/- 683 micrograms/ml/min from prednisolone phosphate, 1209 +/- 324 micrograms/ml/min from prednisolone phthalate, and 1584 +/- 556 micrograms/ml/min from oral prednisone.",Pharmacokinetics of 3 prednisolone prodrugs. Evidence of therapeutic inequivalence in renal transplant patients with rejection. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3883592/),[μg] / [min·ml],1209,206642,DB00860,Prednisolone
,3883592,AUCs,"The mean AUCs of unbound prednisolone were 2324 +/- 683 micrograms/ml/min from prednisolone phosphate, 1209 +/- 324 micrograms/ml/min from prednisolone phthalate, and 1584 +/- 556 micrograms/ml/min from oral prednisone.",Pharmacokinetics of 3 prednisolone prodrugs. Evidence of therapeutic inequivalence in renal transplant patients with rejection. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3883592/),[μg] / [min·ml],1584,206643,DB00860,Prednisolone
,2898348,area under the blood concentration versus time curve,The mean area under the blood concentration versus time curve of CyA (HPLC measurements) was lower in pigs than in humans after oral (67 +/- 31 micrograms/ml x min vs. 296 +/- 101 micrograms/ml x min) and after iv (358 +/- 71 micrograms/ml x min vs. 858 +/- 292 micrograms/ml x min) doses of CyA.,Marked interspecies differences between humans and pigs in cyclosporine and prednisolone disposition. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2898348/),[μg] / [min·ml],67,207360,DB00860,Prednisolone
,2898348,area under the blood concentration versus time curve,The mean area under the blood concentration versus time curve of CyA (HPLC measurements) was lower in pigs than in humans after oral (67 +/- 31 micrograms/ml x min vs. 296 +/- 101 micrograms/ml x min) and after iv (358 +/- 71 micrograms/ml x min vs. 858 +/- 292 micrograms/ml x min) doses of CyA.,Marked interspecies differences between humans and pigs in cyclosporine and prednisolone disposition. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2898348/),[μg] / [min·ml],296,207361,DB00860,Prednisolone
,2898348,area under the blood concentration versus time curve,The mean area under the blood concentration versus time curve of CyA (HPLC measurements) was lower in pigs than in humans after oral (67 +/- 31 micrograms/ml x min vs. 296 +/- 101 micrograms/ml x min) and after iv (358 +/- 71 micrograms/ml x min vs. 858 +/- 292 micrograms/ml x min) doses of CyA.,Marked interspecies differences between humans and pigs in cyclosporine and prednisolone disposition. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2898348/),[μg] / [min·ml],358,207362,DB00860,Prednisolone
,2898348,area under the blood concentration versus time curve,The mean area under the blood concentration versus time curve of CyA (HPLC measurements) was lower in pigs than in humans after oral (67 +/- 31 micrograms/ml x min vs. 296 +/- 101 micrograms/ml x min) and after iv (358 +/- 71 micrograms/ml x min vs. 858 +/- 292 micrograms/ml x min) doses of CyA.,Marked interspecies differences between humans and pigs in cyclosporine and prednisolone disposition. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2898348/),[μg] / [min·ml],858,207363,DB00860,Prednisolone
,1970778,elimination half-lives,"The elimination half-lives of P4 alpha, P4 beta, and prednisolone were independent of dose and were 1.12, 0.28, and 0.53 hr at 10 mg/kg doses, respectively.",Pharmacokinetics of prednisolone and its local anti-inflammatory steroid-21-oate ester derivatives. In vitro and in vivo comparative study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1970778/),h,1.12,208043,DB00860,Prednisolone
,1970778,elimination half-lives,"The elimination half-lives of P4 alpha, P4 beta, and prednisolone were independent of dose and were 1.12, 0.28, and 0.53 hr at 10 mg/kg doses, respectively.",Pharmacokinetics of prednisolone and its local anti-inflammatory steroid-21-oate ester derivatives. In vitro and in vivo comparative study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1970778/),h,0.28,208044,DB00860,Prednisolone
,1970778,elimination half-lives,"The elimination half-lives of P4 alpha, P4 beta, and prednisolone were independent of dose and were 1.12, 0.28, and 0.53 hr at 10 mg/kg doses, respectively.",Pharmacokinetics of prednisolone and its local anti-inflammatory steroid-21-oate ester derivatives. In vitro and in vivo comparative study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1970778/),h,0.53,208045,DB00860,Prednisolone
,1970778,AUCs,"The AUCs of P4 alpha, P4 beta, and prednisolone following a 10 mg/kg dose were 7678, 242, and 3037 ng/ml.hr, respectively.",Pharmacokinetics of prednisolone and its local anti-inflammatory steroid-21-oate ester derivatives. In vitro and in vivo comparative study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1970778/),[ng] / [h·ml],7678,208046,DB00860,Prednisolone
,1970778,AUCs,"The AUCs of P4 alpha, P4 beta, and prednisolone following a 10 mg/kg dose were 7678, 242, and 3037 ng/ml.hr, respectively.",Pharmacokinetics of prednisolone and its local anti-inflammatory steroid-21-oate ester derivatives. In vitro and in vivo comparative study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1970778/),[ng] / [h·ml],242,208047,DB00860,Prednisolone
,1970778,AUCs,"The AUCs of P4 alpha, P4 beta, and prednisolone following a 10 mg/kg dose were 7678, 242, and 3037 ng/ml.hr, respectively.",Pharmacokinetics of prednisolone and its local anti-inflammatory steroid-21-oate ester derivatives. In vitro and in vivo comparative study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1970778/),[ng] / [h·ml],3037,208048,DB00860,Prednisolone
,8530713,systemic bioavailability,Oral estrogens have minimal systemic bioavailability (2% to 10%) due to gut and liver (first-pass) metabolism.,Pharmacokinetic and pharmacologic variation between different estrogen products. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8530713/),%,2,209255,DB00860,Prednisolone
,8530713,systemic bioavailability,Oral estrogens have minimal systemic bioavailability (2% to 10%) due to gut and liver (first-pass) metabolism.,Pharmacokinetic and pharmacologic variation between different estrogen products. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8530713/),%,10,209256,DB00860,Prednisolone
,8530713,terminal half lives,The terminal half lives for the different estrogen compounds (after oral or intravenous administration) vary from 1-12 hours.,Pharmacokinetic and pharmacologic variation between different estrogen products. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8530713/),h,1-12,209257,DB00860,Prednisolone
,9278201,areas under the pruritus intensity-time curve,"The areas under the pruritus intensity-time curve were promethazine 105 +/- 28 (units h), niacin 76 +/- 22, prednisolone 28 +/- 24, and prednisolone and niacin 34 +/- 17 (P < 0.001 ANOVA).","Chloroquine-induced pruritus in malaria fever: contribution of malaria parasitaemia and the effects of prednisolone, niacin, and their combination, compared with antihistamine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9278201/),h·units,105,209541,DB00860,Prednisolone
,9278201,areas under the pruritus intensity-time curve,"The areas under the pruritus intensity-time curve were promethazine 105 +/- 28 (units h), niacin 76 +/- 22, prednisolone 28 +/- 24, and prednisolone and niacin 34 +/- 17 (P < 0.001 ANOVA).","Chloroquine-induced pruritus in malaria fever: contribution of malaria parasitaemia and the effects of prednisolone, niacin, and their combination, compared with antihistamine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9278201/),h·units,76,209542,DB00860,Prednisolone
,9278201,areas under the pruritus intensity-time curve,"The areas under the pruritus intensity-time curve were promethazine 105 +/- 28 (units h), niacin 76 +/- 22, prednisolone 28 +/- 24, and prednisolone and niacin 34 +/- 17 (P < 0.001 ANOVA).","Chloroquine-induced pruritus in malaria fever: contribution of malaria parasitaemia and the effects of prednisolone, niacin, and their combination, compared with antihistamine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9278201/),h·units,28,209543,DB00860,Prednisolone
,9278201,areas under the pruritus intensity-time curve,"The areas under the pruritus intensity-time curve were promethazine 105 +/- 28 (units h), niacin 76 +/- 22, prednisolone 28 +/- 24, and prednisolone and niacin 34 +/- 17 (P < 0.001 ANOVA).","Chloroquine-induced pruritus in malaria fever: contribution of malaria parasitaemia and the effects of prednisolone, niacin, and their combination, compared with antihistamine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9278201/),h·units,34,209544,DB00860,Prednisolone
,8612388,unbound clearance,The unbound clearance of prednisolone was significantly lower in postmenopausal women (11.6 +/- 2.3 ml/min/kg) than in premenopausal women (16.6 +/- 3.5 ml/min/kg).,The effects of menopause and hormone replacement therapies on prednisolone and erythromycin pharmacokinetics. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8612388/),[ml] / [kg·min],11.6,209622,DB00860,Prednisolone
,8612388,unbound clearance,The unbound clearance of prednisolone was significantly lower in postmenopausal women (11.6 +/- 2.3 ml/min/kg) than in premenopausal women (16.6 +/- 3.5 ml/min/kg).,The effects of menopause and hormone replacement therapies on prednisolone and erythromycin pharmacokinetics. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8612388/),[ml] / [kg·min],16.6,209623,DB00860,Prednisolone
,1425620,tmax,Ondansetron is rapidly absorbed after oral administration (tmax 1.9 h) with an absolute bioavailability of around 60%.,Clinical pharmacology of ondansetron in postoperative nausea and vomiting. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1425620/),h,1.9,210774,DB00860,Prednisolone
,1425620,absolute bioavailability,Ondansetron is rapidly absorbed after oral administration (tmax 1.9 h) with an absolute bioavailability of around 60%.,Clinical pharmacology of ondansetron in postoperative nausea and vomiting. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1425620/),%,60,210775,DB00860,Prednisolone
,1425620,terminal elimination half-life,Its terminal elimination half-life is 3.5 h and it is extensively hepatically metabolized.,Clinical pharmacology of ondansetron in postoperative nausea and vomiting. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1425620/),h,3.5,210776,DB00860,Prednisolone
,1425620,Plasma clearance,Plasma clearance is 0.38 litre h-1 kg-1 and volume of distribution is 1.8 litre kg-1.,Clinical pharmacology of ondansetron in postoperative nausea and vomiting. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1425620/),[l] / [h·kg],0.38,210777,DB00860,Prednisolone
,1425620,volume of distribution,Plasma clearance is 0.38 litre h-1 kg-1 and volume of distribution is 1.8 litre kg-1.,Clinical pharmacology of ondansetron in postoperative nausea and vomiting. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1425620/),[l] / [kg],1.8,210778,DB00860,Prednisolone
,9085328,Peak concentration,"Peak concentration was significantly higher with liquid prednisolone (mean +/- SD 430.3 +/- 62.5 vs 333.0 +/- 27.8 ng/ml, p = 0.013), with similar times to peak concentration.",A pharmacokinetic comparison of two oral liquid glucocorticoid formulations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9085328/),[ng] / [ml],430.3,214051,DB00860,Prednisolone
,9085328,Peak concentration,"Peak concentration was significantly higher with liquid prednisolone (mean +/- SD 430.3 +/- 62.5 vs 333.0 +/- 27.8 ng/ml, p = 0.013), with similar times to peak concentration.",A pharmacokinetic comparison of two oral liquid glucocorticoid formulations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9085328/),[ng] / [ml],333.0,214052,DB00860,Prednisolone
,9085328,total area under the curve,"Prednisolone liquid gave higher concentrations at every time point (statistically significant for all except 0.25 hrs after the dose), resulting in a significantly greater total area under the curve (2029.8 +/- 246.9 vs 1633.3 +/- 221.1 ng/ml.hour, respectively, p = 0.002).",A pharmacokinetic comparison of two oral liquid glucocorticoid formulations. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9085328/),[ng] / [h·ml],2029.8,214053,DB00860,Prednisolone
,9085328,total area under the curve,"Prednisolone liquid gave higher concentrations at every time point (statistically significant for all except 0.25 hrs after the dose), resulting in a significantly greater total area under the curve (2029.8 +/- 246.9 vs 1633.3 +/- 221.1 ng/ml.hour, respectively, p = 0.002).",A pharmacokinetic comparison of two oral liquid glucocorticoid formulations. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9085328/),[ng] / [h·ml],1633.3,214054,DB00860,Prednisolone
,9085328,Clearance,"Clearance was slower for prednisolone (128.3 +/- 15.1 vs 149.1 +/- 17.6 ml/min/1.73 m2, p = 0.01), and the relative bioavailability of the prednisolone liquid using prednisone liquid as the reference standard was 116 +/- 14%.",A pharmacokinetic comparison of two oral liquid glucocorticoid formulations. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9085328/),[ml] / [1.73·m2·min],128.3,214055,DB00860,Prednisolone
,9085328,Clearance,"Clearance was slower for prednisolone (128.3 +/- 15.1 vs 149.1 +/- 17.6 ml/min/1.73 m2, p = 0.01), and the relative bioavailability of the prednisolone liquid using prednisone liquid as the reference standard was 116 +/- 14%.",A pharmacokinetic comparison of two oral liquid glucocorticoid formulations. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9085328/),[ml] / [1.73·m2·min],149.1,214056,DB00860,Prednisolone
,9085328,relative bioavailability,"Clearance was slower for prednisolone (128.3 +/- 15.1 vs 149.1 +/- 17.6 ml/min/1.73 m2, p = 0.01), and the relative bioavailability of the prednisolone liquid using prednisone liquid as the reference standard was 116 +/- 14%.",A pharmacokinetic comparison of two oral liquid glucocorticoid formulations. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9085328/),%,116,214057,DB00860,Prednisolone
,17925494,area under the curves (AUCs),Oral administration of prednisone resulted in prednisone mean +/- SD area under the curves (AUCs) of 115.89 +/- 39.52 microg x h/L prior to SJW treatment and 128.76 +/- 32.71 microg x h/L after 28 days of treatment.,Lack of pharmacokinetic interaction between St. John's wort and prednisone. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17925494/),[h·μg] / [l],115.89,214237,DB00860,Prednisolone
,17925494,area under the curves (AUCs),Oral administration of prednisone resulted in prednisone mean +/- SD area under the curves (AUCs) of 115.89 +/- 39.52 microg x h/L prior to SJW treatment and 128.76 +/- 32.71 microg x h/L after 28 days of treatment.,Lack of pharmacokinetic interaction between St. John's wort and prednisone. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17925494/),[h·μg] / [l],128.76,214238,DB00860,Prednisolone
,17925494,AUCs,Prednisolone mean AUCs were 714.19 +/- 153.29 microg x h/L before SJW administration and 700.74 +/- 89.68 microg x h/L after treatment.,Lack of pharmacokinetic interaction between St. John's wort and prednisone. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17925494/),[h·μg] / [l],714.19,214239,DB00860,Prednisolone
,17925494,AUCs,Prednisolone mean AUCs were 714.19 +/- 153.29 microg x h/L before SJW administration and 700.74 +/- 89.68 microg x h/L after treatment.,Lack of pharmacokinetic interaction between St. John's wort and prednisone. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17925494/),[h·μg] / [l],700.74,214240,DB00860,Prednisolone
,8272400,terminal half-life,"Incorporation of MPL into liposomes caused the following increases: terminal half-life, from 0.48 (MPL) to 30.13 hr (L-MPL); MRT, from 0.42 to 11.95 hr, Vss, from 2.10 to 21.87 L/kg; and AUC, from 339 to 1093 ng x hr/mL.",Enhancement of tissue delivery and receptor occupancy of methylprednisolone in rats by a liposomal formulation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8272400/),h,0.48,214820,DB00860,Prednisolone
,8272400,terminal half-life,"Incorporation of MPL into liposomes caused the following increases: terminal half-life, from 0.48 (MPL) to 30.13 hr (L-MPL); MRT, from 0.42 to 11.95 hr, Vss, from 2.10 to 21.87 L/kg; and AUC, from 339 to 1093 ng x hr/mL.",Enhancement of tissue delivery and receptor occupancy of methylprednisolone in rats by a liposomal formulation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8272400/),h,30.13,214821,DB00860,Prednisolone
,8272400,MRT,"Incorporation of MPL into liposomes caused the following increases: terminal half-life, from 0.48 (MPL) to 30.13 hr (L-MPL); MRT, from 0.42 to 11.95 hr, Vss, from 2.10 to 21.87 L/kg; and AUC, from 339 to 1093 ng x hr/mL.",Enhancement of tissue delivery and receptor occupancy of methylprednisolone in rats by a liposomal formulation. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8272400/),h,0.42 to 11.95,214822,DB00860,Prednisolone
,8272400,Vss,"Incorporation of MPL into liposomes caused the following increases: terminal half-life, from 0.48 (MPL) to 30.13 hr (L-MPL); MRT, from 0.42 to 11.95 hr, Vss, from 2.10 to 21.87 L/kg; and AUC, from 339 to 1093 ng x hr/mL.",Enhancement of tissue delivery and receptor occupancy of methylprednisolone in rats by a liposomal formulation. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8272400/),[l] / [kg],2.10 to 21.87,214823,DB00860,Prednisolone
,8272400,AUC,"Incorporation of MPL into liposomes caused the following increases: terminal half-life, from 0.48 (MPL) to 30.13 hr (L-MPL); MRT, from 0.42 to 11.95 hr, Vss, from 2.10 to 21.87 L/kg; and AUC, from 339 to 1093 ng x hr/mL.",Enhancement of tissue delivery and receptor occupancy of methylprednisolone in rats by a liposomal formulation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8272400/),[h·ng] / [ml],339 to 1093,214824,DB00860,Prednisolone
,1891177,bioavailability,"The mean bioavailability was 14% for chlorambucil, 21% for phenylacetic acid mustard, and 22% for prednisolone, when given as prednimustine, compared to the administration of free compounds in stoichiometrically equivalent doses.",Comparative pharmacokinetics of chlorambucil and prednimustine after oral administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1891177/),%,14,215332,DB00860,Prednisolone
,1891177,bioavailability,"The mean bioavailability was 14% for chlorambucil, 21% for phenylacetic acid mustard, and 22% for prednisolone, when given as prednimustine, compared to the administration of free compounds in stoichiometrically equivalent doses.",Comparative pharmacokinetics of chlorambucil and prednimustine after oral administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1891177/),%,21,215333,DB00860,Prednisolone
,1891177,bioavailability,"The mean bioavailability was 14% for chlorambucil, 21% for phenylacetic acid mustard, and 22% for prednisolone, when given as prednimustine, compared to the administration of free compounds in stoichiometrically equivalent doses.",Comparative pharmacokinetics of chlorambucil and prednimustine after oral administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1891177/),%,22,215334,DB00860,Prednisolone
,6338168,half-time,This rapid elimination phase was followed by a slower phase which paralleled the constant elimination rate from uninjured tissue of traumatized cord (approximate half-time = 6 hours).,Uptake and elimination of methylprednisolone from contused cat spinal cord following intravenous injection of the sodium succinate ester. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6338168/),h,6,216159,DB00860,Prednisolone
,15098802,area under the prednisolone concentration-time curve,"No significant differences were observed for the mean +/- SD area under the prednisolone concentration-time curve (3739 +/- 992 vs 3498 +/- 797 microg x hr/L, respectively), clearance (8.58 +/- 2.62 vs 8.92 +/- 2.05 L/hr, respectively), volume of distribution (39.5 +/- 12.4 vs 38.2 +/- 9.9 L, respectively), elimination half-life (3.32 +/- 0.83 vs 3.05 +/- 0.80 hrs, respectively), or duration of plasma cortisol suppression (23.5 +/- 3.1 vs 22.0 +/- 4.2 hrs, respectively).",Lack of a fluoxetine effect on prednisolone disposition and cortisol suppression. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15098802/),[h·μg] / [l],3739,216252,DB00860,Prednisolone
,15098802,area under the prednisolone concentration-time curve,"No significant differences were observed for the mean +/- SD area under the prednisolone concentration-time curve (3739 +/- 992 vs 3498 +/- 797 microg x hr/L, respectively), clearance (8.58 +/- 2.62 vs 8.92 +/- 2.05 L/hr, respectively), volume of distribution (39.5 +/- 12.4 vs 38.2 +/- 9.9 L, respectively), elimination half-life (3.32 +/- 0.83 vs 3.05 +/- 0.80 hrs, respectively), or duration of plasma cortisol suppression (23.5 +/- 3.1 vs 22.0 +/- 4.2 hrs, respectively).",Lack of a fluoxetine effect on prednisolone disposition and cortisol suppression. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15098802/),[h·μg] / [l],3498,216253,DB00860,Prednisolone
,15098802,clearance,"No significant differences were observed for the mean +/- SD area under the prednisolone concentration-time curve (3739 +/- 992 vs 3498 +/- 797 microg x hr/L, respectively), clearance (8.58 +/- 2.62 vs 8.92 +/- 2.05 L/hr, respectively), volume of distribution (39.5 +/- 12.4 vs 38.2 +/- 9.9 L, respectively), elimination half-life (3.32 +/- 0.83 vs 3.05 +/- 0.80 hrs, respectively), or duration of plasma cortisol suppression (23.5 +/- 3.1 vs 22.0 +/- 4.2 hrs, respectively).",Lack of a fluoxetine effect on prednisolone disposition and cortisol suppression. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15098802/),[l] / [h],8.58,216254,DB00860,Prednisolone
,15098802,clearance,"No significant differences were observed for the mean +/- SD area under the prednisolone concentration-time curve (3739 +/- 992 vs 3498 +/- 797 microg x hr/L, respectively), clearance (8.58 +/- 2.62 vs 8.92 +/- 2.05 L/hr, respectively), volume of distribution (39.5 +/- 12.4 vs 38.2 +/- 9.9 L, respectively), elimination half-life (3.32 +/- 0.83 vs 3.05 +/- 0.80 hrs, respectively), or duration of plasma cortisol suppression (23.5 +/- 3.1 vs 22.0 +/- 4.2 hrs, respectively).",Lack of a fluoxetine effect on prednisolone disposition and cortisol suppression. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15098802/),[l] / [h],8.92,216255,DB00860,Prednisolone
,15098802,volume of distribution,"No significant differences were observed for the mean +/- SD area under the prednisolone concentration-time curve (3739 +/- 992 vs 3498 +/- 797 microg x hr/L, respectively), clearance (8.58 +/- 2.62 vs 8.92 +/- 2.05 L/hr, respectively), volume of distribution (39.5 +/- 12.4 vs 38.2 +/- 9.9 L, respectively), elimination half-life (3.32 +/- 0.83 vs 3.05 +/- 0.80 hrs, respectively), or duration of plasma cortisol suppression (23.5 +/- 3.1 vs 22.0 +/- 4.2 hrs, respectively).",Lack of a fluoxetine effect on prednisolone disposition and cortisol suppression. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15098802/),l,39.5,216256,DB00860,Prednisolone
,15098802,volume of distribution,"No significant differences were observed for the mean +/- SD area under the prednisolone concentration-time curve (3739 +/- 992 vs 3498 +/- 797 microg x hr/L, respectively), clearance (8.58 +/- 2.62 vs 8.92 +/- 2.05 L/hr, respectively), volume of distribution (39.5 +/- 12.4 vs 38.2 +/- 9.9 L, respectively), elimination half-life (3.32 +/- 0.83 vs 3.05 +/- 0.80 hrs, respectively), or duration of plasma cortisol suppression (23.5 +/- 3.1 vs 22.0 +/- 4.2 hrs, respectively).",Lack of a fluoxetine effect on prednisolone disposition and cortisol suppression. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15098802/),l,38.2,216257,DB00860,Prednisolone
,15098802,elimination half-life,"No significant differences were observed for the mean +/- SD area under the prednisolone concentration-time curve (3739 +/- 992 vs 3498 +/- 797 microg x hr/L, respectively), clearance (8.58 +/- 2.62 vs 8.92 +/- 2.05 L/hr, respectively), volume of distribution (39.5 +/- 12.4 vs 38.2 +/- 9.9 L, respectively), elimination half-life (3.32 +/- 0.83 vs 3.05 +/- 0.80 hrs, respectively), or duration of plasma cortisol suppression (23.5 +/- 3.1 vs 22.0 +/- 4.2 hrs, respectively).",Lack of a fluoxetine effect on prednisolone disposition and cortisol suppression. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15098802/),h,3.32,216258,DB00860,Prednisolone
,15098802,elimination half-life,"No significant differences were observed for the mean +/- SD area under the prednisolone concentration-time curve (3739 +/- 992 vs 3498 +/- 797 microg x hr/L, respectively), clearance (8.58 +/- 2.62 vs 8.92 +/- 2.05 L/hr, respectively), volume of distribution (39.5 +/- 12.4 vs 38.2 +/- 9.9 L, respectively), elimination half-life (3.32 +/- 0.83 vs 3.05 +/- 0.80 hrs, respectively), or duration of plasma cortisol suppression (23.5 +/- 3.1 vs 22.0 +/- 4.2 hrs, respectively).",Lack of a fluoxetine effect on prednisolone disposition and cortisol suppression. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15098802/),h,3.05,216259,DB00860,Prednisolone
,15098802,elimination half-life,"No significant differences were observed for the mean +/- SD area under the prednisolone concentration-time curve (3739 +/- 992 vs 3498 +/- 797 microg x hr/L, respectively), clearance (8.58 +/- 2.62 vs 8.92 +/- 2.05 L/hr, respectively), volume of distribution (39.5 +/- 12.4 vs 38.2 +/- 9.9 L, respectively), elimination half-life (3.32 +/- 0.83 vs 3.05 +/- 0.80 hrs, respectively), or duration of plasma cortisol suppression (23.5 +/- 3.1 vs 22.0 +/- 4.2 hrs, respectively).",Lack of a fluoxetine effect on prednisolone disposition and cortisol suppression. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15098802/),h,23.5,216260,DB00860,Prednisolone
,15098802,elimination half-life,"No significant differences were observed for the mean +/- SD area under the prednisolone concentration-time curve (3739 +/- 992 vs 3498 +/- 797 microg x hr/L, respectively), clearance (8.58 +/- 2.62 vs 8.92 +/- 2.05 L/hr, respectively), volume of distribution (39.5 +/- 12.4 vs 38.2 +/- 9.9 L, respectively), elimination half-life (3.32 +/- 0.83 vs 3.05 +/- 0.80 hrs, respectively), or duration of plasma cortisol suppression (23.5 +/- 3.1 vs 22.0 +/- 4.2 hrs, respectively).",Lack of a fluoxetine effect on prednisolone disposition and cortisol suppression. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15098802/),h,22.0,216261,DB00860,Prednisolone
,15098802,duration,"No significant differences were observed for the mean +/- SD area under the prednisolone concentration-time curve (3739 +/- 992 vs 3498 +/- 797 microg x hr/L, respectively), clearance (8.58 +/- 2.62 vs 8.92 +/- 2.05 L/hr, respectively), volume of distribution (39.5 +/- 12.4 vs 38.2 +/- 9.9 L, respectively), elimination half-life (3.32 +/- 0.83 vs 3.05 +/- 0.80 hrs, respectively), or duration of plasma cortisol suppression (23.5 +/- 3.1 vs 22.0 +/- 4.2 hrs, respectively).",Lack of a fluoxetine effect on prednisolone disposition and cortisol suppression. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15098802/),h,23.5,216262,DB00860,Prednisolone
,15098802,duration,"No significant differences were observed for the mean +/- SD area under the prednisolone concentration-time curve (3739 +/- 992 vs 3498 +/- 797 microg x hr/L, respectively), clearance (8.58 +/- 2.62 vs 8.92 +/- 2.05 L/hr, respectively), volume of distribution (39.5 +/- 12.4 vs 38.2 +/- 9.9 L, respectively), elimination half-life (3.32 +/- 0.83 vs 3.05 +/- 0.80 hrs, respectively), or duration of plasma cortisol suppression (23.5 +/- 3.1 vs 22.0 +/- 4.2 hrs, respectively).",Lack of a fluoxetine effect on prednisolone disposition and cortisol suppression. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15098802/),h,22.0,216263,DB00860,Prednisolone
,7107818,fraction of unbound prednisolone,The fraction of unbound prednisolone increased from 0.12 +/- 0.02 to 0.24 +/- 0.02 with increasing dose.,Prednisolone clearance at steady state in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7107818/),,0.12,216422,DB00860,Prednisolone
,7107818,fraction of unbound prednisolone,The fraction of unbound prednisolone increased from 0.12 +/- 0.02 to 0.24 +/- 0.02 with increasing dose.,Prednisolone clearance at steady state in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7107818/),,0.24,216423,DB00860,Prednisolone
,7107818,maximum prednisone concentration,"In humans, we found this maximum prednisone concentration to be 52 ng/ml when prednisolone is infused.",Prednisolone clearance at steady state in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7107818/),[ng] / [ml],52,216424,DB00860,Prednisolone
,31819422,polydispersity index,"N-PD/CU showed a narrow size distribution around 150.4 ± 2.4 nm, a polydispersity index of 0.22 ± 0.02 and drug loading efficiency (DLE) of 88.75 ± 1.82% for PD and 85.79 ± 1.43% for CU.",Co-Delivery of Prednisolone and Curcumin in Human Serum Albumin Nanoparticles for Effective Treatment of Rheumatoid Arthritis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31819422/),,0.22,216904,DB00860,Prednisolone
,31819422,drug loading efficiency (DLE),"N-PD/CU showed a narrow size distribution around 150.4 ± 2.4 nm, a polydispersity index of 0.22 ± 0.02 and drug loading efficiency (DLE) of 88.75 ± 1.82% for PD and 85.79 ± 1.43% for CU.",Co-Delivery of Prednisolone and Curcumin in Human Serum Albumin Nanoparticles for Effective Treatment of Rheumatoid Arthritis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31819422/),%,88.75,216905,DB00860,Prednisolone
,31819422,drug loading efficiency (DLE),"N-PD/CU showed a narrow size distribution around 150.4 ± 2.4 nm, a polydispersity index of 0.22 ± 0.02 and drug loading efficiency (DLE) of 88.75 ± 1.82% for PD and 85.79 ± 1.43% for CU.",Co-Delivery of Prednisolone and Curcumin in Human Serum Albumin Nanoparticles for Effective Treatment of Rheumatoid Arthritis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31819422/),%,85.79,216906,DB00860,Prednisolone
,15518754,trough levels,"Oral tacrolimus was initiated at about 0.2 mg/kg/d, dose which was adjusted to achieve target trough levels of 10 to 20 ng/mL at 3 months and 5 to 10 ng/mL thereafter.",Primary immunosuppression with tacrolimus and low-dose mycophenolate mofetil in renal transplant recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15518754/),[ng] / [ml],10 to 20,217652,DB00860,Prednisolone
,15518754,trough levels,"Oral tacrolimus was initiated at about 0.2 mg/kg/d, dose which was adjusted to achieve target trough levels of 10 to 20 ng/mL at 3 months and 5 to 10 ng/mL thereafter.",Primary immunosuppression with tacrolimus and low-dose mycophenolate mofetil in renal transplant recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15518754/),[ng] / [ml],5 to 10,217653,DB00860,Prednisolone
,15518754,AUC,"Mean MPA AUC values at 1, 3, and 6 months were 40.5 +/- 9.4, 44.4 +/- 17.3, and 57.2 +/- 20.7 mug*h/mL, respectively (P = .0486, n = 7).",Primary immunosuppression with tacrolimus and low-dose mycophenolate mofetil in renal transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15518754/),[h·μg] / [ml],40.5,217654,DB00860,Prednisolone
,15518754,AUC,"Mean MPA AUC values at 1, 3, and 6 months were 40.5 +/- 9.4, 44.4 +/- 17.3, and 57.2 +/- 20.7 mug*h/mL, respectively (P = .0486, n = 7).",Primary immunosuppression with tacrolimus and low-dose mycophenolate mofetil in renal transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15518754/),[h·μg] / [ml],44.4,217655,DB00860,Prednisolone
,15518754,AUC,"Mean MPA AUC values at 1, 3, and 6 months were 40.5 +/- 9.4, 44.4 +/- 17.3, and 57.2 +/- 20.7 mug*h/mL, respectively (P = .0486, n = 7).",Primary immunosuppression with tacrolimus and low-dose mycophenolate mofetil in renal transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15518754/),[h·μg] / [ml],57.2,217656,DB00860,Prednisolone
,455892,bioavailability,"The median value of bioavailability (relative to oral dose) of methylprednisolone acetate based on unchanged methylprednisolone plasma levels was 14.2% after rectal administration, suggesting that the drug exerts its therapeutic effect topically rather than systemically.",Rectal and oral absorption of methylprednisolone acetate. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/455892/),%,14.2,217664,DB00860,Prednisolone
,455892,bioavailability,"Mean bioavailability (relative to oral administration of methylprednisolone acetate) of methylprednisolone after oral administration was 89.9%, indicating somewhat better systemic availability of the ester than the alcohol.",Rectal and oral absorption of methylprednisolone acetate. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/455892/),%,89.9,217665,DB00860,Prednisolone
,455892,apparent elimination rate constant,"The average apparent elimination rate constant for methylprednisolone after oral administration of both ester and alcohol was 0.290 hr-1, corresponding to a half-life of 2.39 hr.",Rectal and oral absorption of methylprednisolone acetate. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/455892/),1/[h],0.290,217666,DB00860,Prednisolone
,455892,half-life,"The average apparent elimination rate constant for methylprednisolone after oral administration of both ester and alcohol was 0.290 hr-1, corresponding to a half-life of 2.39 hr.",Rectal and oral absorption of methylprednisolone acetate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/455892/),h,2.39,217667,DB00860,Prednisolone
,383357,bioavailability,"Prednisone is effectively absorbed and converted to its active therapeutic derivative, prednisolone, in healthy volunteers and in patients with liver disease; the bioavailability of oral prednisone approximates 100% of an intravenous dose and is comparable after administration of either prednisone or prednisolone.",Corticosteroid pharmacokinetics in liver disease. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/383357/),%,100,217713,DB00860,Prednisolone
,19845437,serum half-life,The serum half-life was estimated as being between 2 and 4 h.,Pharmacokinetics and anti-inflammatory pharmacodynamics of prednisolone in cynomolgus monkey. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19845437/),h,2 and 4,217731,DB00860,Prednisolone
,19845437,IC50,"Prednisolone exhibits near complete inhibition of the cytokines TNF-alpha, IL-1beta, IL-6 and IL-8 with very similar IC50 estimates from 0.09 to 0.16 microg ml(-1) (from 0.24 to 0.44 microM).",Pharmacokinetics and anti-inflammatory pharmacodynamics of prednisolone in cynomolgus monkey. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19845437/),[μg] / [ml],0.09 to 0.16,217732,DB00860,Prednisolone
,19845437,IC50,"Prednisolone exhibits near complete inhibition of the cytokines TNF-alpha, IL-1beta, IL-6 and IL-8 with very similar IC50 estimates from 0.09 to 0.16 microg ml(-1) (from 0.24 to 0.44 microM).",Pharmacokinetics and anti-inflammatory pharmacodynamics of prednisolone in cynomolgus monkey. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19845437/),μM,0.24 to 0.44,217733,DB00860,Prednisolone
,9874701,clearance,"Mean (+/- SD) prednisolone clearance values were 3.22 +/- 0.88 and 3.46 +/- 0.96 L/h/kg in males and females, respectively.",Influence of gender on prednisolone effects on whole blood T-cell deactivation and trafficking in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9874701/),[l] / [h·kg],3.22,218001,DB00860,Prednisolone
,9874701,clearance,"Mean (+/- SD) prednisolone clearance values were 3.22 +/- 0.88 and 3.46 +/- 0.96 L/h/kg in males and females, respectively.",Influence of gender on prednisolone effects on whole blood T-cell deactivation and trafficking in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9874701/),[l] / [h·kg],3.46,218002,DB00860,Prednisolone
,9874701,50% inhibitory concentration,Fitting data using an indirect response model yielded mean prednisolone 50% inhibitory concentration for inhibition of WBTC trafficking (IC50T) that was lower in males compared with females (0.14 +/- 0.16 versus 1.03 +/- 0.06 ng/mL; p < 0.05).,Influence of gender on prednisolone effects on whole blood T-cell deactivation and trafficking in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9874701/),[ng] / [ml],0.14,218003,DB00860,Prednisolone
,9874701,50% inhibitory concentration,Fitting data using an indirect response model yielded mean prednisolone 50% inhibitory concentration for inhibition of WBTC trafficking (IC50T) that was lower in males compared with females (0.14 +/- 0.16 versus 1.03 +/- 0.06 ng/mL; p < 0.05).,Influence of gender on prednisolone effects on whole blood T-cell deactivation and trafficking in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9874701/),[ng] / [ml],1.03,218004,DB00860,Prednisolone
,9874701,50% inhibitory concentration for inhibition of,The mean 50% inhibitory concentration for inhibition of WBTC deactivation (IC50D) based on an inhibitory Imax model was similar in males and females (0.20 +/- 0.24 versus 0.18 +/- 0.12 ng/mL).,Influence of gender on prednisolone effects on whole blood T-cell deactivation and trafficking in rats. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9874701/),[ng] / [ml],0.20,218005,DB00860,Prednisolone
,9874701,50% inhibitory concentration for inhibition of,The mean 50% inhibitory concentration for inhibition of WBTC deactivation (IC50D) based on an inhibitory Imax model was similar in males and females (0.20 +/- 0.24 versus 0.18 +/- 0.12 ng/mL).,Influence of gender on prednisolone effects on whole blood T-cell deactivation and trafficking in rats. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9874701/),[ng] / [ml],0.18,218006,DB00860,Prednisolone
,10656433,maximum tolerated dose,The maximum tolerated dose determined during the first cycle was 1000 mg/m2/day for 5 days of 5FU with either 75 or 85 mg/m2 docetaxel.,A phase I and pharmacokinetic study of docetaxel administered in combination with continuous intravenous infusion of 5-fluorouracil in patients with advanced solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10656433/),,1000,219020,DB00860,Prednisolone
,3705671,excretion rate,The excretion rate was 5 to 6% of the dose applied to rats and maximally 1.9% in pigs.,[Pharmacokinetics and biotransformation following topical use of the local corticoid prednicarbate]. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3705671/),%,5 to 6,220488,DB00860,Prednisolone
,3705671,excretion rate,The excretion rate was 5 to 6% of the dose applied to rats and maximally 1.9% in pigs.,[Pharmacokinetics and biotransformation following topical use of the local corticoid prednicarbate]. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3705671/),%,1.9,220489,DB00860,Prednisolone
,3705671,absorption,"In rats, the absorption after dermal application on an average amounted to 14% in healthy skin and to 22% in abraded skin.",[Pharmacokinetics and biotransformation following topical use of the local corticoid prednicarbate]. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3705671/),%,14,220490,DB00860,Prednisolone
,3705671,absorption,"In rats, the absorption after dermal application on an average amounted to 14% in healthy skin and to 22% in abraded skin.",[Pharmacokinetics and biotransformation following topical use of the local corticoid prednicarbate]. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3705671/),%,22,220491,DB00860,Prednisolone
,3380524,half-life,"The present model predicted that absorption into precorneal area and epithelium and direct penetration into aqueous humor and vitreous humor are 1.7, 0.1, and 0.2% of the applied dose, respectively, and that almost the entire dose (98%) is absorbed into the systemic circulation, with a half-life of 38 min.",Intraocular penetration kinetics of prednisolone after subconjunctival injection in rabbits. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3380524/),min,38,221004,DB00860,Prednisolone
,18387858,protein binding,"Since the protein binding of prednisolone did not change in the presence of prednisone (114.0 ng/ml), it appeared that prednisone produced from the therapeutic dose of prednisolone did not affect the unbound fraction of prednisolone.","Simultaneous determination of prednisolone, prednisone, cortisol, and cortisone in plasma by GC-MS: estimating unbound prednisolone concentration in patients with nephrotic syndrome during oral prednisolone therapy. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18387858/),[ng] / [ml],114.0,221418,DB00860,Prednisolone
,10886464,ka,A one-compartment open model with first-order absorption (ka for PKS=0. 5/h; ka for CAPCIL=0.3/h ) and first- order elimination.,Theophylline pharmacokinetics with concomitant steroid and gold therapy. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10886464/),1/[h],0. 5,221769,DB00860,Prednisolone
,10886464,ka,A one-compartment open model with first-order absorption (ka for PKS=0. 5/h; ka for CAPCIL=0.3/h ) and first- order elimination.,Theophylline pharmacokinetics with concomitant steroid and gold therapy. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10886464/),1/[h],0.3,221770,DB00860,Prednisolone
,20614688,total clearance (CL(tot)),"Following a 10 mg x kg(-1) intravenous bolus dose, the total clearance (CL(tot)) of PRN (27.0 +/- 1.4 mL x min(-1) kg(-1)) was significantly lower than that of LE (67.4 +/- 11.6 mL x min(-1) kg(-1)) or delta1-CA (53.8 +/- 1.4 mL x min(-1) kg(-1)) indicating that the metabolism/elimination of PRN in the liver (primarily, conjugation) may be less efficient than that of LE (primarily, hydrolysis) or delta1-CA (unchanged).",Pharmacokinetics and delta1-cortienic acid excretion after intravenous administration of prednisolone and loteprednol etabonate in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20614688/),[ml] / [kg·min],27.0,223387,DB00860,Prednisolone
,20614688,total clearance (CL(tot)),"Following a 10 mg x kg(-1) intravenous bolus dose, the total clearance (CL(tot)) of PRN (27.0 +/- 1.4 mL x min(-1) kg(-1)) was significantly lower than that of LE (67.4 +/- 11.6 mL x min(-1) kg(-1)) or delta1-CA (53.8 +/- 1.4 mL x min(-1) kg(-1)) indicating that the metabolism/elimination of PRN in the liver (primarily, conjugation) may be less efficient than that of LE (primarily, hydrolysis) or delta1-CA (unchanged).",Pharmacokinetics and delta1-cortienic acid excretion after intravenous administration of prednisolone and loteprednol etabonate in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20614688/),[ml] / [kg·min],67.4,223388,DB00860,Prednisolone
,20614688,total clearance (CL(tot)),"Following a 10 mg x kg(-1) intravenous bolus dose, the total clearance (CL(tot)) of PRN (27.0 +/- 1.4 mL x min(-1) kg(-1)) was significantly lower than that of LE (67.4 +/- 11.6 mL x min(-1) kg(-1)) or delta1-CA (53.8 +/- 1.4 mL x min(-1) kg(-1)) indicating that the metabolism/elimination of PRN in the liver (primarily, conjugation) may be less efficient than that of LE (primarily, hydrolysis) or delta1-CA (unchanged).",Pharmacokinetics and delta1-cortienic acid excretion after intravenous administration of prednisolone and loteprednol etabonate in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20614688/),[ml] / [kg·min],53.8,223389,DB00860,Prednisolone
,20614688,volume of distribution (Vd(ss)),The volume of distribution (Vd(ss)) of PRN (823 +/- 78 mL x kg(-1)) was significantly lower than that of LE (3078 +/- 79 mL x kg(-1)) indicating that LE is more distributed to lipophilic tissues.,Pharmacokinetics and delta1-cortienic acid excretion after intravenous administration of prednisolone and loteprednol etabonate in rats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20614688/),[ml] / [kg],823,223390,DB00860,Prednisolone
,20614688,volume of distribution (Vd(ss)),The volume of distribution (Vd(ss)) of PRN (823 +/- 78 mL x kg(-1)) was significantly lower than that of LE (3078 +/- 79 mL x kg(-1)) indicating that LE is more distributed to lipophilic tissues.,Pharmacokinetics and delta1-cortienic acid excretion after intravenous administration of prednisolone and loteprednol etabonate in rats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20614688/),[ml] / [kg],3078,223391,DB00860,Prednisolone
,3950871,half-times,"From in vitro assay, it was shown that hydrolysis of MPA to MP was rapid both in blood (half-times from 11.8 to 21.7 min) and in synovial fluid (half-times from 45.6 to 130.3 min).",Bovine plasma and synovial fluid kinetics of methylprednisolone and methylprednisolone acetate after intra-articular administration of methylprednisolone acetate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3950871/),min,11.8 to 21.7,224538,DB00860,Prednisolone
,3950871,half-times,"From in vitro assay, it was shown that hydrolysis of MPA to MP was rapid both in blood (half-times from 11.8 to 21.7 min) and in synovial fluid (half-times from 45.6 to 130.3 min).",Bovine plasma and synovial fluid kinetics of methylprednisolone and methylprednisolone acetate after intra-articular administration of methylprednisolone acetate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3950871/),min,45.6 to 130.3,224539,DB00860,Prednisolone
,3950871,systemic availability,"After intra-articular administration of MPA as a suspension (200 mg in toto), both MP and MPA decline very rapidly and, 24 hr after injection, less than 1% of the dose was present in the synovial fluid, but systemic availability of MP during the first 24 hr was only 30% of the dose.",Bovine plasma and synovial fluid kinetics of methylprednisolone and methylprednisolone acetate after intra-articular administration of methylprednisolone acetate. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3950871/),%,30,224540,DB00860,Prednisolone
,3950871,apparent half-time,"After this delay, the synovial fluid concentration decreased very slowly with an apparent half-time of 18 days.",Bovine plasma and synovial fluid kinetics of methylprednisolone and methylprednisolone acetate after intra-articular administration of methylprednisolone acetate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3950871/),d,18,224541,DB00860,Prednisolone
,3312572,clearance,"In the normal state, the clearance of methylprednisolone succinate was 1.64 +/- 0.499 L/h/kg and its half-life was 15.33 +/- 3.84 min.","Pharmacokinetics of methylprednisolone succinate, methylprednisolone, and lidocaine in the normal dog and during hemorrhagic shock. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3312572/),[l] / [h·kg],1.64,224589,DB00860,Prednisolone
,3312572,half-life,"In the normal state, the clearance of methylprednisolone succinate was 1.64 +/- 0.499 L/h/kg and its half-life was 15.33 +/- 3.84 min.","Pharmacokinetics of methylprednisolone succinate, methylprednisolone, and lidocaine in the normal dog and during hemorrhagic shock. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3312572/),min,15.33,224590,DB00860,Prednisolone
,3312572,systemic availability,"The systemic availability of methylprednisolone from methylprednisolone succinate was 59.9 +/- 8.3%, and the maximal methylprednisolone concentration was observed after a delay of 7.68 +/- 6.31 min.","Pharmacokinetics of methylprednisolone succinate, methylprednisolone, and lidocaine in the normal dog and during hemorrhagic shock. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3312572/),%,59.9,224591,DB00860,Prednisolone
,3312572,clearance,"The clearance of methylprednisolone succinate decreased to 0.488 +/- 0.240 L/kg/h, and the half-life increased to 40.66 +/- 23.48 min.","Pharmacokinetics of methylprednisolone succinate, methylprednisolone, and lidocaine in the normal dog and during hemorrhagic shock. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3312572/),[l] / [h·kg],0.488,224592,DB00860,Prednisolone
,3312572,half-life,"The clearance of methylprednisolone succinate decreased to 0.488 +/- 0.240 L/kg/h, and the half-life increased to 40.66 +/- 23.48 min.","Pharmacokinetics of methylprednisolone succinate, methylprednisolone, and lidocaine in the normal dog and during hemorrhagic shock. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3312572/),min,40.66,224593,DB00860,Prednisolone
,17569107,terminal slope,MPL exhibited bi-exponential kinetics after i.v. dosing with a terminal slope of 2.1 h(-1).,Pharmacokinetics of methylprednisolone after intravenous and intramuscular administration in rats. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17569107/),1/[h],2.1,224879,DB00860,Prednisolone
,17569107,first-order absorption rate constants,"The i.m. drug was absorbed slowly with two first-order absorption rate constants, 1.26 and 0.219 h(-1) indicating flip-flop kinetics with overall 50% bioavailability.",Pharmacokinetics of methylprednisolone after intravenous and intramuscular administration in rats. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17569107/),1/[h],1.26,224880,DB00860,Prednisolone
,17569107,first-order absorption rate constants,"The i.m. drug was absorbed slowly with two first-order absorption rate constants, 1.26 and 0.219 h(-1) indicating flip-flop kinetics with overall 50% bioavailability.",Pharmacokinetics of methylprednisolone after intravenous and intramuscular administration in rats. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17569107/),1/[h],0.219,224881,DB00860,Prednisolone
,23802738,overall response rate,The overall response rate was 96% (69/72) including complete response (CR) in 65 (90%) and unconfirmed CR in 2 (3%).,"Long term results of a phase 2 study of vincristine sulfate liposome injection (Marqibo(®) ) substituted for non-liposomal vincristine in cyclophosphamide, doxorubicin, vincristine, prednisone with or without rituximab for patients with untreated aggressive non-Hodgkin lymphomas. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23802738/),%,96,226475,DB00860,Prednisolone
,3943272,volume of distribution,"Prednisolone volume of distribution, elimination clearance, and elimination t1/2 averaged 0.606 +/- 0.061 and 0.553 +/- 0.162 L/kg, 2.28 +/- 0.43 and 1.93 +/- 0.54 ml/min/kg, and 204 +/- 44 and 214 +/- 19 minutes in patients receiving alternate-day or daily prednisone therapy, respectively.",Comparison of prednisolone kinetics in patients receiving daily or alternate-day prednisone for asthma. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3943272/),[l] / [kg],0.606,226932,DB00860,Prednisolone
,3943272,elimination clearance,"Prednisolone volume of distribution, elimination clearance, and elimination t1/2 averaged 0.606 +/- 0.061 and 0.553 +/- 0.162 L/kg, 2.28 +/- 0.43 and 1.93 +/- 0.54 ml/min/kg, and 204 +/- 44 and 214 +/- 19 minutes in patients receiving alternate-day or daily prednisone therapy, respectively.",Comparison of prednisolone kinetics in patients receiving daily or alternate-day prednisone for asthma. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3943272/),[l] / [kg],0.553,226933,DB00860,Prednisolone
,3943272,elimination clearance,"Prednisolone volume of distribution, elimination clearance, and elimination t1/2 averaged 0.606 +/- 0.061 and 0.553 +/- 0.162 L/kg, 2.28 +/- 0.43 and 1.93 +/- 0.54 ml/min/kg, and 204 +/- 44 and 214 +/- 19 minutes in patients receiving alternate-day or daily prednisone therapy, respectively.",Comparison of prednisolone kinetics in patients receiving daily or alternate-day prednisone for asthma. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3943272/),[ml] / [kg·min],2.28,226934,DB00860,Prednisolone
,3943272,elimination t1/2,"Prednisolone volume of distribution, elimination clearance, and elimination t1/2 averaged 0.606 +/- 0.061 and 0.553 +/- 0.162 L/kg, 2.28 +/- 0.43 and 1.93 +/- 0.54 ml/min/kg, and 204 +/- 44 and 214 +/- 19 minutes in patients receiving alternate-day or daily prednisone therapy, respectively.",Comparison of prednisolone kinetics in patients receiving daily or alternate-day prednisone for asthma. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3943272/),[ml] / [kg·min],1.93,226935,DB00860,Prednisolone
,3943272,elimination t1/2,"Prednisolone volume of distribution, elimination clearance, and elimination t1/2 averaged 0.606 +/- 0.061 and 0.553 +/- 0.162 L/kg, 2.28 +/- 0.43 and 1.93 +/- 0.54 ml/min/kg, and 204 +/- 44 and 214 +/- 19 minutes in patients receiving alternate-day or daily prednisone therapy, respectively.",Comparison of prednisolone kinetics in patients receiving daily or alternate-day prednisone for asthma. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3943272/),min,204,226936,DB00860,Prednisolone
,3943272,elimination t1/2,"Prednisolone volume of distribution, elimination clearance, and elimination t1/2 averaged 0.606 +/- 0.061 and 0.553 +/- 0.162 L/kg, 2.28 +/- 0.43 and 1.93 +/- 0.54 ml/min/kg, and 204 +/- 44 and 214 +/- 19 minutes in patients receiving alternate-day or daily prednisone therapy, respectively.",Comparison of prednisolone kinetics in patients receiving daily or alternate-day prednisone for asthma. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3943272/),min,214,226937,DB00860,Prednisolone
,15905802,AUC,"The median MPA AUC on day 6 (29.7 mg.h/L) after the first oral dose was slightly lower than the AUCs on the other study days (34.2, 33.8, and 33.8 mg.h/L on days 3, 5, and 10, respectively).",Pharmacokinetics and bioavailability of mycophenolic acid after intravenous administration and oral administration of mycophenolate mofetil to heart transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15905802/),[h·mg] / [l],29.7,227067,DB00860,Prednisolone
,15905802,AUCs,"The median MPA AUC on day 6 (29.7 mg.h/L) after the first oral dose was slightly lower than the AUCs on the other study days (34.2, 33.8, and 33.8 mg.h/L on days 3, 5, and 10, respectively).",Pharmacokinetics and bioavailability of mycophenolic acid after intravenous administration and oral administration of mycophenolate mofetil to heart transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15905802/),[h·mg] / [l],34.2,227068,DB00860,Prednisolone
,15905802,AUCs,"The median MPA AUC on day 6 (29.7 mg.h/L) after the first oral dose was slightly lower than the AUCs on the other study days (34.2, 33.8, and 33.8 mg.h/L on days 3, 5, and 10, respectively).",Pharmacokinetics and bioavailability of mycophenolic acid after intravenous administration and oral administration of mycophenolate mofetil to heart transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15905802/),[h·mg] / [l],33.8,227069,DB00860,Prednisolone
,15905802,bioavailability,"The results of this study show that heart transplant recipients receiving the IV formulation of MMF (1.5 g BID) are not subject to a greater drug exposure than that seen with the oral formulation (1.5 g BID) and that the oral MMF formulation shows excellent, high, and consistent bioavailability (mean 95%) based on comparison with the IV formulation.",Pharmacokinetics and bioavailability of mycophenolic acid after intravenous administration and oral administration of mycophenolate mofetil to heart transplant recipients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15905802/),%,95,227070,DB00860,Prednisolone
,15728147,AUC(0-8),"When indinavir was given concomitantly with CHOP, the AUC(0-8) increased by 38% (20.5 +/- 9.0 versus 14.9 +/- 9.5 mg.h/L; P=0.03), and was comparable to historical controls.",Pharmacokinetic interaction between chemotherapy for non-Hodgkin's lymphoma and protease inhibitors in HIV-1-infected patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15728147/),[h·mg] / [l],20.5,227142,DB00860,Prednisolone
,15728147,AUC(0-8),"When indinavir was given concomitantly with CHOP, the AUC(0-8) increased by 38% (20.5 +/- 9.0 versus 14.9 +/- 9.5 mg.h/L; P=0.03), and was comparable to historical controls.",Pharmacokinetic interaction between chemotherapy for non-Hodgkin's lymphoma and protease inhibitors in HIV-1-infected patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15728147/),[h·mg] / [l],14.9,227143,DB00860,Prednisolone
,15728147,IC(50),"Likewise, we observed a significant number of patients with C(0) and C(8) below the IC(50) for the wild-type virus (0.1 mg/L) when the drug was administered without CHOP.",Pharmacokinetic interaction between chemotherapy for non-Hodgkin's lymphoma and protease inhibitors in HIV-1-infected patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15728147/),[mg] / [l],0.1,227144,DB00860,Prednisolone
,15355126,systemic availability,A low systemic availability of 9-21% indicates extensive first-pass elimination.,Pharmacokinetics of budesonide (Entocort EC) capsules for Crohn's disease. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15355126/),%,9-21,227652,DB00860,Prednisolone
,10533695,plasma clearance,Mean Pred plasma clearance was 0.655 L/hr (interrat++ variability: 11%) and significantly increased with weight.,Pharmacokinetic and pharmacoimmunodynamic interactions between prednisolone and sirolimus in adrenalectomized rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10533695/),[l] / [h],0.655,227701,DB00860,Prednisolone
,10533695,whole blood volume of distribution,"Mean SIR whole blood volume of distribution and clearance were 5.6 L (62%) and 0.28 L/hr (32%), and animal scaling showed weight-power proportionality.",Pharmacokinetic and pharmacoimmunodynamic interactions between prednisolone and sirolimus in adrenalectomized rats. ,Vb-Q62,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10533695/),l,5.6,227702,DB00860,Prednisolone
,10533695,clearance,"Mean SIR whole blood volume of distribution and clearance were 5.6 L (62%) and 0.28 L/hr (32%), and animal scaling showed weight-power proportionality.",Pharmacokinetic and pharmacoimmunodynamic interactions between prednisolone and sirolimus in adrenalectomized rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10533695/),[l] / [h],0.28,227703,DB00860,Prednisolone
,10533695,IC50,Pred decreased numbers of T-helper lymphocytes with a mean IC50 of 37.8 nM (21%) alone or 12.3 nM (130%) with SIR.,Pharmacokinetic and pharmacoimmunodynamic interactions between prednisolone and sirolimus in adrenalectomized rats. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10533695/),nM,37.8,227704,DB00860,Prednisolone
,10533695,IC50,Pred decreased numbers of T-helper lymphocytes with a mean IC50 of 37.8 nM (21%) alone or 12.3 nM (130%) with SIR.,Pharmacokinetic and pharmacoimmunodynamic interactions between prednisolone and sirolimus in adrenalectomized rats. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10533695/),nM,12.3,227705,DB00860,Prednisolone
,10533695,IC50,SIR increased lymphocyte numbers with a mean IC50 of 52.2 nM (24%) for T-helper and 28.8 nM (51%) for T-cytotoxic cells.,Pharmacokinetic and pharmacoimmunodynamic interactions between prednisolone and sirolimus in adrenalectomized rats. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10533695/),nM,52.2,227706,DB00860,Prednisolone
,10533695,IC50,SIR increased lymphocyte numbers with a mean IC50 of 52.2 nM (24%) for T-helper and 28.8 nM (51%) for T-cytotoxic cells.,Pharmacokinetic and pharmacoimmunodynamic interactions between prednisolone and sirolimus in adrenalectomized rats. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10533695/),nM,28.8,227707,DB00860,Prednisolone
,10533695,IC50,"Taking into account drug effects on lymphocyte trafficking, Pred directly inhibited ex vivo lymphocyte proliferation with a mean IC50 of 1.08 nM (38%).",Pharmacokinetic and pharmacoimmunodynamic interactions between prednisolone and sirolimus in adrenalectomized rats. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10533695/),nM,1.08,227708,DB00860,Prednisolone
,10533695,IC50,"SIR, after a transduction step, inhibited proliferation with a mean IC50 of 1.00 nM (26%).",Pharmacokinetic and pharmacoimmunodynamic interactions between prednisolone and sirolimus in adrenalectomized rats. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10533695/),nM,1.00,227709,DB00860,Prednisolone
,3311551,AUC ratio,"This cortisol AUC ratio was reduced from 0.45 (methylprednisolone) to 0.39 (methylprednisolone plus ketoconazole), suggesting that ketoconazole modestly enhanced (P less than 0.01) cortisol suppression.",Ketoconazole effects on methylprednisolone disposition and their joint suppression of endogenous cortisol. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3311551/),,0.45,229623,DB00860,Prednisolone
,3311551,AUC ratio,"This cortisol AUC ratio was reduced from 0.45 (methylprednisolone) to 0.39 (methylprednisolone plus ketoconazole), suggesting that ketoconazole modestly enhanced (P less than 0.01) cortisol suppression.",Ketoconazole effects on methylprednisolone disposition and their joint suppression of endogenous cortisol. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3311551/),,0.39,229624,DB00860,Prednisolone
,3189959,Clearance,"Clearance after administration of steroids in the former was 43 +/- 7 mL/kg/h (SD) and after placebo 42 +/- 10, mL/kg/h.",Acute dosing with methylprednisolone in normal subjects does not affect theophylline clearance. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3189959/),[ml] / [h·kg],43,229967,DB00860,Prednisolone
,3189959,Clearance,"Clearance after administration of steroids in the former was 43 +/- 7 mL/kg/h (SD) and after placebo 42 +/- 10, mL/kg/h.",Acute dosing with methylprednisolone in normal subjects does not affect theophylline clearance. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3189959/),[ml] / [h·kg],42,229968,DB00860,Prednisolone
,2713960,elimination half-life,"For total prednisolone, the mean elimination half-life was relatively short (1.37 h) and the total clearance, relatively high (15.1 ml min-1 kg-1).",Pharmacokinetics of prednisolone in children with acute lymphoblastic leukaemia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2713960/),h,1.37,230108,DB00860,Prednisolone
,2713960,total clearance,"For total prednisolone, the mean elimination half-life was relatively short (1.37 h) and the total clearance, relatively high (15.1 ml min-1 kg-1).",Pharmacokinetics of prednisolone in children with acute lymphoblastic leukaemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2713960/),[ml] / [kg·min],15.1,230109,DB00860,Prednisolone
,2713960,free fraction,The mean free fraction was high (0.37).,Pharmacokinetics of prednisolone in children with acute lymphoblastic leukaemia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2713960/),,0.37,230110,DB00860,Prednisolone
,7881703,AUCi.v.,"The geometric means of AUCi.v. and AUCtablet were 4,049 and 3,334 ng.h/ml, respectively.",Absolute bioavailability of a new high dose methylprednisolone tablet formulation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7881703/),[h·ng] / [ml],"4,049",230547,DB00860,Prednisolone
,7881703,AUCtablet,"The geometric means of AUCi.v. and AUCtablet were 4,049 and 3,334 ng.h/ml, respectively.",Absolute bioavailability of a new high dose methylprednisolone tablet formulation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7881703/),[h·ng] / [ml],"3,334",230548,DB00860,Prednisolone
,7881703,absolute bioavailability,"The absolute bioavailability of the tablet product was 82%, which is in agreement with published data for other oral dosage forms of methylprednisolone.",Absolute bioavailability of a new high dose methylprednisolone tablet formulation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7881703/),%,82,230549,DB00860,Prednisolone
,6507464,bioavailability,Assessment of methylprednisolone disposition following oral and intravenous doses revealed no effect of cimetidine on the bioavailability (74 to 81 percent absorption) or plasma clearance (22 to 24 liters per hour) of the steroid.,Cimetidine-methylprednisolone-theophylline metabolic interaction. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6507464/),%,74 to 81,233352,DB00860,Prednisolone
,6507464,plasma clearance,Assessment of methylprednisolone disposition following oral and intravenous doses revealed no effect of cimetidine on the bioavailability (74 to 81 percent absorption) or plasma clearance (22 to 24 liters per hour) of the steroid.,Cimetidine-methylprednisolone-theophylline metabolic interaction. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6507464/),[l] / [h],22 to 24,233353,DB00860,Prednisolone
,3234253,Oral bioavailability,"Oral bioavailability was essentially 100 percent, ruling out impaired absorption.",Rapid methylprednisolone clearance in a patient with cystic fibrosis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3234253/),%,100,234170,DB00860,Prednisolone
,1340442,half-life,"After intravenous infusion, methylprednisolone hemisuccinate was rapidly converted to methylprednisolone with a half-life of about 20 min.",Pharmacokinetics of high-dose methylprednisolone in children. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1340442/),min,20,234275,DB00860,Prednisolone
,1340442,mean residence time,"Methylprednisolone in serum, eliminated monoexponentially in 8 patients and biexponentially in the remaining three, had the mean residence time of about 3 h, and a terminal half-life of 2.5 h.",Pharmacokinetics of high-dose methylprednisolone in children. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1340442/),h,3,234276,DB00860,Prednisolone
,1340442,terminal half-life,"Methylprednisolone in serum, eliminated monoexponentially in 8 patients and biexponentially in the remaining three, had the mean residence time of about 3 h, and a terminal half-life of 2.5 h.",Pharmacokinetics of high-dose methylprednisolone in children. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1340442/),h,2.5,234277,DB00860,Prednisolone
,1340442,volume of distribution at steady state,"The volume of distribution at steady state, and the clearance were 1.3 liters/kg and 0.5 liters/kg/h, respectively.",Pharmacokinetics of high-dose methylprednisolone in children. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1340442/),[l] / [kg],1.3,234278,DB00860,Prednisolone
,1340442,clearance,"The volume of distribution at steady state, and the clearance were 1.3 liters/kg and 0.5 liters/kg/h, respectively.",Pharmacokinetics of high-dose methylprednisolone in children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1340442/),[l] / [h·kg],0.5,234279,DB00860,Prednisolone
,3426108,half time of absorption,Analysis of absorption revealed that a first fraction of the dose (about 20%) was rapidly absorbed with an half time of absorption of 1.76 +/- 0.725 h; the second fraction (about 80% of the dose) was absorbed more slowly with an half time of absorption of 12.3 +/- 3.16 h.,[Pharmacokinetics of prednisolone administered to cows in the form of a prednisolone acetate solution in dimethyl sulfoxide in association with antibiotics]. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3426108/),h,1.76,238649,DB00860,Prednisolone
,3426108,half time of absorption,Analysis of absorption revealed that a first fraction of the dose (about 20%) was rapidly absorbed with an half time of absorption of 1.76 +/- 0.725 h; the second fraction (about 80% of the dose) was absorbed more slowly with an half time of absorption of 12.3 +/- 3.16 h.,[Pharmacokinetics of prednisolone administered to cows in the form of a prednisolone acetate solution in dimethyl sulfoxide in association with antibiotics]. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3426108/),h,12.3,238650,DB00860,Prednisolone
,10517356,flow-rate,The flow-rate was 1.5 ml/min and UV detection was achieved at 248 nm.,"High-performance liquid chromatography analysis, preliminary pharmacokinetics, metabolism and renal excretion of methylprednisolone with its C6 and C20 hydroxy metabolites in multiple sclerosis patients receiving high-dose pulse therapy. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10517356/),[ml] / [min],1.5,238744,DB00860,Prednisolone
,10517356,half-life,"The half-life of prodrug methylprednisolone-21-hemisuccinate (MPS) was 0.3 h, that of metabolite MPX (21-carboxy MP) was 0.4 h and that of the parent drug methylprednisolone (MP) was 1.4 h.","High-performance liquid chromatography analysis, preliminary pharmacokinetics, metabolism and renal excretion of methylprednisolone with its C6 and C20 hydroxy metabolites in multiple sclerosis patients receiving high-dose pulse therapy. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10517356/),h,0.3,238745,DB00860,Prednisolone
,10517356,half-life,"The half-life of prodrug methylprednisolone-21-hemisuccinate (MPS) was 0.3 h, that of metabolite MPX (21-carboxy MP) was 0.4 h and that of the parent drug methylprednisolone (MP) was 1.4 h.","High-performance liquid chromatography analysis, preliminary pharmacokinetics, metabolism and renal excretion of methylprednisolone with its C6 and C20 hydroxy metabolites in multiple sclerosis patients receiving high-dose pulse therapy. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10517356/),h,0.4,238746,DB00860,Prednisolone
,10517356,half-life,"The half-life of prodrug methylprednisolone-21-hemisuccinate (MPS) was 0.3 h, that of metabolite MPX (21-carboxy MP) was 0.4 h and that of the parent drug methylprednisolone (MP) was 1.4 h.","High-performance liquid chromatography analysis, preliminary pharmacokinetics, metabolism and renal excretion of methylprednisolone with its C6 and C20 hydroxy metabolites in multiple sclerosis patients receiving high-dose pulse therapy. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10517356/),h,1.4,238747,DB00860,Prednisolone
,10517356,half-lives,The half-lives of the metabolites are almost similar (4 h).,"High-performance liquid chromatography analysis, preliminary pharmacokinetics, metabolism and renal excretion of methylprednisolone with its C6 and C20 hydroxy metabolites in multiple sclerosis patients receiving high-dose pulse therapy. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10517356/),h,4,238748,DB00860,Prednisolone
,10517356,renal clearance,"The renal clearance values of metabolites MPB, MPC and MPD are approximately 500 ml/min, that of MP is 100 ml/min.","High-performance liquid chromatography analysis, preliminary pharmacokinetics, metabolism and renal excretion of methylprednisolone with its C6 and C20 hydroxy metabolites in multiple sclerosis patients receiving high-dose pulse therapy. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10517356/),[ml] / [min],500,238749,DB00860,Prednisolone
,10517356,renal clearance,"The renal clearance values of metabolites MPB, MPC and MPD are approximately 500 ml/min, that of MP is 100 ml/min.","High-performance liquid chromatography analysis, preliminary pharmacokinetics, metabolism and renal excretion of methylprednisolone with its C6 and C20 hydroxy metabolites in multiple sclerosis patients receiving high-dose pulse therapy. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10517356/),[ml] / [min],100,238750,DB00860,Prednisolone
,25556984,IC50,"This strategy, coupled with in silico modelling analysis, allowed for the identification of Cpd #15, an isoxazoline showing a sub-nanomolar inhibitory potency (IC50=0.84 nM) against TNFα-evoked IL-8 release in primary human airways smooth muscle cells.",Discovery of a novel isoxazoline derivative of prednisolone endowed with a robust anti-inflammatory profile and suitable for topical pulmonary administration. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25556984/),nM,0.84,239539,DB00860,Prednisolone
,25556984,IC50,"In Raw264.7 mouse macrophages, Cpd #15 inhibited LPS-induced NO release with a potency (IC50=6 nM)>10-fold higher with respect to Dexamethasone.",Discovery of a novel isoxazoline derivative of prednisolone endowed with a robust anti-inflammatory profile and suitable for topical pulmonary administration. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25556984/),nM,6,239540,DB00860,Prednisolone
,25556984,lung retention (t1/2,"Moreover, Cpd #15 proved to be suitable for pulmonary topical administration given its sustained lung retention (t1/2=6.5h) and high pulmonary levels (>100-fold higher than plasma levels) upon intratracheal administration in rats.",Discovery of a novel isoxazoline derivative of prednisolone endowed with a robust anti-inflammatory profile and suitable for topical pulmonary administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25556984/),h,6.5,239541,DB00860,Prednisolone
,7120877,peak serum levels,"After 5, 7.5 and 10 mg prednisone peak serum levels averaged 11.9 +/- 2.2, 15.9+/-3.4 and 21.5+/-5.9 microgram/dl, respectively.",[Pharmacokinetics of prednisolone in adrenal insufficiency ]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7120877/),[μg] / [dl],11.9,239579,DB00860,Prednisolone
,7120877,peak serum levels,"After 5, 7.5 and 10 mg prednisone peak serum levels averaged 11.9 +/- 2.2, 15.9+/-3.4 and 21.5+/-5.9 microgram/dl, respectively.",[Pharmacokinetics of prednisolone in adrenal insufficiency ]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7120877/),[μg] / [dl],15.9,239580,DB00860,Prednisolone
,7120877,peak serum levels,"After 5, 7.5 and 10 mg prednisone peak serum levels averaged 11.9 +/- 2.2, 15.9+/-3.4 and 21.5+/-5.9 microgram/dl, respectively.",[Pharmacokinetics of prednisolone in adrenal insufficiency ]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7120877/),[μg] / [dl],21.5,239581,DB00860,Prednisolone
,7120877,plasma half-time,The plasma half-time of approximately 5 1/2 h suggests that prednisolone is present in serum far about 2 days after application of higher doses.,[Pharmacokinetics of prednisolone in adrenal insufficiency ]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7120877/),h,5 1/2,239582,DB00860,Prednisolone
,7120877,metabolic clearance rate,The metabolic clearance rate of prednisolone was decreased (56.0+/-7.2 1/24 h/m2) in patients with adrenal insufficiency.,[Pharmacokinetics of prednisolone in adrenal insufficiency ]. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7120877/),[1] / [24·h·m2],56.0,239583,DB00860,Prednisolone
,3485989,steady state plasma concentration,"The mean steady state plasma concentration (+/- s.e. mean) of salicylate decreased significantly after intra-articular steroid (90.9 +/- 14.8 mg l-1-64.7 +/- 8.9, P less than 0.05), whilst the mean clearance increased significantly (87.3 +/- 20.6 ml min-1-120.6 +/- 28.3, P less than 0.05).",The effect of intra-articular steroids on plasma salicylate concentrations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3485989/),[mg] / [l],90.9,239639,DB00860,Prednisolone
,3485989,steady state plasma concentration,"The mean steady state plasma concentration (+/- s.e. mean) of salicylate decreased significantly after intra-articular steroid (90.9 +/- 14.8 mg l-1-64.7 +/- 8.9, P less than 0.05), whilst the mean clearance increased significantly (87.3 +/- 20.6 ml min-1-120.6 +/- 28.3, P less than 0.05).",The effect of intra-articular steroids on plasma salicylate concentrations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3485989/),[mg] / [l],64.7,239640,DB00860,Prednisolone
,3485989,clearance,"The mean steady state plasma concentration (+/- s.e. mean) of salicylate decreased significantly after intra-articular steroid (90.9 +/- 14.8 mg l-1-64.7 +/- 8.9, P less than 0.05), whilst the mean clearance increased significantly (87.3 +/- 20.6 ml min-1-120.6 +/- 28.3, P less than 0.05).",The effect of intra-articular steroids on plasma salicylate concentrations. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3485989/),[ml] / [min],87.3,239641,DB00860,Prednisolone
,3485989,clearance,"The mean steady state plasma concentration (+/- s.e. mean) of salicylate decreased significantly after intra-articular steroid (90.9 +/- 14.8 mg l-1-64.7 +/- 8.9, P less than 0.05), whilst the mean clearance increased significantly (87.3 +/- 20.6 ml min-1-120.6 +/- 28.3, P less than 0.05).",The effect of intra-articular steroids on plasma salicylate concentrations. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3485989/),,120.6,239642,DB00860,Prednisolone
,6702820,association constants,"Compared to normal volunteers, nephrotic patients had significantly higher mean (+/- SD) association constants for the albumin-prednisolone complex (4.20 +/- 2.10 X 10(3) M-1 v 2.26 +/- 0.46 X 10(3) M-1, P less than 0.005) and tended to have higher association constants for the transcortin-prednisolone complex.",Altered plasma protein-binding of prednisolone in patients with the nephrotic syndrome. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6702820/),1/[M],4.20,240771,DB00860,Prednisolone
,6702820,association constants,"Compared to normal volunteers, nephrotic patients had significantly higher mean (+/- SD) association constants for the albumin-prednisolone complex (4.20 +/- 2.10 X 10(3) M-1 v 2.26 +/- 0.46 X 10(3) M-1, P less than 0.005) and tended to have higher association constants for the transcortin-prednisolone complex.",Altered plasma protein-binding of prednisolone in patients with the nephrotic syndrome. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6702820/),1/[M],2.26,240772,DB00860,Prednisolone
,6702820,nonrenal clearance rate,"When calculated with reference to total prednisolone concentrations in plasma, the mean nonrenal clearance rate, but not the mean renal clearance rate, was higher in the nephrotic patients than in the controls (2.63 +/- 0.61 mL/min/kg v 1.85 +/- 0.33 mL/min/kg, P less than 0.005).",Altered plasma protein-binding of prednisolone in patients with the nephrotic syndrome. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6702820/),[ml] / [kg·min],2.63,240773,DB00860,Prednisolone
,6702820,renal clearance rate,"When calculated with reference to total prednisolone concentrations in plasma, the mean nonrenal clearance rate, but not the mean renal clearance rate, was higher in the nephrotic patients than in the controls (2.63 +/- 0.61 mL/min/kg v 1.85 +/- 0.33 mL/min/kg, P less than 0.005).",Altered plasma protein-binding of prednisolone in patients with the nephrotic syndrome. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6702820/),[ml] / [kg·min],1.85,240774,DB00860,Prednisolone
,6702820,renal clearance rates,"Compared to normal volunteers, patients with the nephrotic syndrome had lower renal clearance rates of unbound prednisolone when prednisolone was given intravenously (1.58 +/- 0.88 mL/min/kg v 2.89 +/- 0.89 mL/min/kg, P less than 0.005) or when prednisone was given orally (1.18 +/- 0.86 mL/min/kg v 2.80 +/- 1.13 mL/min/kg, P less than 0.005).",Altered plasma protein-binding of prednisolone in patients with the nephrotic syndrome. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6702820/),[ml] / [kg·min],1.58,240775,DB00860,Prednisolone
,6702820,renal clearance rates,"Compared to normal volunteers, patients with the nephrotic syndrome had lower renal clearance rates of unbound prednisolone when prednisolone was given intravenously (1.58 +/- 0.88 mL/min/kg v 2.89 +/- 0.89 mL/min/kg, P less than 0.005) or when prednisone was given orally (1.18 +/- 0.86 mL/min/kg v 2.80 +/- 1.13 mL/min/kg, P less than 0.005).",Altered plasma protein-binding of prednisolone in patients with the nephrotic syndrome. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6702820/),[ml] / [kg·min],2.89,240776,DB00860,Prednisolone
,6702820,renal clearance rates,"Compared to normal volunteers, patients with the nephrotic syndrome had lower renal clearance rates of unbound prednisolone when prednisolone was given intravenously (1.58 +/- 0.88 mL/min/kg v 2.89 +/- 0.89 mL/min/kg, P less than 0.005) or when prednisone was given orally (1.18 +/- 0.86 mL/min/kg v 2.80 +/- 1.13 mL/min/kg, P less than 0.005).",Altered plasma protein-binding of prednisolone in patients with the nephrotic syndrome. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6702820/),[ml] / [kg·min],1.18,240777,DB00860,Prednisolone
,6702820,renal clearance rates,"Compared to normal volunteers, patients with the nephrotic syndrome had lower renal clearance rates of unbound prednisolone when prednisolone was given intravenously (1.58 +/- 0.88 mL/min/kg v 2.89 +/- 0.89 mL/min/kg, P less than 0.005) or when prednisone was given orally (1.18 +/- 0.86 mL/min/kg v 2.80 +/- 1.13 mL/min/kg, P less than 0.005).",Altered plasma protein-binding of prednisolone in patients with the nephrotic syndrome. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6702820/),[ml] / [kg·min],2.80,240778,DB00860,Prednisolone
,3799579,time of peak concentration,No significant differences were noted in any of the treatment phases for any of the parameters except for the time of peak concentration which was slightly delayed from 1.0 +/- 0.6 to 1.7 +/- 0.9 h when sucralfate was concomitantly administered with the prednisone.,Lack of effect of sucralfate on prednisone bioavailability. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3799579/),h,1.0,241300,DB00860,Prednisolone
,3799579,time of peak concentration,No significant differences were noted in any of the treatment phases for any of the parameters except for the time of peak concentration which was slightly delayed from 1.0 +/- 0.6 to 1.7 +/- 0.9 h when sucralfate was concomitantly administered with the prednisone.,Lack of effect of sucralfate on prednisone bioavailability. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3799579/),h,1.7,241301,DB00860,Prednisolone
,15487809,concentration,"At steady state, the average measured MP concentration in plasma was 12.3+/-7.0 microg/ml and 1.74+/-0.85 microg/ml in CSF.",Population pharmacokinetics of methylprednisolone in accident victims with spinal cord injury. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15487809/),[μg] / [ml],12.3,241566,DB00860,Prednisolone
,15487809,concentration,"At steady state, the average measured MP concentration in plasma was 12.3+/-7.0 microg/ml and 1.74+/-0.85 microg/ml in CSF.",Population pharmacokinetics of methylprednisolone in accident victims with spinal cord injury. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15487809/),[μg] / [ml],1.74,241567,DB00860,Prednisolone
,6237151,AUIC,"After i.v. prednisolone phthalate or oral prednisone, the mean AUC of unbound prednisolone were 45 and 61% of that obtained after i.v. prednisolone phosphate, and the corresponding AUIC were 76 and 68%, respectively, indicating lower systemic availability of prednisolone and less of an immunosuppressive effect in plasma after i.v. prednisolone phthalate or oral prednisone than after i.v. prednisolone phosphate.",Pharmacokinetics and pharmacodynamics of three different prednisolone prodrugs: effect on circulating lymphocyte subsets and function. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6237151/),%,76,241744,DB00860,Prednisolone
,6237151,AUIC,"After i.v. prednisolone phthalate or oral prednisone, the mean AUC of unbound prednisolone were 45 and 61% of that obtained after i.v. prednisolone phosphate, and the corresponding AUIC were 76 and 68%, respectively, indicating lower systemic availability of prednisolone and less of an immunosuppressive effect in plasma after i.v. prednisolone phthalate or oral prednisone than after i.v. prednisolone phosphate.",Pharmacokinetics and pharmacodynamics of three different prednisolone prodrugs: effect on circulating lymphocyte subsets and function. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6237151/),%,68,241745,DB00860,Prednisolone
,6237151,maximal,"After steroid doses corresponding to 1 mg/kg of prednisolone, a transient inhibition of 80% of IL 2 production was observed with all three glucocorticoids given, whereas the maximal inhibition of the IL 2 production was 60, 30, and 22% after a low dose (0.1 mg/kg) of prednisolone phosphate, prednisone, or prednisolone phthalate, respectively.",Pharmacokinetics and pharmacodynamics of three different prednisolone prodrugs: effect on circulating lymphocyte subsets and function. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6237151/),,60,241746,DB00860,Prednisolone
,6237151,maximal,"After steroid doses corresponding to 1 mg/kg of prednisolone, a transient inhibition of 80% of IL 2 production was observed with all three glucocorticoids given, whereas the maximal inhibition of the IL 2 production was 60, 30, and 22% after a low dose (0.1 mg/kg) of prednisolone phosphate, prednisone, or prednisolone phthalate, respectively.",Pharmacokinetics and pharmacodynamics of three different prednisolone prodrugs: effect on circulating lymphocyte subsets and function. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6237151/),,30,241747,DB00860,Prednisolone
,6237151,maximal,"After steroid doses corresponding to 1 mg/kg of prednisolone, a transient inhibition of 80% of IL 2 production was observed with all three glucocorticoids given, whereas the maximal inhibition of the IL 2 production was 60, 30, and 22% after a low dose (0.1 mg/kg) of prednisolone phosphate, prednisone, or prednisolone phthalate, respectively.",Pharmacokinetics and pharmacodynamics of three different prednisolone prodrugs: effect on circulating lymphocyte subsets and function. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6237151/),,22,241748,DB00860,Prednisolone
,10758783,AUC0-infinity,Values of 342.53 ng.h/ml (test preparation) and 336.61 ng.h/ml (reference preparation) for the parameter AUC0-infinity demonstrate an nearly identical extent of drug absorption.,Bioavailability investigation of two different oral formulations of methylprednisolone. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10758783/),[h·ng] / [ml],342.53,243124,DB00860,Prednisolone
,10758783,AUC0-infinity,Values of 342.53 ng.h/ml (test preparation) and 336.61 ng.h/ml (reference preparation) for the parameter AUC0-infinity demonstrate an nearly identical extent of drug absorption.,Bioavailability investigation of two different oral formulations of methylprednisolone. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10758783/),[h·ng] / [ml],336.61,243125,DB00860,Prednisolone
,10758783,Maximum concentrations (Cmax),Maximum concentrations (Cmax) of 66.58 ng/ml and 70.51 ng/ml were achieved for test and reference preparation.,Bioavailability investigation of two different oral formulations of methylprednisolone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10758783/),[ng] / [ml],66.58,243126,DB00860,Prednisolone
,10758783,Maximum concentrations (Cmax),Maximum concentrations (Cmax) of 66.58 ng/ml and 70.51 ng/ml were achieved for test and reference preparation.,Bioavailability investigation of two different oral formulations of methylprednisolone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10758783/),[ng] / [ml],70.51,243127,DB00860,Prednisolone
,10758783,Time to reach maximum plasma concentration (tmax),Time to reach maximum plasma concentration (tmax) was 2.2 h for both preparations.,Bioavailability investigation of two different oral formulations of methylprednisolone. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10758783/),h,2.2,243128,DB00860,Prednisolone
,7886801,clearance,"In the black patients, the mean clearance of methylprednisolone (206 +/- 70 ml/hr/kg) was significantly slower with a smaller volume of distribution (0.95 +/- 0.32 L/kg) when compared with the white group (327 +/- 129 ml/hr/kg, P = 0.03; volume of distribution = 1.33 +/- 0.27 L/kg, P = 0.015).","Methylprednisolone pharmacokinetics, cortisol response, and adverse effects in black and white renal transplant recipients. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7886801/),[ml] / [h·kg],206,243352,DB00860,Prednisolone
,7886801,volume of distribution,"In the black patients, the mean clearance of methylprednisolone (206 +/- 70 ml/hr/kg) was significantly slower with a smaller volume of distribution (0.95 +/- 0.32 L/kg) when compared with the white group (327 +/- 129 ml/hr/kg, P = 0.03; volume of distribution = 1.33 +/- 0.27 L/kg, P = 0.015).","Methylprednisolone pharmacokinetics, cortisol response, and adverse effects in black and white renal transplant recipients. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7886801/),[l] / [kg],0.95,243353,DB00860,Prednisolone
,7886801,volume of distribution,"In the black patients, the mean clearance of methylprednisolone (206 +/- 70 ml/hr/kg) was significantly slower with a smaller volume of distribution (0.95 +/- 0.32 L/kg) when compared with the white group (327 +/- 129 ml/hr/kg, P = 0.03; volume of distribution = 1.33 +/- 0.27 L/kg, P = 0.015).","Methylprednisolone pharmacokinetics, cortisol response, and adverse effects in black and white renal transplant recipients. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7886801/),[ml] / [h·kg],327,243354,DB00860,Prednisolone
,7886801,volume of distribution,"In the black patients, the mean clearance of methylprednisolone (206 +/- 70 ml/hr/kg) was significantly slower with a smaller volume of distribution (0.95 +/- 0.32 L/kg) when compared with the white group (327 +/- 129 ml/hr/kg, P = 0.03; volume of distribution = 1.33 +/- 0.27 L/kg, P = 0.015).","Methylprednisolone pharmacokinetics, cortisol response, and adverse effects in black and white renal transplant recipients. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7886801/),[l] / [kg],1.33,243355,DB00860,Prednisolone
,7886801,total cortisol,"Despite chronic methylprednisolone therapy, a definite 24-hr cortisol response pattern was noted in 15 of the 18 patients with a mean total cortisol AUC of 732 +/- 443 ng.hr/ml in blacks and 539 +/- 361 ng.hr/ml in whites (P = 0.17, black vs. white).","Methylprednisolone pharmacokinetics, cortisol response, and adverse effects in black and white renal transplant recipients. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7886801/),[h·ng] / [ml],732,243356,DB00860,Prednisolone
,7886801,AUC,"Despite chronic methylprednisolone therapy, a definite 24-hr cortisol response pattern was noted in 15 of the 18 patients with a mean total cortisol AUC of 732 +/- 443 ng.hr/ml in blacks and 539 +/- 361 ng.hr/ml in whites (P = 0.17, black vs. white).","Methylprednisolone pharmacokinetics, cortisol response, and adverse effects in black and white renal transplant recipients. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7886801/),[h·ng] / [ml],732,243357,DB00860,Prednisolone
,7886801,AUC,"Despite chronic methylprednisolone therapy, a definite 24-hr cortisol response pattern was noted in 15 of the 18 patients with a mean total cortisol AUC of 732 +/- 443 ng.hr/ml in blacks and 539 +/- 361 ng.hr/ml in whites (P = 0.17, black vs. white).","Methylprednisolone pharmacokinetics, cortisol response, and adverse effects in black and white renal transplant recipients. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7886801/),[h·ng] / [ml],539,243358,DB00860,Prednisolone
,7886801,suppression half-life,The mean cortisol suppression half-life was 4.31 +/- 1.54 hr in black recipients and 4.11 +/- 1.49 hr in whites (P = 0.48).,"Methylprednisolone pharmacokinetics, cortisol response, and adverse effects in black and white renal transplant recipients. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7886801/),h,4.31,243359,DB00860,Prednisolone
,7886801,suppression half-life,The mean cortisol suppression half-life was 4.31 +/- 1.54 hr in black recipients and 4.11 +/- 1.49 hr in whites (P = 0.48).,"Methylprednisolone pharmacokinetics, cortisol response, and adverse effects in black and white renal transplant recipients. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7886801/),h,4.11,243360,DB00860,Prednisolone
,7886801,AUC,The mean return cortisol AUC for the black patients was 327 +/- 279 ng.hr/ml and 370 +/- 207 ng.hr/ml for white patients (P = 0.28).,"Methylprednisolone pharmacokinetics, cortisol response, and adverse effects in black and white renal transplant recipients. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7886801/),[h·ng] / [ml],327,243361,DB00860,Prednisolone
,7886801,AUC,The mean return cortisol AUC for the black patients was 327 +/- 279 ng.hr/ml and 370 +/- 207 ng.hr/ml for white patients (P = 0.28).,"Methylprednisolone pharmacokinetics, cortisol response, and adverse effects in black and white renal transplant recipients. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7886801/),[h·ng] / [ml],370,243362,DB00860,Prednisolone
,7886801,nadir,"The serum cortisol nadir for black patients was 12.3 +/- 7.2 ng/ml, which was significantly higher than the cortisol nadir in white patients (6.4 +/- 4.4 ng/ml; P = 0.03).","Methylprednisolone pharmacokinetics, cortisol response, and adverse effects in black and white renal transplant recipients. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7886801/),[ng] / [ml],12.3,243363,DB00860,Prednisolone
,7886801,nadir,"The serum cortisol nadir for black patients was 12.3 +/- 7.2 ng/ml, which was significantly higher than the cortisol nadir in white patients (6.4 +/- 4.4 ng/ml; P = 0.03).","Methylprednisolone pharmacokinetics, cortisol response, and adverse effects in black and white renal transplant recipients. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7886801/),[ng] / [ml],6.4,243364,DB00860,Prednisolone
,11765593,Maximum concentrations (Cmax),"Maximum concentrations (Cmax) of 1020.9 +/- 57.8 and 1053.3 +/- 55.7 ng/ml were achieved for the test and the reference preparation, respectively.",Pharmacokinetics of two oral prednisolone tablet formulations in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11765593/),[ng] / [ml],1020.9,244129,DB00860,Prednisolone
,11765593,Maximum concentrations (Cmax),"Maximum concentrations (Cmax) of 1020.9 +/- 57.8 and 1053.3 +/- 55.7 ng/ml were achieved for the test and the reference preparation, respectively.",Pharmacokinetics of two oral prednisolone tablet formulations in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11765593/),[ng] / [ml],1053.3,244130,DB00860,Prednisolone
,11765593,AUC0-infinity,The AUC0-infinity was 212.2 +/- 13.2 micrograms.min/ml (test preparation) and 222.2 +/- 14.3 micrograms.min/ml (reference preparation).,Pharmacokinetics of two oral prednisolone tablet formulations in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11765593/),[min·μg] / [ml],212.2,244131,DB00860,Prednisolone
,11765593,AUC0-infinity,The AUC0-infinity was 212.2 +/- 13.2 micrograms.min/ml (test preparation) and 222.2 +/- 14.3 micrograms.min/ml (reference preparation).,Pharmacokinetics of two oral prednisolone tablet formulations in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11765593/),[min·μg] / [ml],222.2,244132,DB00860,Prednisolone
,11765593,time to reach maximum plasma concentration (tmax),The time to reach maximum plasma concentration (tmax) tended to be lower (-25%) in the test (39.6 +/- 6.4 min) as compared to the reference preparation (52.8 +/- 9.0 min).,Pharmacokinetics of two oral prednisolone tablet formulations in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11765593/),min,39.6,244133,DB00860,Prednisolone
,11765593,time to reach maximum plasma concentration (tmax),The time to reach maximum plasma concentration (tmax) tended to be lower (-25%) in the test (39.6 +/- 6.4 min) as compared to the reference preparation (52.8 +/- 9.0 min).,Pharmacokinetics of two oral prednisolone tablet formulations in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11765593/),min,52.8,244134,DB00860,Prednisolone
,18240180,AUC,There was a trend toward significance in difference in mean AUC of IVMP (116.72 microg x ml/hour) compared with OP (65.16 microg x ml/hour; P = 0.059).,Pharmacokinetic study of oral prednisolone compared with intravenous methylprednisolone in patients with juvenile dermatomyositis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18240180/),[ml·μg] / [h],116.72,244401,DB00860,Prednisolone
,18240180,AUC,There was a trend toward significance in difference in mean AUC of IVMP (116.72 microg x ml/hour) compared with OP (65.16 microg x ml/hour; P = 0.059).,Pharmacokinetic study of oral prednisolone compared with intravenous methylprednisolone in patients with juvenile dermatomyositis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18240180/),[ml·μg] / [h],65.16,244402,DB00860,Prednisolone
,18240180,peak concentration,Mean peak concentration was higher for IVMP (34.49 microg/ml) than OP (7.08 microg/ml); mean half-life was shorter for IVMP (1.90 hours) than OP (2.36 hours).,Pharmacokinetic study of oral prednisolone compared with intravenous methylprednisolone in patients with juvenile dermatomyositis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18240180/),[μg] / [ml],34.49,244403,DB00860,Prednisolone
,18240180,peak concentration,Mean peak concentration was higher for IVMP (34.49 microg/ml) than OP (7.08 microg/ml); mean half-life was shorter for IVMP (1.90 hours) than OP (2.36 hours).,Pharmacokinetic study of oral prednisolone compared with intravenous methylprednisolone in patients with juvenile dermatomyositis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18240180/),[μg] / [ml],7.08,244404,DB00860,Prednisolone
,18240180,half-life,Mean peak concentration was higher for IVMP (34.49 microg/ml) than OP (7.08 microg/ml); mean half-life was shorter for IVMP (1.90 hours) than OP (2.36 hours).,Pharmacokinetic study of oral prednisolone compared with intravenous methylprednisolone in patients with juvenile dermatomyositis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18240180/),h,1.90,244405,DB00860,Prednisolone
,18240180,half-life,Mean peak concentration was higher for IVMP (34.49 microg/ml) than OP (7.08 microg/ml); mean half-life was shorter for IVMP (1.90 hours) than OP (2.36 hours).,Pharmacokinetic study of oral prednisolone compared with intravenous methylprednisolone in patients with juvenile dermatomyositis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18240180/),h,2.36,244406,DB00860,Prednisolone
,7628493,plasma/CSF ratio,Passage of MP into the CSF was delayed since mean plasma/CSF ratio dropped dramatically from 150 at the 2nd h to 25 at the 3rd h after starting infusion.,Methylprednisolone infusion during acute exacerbation of MS: plasma and CSF concentrations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7628493/),,150,245156,DB00860,Prednisolone
,7628493,plasma/CSF ratio,Passage of MP into the CSF was delayed since mean plasma/CSF ratio dropped dramatically from 150 at the 2nd h to 25 at the 3rd h after starting infusion.,Methylprednisolone infusion during acute exacerbation of MS: plasma and CSF concentrations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7628493/),,25,245157,DB00860,Prednisolone
,7628493,CSF,CSF concentrations of MP were high with a mean reaching 522 micrograms/l at the 6th h.,Methylprednisolone infusion during acute exacerbation of MS: plasma and CSF concentrations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7628493/),[μg] / [l],522,245158,DB00860,Prednisolone
,7628493,concentrations,CSF concentrations of MP were high with a mean reaching 522 micrograms/l at the 6th h.,Methylprednisolone infusion during acute exacerbation of MS: plasma and CSF concentrations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7628493/),[μg] / [l],522,245159,DB00860,Prednisolone
,2598978,absolute bioavailability fraction,"In fasted subjects, the absolute bioavailability fraction, as normalised for intravenous doses, of prednisolone from plain tablets was 1.055 and from EC tablets was 0.996.",Effect of food on the absorption and pharmacokinetics of prednisolone from enteric-coated tablets. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2598978/),,1.055,246037,DB00860,Prednisolone
,2598978,absolute bioavailability fraction,"In fasted subjects, the absolute bioavailability fraction, as normalised for intravenous doses, of prednisolone from plain tablets was 1.055 and from EC tablets was 0.996.",Effect of food on the absorption and pharmacokinetics of prednisolone from enteric-coated tablets. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2598978/),,0.996,246038,DB00860,Prednisolone
,2598978,peak concentrations,"The peak concentrations after plain and EC tablets were 309 and 249 ng/ml attained at 0.98 and 5.14 h, respectively.",Effect of food on the absorption and pharmacokinetics of prednisolone from enteric-coated tablets. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2598978/),[ng] / [ml],309,246039,DB00860,Prednisolone
,2598978,peak concentrations,"The peak concentrations after plain and EC tablets were 309 and 249 ng/ml attained at 0.98 and 5.14 h, respectively.",Effect of food on the absorption and pharmacokinetics of prednisolone from enteric-coated tablets. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2598978/),[ng] / [ml],249,246040,DB00860,Prednisolone
,2598978,plasma elimination half-lives,"The means plasma elimination half-lives following the plain, EC tablets and intravenous administration in fasting conditions were 3.73, 3.89 and 3.78 h, respectively.",Effect of food on the absorption and pharmacokinetics of prednisolone from enteric-coated tablets. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2598978/),h,3.73,246041,DB00860,Prednisolone
,2598978,plasma elimination half-lives,"The means plasma elimination half-lives following the plain, EC tablets and intravenous administration in fasting conditions were 3.73, 3.89 and 3.78 h, respectively.",Effect of food on the absorption and pharmacokinetics of prednisolone from enteric-coated tablets. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2598978/),h,3.89,246042,DB00860,Prednisolone
,2598978,plasma elimination half-lives,"The means plasma elimination half-lives following the plain, EC tablets and intravenous administration in fasting conditions were 3.73, 3.89 and 3.78 h, respectively.",Effect of food on the absorption and pharmacokinetics of prednisolone from enteric-coated tablets. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2598978/),h,3.78,246043,DB00860,Prednisolone
,8342296,plasma clearance,"2. After i.v. administration, plasma clearance of prednisolone was increased from 0.93 +/- 0.13 l/kg per h before infection to 1.73 +/- 0.50 l/kg per h at week 21 post-infection.",Disposition of prednisolone in the course of subclinical fascioliasis in sheep. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8342296/),[l] / [h·kg],0.93,246133,DB00860,Prednisolone
,8342296,plasma clearance,"2. After i.v. administration, plasma clearance of prednisolone was increased from 0.93 +/- 0.13 l/kg per h before infection to 1.73 +/- 0.50 l/kg per h at week 21 post-infection.",Disposition of prednisolone in the course of subclinical fascioliasis in sheep. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8342296/),[l] / [h·kg],1.73,246134,DB00860,Prednisolone
,8342296,steady state volume of distribution,The steady state volume of distribution was increased from 0.45 +/- 0.08 l/kg during the control period to 1.26 +/- 0.44 l/kg at week 5 post-infection.,Disposition of prednisolone in the course of subclinical fascioliasis in sheep. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8342296/),[l] / [kg],0.45,246135,DB00860,Prednisolone
,8342296,steady state volume of distribution,The steady state volume of distribution was increased from 0.45 +/- 0.08 l/kg during the control period to 1.26 +/- 0.44 l/kg at week 5 post-infection.,Disposition of prednisolone in the course of subclinical fascioliasis in sheep. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8342296/),[l] / [kg],1.26,246136,DB00860,Prednisolone
,8342296,unbound fraction,"3. None of the prednisolone binding parameters (specific and non-specific sites) was modified, and the overall mean unbound fraction was 24%.",Disposition of prednisolone in the course of subclinical fascioliasis in sheep. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8342296/),%,24,246137,DB00860,Prednisolone
,12698270,unbound clearance,"The median unbound clearance (32 l/h per m(2)) was lower, and the half-life (3.6 h) longer than previously reported in childhood ALL.",Population pharmacokinetics of prednisolone in children with acute lymphoblastic leukemia. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12698270/),[h·l] / [m(2],32,246472,DB00860,Prednisolone
,12698270,half-life,"The median unbound clearance (32 l/h per m(2)) was lower, and the half-life (3.6 h) longer than previously reported in childhood ALL.",Population pharmacokinetics of prednisolone in children with acute lymphoblastic leukemia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12698270/),h,3.6,246473,DB00860,Prednisolone
,8058612,area under the curve (AUC),Chronic inflammation produced a significant increase in the area under the curve (AUC) of prednisolone compared to control animals (6594 +/- 2144 vs 3530 +/- 2164 micrograms.hr/L).,Effects of acute and chronic inflammation on the pharmacokinetics of prednisolone in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8058612/),[h·μg] / [l],6594,248461,DB00860,Prednisolone
,8058612,area under the curve (AUC),Chronic inflammation produced a significant increase in the area under the curve (AUC) of prednisolone compared to control animals (6594 +/- 2144 vs 3530 +/- 2164 micrograms.hr/L).,Effects of acute and chronic inflammation on the pharmacokinetics of prednisolone in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8058612/),[h·μg] / [l],3530,248462,DB00860,Prednisolone
,8058612,AUC,The effect of acute inflammation was not significant (AUC = 4996 +/- 3813).,Effects of acute and chronic inflammation on the pharmacokinetics of prednisolone in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8058612/),,4996,248463,DB00860,Prednisolone
,8058612,AUC,"The AUC of free prednisolone after chronic inflammation was 3141 micrograms.hr/L, compared to 1121 micrograms.hr/L in the control group and 1823 micrograms.hr/L after acute inflammation.",Effects of acute and chronic inflammation on the pharmacokinetics of prednisolone in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8058612/),[h·μg] / [l],3141,248464,DB00860,Prednisolone
,8058612,AUC,"The AUC of free prednisolone after chronic inflammation was 3141 micrograms.hr/L, compared to 1121 micrograms.hr/L in the control group and 1823 micrograms.hr/L after acute inflammation.",Effects of acute and chronic inflammation on the pharmacokinetics of prednisolone in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8058612/),[h·μg] / [l],1121,248465,DB00860,Prednisolone
,8058612,AUC,"The AUC of free prednisolone after chronic inflammation was 3141 micrograms.hr/L, compared to 1121 micrograms.hr/L in the control group and 1823 micrograms.hr/L after acute inflammation.",Effects of acute and chronic inflammation on the pharmacokinetics of prednisolone in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8058612/),[h·μg] / [l],1823,248466,DB00860,Prednisolone
,28923619,trough level,Target trough level of EVL was 3-8 ng/mL.,Ten-Year Follow-up of Pharmacokinetics-Guided Very Early Cyclosporine Minimization Synchronized With Everolimus Initiation in De Novo Kidney Transplantation. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28923619/),[ng] / [ml],3-8,249097,DB00860,Prednisolone
,28923619,Cmax,"Pharmacokinetics study found that Cmax of CsA ranged from 309 to 1,896 ng/mL, mean area under the receiver operating characteristic curve (AUC) of CsA was 3,449 ± 1,402 ng·h/mL, C0 of EVL was 5.2 ± 1.5 ng/mL, Cmax of EVL was 15.4 ± 4.6 ng/mL, and AUC of EVL was 99.7 ± 26.1 ng·h/mL.",Ten-Year Follow-up of Pharmacokinetics-Guided Very Early Cyclosporine Minimization Synchronized With Everolimus Initiation in De Novo Kidney Transplantation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28923619/),[ng] / [ml],"309 to 1,896",249098,DB00860,Prednisolone
,28923619,area under the receiver operating characteristic curve (AUC),"Pharmacokinetics study found that Cmax of CsA ranged from 309 to 1,896 ng/mL, mean area under the receiver operating characteristic curve (AUC) of CsA was 3,449 ± 1,402 ng·h/mL, C0 of EVL was 5.2 ± 1.5 ng/mL, Cmax of EVL was 15.4 ± 4.6 ng/mL, and AUC of EVL was 99.7 ± 26.1 ng·h/mL.",Ten-Year Follow-up of Pharmacokinetics-Guided Very Early Cyclosporine Minimization Synchronized With Everolimus Initiation in De Novo Kidney Transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28923619/),[h·ng] / [ml],"3,449",249099,DB00860,Prednisolone
,28923619,C0,"Pharmacokinetics study found that Cmax of CsA ranged from 309 to 1,896 ng/mL, mean area under the receiver operating characteristic curve (AUC) of CsA was 3,449 ± 1,402 ng·h/mL, C0 of EVL was 5.2 ± 1.5 ng/mL, Cmax of EVL was 15.4 ± 4.6 ng/mL, and AUC of EVL was 99.7 ± 26.1 ng·h/mL.",Ten-Year Follow-up of Pharmacokinetics-Guided Very Early Cyclosporine Minimization Synchronized With Everolimus Initiation in De Novo Kidney Transplantation. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28923619/),[ng] / [ml],5.2,249100,DB00860,Prednisolone
,28923619,Cmax,"Pharmacokinetics study found that Cmax of CsA ranged from 309 to 1,896 ng/mL, mean area under the receiver operating characteristic curve (AUC) of CsA was 3,449 ± 1,402 ng·h/mL, C0 of EVL was 5.2 ± 1.5 ng/mL, Cmax of EVL was 15.4 ± 4.6 ng/mL, and AUC of EVL was 99.7 ± 26.1 ng·h/mL.",Ten-Year Follow-up of Pharmacokinetics-Guided Very Early Cyclosporine Minimization Synchronized With Everolimus Initiation in De Novo Kidney Transplantation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28923619/),[ng] / [ml],15.4,249101,DB00860,Prednisolone
,28923619,AUC,"Pharmacokinetics study found that Cmax of CsA ranged from 309 to 1,896 ng/mL, mean area under the receiver operating characteristic curve (AUC) of CsA was 3,449 ± 1,402 ng·h/mL, C0 of EVL was 5.2 ± 1.5 ng/mL, Cmax of EVL was 15.4 ± 4.6 ng/mL, and AUC of EVL was 99.7 ± 26.1 ng·h/mL.",Ten-Year Follow-up of Pharmacokinetics-Guided Very Early Cyclosporine Minimization Synchronized With Everolimus Initiation in De Novo Kidney Transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28923619/),[h·ng] / [ml],99.7,249102,DB00860,Prednisolone
,24385281,AUC from 0 to 6 h,"No significant difference in mean dose-adjusted total prednisolone AUC from 0 to 6 h post-dose or mean dose-adjusted free prednisolone AUC from 0 to 12 h was observed between the cyclosporine and tacrolimus groups (449 versus 428 nmol·h/L/mg, p = 0.43, and 32 versus 30 nmol·h/L/mg, p = 0.51, respectively).",Comparison of the influence of cyclosporine and tacrolimus on the pharmacokinetics of prednisolone in adult male kidney transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24385281/),[h·nM] / [l·mg],449,249174,DB00860,Prednisolone
,24385281,AUC from 0 to 6 h,"No significant difference in mean dose-adjusted total prednisolone AUC from 0 to 6 h post-dose or mean dose-adjusted free prednisolone AUC from 0 to 12 h was observed between the cyclosporine and tacrolimus groups (449 versus 428 nmol·h/L/mg, p = 0.43, and 32 versus 30 nmol·h/L/mg, p = 0.51, respectively).",Comparison of the influence of cyclosporine and tacrolimus on the pharmacokinetics of prednisolone in adult male kidney transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24385281/),[h·nM] / [l·mg],428,249175,DB00860,Prednisolone
,24385281,AUC from 0 to 12 h,"No significant difference in mean dose-adjusted total prednisolone AUC from 0 to 6 h post-dose or mean dose-adjusted free prednisolone AUC from 0 to 12 h was observed between the cyclosporine and tacrolimus groups (449 versus 428 nmol·h/L/mg, p = 0.43, and 32 versus 30 nmol·h/L/mg, p = 0.51, respectively).",Comparison of the influence of cyclosporine and tacrolimus on the pharmacokinetics of prednisolone in adult male kidney transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24385281/),[h·nM] / [l·mg],32,249176,DB00860,Prednisolone
,24385281,AUC from 0 to 12 h,"No significant difference in mean dose-adjusted total prednisolone AUC from 0 to 6 h post-dose or mean dose-adjusted free prednisolone AUC from 0 to 12 h was observed between the cyclosporine and tacrolimus groups (449 versus 428 nmol·h/L/mg, p = 0.43, and 32 versus 30 nmol·h/L/mg, p = 0.51, respectively).",Comparison of the influence of cyclosporine and tacrolimus on the pharmacokinetics of prednisolone in adult male kidney transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24385281/),[h·nM] / [l·mg],30,249177,DB00860,Prednisolone
,1564126,area under concentration,"For example, for free prednisolone, the intravenous area under concentration was 1,144 +/- 195 ng.h/mL and 1,244 +/- 140 ng.h/mL, and the systemic availability after oral prednisone was 53 +/- 10% and 51 +/- 12% with placebo and tenidap, respectively.",Effect of the anti-inflammatory agent tenidap on the pharmacokinetics and pharmacodynamics of prednisolone. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1564126/),[h·ng] / [ml],"1,144",251239,DB00860,Prednisolone
,1564126,area under concentration,"For example, for free prednisolone, the intravenous area under concentration was 1,144 +/- 195 ng.h/mL and 1,244 +/- 140 ng.h/mL, and the systemic availability after oral prednisone was 53 +/- 10% and 51 +/- 12% with placebo and tenidap, respectively.",Effect of the anti-inflammatory agent tenidap on the pharmacokinetics and pharmacodynamics of prednisolone. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1564126/),[h·ng] / [ml],"1,244",251240,DB00860,Prednisolone
,1564126,systemic availability,"For example, for free prednisolone, the intravenous area under concentration was 1,144 +/- 195 ng.h/mL and 1,244 +/- 140 ng.h/mL, and the systemic availability after oral prednisone was 53 +/- 10% and 51 +/- 12% with placebo and tenidap, respectively.",Effect of the anti-inflammatory agent tenidap on the pharmacokinetics and pharmacodynamics of prednisolone. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1564126/),%,53,251241,DB00860,Prednisolone
,1564126,systemic availability,"For example, for free prednisolone, the intravenous area under concentration was 1,144 +/- 195 ng.h/mL and 1,244 +/- 140 ng.h/mL, and the systemic availability after oral prednisone was 53 +/- 10% and 51 +/- 12% with placebo and tenidap, respectively.",Effect of the anti-inflammatory agent tenidap on the pharmacokinetics and pharmacodynamics of prednisolone. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1564126/),%,51,251242,DB00860,Prednisolone
,1564126,renal clearance,"The renal clearance of prednisolone was significantly reduced after tenidap pretreatment, however (from 143 to 77 mL/min/1.73 m2).",Effect of the anti-inflammatory agent tenidap on the pharmacokinetics and pharmacodynamics of prednisolone. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1564126/),[ml] / [1.73·m2·min],143 to 77,251243,DB00860,Prednisolone
,6230241,total body clearance,"Before and during phenytoin dosage in ten volunteers, the mean (+/-SD) total body clearance (ml min-1 kg-1) of both total and unbound prednisolone increased from 2.74 +/- 0.47 to 3.94 +/- 0.66 (P less than 0.001) and from 10.76 +/- 2.68 to 16.00 +/- 3.17 (P less than 0.001), respectively.",Phenytoin modulates the pharmacokinetics of prednisolone and the pharmacodynamics of prednisolone as assessed by the inhibition of the mixed lymphocyte reaction in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6230241/),[ml] / [kg·min],2.74,251561,DB00860,Prednisolone
,6230241,total body clearance,"Before and during phenytoin dosage in ten volunteers, the mean (+/-SD) total body clearance (ml min-1 kg-1) of both total and unbound prednisolone increased from 2.74 +/- 0.47 to 3.94 +/- 0.66 (P less than 0.001) and from 10.76 +/- 2.68 to 16.00 +/- 3.17 (P less than 0.001), respectively.",Phenytoin modulates the pharmacokinetics of prednisolone and the pharmacodynamics of prednisolone as assessed by the inhibition of the mixed lymphocyte reaction in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6230241/),[ml] / [kg·min],3.94,251562,DB00860,Prednisolone
,6230241,total body clearance,"Before and during phenytoin dosage in ten volunteers, the mean (+/-SD) total body clearance (ml min-1 kg-1) of both total and unbound prednisolone increased from 2.74 +/- 0.47 to 3.94 +/- 0.66 (P less than 0.001) and from 10.76 +/- 2.68 to 16.00 +/- 3.17 (P less than 0.001), respectively.",Phenytoin modulates the pharmacokinetics of prednisolone and the pharmacodynamics of prednisolone as assessed by the inhibition of the mixed lymphocyte reaction in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6230241/),[ml] / [kg·min],10.76,251563,DB00860,Prednisolone
,6230241,total body clearance,"Before and during phenytoin dosage in ten volunteers, the mean (+/-SD) total body clearance (ml min-1 kg-1) of both total and unbound prednisolone increased from 2.74 +/- 0.47 to 3.94 +/- 0.66 (P less than 0.001) and from 10.76 +/- 2.68 to 16.00 +/- 3.17 (P less than 0.001), respectively.",Phenytoin modulates the pharmacokinetics of prednisolone and the pharmacodynamics of prednisolone as assessed by the inhibition of the mixed lymphocyte reaction in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6230241/),[ml] / [kg·min],16.00,251564,DB00860,Prednisolone
,11422002,area under the methylprednisolone concentration-time curve,Itraconazole increased the mean area under the methylprednisolone concentration-time curve from 2773 ng ml-1 h to 7011 ng ml-1 h (P < 0.001) and the elimination half-life from 3.2 h to 5.5 h (P < 0.001).,Effect of itraconazole on the pharmacokinetics of prednisolone and methylprednisolone and cortisol secretion in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11422002/),[h·ng] / [ml],2773,252860,DB00860,Prednisolone
,11422002,area under the methylprednisolone concentration-time curve,Itraconazole increased the mean area under the methylprednisolone concentration-time curve from 2773 ng ml-1 h to 7011 ng ml-1 h (P < 0.001) and the elimination half-life from 3.2 h to 5.5 h (P < 0.001).,Effect of itraconazole on the pharmacokinetics of prednisolone and methylprednisolone and cortisol secretion in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11422002/),[h·ng] / [ml],7011,252861,DB00860,Prednisolone
,11422002,elimination half-life,Itraconazole increased the mean area under the methylprednisolone concentration-time curve from 2773 ng ml-1 h to 7011 ng ml-1 h (P < 0.001) and the elimination half-life from 3.2 h to 5.5 h (P < 0.001).,Effect of itraconazole on the pharmacokinetics of prednisolone and methylprednisolone and cortisol secretion in healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11422002/),h,3.2,252862,DB00860,Prednisolone
,11422002,elimination half-life,Itraconazole increased the mean area under the methylprednisolone concentration-time curve from 2773 ng ml-1 h to 7011 ng ml-1 h (P < 0.001) and the elimination half-life from 3.2 h to 5.5 h (P < 0.001).,Effect of itraconazole on the pharmacokinetics of prednisolone and methylprednisolone and cortisol secretion in healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11422002/),h,5.5,252863,DB00860,Prednisolone
,21182429,K(i),"BMP had the highest K(i) value (8.4 × 10(-8) nmol/L), whereas DFB had the lowest (6.1 × 10(-11) nmol/L).",Pharmacokinetic features of difluprednate ophthalmic emulsion in rabbits as determined by glucocorticoid receptor-binding bioassay. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21182429/),[nM] / [l],8.4 × 10(-8),253153,DB00860,Prednisolone
,21182429,K(i),"BMP had the highest K(i) value (8.4 × 10(-8) nmol/L), whereas DFB had the lowest (6.1 × 10(-11) nmol/L).",Pharmacokinetic features of difluprednate ophthalmic emulsion in rabbits as determined by glucocorticoid receptor-binding bioassay. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21182429/),[nM] / [l],6.1 × 10(-11),253154,DB00860,Prednisolone
,21182429,GCRBA,The GCRBA of DFBA was intermediate to these 2 values (7.8 × 10(-10) nmol/L).,Pharmacokinetic features of difluprednate ophthalmic emulsion in rabbits as determined by glucocorticoid receptor-binding bioassay. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21182429/),[nM] / [l],7.8 × 10(-10),253155,DB00860,Prednisolone
,7697949,peak concentration,"Grapefruit juice increased the peak concentration of cyclosporine by 185 ng/ml (95% confidence interval, 60 to 310; p = 0.008).",The effect of grapefruit juice on cyclosporine and prednisone metabolism in transplant patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7697949/),[ng] / [ml],185,255923,DB00860,Prednisolone
,9469676,total systemic clearance,The total systemic clearance of methylprednisolone was significantly less in acutely injured patients (mean +/- SD 30.04 +/- 12.03 L/hr) than in historically reported able-bodied controls (44.70 +/- 4.90 L/hr).,Methylprednisolone disposition kinetics in patients with acute spinal cord injury. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9469676/),[l] / [h],30.04,256958,DB00860,Prednisolone
,9469676,total systemic clearance,The total systemic clearance of methylprednisolone was significantly less in acutely injured patients (mean +/- SD 30.04 +/- 12.03 L/hr) than in historically reported able-bodied controls (44.70 +/- 4.90 L/hr).,Methylprednisolone disposition kinetics in patients with acute spinal cord injury. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9469676/),[l] / [h],44.70,256959,DB00860,Prednisolone
,9469676,volume of distribution,No differences in volume of distribution were discernible between patients (126.90 L) and controls (135.45 L).,Methylprednisolone disposition kinetics in patients with acute spinal cord injury. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9469676/),l,126.90,256960,DB00860,Prednisolone
,9469676,volume of distribution,No differences in volume of distribution were discernible between patients (126.90 L) and controls (135.45 L).,Methylprednisolone disposition kinetics in patients with acute spinal cord injury. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9469676/),l,135.45,256961,DB00860,Prednisolone
,9797792,total area under the plasma methylprednisolone concentration-time curve,Itraconazole increased the total area under the plasma methylprednisolone concentration-time curve 3.9-fold compared with placebo (1968 +/- 470 ng.hr/mL versus 520 +/- 125 ng.hr/mL [mean +/- SD]; P < .001).,Plasma concentrations and effects of oral methylprednisolone are considerably increased by itraconazole. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9797792/),[h·ng] / [ml],1968,258033,DB00860,Prednisolone
,9797792,total area under the plasma methylprednisolone concentration-time curve,Itraconazole increased the total area under the plasma methylprednisolone concentration-time curve 3.9-fold compared with placebo (1968 +/- 470 ng.hr/mL versus 520 +/- 125 ng.hr/mL [mean +/- SD]; P < .001).,Plasma concentrations and effects of oral methylprednisolone are considerably increased by itraconazole. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9797792/),[h·ng] / [ml],520,258034,DB00860,Prednisolone
,9797792,peak plasma concentration,"The peak plasma concentration of methylprednisolone was increased 1.9-fold (221 +/- 49 ng/mL versus 118 +/- 25 ng/mL; P < .001), and its elimination half-life was increased 2.4-fold (4.4 +/- 0.7 hours versus 1.9 +/- 0.3 hours; P < .001) by itraconazole.",Plasma concentrations and effects of oral methylprednisolone are considerably increased by itraconazole. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9797792/),[ng] / [ml],221,258035,DB00860,Prednisolone
,9797792,peak plasma concentration,"The peak plasma concentration of methylprednisolone was increased 1.9-fold (221 +/- 49 ng/mL versus 118 +/- 25 ng/mL; P < .001), and its elimination half-life was increased 2.4-fold (4.4 +/- 0.7 hours versus 1.9 +/- 0.3 hours; P < .001) by itraconazole.",Plasma concentrations and effects of oral methylprednisolone are considerably increased by itraconazole. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9797792/),[ng] / [ml],118,258036,DB00860,Prednisolone
,9797792,elimination half-life,"The peak plasma concentration of methylprednisolone was increased 1.9-fold (221 +/- 49 ng/mL versus 118 +/- 25 ng/mL; P < .001), and its elimination half-life was increased 2.4-fold (4.4 +/- 0.7 hours versus 1.9 +/- 0.3 hours; P < .001) by itraconazole.",Plasma concentrations and effects of oral methylprednisolone are considerably increased by itraconazole. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9797792/),h,4.4,258037,DB00860,Prednisolone
,9797792,elimination half-life,"The peak plasma concentration of methylprednisolone was increased 1.9-fold (221 +/- 49 ng/mL versus 118 +/- 25 ng/mL; P < .001), and its elimination half-life was increased 2.4-fold (4.4 +/- 0.7 hours versus 1.9 +/- 0.3 hours; P < .001) by itraconazole.",Plasma concentrations and effects of oral methylprednisolone are considerably increased by itraconazole. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9797792/),h,1.9,258038,DB00860,Prednisolone
,9797792,plasma cortisol concentration,"The mean plasma cortisol concentration during the itraconazole phase, measured 24 hours after ingestion of methylprednisolone, was only about 13% of that during the placebo phase (18 +/- 23 ng/mL versus 139 +/- 60 ng/mL; P < .001).",Plasma concentrations and effects of oral methylprednisolone are considerably increased by itraconazole. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9797792/),[ng] / [ml],18,258039,DB00860,Prednisolone
,9797792,plasma cortisol concentration,"The mean plasma cortisol concentration during the itraconazole phase, measured 24 hours after ingestion of methylprednisolone, was only about 13% of that during the placebo phase (18 +/- 23 ng/mL versus 139 +/- 60 ng/mL; P < .001).",Plasma concentrations and effects of oral methylprednisolone are considerably increased by itraconazole. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9797792/),[ng] / [ml],139,258040,DB00860,Prednisolone
,6968763,total body clearance,Baseline total body clearance of methylprednisolone was 406 +/- 139 (mean +/- SD) ml/min/1.73 m2 and decreased significantly (p < 0.001) to 146 +/- 57 ml/min/1.73 m2 1 wk after TAO therapy was initiated.,The effect of troleandomycin on methylprednisolone elimination. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6968763/),[ml] / [1.73·m2·min],406,258381,DB00860,Prednisolone
,6968763,total body clearance,Baseline total body clearance of methylprednisolone was 406 +/- 139 (mean +/- SD) ml/min/1.73 m2 and decreased significantly (p < 0.001) to 146 +/- 57 ml/min/1.73 m2 1 wk after TAO therapy was initiated.,The effect of troleandomycin on methylprednisolone elimination. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6968763/),[ml] / [1.73·m2·min],146,258382,DB00860,Prednisolone
,6968763,half-life,Methylprednisolone half-life was 2.46 +/- 0.75 hr before TAO and increased significantly (p < 0.01) to 4.63 +/- 1.35 hr after 1 wk on TAO therapy.,The effect of troleandomycin on methylprednisolone elimination. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6968763/),h,2.46,258383,DB00860,Prednisolone
,6968763,half-life,Methylprednisolone half-life was 2.46 +/- 0.75 hr before TAO and increased significantly (p < 0.01) to 4.63 +/- 1.35 hr after 1 wk on TAO therapy.,The effect of troleandomycin on methylprednisolone elimination. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6968763/),h,4.63,258384,DB00860,Prednisolone
,28025957,Hill coefficient H,The pharmacodynamic parameters of the action of tacrolimus were estimated with the Hill coefficient H at 1.5 and the CE50 at 6.7 ng/mL.,Correlation between pharmacokinetics of tacrolimus and pharmacodynamics on NFAT-regulated gene expression in stable kidney transplant recipients . ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28025957/),[ng] / [ml],1.5,259787,DB00860,Prednisolone
,28025957,CE50,The pharmacodynamic parameters of the action of tacrolimus were estimated with the Hill coefficient H at 1.5 and the CE50 at 6.7 ng/mL.,Correlation between pharmacokinetics of tacrolimus and pharmacodynamics on NFAT-regulated gene expression in stable kidney transplant recipients . ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28025957/),[ng] / [ml],6.7,259788,DB00860,Prednisolone
,28025957,ceiling concentration,"Accordingly, the pharmacodynamic threshold concentration was estimated at 0.9 ng/mL and the ceiling concentration at 48 ng/mL, indicating a wide span between target trough and peak levels.",Correlation between pharmacokinetics of tacrolimus and pharmacodynamics on NFAT-regulated gene expression in stable kidney transplant recipients . ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28025957/),[ng] / [ml],48,259789,DB00860,Prednisolone
,21168621,C(0),We enrolled 10 de novo kidney transplant recipients to receive CsA (target C(0) 250-350 ng/mL) and prednisolone as initial therapy.,Long-term outcome of very early cyclosporine minimization and de novo everolimus therapy in kidney transplant recipients: a pharmacokinetic guided approach. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21168621/),[ng] / [ml],250-350,260925,DB00860,Prednisolone
,21168621,target,"Everolimus (target trough level, 3-8 ng/mL) was concomitantly started at the day of CsA reduction.",Long-term outcome of very early cyclosporine minimization and de novo everolimus therapy in kidney transplant recipients: a pharmacokinetic guided approach. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21168621/),[ng] / [ml],3-8,260926,DB00860,Prednisolone
,21168621,trough level,"Everolimus (target trough level, 3-8 ng/mL) was concomitantly started at the day of CsA reduction.",Long-term outcome of very early cyclosporine minimization and de novo everolimus therapy in kidney transplant recipients: a pharmacokinetic guided approach. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21168621/),[ng] / [ml],3-8,260927,DB00860,Prednisolone
,21168621,trough level,CsA was then gradually reduced to maintain a trough level of 50-100 ng/mL and/or C(max) <600 ng/mL.,Long-term outcome of very early cyclosporine minimization and de novo everolimus therapy in kidney transplant recipients: a pharmacokinetic guided approach. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21168621/),[ng] / [ml],50-100,260928,DB00860,Prednisolone
<,21168621,C(max),CsA was then gradually reduced to maintain a trough level of 50-100 ng/mL and/or C(max) <600 ng/mL.,Long-term outcome of very early cyclosporine minimization and de novo everolimus therapy in kidney transplant recipients: a pharmacokinetic guided approach. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21168621/),[ng] / [ml],600,260929,DB00860,Prednisolone
,21168621,initial trough everolimus,The mean initial trough everolimus was 5.2 ± 1.5 ng/mL.,Long-term outcome of very early cyclosporine minimization and de novo everolimus therapy in kidney transplant recipients: a pharmacokinetic guided approach. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21168621/),[ng] / [ml],5.2,260930,DB00860,Prednisolone
,6734709,area under the plasma concentration versus time curves,"After an oral dose of prednisone, women on oral contraceptive steroids (n = 10) had higher mean (+/- SD) area under the plasma concentration versus time curves of total (428 +/- 67 micrograms/ml/min vs 188 +/- 28 micrograms/ml/min, p less than 0.001) and unbound prednisolone (64 +/- 10 micrograms/ml/min vs 41 +/- 10 micrograms/ml/min, p less than 0.001) than women not taking oral contraceptive steroids (n = 10).",Pharmacokinetic interaction of contraceptive steroids with prednisone and prednisolone. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6734709/),[μg] / [min·ml],428,261415,DB00860,Prednisolone
,6734709,area under the plasma concentration versus time curves,"After an oral dose of prednisone, women on oral contraceptive steroids (n = 10) had higher mean (+/- SD) area under the plasma concentration versus time curves of total (428 +/- 67 micrograms/ml/min vs 188 +/- 28 micrograms/ml/min, p less than 0.001) and unbound prednisolone (64 +/- 10 micrograms/ml/min vs 41 +/- 10 micrograms/ml/min, p less than 0.001) than women not taking oral contraceptive steroids (n = 10).",Pharmacokinetic interaction of contraceptive steroids with prednisone and prednisolone. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6734709/),[μg] / [min·ml],188,261416,DB00860,Prednisolone
,6734709,area under the plasma concentration versus time curves,"After an oral dose of prednisone, women on oral contraceptive steroids (n = 10) had higher mean (+/- SD) area under the plasma concentration versus time curves of total (428 +/- 67 micrograms/ml/min vs 188 +/- 28 micrograms/ml/min, p less than 0.001) and unbound prednisolone (64 +/- 10 micrograms/ml/min vs 41 +/- 10 micrograms/ml/min, p less than 0.001) than women not taking oral contraceptive steroids (n = 10).",Pharmacokinetic interaction of contraceptive steroids with prednisone and prednisolone. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6734709/),[μg] / [min·ml],64,261417,DB00860,Prednisolone
,6734709,area under the plasma concentration versus time curves,"After an oral dose of prednisone, women on oral contraceptive steroids (n = 10) had higher mean (+/- SD) area under the plasma concentration versus time curves of total (428 +/- 67 micrograms/ml/min vs 188 +/- 28 micrograms/ml/min, p less than 0.001) and unbound prednisolone (64 +/- 10 micrograms/ml/min vs 41 +/- 10 micrograms/ml/min, p less than 0.001) than women not taking oral contraceptive steroids (n = 10).",Pharmacokinetic interaction of contraceptive steroids with prednisone and prednisolone. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6734709/),[μg] / [min·ml],41,261418,DB00860,Prednisolone
,18502461,C(max),"The mean prednisolone C(max) for recipients (n=14) having both the ABCB1 3435CC genotype and the CYP3A5*3/*3 genotype was significantly higher than those (n=11) having both ABCB1 3435TT and CYP3A5*3/*3 genotypes (180ng/mL versus 129ng/mL, P=0.0392).","Influence of CYP3A5, ABCB1 and NR1I2 polymorphisms on prednisolone pharmacokinetics in renal transplant recipients. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18502461/),[ng] / [ml],180,261505,DB00860,Prednisolone
,18502461,C(max),"The mean prednisolone C(max) for recipients (n=14) having both the ABCB1 3435CC genotype and the CYP3A5*3/*3 genotype was significantly higher than those (n=11) having both ABCB1 3435TT and CYP3A5*3/*3 genotypes (180ng/mL versus 129ng/mL, P=0.0392).","Influence of CYP3A5, ABCB1 and NR1I2 polymorphisms on prednisolone pharmacokinetics in renal transplant recipients. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18502461/),[ng] / [ml],129,261506,DB00860,Prednisolone
,744499,bioavailability,"After prednisone (10 mg) was given by mouth and by vein to similar groups of volunteers and 11 additional patients with CALD, bioavailability of oral prednisone approximated 100% of the intravenous dose and no differences were found in the pharmacokinetics of prednisolone.",Oral prednisone for chronic active liver disease: dose responses and bioavailability studies. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/744499/),%,100,261570,DB00860,Prednisolone
,7437263,bioavailability fraction,2 The bioavailability fraction was 1.063 +/- 0.154 (s.d.) indicating complete availability of prednisolone following oral administration.,Pharmacokinetics of intravenous and oral prednisolone. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7437263/),,1.063,261762,DB00860,Prednisolone
,7437263,T 1/2,The mean T 1/2 over all doses were 4.11 +/- 0.97 (s.d.) h and there was no evidence of a dose-related change in its value.,Pharmacokinetics of intravenous and oral prednisolone. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7437263/),h,4.11,261763,DB00860,Prednisolone
,7437263,systemic clearance,The mean systemic clearance over all doses was 0.104 +/- 0.034 (s.d) 1 h-1 kg-1.,Pharmacokinetics of intravenous and oral prednisolone. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7437263/),[1] / [h·kg],0.104,261764,DB00860,Prednisolone
,7437263,clearance,There was no evidence of a dose-related change in clearance or in the apparent volume of distribution (overall mean 0.588 +/- 0.152 1 kg-1).,Pharmacokinetics of intravenous and oral prednisolone. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7437263/),[1] / [kg],0.588,261765,DB00860,Prednisolone
,7437263,apparent volume of distribution,There was no evidence of a dose-related change in clearance or in the apparent volume of distribution (overall mean 0.588 +/- 0.152 1 kg-1).,Pharmacokinetics of intravenous and oral prednisolone. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7437263/),[1] / [kg],0.588,261766,DB00860,Prednisolone
,34179161,total body,"After administration of prednisolone sodium succinate IV, the typical value (between subject variation) for total body prednisolone clearance was 1,370 ml/h·kg (13.4%).",Prednisolone in Dogs-Plasma Exposure and White Blood Cell Response. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34179161/),[ml] / [h·kg],"1,370",261822,DB00860,Prednisolone
,34179161,clearance,"After administration of prednisolone sodium succinate IV, the typical value (between subject variation) for total body prednisolone clearance was 1,370 ml/h·kg (13.4%).",Prednisolone in Dogs-Plasma Exposure and White Blood Cell Response. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34179161/),[ml] / [h·kg],"1,370",261823,DB00860,Prednisolone
,34179161,volumes of the central,"The volumes of the central and peripheral compartment were 2,300 ml/kg (10.7%) and 600 ml/kg (16.0%), respectively.",Prednisolone in Dogs-Plasma Exposure and White Blood Cell Response. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34179161/),[ml] / [kg],"2,300",261824,DB00860,Prednisolone
,34179161,peripheral compartment,"The volumes of the central and peripheral compartment were 2,300 ml/kg (10.7%) and 600 ml/kg (16.0%), respectively.",Prednisolone in Dogs-Plasma Exposure and White Blood Cell Response. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34179161/),[ml] / [kg],600,261825,DB00860,Prednisolone
,34179161,terminal plasma half-life,The terminal plasma half-life was 1.7 h.,Prednisolone in Dogs-Plasma Exposure and White Blood Cell Response. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/34179161/),h,1.7,261826,DB00860,Prednisolone
,34179161,plasma concentration,"The prednisolone plasma concentration producing 50% of the maximum response was 10 ng/mL (90.3%), 22.5 ng/ml (52.3%) and 0.04 ng/mL (197.3%) for neutrophil, lymphocyte and cortisol response, respectively.",Prednisolone in Dogs-Plasma Exposure and White Blood Cell Response. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34179161/),[ng] / [ml],10,261827,DB00860,Prednisolone
,34179161,plasma concentration,"The prednisolone plasma concentration producing 50% of the maximum response was 10 ng/mL (90.3%), 22.5 ng/ml (52.3%) and 0.04 ng/mL (197.3%) for neutrophil, lymphocyte and cortisol response, respectively.",Prednisolone in Dogs-Plasma Exposure and White Blood Cell Response. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34179161/),[ng] / [ml],22.5,261828,DB00860,Prednisolone
,34179161,plasma concentration,"The prednisolone plasma concentration producing 50% of the maximum response was 10 ng/mL (90.3%), 22.5 ng/ml (52.3%) and 0.04 ng/mL (197.3%) for neutrophil, lymphocyte and cortisol response, respectively.",Prednisolone in Dogs-Plasma Exposure and White Blood Cell Response. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34179161/),[ng] / [ml],0.04,261829,DB00860,Prednisolone
<,16045952,fT4,One 9.9-year-old administered prednisone 0.5mg/kg p.o. was found to be hypothyroid (TSH: 351microIU/mL; fT4: <2pg/mL; fT3: <1pg/mL); four age-matched normal boys (aged 6.6+/-4.9 years) served as a control group.,Pharmacokinetics of prednisone and prednisolone in a case of hypothyroidism: effect of replacement therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16045952/),[pg] / [ml],2,262136,DB00860,Prednisolone
<,16045952,fT3,One 9.9-year-old administered prednisone 0.5mg/kg p.o. was found to be hypothyroid (TSH: 351microIU/mL; fT4: <2pg/mL; fT3: <1pg/mL); four age-matched normal boys (aged 6.6+/-4.9 years) served as a control group.,Pharmacokinetics of prednisone and prednisolone in a case of hypothyroidism: effect of replacement therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16045952/),[pg] / [ml],1,262137,DB00860,Prednisolone
,16045952,total AUC,"In comparison with the controls, the hypothyroid boy showed a marked increase in the total AUC of prednisone (3360microg h/L versus 215+/-83microg h/L) and prednisolone (4040microg h/L versus 724+/-77microg h/L), and an altered pattern of endogenous cortisol, which is known to be impaired in hypothyroid subjects.",Pharmacokinetics of prednisone and prednisolone in a case of hypothyroidism: effect of replacement therapy. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16045952/),[h·μg] / [l],3360,262138,DB00860,Prednisolone
,16045952,total AUC,"In comparison with the controls, the hypothyroid boy showed a marked increase in the total AUC of prednisone (3360microg h/L versus 215+/-83microg h/L) and prednisolone (4040microg h/L versus 724+/-77microg h/L), and an altered pattern of endogenous cortisol, which is known to be impaired in hypothyroid subjects.",Pharmacokinetics of prednisone and prednisolone in a case of hypothyroidism: effect of replacement therapy. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16045952/),[h·μg] / [l],215,262139,DB00860,Prednisolone
,16045952,total AUC,"In comparison with the controls, the hypothyroid boy showed a marked increase in the total AUC of prednisone (3360microg h/L versus 215+/-83microg h/L) and prednisolone (4040microg h/L versus 724+/-77microg h/L), and an altered pattern of endogenous cortisol, which is known to be impaired in hypothyroid subjects.",Pharmacokinetics of prednisone and prednisolone in a case of hypothyroidism: effect of replacement therapy. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16045952/),[h·μg] / [l],4040,262140,DB00860,Prednisolone
,16045952,total AUC,"In comparison with the controls, the hypothyroid boy showed a marked increase in the total AUC of prednisone (3360microg h/L versus 215+/-83microg h/L) and prednisolone (4040microg h/L versus 724+/-77microg h/L), and an altered pattern of endogenous cortisol, which is known to be impaired in hypothyroid subjects.",Pharmacokinetics of prednisone and prednisolone in a case of hypothyroidism: effect of replacement therapy. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16045952/),[h·μg] / [l],724,262141,DB00860,Prednisolone
,16045952,AUCs,"After 6 months of thyroxine replacement therapy (75microg/day), the AUCs of prednisone and prednisolone returned to normal values (prednisone: 248microg h/L; prednisolone: 528microg h/L), as did the pattern of circadian cortisol secretion.",Pharmacokinetics of prednisone and prednisolone in a case of hypothyroidism: effect of replacement therapy. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16045952/),[h·μg] / [l],248,262142,DB00860,Prednisolone
,16045952,AUCs,"After 6 months of thyroxine replacement therapy (75microg/day), the AUCs of prednisone and prednisolone returned to normal values (prednisone: 248microg h/L; prednisolone: 528microg h/L), as did the pattern of circadian cortisol secretion.",Pharmacokinetics of prednisone and prednisolone in a case of hypothyroidism: effect of replacement therapy. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16045952/),[h·μg] / [l],528,262143,DB00860,Prednisolone
,9428565,half-life of elimination phase,The pharmacokinetic parameters were as follows: half-life of elimination phase 12.6 hrs; total clearance 0.55 mL/min/kg; and volume distribution of steady state 27.07 L.,Pharmacokinetics and clearance of ganciclovir during continuous hemodiafiltration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9428565/),h,12.6,263102,DB00860,Prednisolone
,9428565,total clearance,The pharmacokinetic parameters were as follows: half-life of elimination phase 12.6 hrs; total clearance 0.55 mL/min/kg; and volume distribution of steady state 27.07 L.,Pharmacokinetics and clearance of ganciclovir during continuous hemodiafiltration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9428565/),[ml] / [kg·min],0.55,263103,DB00860,Prednisolone
,9428565,volume distribution of steady state,The pharmacokinetic parameters were as follows: half-life of elimination phase 12.6 hrs; total clearance 0.55 mL/min/kg; and volume distribution of steady state 27.07 L.,Pharmacokinetics and clearance of ganciclovir during continuous hemodiafiltration. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9428565/),l,27.07,263104,DB00860,Prednisolone
,9428565,clearance of hemodiafiltration,The clearance of hemodiafiltration was 0.63 mL/min/kg.,Pharmacokinetics and clearance of ganciclovir during continuous hemodiafiltration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9428565/),[ml] / [kg·min],0.63,263105,DB00860,Prednisolone
,30999274,supply rate,"This developed method comprised of a ""BEH™ C18 column (50 mm × 2.1 mm, 1.7 μm)"" using acetonitrile and 0.1% formic acid (35:65 v/v) at a supply rate of 0.25 mL·min-1 as eluent.",UHPLC assisted simultaneous separation of apigenin and prednisolone and its application in the pharmacokinetics of apigenin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30999274/),[ml] / [min],0.25,263355,DB00860,Prednisolone
,30999274,resolution,"Satisfactory values of chromatographic parameters such as resolution (Rs = 2.5), capacity factor (k; 13.6 and 23.4 for API and PRD respectively, selectivity (α = 1.72) and number of theoretical plates (N; 3789 and 42,435 for API and PRD respectively) indicate the efficiency of the developed method.",UHPLC assisted simultaneous separation of apigenin and prednisolone and its application in the pharmacokinetics of apigenin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30999274/),,2.5,263356,DB00860,Prednisolone
,30999274,capacity factor (k,"Satisfactory values of chromatographic parameters such as resolution (Rs = 2.5), capacity factor (k; 13.6 and 23.4 for API and PRD respectively, selectivity (α = 1.72) and number of theoretical plates (N; 3789 and 42,435 for API and PRD respectively) indicate the efficiency of the developed method.",UHPLC assisted simultaneous separation of apigenin and prednisolone and its application in the pharmacokinetics of apigenin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30999274/),,13.6,263357,DB00860,Prednisolone
,30999274,capacity factor (k,"Satisfactory values of chromatographic parameters such as resolution (Rs = 2.5), capacity factor (k; 13.6 and 23.4 for API and PRD respectively, selectivity (α = 1.72) and number of theoretical plates (N; 3789 and 42,435 for API and PRD respectively) indicate the efficiency of the developed method.",UHPLC assisted simultaneous separation of apigenin and prednisolone and its application in the pharmacokinetics of apigenin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30999274/),,23.4,263358,DB00860,Prednisolone
,30999274,number of theoretical plates,"Satisfactory values of chromatographic parameters such as resolution (Rs = 2.5), capacity factor (k; 13.6 and 23.4 for API and PRD respectively, selectivity (α = 1.72) and number of theoretical plates (N; 3789 and 42,435 for API and PRD respectively) indicate the efficiency of the developed method.",UHPLC assisted simultaneous separation of apigenin and prednisolone and its application in the pharmacokinetics of apigenin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30999274/),,3789,263359,DB00860,Prednisolone
,30999274,number of theoretical plates,"Satisfactory values of chromatographic parameters such as resolution (Rs = 2.5), capacity factor (k; 13.6 and 23.4 for API and PRD respectively, selectivity (α = 1.72) and number of theoretical plates (N; 3789 and 42,435 for API and PRD respectively) indicate the efficiency of the developed method.",UHPLC assisted simultaneous separation of apigenin and prednisolone and its application in the pharmacokinetics of apigenin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30999274/),,"42,435",263360,DB00860,Prednisolone
,30999274,N,"Satisfactory values of chromatographic parameters such as resolution (Rs = 2.5), capacity factor (k; 13.6 and 23.4 for API and PRD respectively, selectivity (α = 1.72) and number of theoretical plates (N; 3789 and 42,435 for API and PRD respectively) indicate the efficiency of the developed method.",UHPLC assisted simultaneous separation of apigenin and prednisolone and its application in the pharmacokinetics of apigenin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30999274/),,3789,263361,DB00860,Prednisolone
,30999274,N,"Satisfactory values of chromatographic parameters such as resolution (Rs = 2.5), capacity factor (k; 13.6 and 23.4 for API and PRD respectively, selectivity (α = 1.72) and number of theoretical plates (N; 3789 and 42,435 for API and PRD respectively) indicate the efficiency of the developed method.",UHPLC assisted simultaneous separation of apigenin and prednisolone and its application in the pharmacokinetics of apigenin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30999274/),,"42,435",263362,DB00860,Prednisolone
,30999274,limit of quantification,"The calibration curves followed linearity in concentration range of 05-1000 ng mL-1 with limit of detection ""LOD"" and limit of quantification ""LOQ"" of 7.30 and 22.77 ng mL-1, respectively.",UHPLC assisted simultaneous separation of apigenin and prednisolone and its application in the pharmacokinetics of apigenin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30999274/),[ng] / [ml],7.30,263363,DB00860,Prednisolone
,30999274,limit of quantification,"The calibration curves followed linearity in concentration range of 05-1000 ng mL-1 with limit of detection ""LOD"" and limit of quantification ""LOQ"" of 7.30 and 22.77 ng mL-1, respectively.",UHPLC assisted simultaneous separation of apigenin and prednisolone and its application in the pharmacokinetics of apigenin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30999274/),[ng] / [ml],22,263364,DB00860,Prednisolone
,15487811,AUCt,"The geometric mean of AUCt was 1,786 ng/ml x h (test medication) and 1,787 ng/ml xh (reference medication).",Bioequivalence of a prednisolone tablet administered as a single oral dose in healthy male volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15487811/),[ng] / [h·ml],"1,786",263603,DB00860,Prednisolone
,15487811,AUCt,"The geometric mean of AUCt was 1,786 ng/ml x h (test medication) and 1,787 ng/ml xh (reference medication).",Bioequivalence of a prednisolone tablet administered as a single oral dose in healthy male volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15487811/),[ng] / [h·ml],"1,787",263604,DB00860,Prednisolone
,15487811,Cmax,"A Cmax of 409 ng/ml and 404 ng/ml was achieved for the test and the reference medication, respectively.",Bioequivalence of a prednisolone tablet administered as a single oral dose in healthy male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15487811/),[ng] / [ml],409,263605,DB00860,Prednisolone
,15487811,Cmax,"A Cmax of 409 ng/ml and 404 ng/ml was achieved for the test and the reference medication, respectively.",Bioequivalence of a prednisolone tablet administered as a single oral dose in healthy male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15487811/),[ng] / [ml],404,263606,DB00860,Prednisolone
,1974305,Clearance,Clearance of total plasma prednisolone was 4.16 and 3.21 L/hr per kg in low- and high-dose groups.,Receptor-mediated prednisolone pharmacodynamics in rats: model verification using a dose-sparing regimen. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1974305/),[l] / [h·kg],4.16,263844,DB00860,Prednisolone
,1974305,Clearance,Clearance of total plasma prednisolone was 4.16 and 3.21 L/hr per kg in low- and high-dose groups.,Receptor-mediated prednisolone pharmacodynamics in rats: model verification using a dose-sparing regimen. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1974305/),[l] / [h·kg],3.21,263845,DB00860,Prednisolone
,1974305,Volume of distribution at steady state,Volume of distribution at steady state (approximately 1.50 L/kg) and central volume (approximately 0.6 L/kg) were similar for both groups.,Receptor-mediated prednisolone pharmacodynamics in rats: model verification using a dose-sparing regimen. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1974305/),[l] / [kg],1.50,263846,DB00860,Prednisolone
,1974305,central volume,Volume of distribution at steady state (approximately 1.50 L/kg) and central volume (approximately 0.6 L/kg) were similar for both groups.,Receptor-mediated prednisolone pharmacodynamics in rats: model verification using a dose-sparing regimen. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1974305/),[l] / [kg],0.6,263847,DB00860,Prednisolone
,1524961,time taken,The difference in time taken (median and range) to maximum suppression of cortisol was statistically significant (P less than 0.05) between P (2.5 h; 2-4 h) and EP (4 h; 3-12 h) preparations administered to volunteers.,A pharmacokinetic and pharmacodynamic comparison of plain and enteric-coated prednisolone tablets. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1524961/),h,2.5,264178,DB00860,Prednisolone
,1524961,time taken,The difference in time taken (median and range) to maximum suppression of cortisol was statistically significant (P less than 0.05) between P (2.5 h; 2-4 h) and EP (4 h; 3-12 h) preparations administered to volunteers.,A pharmacokinetic and pharmacodynamic comparison of plain and enteric-coated prednisolone tablets. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1524961/),h,4,264179,DB00860,Prednisolone
,1524961,maximum suppression,The difference in time taken (median and range) to maximum suppression of cortisol was statistically significant (P less than 0.05) between P (2.5 h; 2-4 h) and EP (4 h; 3-12 h) preparations administered to volunteers.,A pharmacokinetic and pharmacodynamic comparison of plain and enteric-coated prednisolone tablets. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1524961/),h,2.5,264180,DB00860,Prednisolone
,1524961,maximum suppression,The difference in time taken (median and range) to maximum suppression of cortisol was statistically significant (P less than 0.05) between P (2.5 h; 2-4 h) and EP (4 h; 3-12 h) preparations administered to volunteers.,A pharmacokinetic and pharmacodynamic comparison of plain and enteric-coated prednisolone tablets. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1524961/),h,4,264181,DB00860,Prednisolone
,29733485,apparent oral clearance,"During pregnancy, prednisone apparent oral clearance increased with dose (35.1 ± 11.4 L/h with 5 mg, 52.6 ± 5.2 L/h with 10 mg, and 64.3 ± 6.9 L/h with 20 mg, P = .001).",Prednisone Pharmacokinetics During Pregnancy and Lactation. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29733485/),[l] / [h],35.1,264449,DB00860,Prednisolone
,29733485,apparent oral clearance,"During pregnancy, prednisone apparent oral clearance increased with dose (35.1 ± 11.4 L/h with 5 mg, 52.6 ± 5.2 L/h with 10 mg, and 64.3 ± 6.9 L/h with 20 mg, P = .001).",Prednisone Pharmacokinetics During Pregnancy and Lactation. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29733485/),[l] / [h],52.6,264450,DB00860,Prednisolone
,29733485,apparent oral clearance,"During pregnancy, prednisone apparent oral clearance increased with dose (35.1 ± 11.4 L/h with 5 mg, 52.6 ± 5.2 L/h with 10 mg, and 64.3 ± 6.9 L/h with 20 mg, P = .001).",Prednisone Pharmacokinetics During Pregnancy and Lactation. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29733485/),[l] / [h],64.3,264451,DB00860,Prednisolone
,29733485,renal clearance,"In addition, prednisolone renal clearance increased with dose (0.3 ± 0.3 L/h with 5 mg, 0.5 ± 0.4 L/h with 10 mg, and 1.3 ± 1.1 L/h with 20 mg, P = .002).",Prednisone Pharmacokinetics During Pregnancy and Lactation. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29733485/),[l] / [h],0.3,264452,DB00860,Prednisolone
,29733485,renal clearance,"In addition, prednisolone renal clearance increased with dose (0.3 ± 0.3 L/h with 5 mg, 0.5 ± 0.4 L/h with 10 mg, and 1.3 ± 1.1 L/h with 20 mg, P = .002).",Prednisone Pharmacokinetics During Pregnancy and Lactation. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29733485/),[l] / [h],0.5,264453,DB00860,Prednisolone
,29733485,renal clearance,"In addition, prednisolone renal clearance increased with dose (0.3 ± 0.3 L/h with 5 mg, 0.5 ± 0.4 L/h with 10 mg, and 1.3 ± 1.1 L/h with 20 mg, P = .002).",Prednisone Pharmacokinetics During Pregnancy and Lactation. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29733485/),[l] / [h],1.3,264454,DB00860,Prednisolone
,16044097,CL/F,"The population estimate of tacrolimus CL/F and apparent volume of distribution (V/F) were found to be 21.3 L/h (95% confidence interval, CI, 18.0-24.6 L/h) and 316.1 L (95% CI 133-495 L), respectively.",Population pharmacokinetic estimation of tacrolimus apparent clearance in adult liver transplant recipients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16044097/),[l] / [h],21.3,264892,DB00860,Prednisolone
,16044097,apparent volume of distribution (V/F),"The population estimate of tacrolimus CL/F and apparent volume of distribution (V/F) were found to be 21.3 L/h (95% confidence interval, CI, 18.0-24.6 L/h) and 316.1 L (95% CI 133-495 L), respectively.",Population pharmacokinetic estimation of tacrolimus apparent clearance in adult liver transplant recipients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16044097/),l,316.1,264893,DB00860,Prednisolone
,14749696,peak plasma concentration (C(max)),"The mean peak plasma concentration (C(max)) of pravastatin was 122.2 +/- 88.2 ng/mL (range, 11.4-305.0 ng/mL), and the area under the plasma concentration-time curve of pravastatin from 0 to 10 hours [AUC(0-10)] was 264.1 +/- 192.4 ng.h/mL (range, 30.8-701.6 ng.h/mL).",Pharmacokinetics and pharmacodynamics of pravastatin in pediatric and adolescent cardiac transplant recipients on a regimen of triple immunosuppression. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749696/),[ng] / [ml],122.2,265126,DB00860,Prednisolone
,14749696,area under the plasma concentration-time curve of pravastatin from 0 to 10 hours [AUC(0-10)],"The mean peak plasma concentration (C(max)) of pravastatin was 122.2 +/- 88.2 ng/mL (range, 11.4-305.0 ng/mL), and the area under the plasma concentration-time curve of pravastatin from 0 to 10 hours [AUC(0-10)] was 264.1 +/- 192.4 ng.h/mL (range, 30.8-701.6 ng.h/mL).",Pharmacokinetics and pharmacodynamics of pravastatin in pediatric and adolescent cardiac transplant recipients on a regimen of triple immunosuppression. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749696/),[h·ng] / [ml],264.1,265127,DB00860,Prednisolone
,14749696,time of peak concentration (t(max)),"The time of peak concentration (t(max)) of pravastatin was 1.1 +/- 0.4 hours (range, 0.5-2 hours), and the mean elimination half-life (t(1/2)) was 1.2 +/- 0.3 hours (range, 0.7-2.2 hours); these parameters were similar to those in the hypercholesterolemic children.",Pharmacokinetics and pharmacodynamics of pravastatin in pediatric and adolescent cardiac transplant recipients on a regimen of triple immunosuppression. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749696/),h,1.1,265128,DB00860,Prednisolone
,14749696,elimination half-life (t(1/2)),"The time of peak concentration (t(max)) of pravastatin was 1.1 +/- 0.4 hours (range, 0.5-2 hours), and the mean elimination half-life (t(1/2)) was 1.2 +/- 0.3 hours (range, 0.7-2.2 hours); these parameters were similar to those in the hypercholesterolemic children.",Pharmacokinetics and pharmacodynamics of pravastatin in pediatric and adolescent cardiac transplant recipients on a regimen of triple immunosuppression. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749696/),h,1.2,265129,DB00860,Prednisolone
,22337718,Total clearance,Total clearance was 9.43 mL/h and Vd(ss) was 9.61 l.,The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22337718/),[ml] / [h],9.43,266008,DB00860,Prednisolone
,22337718,Vd(ss),Total clearance was 9.43 mL/h and Vd(ss) was 9.61 l.,The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22337718/),l,9.61,266009,DB00860,Prednisolone
,22337718,clearance,Rituximab clearance was reduced (8.21 mL/h vs 12.68 mL/h; P = .003) and elimination half-life was prolonged in women compared with men (t(1/2β) = 30.7 vs 24.7 days; P = .003).,The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22337718/),[ml] / [h],8.21,266010,DB00860,Prednisolone
,22337718,clearance,Rituximab clearance was reduced (8.21 mL/h vs 12.68 mL/h; P = .003) and elimination half-life was prolonged in women compared with men (t(1/2β) = 30.7 vs 24.7 days; P = .003).,The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22337718/),[ml] / [h],12.68,266011,DB00860,Prednisolone
,22337718,t(1/2β),Rituximab clearance was reduced (8.21 mL/h vs 12.68 mL/h; P = .003) and elimination half-life was prolonged in women compared with men (t(1/2β) = 30.7 vs 24.7 days; P = .003).,The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22337718/),d,30.7,266012,DB00860,Prednisolone
,22337718,t(1/2β),Rituximab clearance was reduced (8.21 mL/h vs 12.68 mL/h; P = .003) and elimination half-life was prolonged in women compared with men (t(1/2β) = 30.7 vs 24.7 days; P = .003).,The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22337718/),d,24.7,266013,DB00860,Prednisolone
,6958498,plasma half-life,"The plasma half-life was 2.8 +/- 1.1 h (mean +/- SD), distribution volume 301.3 +/ 41.7 1 and plasma clearance 83.7 +/- 27.5 1/h.","Pharmacokinetics and metabolism of budesonide, a selective glucocorticoid. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6958498/),h,2.8,266547,DB00860,Prednisolone
,6958498,distribution volume,"The plasma half-life was 2.8 +/- 1.1 h (mean +/- SD), distribution volume 301.3 +/ 41.7 1 and plasma clearance 83.7 +/- 27.5 1/h.","Pharmacokinetics and metabolism of budesonide, a selective glucocorticoid. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6958498/),1,301.3,266548,DB00860,Prednisolone
,6958498,plasma clearance,"The plasma half-life was 2.8 +/- 1.1 h (mean +/- SD), distribution volume 301.3 +/ 41.7 1 and plasma clearance 83.7 +/- 27.5 1/h.","Pharmacokinetics and metabolism of budesonide, a selective glucocorticoid. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6958498/),[1] / [h],83.7,266549,DB00860,Prednisolone
,6958498,systemic availability,"The systemic availability was 10.7 +/- 4.3% after oral administration and 72.8 +/- 42.0% after inhalation, corrected for the amounts of substance deposited in the inhalation device and oral cavity.","Pharmacokinetics and metabolism of budesonide, a selective glucocorticoid. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6958498/),%,10.7,266550,DB00860,Prednisolone
,6958498,systemic availability,"The systemic availability was 10.7 +/- 4.3% after oral administration and 72.8 +/- 42.0% after inhalation, corrected for the amounts of substance deposited in the inhalation device and oral cavity.","Pharmacokinetics and metabolism of budesonide, a selective glucocorticoid. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6958498/),%,72.8,266551,DB00860,Prednisolone
,9205819,bioavailability,The bioavailability of MP was equivalent when based on AUC with a MP suleptanate median 108% of the MP succinate value (90% CI: 102-114%).,Pharmacokinetic and pharmacodynamic assessment of bioavailability for two prodrugs of methylprednisolone. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9205819/),%,108,267933,DB00860,Prednisolone
,7930339,serum concentration,"However, 4 hours after the dose, the mean serum concentration of methylprednisolone was 50.9 +/- 15.1 ng/mL in the elderly group and 37.6 +/- 7.5 (P = 0.07) ng/mL in the young group.",Pharmacokinetics of methylprednisolone in elderly and young healthy males. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7930339/),[ng] / [ml],50.9,269107,DB00860,Prednisolone
,7930339,serum concentration,"However, 4 hours after the dose, the mean serum concentration of methylprednisolone was 50.9 +/- 15.1 ng/mL in the elderly group and 37.6 +/- 7.5 (P = 0.07) ng/mL in the young group.",Pharmacokinetics of methylprednisolone in elderly and young healthy males. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7930339/),[ng] / [ml],37.6,269108,DB00860,Prednisolone
,7930339,clearance,"The clearance of methylprednisolone was 237 +/- 62 mL/h/kg, with a volume of distribution of 1.10 +/- 0.07 L/kg, for the elderly group, whereas the young males had a mean drug clearance of 359 +/- 90 mL/h/kg (P < 0.05) and a mean volume of distribution of 1.28 +/- 0.34 L/kg.",Pharmacokinetics of methylprednisolone in elderly and young healthy males. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7930339/),[ml] / [h·kg],237,269109,DB00860,Prednisolone
,7930339,volume of distribution,"The clearance of methylprednisolone was 237 +/- 62 mL/h/kg, with a volume of distribution of 1.10 +/- 0.07 L/kg, for the elderly group, whereas the young males had a mean drug clearance of 359 +/- 90 mL/h/kg (P < 0.05) and a mean volume of distribution of 1.28 +/- 0.34 L/kg.",Pharmacokinetics of methylprednisolone in elderly and young healthy males. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7930339/),[l] / [kg],1.10,269110,DB00860,Prednisolone
,7930339,drug clearance,"The clearance of methylprednisolone was 237 +/- 62 mL/h/kg, with a volume of distribution of 1.10 +/- 0.07 L/kg, for the elderly group, whereas the young males had a mean drug clearance of 359 +/- 90 mL/h/kg (P < 0.05) and a mean volume of distribution of 1.28 +/- 0.34 L/kg.",Pharmacokinetics of methylprednisolone in elderly and young healthy males. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7930339/),[ml] / [h·kg],359,269111,DB00860,Prednisolone
,7930339,volume of distribution,"The clearance of methylprednisolone was 237 +/- 62 mL/h/kg, with a volume of distribution of 1.10 +/- 0.07 L/kg, for the elderly group, whereas the young males had a mean drug clearance of 359 +/- 90 mL/h/kg (P < 0.05) and a mean volume of distribution of 1.28 +/- 0.34 L/kg.",Pharmacokinetics of methylprednisolone in elderly and young healthy males. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7930339/),[l] / [kg],1.28,269112,DB00860,Prednisolone
,7930339,half-life,The half-life of methylprednisolone ranged from 1.90 to 5.40 hours in the elderly group; the range was 1.99 to 3.31 hour (P = 0.016) in the young group.,Pharmacokinetics of methylprednisolone in elderly and young healthy males. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7930339/),h,1.90 to 5.40,269113,DB00860,Prednisolone
,7930339,half-life,The half-life of methylprednisolone ranged from 1.90 to 5.40 hours in the elderly group; the range was 1.99 to 3.31 hour (P = 0.016) in the young group.,Pharmacokinetics of methylprednisolone in elderly and young healthy males. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7930339/),h,1.99 to 3.31,269114,DB00860,Prednisolone
,9084459,time to reach peak concentration,"With the exception of nicotine time to reach peak concentration, which was longer in patients (median of 60 minutes compared with 45 minutes; p < 0.005), other comparisons between normal subjects and patients showed no statistically significant difference, although there was considerable inter-subject variation.",Pharmacokinetics of nicotine carbomer enemas: a new treatment modality for ulcerative colitis. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9084459/),min,60,270129,DB00860,Prednisolone
,9084459,time to reach peak concentration,"With the exception of nicotine time to reach peak concentration, which was longer in patients (median of 60 minutes compared with 45 minutes; p < 0.005), other comparisons between normal subjects and patients showed no statistically significant difference, although there was considerable inter-subject variation.",Pharmacokinetics of nicotine carbomer enemas: a new treatment modality for ulcerative colitis. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9084459/),min,45,270130,DB00860,Prednisolone
,9084459,Maximum concentration,"Maximum concentration of nicotine, 8.1 +/- 3.5 ng/ml, in the 16 subjects occurred after a median of 60 minutes (range, 30 to 180 minutes); maximum cotinine concentrations of 60.4 +/- 11.5 ng/ml occurred after 4 hours.",Pharmacokinetics of nicotine carbomer enemas: a new treatment modality for ulcerative colitis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9084459/),[ng] / [ml],8.1,270131,DB00860,Prednisolone
,9084459,maximum cotinine concentrations,"Maximum concentration of nicotine, 8.1 +/- 3.5 ng/ml, in the 16 subjects occurred after a median of 60 minutes (range, 30 to 180 minutes); maximum cotinine concentrations of 60.4 +/- 11.5 ng/ml occurred after 4 hours.",Pharmacokinetics of nicotine carbomer enemas: a new treatment modality for ulcerative colitis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9084459/),[ng] / [ml],60.4,270132,DB00860,Prednisolone
,7141787,steady-state volume of distribution (Vss,"A larger steady-state volume of distribution (Vss = 3.4 vs. 1.2 l/kg) was observed in active disease than in remission, suggesting greater availability of the steroid to tissues.",Effect on nephrotic syndrome on absorption and disposition of prednisolone in children. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7141787/),[l] / [kg],3.4,270293,DB00860,Prednisolone
,7141787,steady-state volume of distribution (Vss,"A larger steady-state volume of distribution (Vss = 3.4 vs. 1.2 l/kg) was observed in active disease than in remission, suggesting greater availability of the steroid to tissues.",Effect on nephrotic syndrome on absorption and disposition of prednisolone in children. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7141787/),[l] / [kg],1.2,270294,DB00860,Prednisolone
,26416605,AUCinf,"For the remaining 5 premature lambs, a non-compartmental analysis demonstrated an AUCinf of 148.77 ± 28.16 h*μg/L, half-life of 4.76 ± 1.79 h, and Cmax of 46.17 ± 17.71 µg/L.",Pharmacokinetics of Budesonide Administered with Surfactant in Premature Lambs: Implications for Neonatal Clinical Trials. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26416605/),[h·μg] / [l],148.77,271264,DB00860,Prednisolone
,26416605,half-life,"For the remaining 5 premature lambs, a non-compartmental analysis demonstrated an AUCinf of 148.77 ± 28.16 h*μg/L, half-life of 4.76 ± 1.79 h, and Cmax of 46.17 ± 17.71 µg/L.",Pharmacokinetics of Budesonide Administered with Surfactant in Premature Lambs: Implications for Neonatal Clinical Trials. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26416605/),h,4.76,271265,DB00860,Prednisolone
,26416605,Cmax,"For the remaining 5 premature lambs, a non-compartmental analysis demonstrated an AUCinf of 148.77 ± 28.16 h*μg/L, half-life of 4.76 ± 1.79 h, and Cmax of 46.17 ± 17.71 µg/L.",Pharmacokinetics of Budesonide Administered with Surfactant in Premature Lambs: Implications for Neonatal Clinical Trials. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26416605/),[μg] / [l],46.17,271266,DB00860,Prednisolone
,26416605,apparent clearance,"The apparent clearance and apparent volume of distribution of budesonide were estimated at 6.29 L/h (1.99 L/h/kg) and 29.1 L (9.2 L/kg), respectively.",Pharmacokinetics of Budesonide Administered with Surfactant in Premature Lambs: Implications for Neonatal Clinical Trials. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26416605/),[l] / [h],6.29,271267,DB00860,Prednisolone
,26416605,apparent volume of distribution,"The apparent clearance and apparent volume of distribution of budesonide were estimated at 6.29 L/h (1.99 L/h/kg) and 29.1 L (9.2 L/kg), respectively.",Pharmacokinetics of Budesonide Administered with Surfactant in Premature Lambs: Implications for Neonatal Clinical Trials. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26416605/),l,29.1,271268,DB00860,Prednisolone
,6721988,AUC,Total serum prednisolone levels were significantly lower during the active phase than in remission (AUC: 2452 +/- 207 vs 3392 +/- 293 ng ml-1 h respectively).,Pharmacokinetics of prednisone and its metabolite prednisolone in children with nephrotic syndrome during the active phase and in remission. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6721988/),[h·ng] / [ml],2452,271659,DB00860,Prednisolone
,6721988,AUC,Total serum prednisolone levels were significantly lower during the active phase than in remission (AUC: 2452 +/- 207 vs 3392 +/- 293 ng ml-1 h respectively).,Pharmacokinetics of prednisone and its metabolite prednisolone in children with nephrotic syndrome during the active phase and in remission. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6721988/),[h·ng] / [ml],3392,271660,DB00860,Prednisolone
,6721988,AUC,Free prednisolone levels during the active phase did not differ significantly from those observed during remission (AUC: 937 +/- 128 vs 847 +/- 81 ng ml-1 h respectively).,Pharmacokinetics of prednisone and its metabolite prednisolone in children with nephrotic syndrome during the active phase and in remission. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6721988/),[h·ng] / [ml],937,271661,DB00860,Prednisolone
,6721988,AUC,Free prednisolone levels during the active phase did not differ significantly from those observed during remission (AUC: 937 +/- 128 vs 847 +/- 81 ng ml-1 h respectively).,Pharmacokinetics of prednisone and its metabolite prednisolone in children with nephrotic syndrome during the active phase and in remission. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6721988/),[h·ng] / [ml],847,271662,DB00860,Prednisolone
,1545348,systemic availability (F),Methylprednisolone systemic availability (F) was 49-57% after iv administration and approximately 35% after oral administration.,Bioavailability and nonlinear disposition of methylprednisolone and methylprednisone in the rat. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1545348/),%,49-57,271663,DB00860,Prednisolone
,1545348,systemic availability (F),Methylprednisolone systemic availability (F) was 49-57% after iv administration and approximately 35% after oral administration.,Bioavailability and nonlinear disposition of methylprednisolone and methylprednisone in the rat. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1545348/),%,35,271664,DB00860,Prednisolone
,1545348,Apparent systemic clearance (CL),"Apparent systemic clearance (CL) of methylprednisolone was 21 mL/min (low dose), approximately twice the liver blood flow.",Bioavailability and nonlinear disposition of methylprednisolone and methylprednisone in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1545348/),[ml] / [min],21,271665,DB00860,Prednisolone
,3580023,plasma half-life,"The hemisuccinate ester is hydrolyzed relatively quickly with a plasma half-life between 18 and 25 min, and the resulting prednisolone has a plasma half-life of 3.5-3.7 h.",[Pharmacokinetics and pharmacodynamics of prednisolone following extremely high dosage as prednisolone hemisuccinate]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3580023/),min,18 and 25,272214,DB00860,Prednisolone
,3580023,plasma half-life,"The hemisuccinate ester is hydrolyzed relatively quickly with a plasma half-life between 18 and 25 min, and the resulting prednisolone has a plasma half-life of 3.5-3.7 h.",[Pharmacokinetics and pharmacodynamics of prednisolone following extremely high dosage as prednisolone hemisuccinate]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3580023/),h,3.5-3.7,272215,DB00860,Prednisolone
,3623424,FACa,"In the basal state, the radiocalcium transit was significantly decreased (P less than 0.02) at 15 min in patients treated with prednisolone, but FACa at 6 h was not significantly decreased (51 +/- 5 vs. 60 +/- 5% TD).",Calcium absorption in corticoid treated subjects effects of a single oral dose of calcitriol. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3623424/),%,51,272503,DB00860,Prednisolone
,3623424,FACa,"In the basal state, the radiocalcium transit was significantly decreased (P less than 0.02) at 15 min in patients treated with prednisolone, but FACa at 6 h was not significantly decreased (51 +/- 5 vs. 60 +/- 5% TD).",Calcium absorption in corticoid treated subjects effects of a single oral dose of calcitriol. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3623424/),%,60,272504,DB00860,Prednisolone
,16463770,half-life time,"The half-life time of MTH in perilymph after otocyst was infused was 1.51 h, and the one after niche was placed with granule gelfoam soaked with MTH was 1.55 h.",[Methylprednisolone pharmacokinetics in perilymph and plasma of guinea pig after topical administration and intracardial injection]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16463770/),h,1.51,272545,DB00860,Prednisolone
,16463770,half-life time,"The half-life time of MTH in perilymph after otocyst was infused was 1.51 h, and the one after niche was placed with granule gelfoam soaked with MTH was 1.55 h.",[Methylprednisolone pharmacokinetics in perilymph and plasma of guinea pig after topical administration and intracardial injection]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16463770/),h,1.55,272546,DB00860,Prednisolone
,26966895,flow rate,"Chromatographic separation was performed on a Waters BEH C18 column with an isocratic elution using a mobile phase composed of acetonitrile and water, each with 0.1% formic acid, (80: 20, v/v), at a flow rate of 0.2 mL/min.",Simultaneous determination of selected tyrosine kinase inhibitors with corticosteroids and antiemetics in rat plasma by solid phase extraction and ultra-performance liquid chromatography-tandem mass spectrometry: Application to pharmacokinetic interaction studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26966895/),[ml] / [min],0.2,273626,DB00860,Prednisolone
,26966895,m/,"Quantitation of the analytes was performed using the multiple reaction monitoring (MRM) mode with the positive ionization mode at m/z 447.25>128.08 (GEF), m/z 394.20>278.04 (ERL), m/z 393.30>147.04 (DEX), m/z 361.29>147.02 (PRED), m/z 294.18>170.16 (OND), and m/z 426.26>175.07 (DOM).",Simultaneous determination of selected tyrosine kinase inhibitors with corticosteroids and antiemetics in rat plasma by solid phase extraction and ultra-performance liquid chromatography-tandem mass spectrometry: Application to pharmacokinetic interaction studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26966895/),,36,273627,DB00860,Prednisolone
,26966895,m/,"Quantitation of the analytes was performed using the multiple reaction monitoring (MRM) mode with the positive ionization mode at m/z 447.25>128.08 (GEF), m/z 394.20>278.04 (ERL), m/z 393.30>147.04 (DEX), m/z 361.29>147.02 (PRED), m/z 294.18>170.16 (OND), and m/z 426.26>175.07 (DOM).",Simultaneous determination of selected tyrosine kinase inhibitors with corticosteroids and antiemetics in rat plasma by solid phase extraction and ultra-performance liquid chromatography-tandem mass spectrometry: Application to pharmacokinetic interaction studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26966895/),,147.02,273628,DB00860,Prednisolone
,26966895,m/,"Quantitation of the analytes was performed using the multiple reaction monitoring (MRM) mode with the positive ionization mode at m/z 447.25>128.08 (GEF), m/z 394.20>278.04 (ERL), m/z 393.30>147.04 (DEX), m/z 361.29>147.02 (PRED), m/z 294.18>170.16 (OND), and m/z 426.26>175.07 (DOM).",Simultaneous determination of selected tyrosine kinase inhibitors with corticosteroids and antiemetics in rat plasma by solid phase extraction and ultra-performance liquid chromatography-tandem mass spectrometry: Application to pharmacokinetic interaction studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26966895/),,170.16,273629,DB00860,Prednisolone
,26966895,Er%,The method provided good extraction recovery of all analytes from rat plasma (Er% from -14.05 to -1.08).,Simultaneous determination of selected tyrosine kinase inhibitors with corticosteroids and antiemetics in rat plasma by solid phase extraction and ultra-performance liquid chromatography-tandem mass spectrometry: Application to pharmacokinetic interaction studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26966895/),,1,273630,DB00860,Prednisolone
,7756707,total body clearance,"The mean +/- SD total body clearance in study 1 was 363 +/- 330 mL/min/kg, whereas the mean volume of distribution was 1.18 +/- 0.53 L/kg.",Repeated assessment of methylprednisolone pharmacokinetics during chronic immunosuppression in renal transplant recipients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7756707/),[ml] / [kg·min],363,273996,DB00860,Prednisolone
,7756707,volume of distribution,"The mean +/- SD total body clearance in study 1 was 363 +/- 330 mL/min/kg, whereas the mean volume of distribution was 1.18 +/- 0.53 L/kg.",Repeated assessment of methylprednisolone pharmacokinetics during chronic immunosuppression in renal transplant recipients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7756707/),[l] / [kg],1.18,273997,DB00860,Prednisolone
,7756707,elimination rate constant,"The mean elimination rate constant was 0.29 +/- 0.14 h-1, with a mean serum half-life of 2.87 +/- 1.15 h during the first phase.",Repeated assessment of methylprednisolone pharmacokinetics during chronic immunosuppression in renal transplant recipients. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7756707/),1/[h],0.29,273998,DB00860,Prednisolone
,7756707,serum half-life,"The mean elimination rate constant was 0.29 +/- 0.14 h-1, with a mean serum half-life of 2.87 +/- 1.15 h during the first phase.",Repeated assessment of methylprednisolone pharmacokinetics during chronic immunosuppression in renal transplant recipients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7756707/),h,2.87,273999,DB00860,Prednisolone
,7756707,clearance,"In study 2, the mean methylprednisolone clearance was 261 +/- 150 mL/min/kg (p > 0.05) and the mean volume of distribution was 0.89 +/- 0.31 L/kg (p > 0.05).",Repeated assessment of methylprednisolone pharmacokinetics during chronic immunosuppression in renal transplant recipients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7756707/),[ml] / [kg·min],261,274000,DB00860,Prednisolone
,7756707,volume of distribution,"In study 2, the mean methylprednisolone clearance was 261 +/- 150 mL/min/kg (p > 0.05) and the mean volume of distribution was 0.89 +/- 0.31 L/kg (p > 0.05).",Repeated assessment of methylprednisolone pharmacokinetics during chronic immunosuppression in renal transplant recipients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7756707/),[l] / [kg],0.89,274001,DB00860,Prednisolone
,7756707,serum half-life,"The mean serum half-life of methylprednisolone was 2.91 +/- 0.60 h (p > 0.05), with the mean elimination rate constant of 0.25 +/- 0.06 h-1 (p > 0.05).",Repeated assessment of methylprednisolone pharmacokinetics during chronic immunosuppression in renal transplant recipients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7756707/),h,2.91,274002,DB00860,Prednisolone
,7756707,elimination rate constant,"The mean serum half-life of methylprednisolone was 2.91 +/- 0.60 h (p > 0.05), with the mean elimination rate constant of 0.25 +/- 0.06 h-1 (p > 0.05).",Repeated assessment of methylprednisolone pharmacokinetics during chronic immunosuppression in renal transplant recipients. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7756707/),1/[h],0.25,274003,DB00860,Prednisolone
<,29574974,trough levels,"In transplant patients, the approved dose of 0.75-1 mg twice daily (BID) results in subtherapeutic trough levels (<6 μg l-1 ) and that a higher starting dose of 2.25-3 mg BID is required.",A pharmacological rationale for improved everolimus dosing in oncology and transplant patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29574974/),[μg] / [l],6,274094,DB00860,Prednisolone
